0001628280-15-008338.txt : 20151109 0001628280-15-008338.hdr.sgml : 20151109 20151105160655 ACCESSION NUMBER: 0001628280-15-008338 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151105 DATE AS OF CHANGE: 20151105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Diversicare Healthcare Services, Inc. CENTRAL INDEX KEY: 0000919956 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 621559667 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12996 FILM NUMBER: 151200640 BUSINESS ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 BUSINESS PHONE: 6157717575 MAIL ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 FORMER COMPANY: FORMER CONFORMED NAME: ADVOCAT INC DATE OF NAME CHANGE: 19940309 10-Q 1 dvcr-20150930x10q.htm 10-Q 10-Q


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________ 
FORM 10-Q
________________________________ 
CHECK ONE:
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended: September 30, 2015
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             .

Commission file No.: 1-12996
________________________________ 
Diversicare Healthcare Services, Inc.
(exact name of registrant as specified in its charter)
 ________________________________
Delaware
 
62-1559667
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
1621 Galleria Boulevard, Brentwood, TN 37027
(Address of principal executive offices) (Zip Code)
(615) 771-7575
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and a “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
 
¨
Accelerated filer
 
¨
 
 
 
 
Non-accelerated filer
 
¨
Smaller reporting Company
 
ý
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  ý
6,259,152
(Outstanding shares of the issuer’s common stock as of October 30, 2015)
 



Part I. FINANCIAL INFORMATION
ITEM 1 – FINANCIAL STATEMENTS
DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands)
 
 
September 30,
2015
 
December 31,
2014
 
(Unaudited)
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
3,710

 
$
3,818

Receivables, less allowance for doubtful accounts of $7,736 and $6,044, respectively
44,276

 
41,272

Other receivables
1,353

 
862

Prepaid expenses and other current assets
2,441

 
2,339

Income tax refundable
559

 
559

Current assets of discontinued operations
67

 
73

Deferred income taxes
8,176

 
7,016

Total current assets
60,582

 
55,939

PROPERTY AND EQUIPMENT, at cost
109,484

 
98,869

Less accumulated depreciation and amortization
(60,338
)
 
(55,014
)
Property and equipment, net
49,146

 
43,855

OTHER ASSETS:
 
 
 
Deferred income taxes
11,544

 
12,885

Deferred financing and other costs, net
1,532

 
1,692

Investment in unconsolidated affiliate
744

 
463

Other noncurrent assets
4,108

 
6,411

Acquired leasehold interest, net
7,556

 
7,844

Total other assets
25,484

 
29,295

 
$
135,212

 
$
129,089

The accompanying notes are an integral part of these interim consolidated financial statements.

2


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(continued)
 
 
September 30,
2015
 
December 31,
2014
 
(Unaudited)
 
 
CURRENT LIABILITIES:
 
 
 
Current portion of long-term debt and capitalized lease obligations
$
14,375

 
$
5,705

Trade accounts payable
8,335

 
8,121

Current liabilities of discontinued operations
365

 
482

Accrued expenses:
 
 
 
Payroll and employee benefits
15,788

 
14,642

Self-insurance reserves, current portion
11,835

 
11,833

Other current liabilities
6,232

 
6,359

Total current liabilities
56,930

 
47,142

NONCURRENT LIABILITIES:
 
 
 
Long-term debt and capitalized lease obligations, less current portion
41,828

 
42,559

Self-insurance reserves, noncurrent portion
12,631

 
14,268

Other noncurrent liabilities
11,822

 
13,366

Total noncurrent liabilities
66,281

 
70,193

COMMITMENTS AND CONTINGENCIES

 

SHAREHOLDERS’ EQUITY:
 
 
 
Series A preferred stock, authorized 200,000 shares, $.10 par value, none issued and outstanding
—

 
—

Common stock, authorized 20,000,000 shares, $.01 par value, 6,491,000 and 6,388,000 shares issued, and 6,259,000 and 6,156,000 shares outstanding, respectively
65

 
64

Treasury stock at cost, 232,000 shares of common stock
(2,500
)
 
(2,500
)
Paid-in capital
20,615

 
19,970

Accumulated deficit
(5,647
)
 
(5,285
)
Accumulated other comprehensive loss
(532
)
 
(495
)
Total shareholders’ equity
12,001


11,754

 
$
135,212

 
$
129,089

The accompanying notes are an integral part of these interim consolidated financial statements.

3


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
Three Months Ended
September 30,
 
2015
 
2014
PATIENT REVENUES, net
$
98,105

 
$
90,331

EXPENSES:
 
 
 
Operating
78,501

 
73,006

Lease and rent expense
7,198

 
6,876

Professional liability
2,069

 
1,743

General and administrative
6,378

 
5,582

Depreciation and amortization
1,887

 
1,812

Total expenses
96,033

 
89,019

OPERATING INCOME
2,072

 
1,312

OTHER EXPENSE:
 
 
 
Equity in net income (loss) of unconsolidated affiliate
97

 
(30
)
Interest expense, net
(998
)
 
(916
)
Total other expense
(901
)
 
(946
)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
1,171

 
366

PROVISION FOR INCOME TAXES
(502
)
 
(147
)
INCOME FROM CONTINUING OPERATIONS
669

 
219

INCOME (LOSS) FROM DISCONTINUED OPERATIONS:
 
 
 
Operating loss, net of tax benefit of $237 and $384, respectively
(238
)
 
(585
)
Gain on disposal, net of tax of $0 and $(3,009), respectively
—

 
4,513

Income (loss) from discontinued operations
(238
)
 
3,928

NET INCOME
431

 
4,147

PREFERRED STOCK DIVIDENDS
—

 
(48
)
NET INCOME FOR DIVERSICARE HEALTHCARE SERVICES, INC. COMMON SHAREHOLDERS
$
431

 
$
4,099

NET INCOME (LOSS) PER COMMON SHARE FOR DIVERSICARE HEALTHCARE SERVICES, INC. SHAREHOLDERS:
 
 
 
Per common share – basic
 
 
 
Continuing operations
$
0.11

 
$
0.03

Discontinued operations
(0.04
)
 
0.65

 
$
0.07

 
$
0.68

Per common share – diluted
 
 
 
Continuing operations
$
0.11

 
$
0.03

Discontinued operations
(0.04
)
 
0.63

 
$
0.07

 
$
0.66

COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$
0.055

 
$
0.055

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic
6,121

 
6,020

Diluted
6,331

 
6,248

                              
The accompanying notes are an integral part of these interim consolidated financial statements.

4


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands and unaudited)
 
 
Three Months Ended
September 30,
 
2015
 
2014
NET INCOME
$
431

 
$
4,147

OTHER COMPREHENSIVE INCOME:
 
 
 
Change in fair value of cash flow hedge, net of tax
151

 
254

Less: reclassification adjustment for amounts recognized in net income
(109
)
 
(128
)
Total other comprehensive income
42

 
126

COMPREHENSIVE INCOME
$
473

 
$
4,273


The accompanying notes are an integral part of these interim consolidated financial statements.

5


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
Nine Months Ended
September 30,
 
2015
 
2014
PATIENT REVENUES, net
$
289,618

 
$
250,443

EXPENSES:

 
 
Operating
232,298

 
200,517

Lease and rent expense
21,529

 
19,094

Professional liability
6,150

 
5,360

General and administrative
18,770

 
16,077

Depreciation and amortization
5,629

 
5,252

Total expenses
284,376

 
246,300

OPERATING INCOME
5,242

 
4,143

OTHER EXPENSE:
 
 
 
Equity in net income (loss) of unconsolidated affiliate
280

 
(89
)
Interest expense, net
(2,997
)
 
(2,757
)
Total other expense
(2,717
)
 
(2,846
)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
2,525

 
1,297

PROVISION FOR INCOME TAXES
(1,044
)
 
(538
)
INCOME FROM CONTINUING OPERATIONS
1,481

 
759

INCOME (LOSS) FROM DISCONTINUED OPERATIONS:
 
 
 
Operating loss, net of tax benefit of $628 and $732, respectively
(800
)
 
(1,069
)
Gain on disposal, net of tax of $0 and $(3,009), respectively
—

 
4,513

Income (loss) from discontinued operations
(800
)
 
3,444

NET INCOME
681

 
4,203

Less: loss attributable to noncontrolling interests
—

 
25

NET INCOME ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC.
681

 
4,228

PREFERRED STOCK DIVIDENDS
—

 
(220
)
NET INCOME FOR DIVERSICARE HEALTHCARE SERVICES, INC. COMMON SHAREHOLDERS
$
681

 
$
4,008

NET INCOME (LOSS) PER COMMON SHARE FOR DIVERSICARE HEALTHCARE SERVICES, INC. SHAREHOLDERS:
 
 
 
Per common share – basic
 
 
 
Continuing operations
$
0.24

 
$
0.09

Discontinued operations
(0.13
)
 
0.57

 
$
0.11

 
$
0.66

Per common share – diluted
 
 
 
Continuing operations
$
0.24

 
$
0.09

Discontinued operations
(0.13
)
 
0.56

 
$
0.11

 
$
0.65

COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$
0.17

 
$
0.17

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic
6,089

 
6,004

Diluted
6,310

 
6,171

                              
The accompanying notes are an integral part of these interim consolidated financial statements.


6


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands and unaudited)
 
 
Nine Months Ended
September 30,
 
2015
 
2014
NET INCOME
$
681

 
$
4,203

OTHER COMPREHENSIVE INCOME:
 
 
 
Change in fair value of cash flow hedge, net of tax
382

 
478

Less: reclassification adjustment for amounts recognized in net income
(345
)
 
(376
)
Total other comprehensive income
37

 
102

COMPREHENSIVE INCOME
718

 
4,305

Less: comprehensive loss attributable to noncontrolling interest
—

 
25

COMPREHENSIVE INCOME ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC.
$
718

 
$
4,330


The accompanying notes are an integral part of these interim consolidated financial statements.



7


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
 
 
Nine Months Ended
September 30,
 
2015
 
2014
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net income
$
681

 
$
4,203

Discontinued operations
(800
)
 
3,444

Income from continuing operations
1,481

 
759

Adjustments to reconcile income from continuing operations to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
5,629

 
5,252

Provision for doubtful accounts
5,425

 
4,235

Deferred income tax benefit
204

 
(467
)
Provision for self-insured professional liability, net of cash payments
2,063

 
815

Stock-based compensation
924

 
441

Equity in net (income) losses of unconsolidated affiliate, net of investment
(281
)
 
88

Provision for leases in excess of cash payments
(1,203
)
 
(779
)
Other
116

 
311

Changes in assets and liabilities affecting operating activities:
 
 
 
Receivables, net
(8,302
)
 
(13,775
)
Prepaid expenses and other assets
(507
)
 
(323
)
Trade accounts payable and accrued expenses
1,136

 
4,131

Net cash provided by continuing operations
6,685

 
688

Discontinued operations
(4,896
)
 
(600
)
Net cash provided by operating activities
1,789

 
88

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(3,624
)
 
(4,228
)
Acquisition of property and equipment through business combination
(7,000
)
 
—

Proceeds from sale of discontinued operations
—

 
16,500

Change in restricted cash
2,490

 
33

Deposits and other deferred balances
(9
)
 
(64
)
Net cash provided by (used in) continuing operations
(8,143
)
 
12,241

Discontinued operations
—

 
(61
)
Net cash provided by (used in) investing activities
(8,143
)
 
12,180

CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Repayment of debt obligations
(14,002
)
 
(14,850
)
Proceeds from issuance of debt
21,941

 
16,808

Financing costs
(192
)
 
(180
)
Issuance and redemption of employee equity awards
(31
)
 
(30
)
Redemption of preferred stock
—

 
(4,918
)
Payment of common stock dividends
(1,008
)
 
(993
)
Payment of preferred stock dividends
—

 
(220
)
Distributions to noncontrolling interest
—

 
(1,411
)
Payment for preferred stock restructuring
(462
)
 
(448
)
Net cash provided by (used in) financing activities
6,246

 
(6,242
)
Discontinued operations
—

 
(5,952
)
Net cash provided by (used in) financing activities
$
6,246

 
$
(12,194
)

8


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
(continued)
 
 
Nine Months Ended
September 30,
 
2015
 
2014
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
$
(108
)
 
$
74

CASH AND CASH EQUIVALENTS, beginning of period
3,818

 
3,781

CASH AND CASH EQUIVALENTS, end of period
$
3,710

 
$
3,855

SUPPLEMENTAL INFORMATION:
 
 
 
Cash payments of interest, net of amounts capitalized
$
2,711

 
$
2,496

Cash payments of income taxes
$
216

 
$
66

The accompanying notes are an integral part of these interim consolidated financial statements.

9


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2015 AND 2014

1.
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare Healthcare Services” or the “Company”) provides long-term care services to nursing center patients in nine states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Missouri, Ohio, Tennessee, and Texas.
As of September 30, 2015, the Company’s continuing operations consist of 54 nursing centers with 6,004 licensed nursing beds. The Company owns 14 and leases 40 of its nursing centers. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 496 licensed assisted and residential living beds.

2.
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The investment in an unconsolidated affiliate (a 50 percent-owned joint venture partnership) is accounted for using the equity method and is described in Note 8.
The interim consolidated financial statements for the three and nine month periods ended September 30, 2015 and 2014, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at September 30, 2015, and the results of operations for the three and nine month periods ended September 30, 2015 and 2014, and cash flows for the nine month periods ended September 30, 2015 and 2014. The Company’s balance sheet information at December 31, 2014, was derived from its audited consolidated financial statements as of December 31, 2014.
The results of operations for the periods ended September 30, 2015 and 2014 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014.

3.
RECENT ACCOUNTING GUIDANCE
In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity changing the criteria for reporting discontinued operations. The ASU states that only those disposed components (or components held-for-sale) representing a strategic shift that have a significant effect on operations and financial results will be reported in discontinued operations. The ASU also required expanded disclosures about discontinued operations in the financial statement notes. The ASU is effective for disposals (or classifications as held-for-sale) that occur within annual periods beginning on or after December 15, 2014 and interim periods within those annual periods. Early application is permitted, but only for those disposals that have not been reported in financial statements previously issued or available for issuance. We chose to early adopt this ASU and applied the new criteria in determining the accounting treatment for the nursing centers exited during 2014. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In July 2015, the FASB announced the deferral of the effective date by one year from the originally stated effective date in ASU 2014-09. The new standard is now effective for the Company on January 1, 2018, but can be adopted as of the original effective date of January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures, as well as the time frame for adoption. The Company has not yet selected an effective date or transition method nor has it determined the effect of the standard on its ongoing financial reporting.

10


In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs (Topic 835), which amends and simplifies the presentation of debt issuance costs. The main provisions of the standard require that debt issuance costs related to a recognized liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, and amortization of the debt issuance costs must be reported as interest expense. ASU 2015-03 will be effective for the interim and annual periods beginning after December 15, 2015 with early adoption permitted. The new standard must be applied on a retroactive basis, and the Company will be required to comply with the applicable disclosures for a change in accounting principle. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.


4.
LONG-TERM DEBT AND INTEREST RATE SWAP
The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On May 1, 2013, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated February 28, 2011. The Credit Agreement increases the Company's borrowing capacity to $65,000,000 allocated between a $45,000,000 Mortgage Loan ("Amended Mortgage Loan") and a $20,000,000 Revolver ("Amended Revolver"). Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $1,341,000 and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of $45,000,000 with a five-year maturity through April 30, 2018, and a $20,000,000 Amended Revolver through April 30, 2018. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest is based on LIBOR plus 4.5%. A portion of the Amended Mortgage Loan is effectively fixed at 6.87% pursuant to an interest rate swap with a notional amount of $21,333,333. As of September 30, 2015, the interest rate related to the Amended Mortgage Loan was 4.70%. The Amended Mortgage Loan is secured by thirteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.5% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective March 31, 2014, the Company entered into the Second Amendment to the Amended and Restated Revolver ("Second Amendment"). The Second Amendment temporarily increased the Amended Revolver capacity from the $20,000,000 in the original Amended Revolver to $27,500,000 through September 30, 2014, as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process. Effective July 1, 2014, the Company entered into the Third Amendment to the Amended and Restated Revolver ("Third Amendment"). The Third Amendment makes the previously temporary increase to the Amended Revolver capacity from the $20,000,000 in the original Amended Revolver to $27,500,000, a permanent change to the borrowing capacity as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process.
As of September 30, 2015, the Company had $8,000,000 borrowings outstanding under the revolving credit facility compared to $4,500,000 outstanding as of December 31, 2014. The outstanding borrowings on the revolver primarily reflect the Company's approach to accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under this Revolver are 3.00% of the amount outstanding. The Company has eleven letters of credit with a total value of $8,106,000 outstanding as of September 30, 2015. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $27,500,000, the balance available for borrowing under the revolving credit center is $8,987,000 at September 30, 2015.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relate to minimum cash deposits, cash flow and debt service coverage ratios. The Company is in compliance with all such covenants at September 30, 2015.
Interest Rate Swap Transaction
As part of the debt agreements entered into in March 2011, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income. In conjunction with the amendment to the credit facility, the Company retained the previously agreed upon interest rate swap terms, and redesignated the interest rate swap as a cash flow hedge. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount of $21,333,333 at an annual fixed rate of 6.87% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at September 30, 2015, the Company determined that the interest rate swap was effective. The interest rate swap valuation model indicated a net liability of $858,000 at September 30, 2015. The fair value of the interest rate swap is included in “other noncurrent liabilities” on the Company’s

11


interim consolidated balance sheet. The balance of accumulated other comprehensive loss at September 30, 2015 is $532,000 and reflects the liability related to the interest rate swap, net of the income tax benefit of $326,000. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.
Glasgow Term Loan
On February 1, 2015, in conjunction with the acquisition of Diversicare of Glasgow, a 94-bed skilled nursing facility in Glasgow, Kentucky, the Company entered into a $5,000,000 Term Loan and Security Agreement (the "Glasgow term loan") with The PrivateBank in order to finance the purchase of the assets. The Glasgow term loan is an interest-only loan that has an 18-month maturity dated August 1, 2016, and a variable interest rate based on LIBOR, with a minimum base rate of 4.75%. See Note 9 for further information regarding the acquisition of the Glasgow facility.

5.
INSURANCE MATTERS
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, consolidated offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”) which has issued a policy insuring claims made against all of the Company's nursing centers in Florida and Tennessee, as well as the Company’s formerly operated Arkansas and West Virginia facilities. Several of the Company’s nursing centers in Alabama, Kentucky, Ohio, and Texas are also covered under this policy. The SHC policy provides coverage limits of either $500,000 or $1,000,000 per medical incident with a sublimit per center of $1,000,000 and total annual aggregate policy limits of $5,000,000. The remaining nursing centers are covered by one of seven claims made professional liability insurance policies purchased from entities unaffiliated with the Company. These policies provide coverage limits of $1,000,000 per claim and have sublimits of $3,000,000 per center, with varying aggregate policy limits. 
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $23,242,000 as of September 30, 2015. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of the current portion of this reserve. Merlinos & Associates, Inc. (“Merlinos”) assisted management in the preparation of an estimate of the appropriate accrual for the current claims period and for incurred, but not reported general and professional liability claims based on data furnished as of May 31, 2015.  The Company used this estimate from Merlinos in the preparation of its estimate of liability for incurred, but unreported professional liability claims as of September 30, 2015.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of September 30, 2015, the Company is engaged in 50 professional liability lawsuits. Five lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $3,306,000 and $3,641,000 for the nine months ended September 30, 2015 and 2014, respectively.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability

12


claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.
Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either an indemnity insurance plan or state-sponsored programs in May 1997. The Company is completely self-insured for workers’ compensation exposures prior to May 1997. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2008 through September 30, 2015, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500,000 per claim, subject to an aggregate maximum of $3,000,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $361,000 at September 30, 2015. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,139,000 as of September 30, 2015. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of September 30, 2015, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $175,000 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $864,000 at September 30, 2015. The differences between actual settlements and reserves are included in expense in the period finalized.
The Company follows current accounting guidance set forth in FASB ASU 2010-24, “Presentation of Insurance Claims and Related Insurance Recoveries,” that clarifies that a health care entity should not net insurance recoveries against a related claim, and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the Company has recorded assets and equal liabilities of $0 at September 30, 2015 and $246,000 at December 31, 2014, respectively.

6.
STOCK-BASED COMPENSATION

Overview of Plans
In December 2005, the Compensation Committee of the Board of Directors adopted the 2005 Long-Term Incentive Plan (“2005 Plan”). The 2005 Plan allows the Company to issue stock options and other share and cash based awards. Under the 2005 Plan, 700,000 shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted thereunder. All grants under this plan expire 10 years from the date the grants were authorized by the Board of Directors.
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers and 150,000 shares of the Company's common stock has been reserved for issuance under the Stock Purchase Plan. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. No grants can be made under the Stock Purchase Plan after April 25, 2018.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. Under the 2010 Plan, 380,000 shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted.

Equity Grants and Valuations

13


During 2015 and 2014, the Compensation Committee of the Board of Directors approved grants totaling approximately 74,000 and 68,000 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares are determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed.
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2014
271,000

 
$
6.67

Granted
—

 
—

Exercised
(28,000
)
 
7.21

Expired or cancelled
—

 
—

Outstanding, September 30, 2015
243,000

 
$
6.61

 
 
 
 
Exercisable, September 30, 2015
243,000

 
$
6.61


 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2014
130,000

 
$
5.45

Granted
74,000

 
12.31

Dividend Equivalents
2,000

 
12.09

Vested
(63,000
)
 
5.50

Cancelled
(3,000
)
 
8.93

Outstanding September 30, 2015
140,000

 
$
9.07


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2014
46,000

 
$
5.35

Granted
36,000

 
12.31

Dividend Equivalents
1,000

 
12.05

Vested
(22,000
)
 
5.09

Cancelled
—

 
—

Outstanding September 30, 2015
61,000

 
$
9.58



Prior to 2014, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date. The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.

14



In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.

While no SOSARs or Options were granted during 2015 and 2014, previously granted SOSARs and Options remain outstanding as of September 30, 2015. The following table summarizes information regarding stock options and SOSAR grants outstanding as of September 30, 2015:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$10.40 to $11.59
 
$
11.09

 
48,000

 
$
—

 
48,000

 
$
—

$2.37 to $6.21
 
$
5.50

 
195,000

 
$
893,000

 
195,000

 
$
893,000

 
 
 
 
243,000

 
 
 
243,000

 
 
Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $924,000 and $441,000 in the nine month periods ended September 30, 2015 and 2014, respectively.

7.
EARNINGS (LOSS) PER COMMON SHARE
Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
 
 
 
 
 
 
2015
 
2014
 
2015
 
2014
Numerator: Income amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:
 
 
 
 
 
 
 
Income from continuing operations
$
669

 
$
219

 
1,481

 
759

Less: loss attributable to noncontrolling interests
—

 
—

 
—

 
25

Income from continuing operations attributable to Diversicare Healthcare Services, Inc.
669

 
219

 
1,481

 
784

Preferred stock dividends
—

 
(48
)
 
—

 
(220
)
Income from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders
669

 
171

 
1,481

 
564

Income (loss) from discontinued operations, net of income taxes
(238
)
 
3,928

 
(800
)
 
3,444

Net income (loss) attributable to Diversicare Healthcare Services, Inc. common shareholders
$
431

 
$
4,099

 
$
681

 
$
4,008

 

15


 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2015
 
2014
 
2015
 
2014
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.11

 
$
0.03

 
$
0.24

 
$
0.09

Income (loss) from discontinued operations
 
 
 
 
 
 
 
Operating income (loss), net of taxes
(0.04
)
 
(0.10
)
 
(0.13
)
 
(0.18
)
Gain on disposal, net of taxes
—

 
0.75

 
—

 
0.75

Discontinued operations, net of taxes
(0.04
)
 
0.65

 
(0.13
)
 
0.57

Net income (loss) per common share – basic
$
0.07

 
$
0.68

 
$
0.11

 
$
0.66

Per common share – diluted
 
 
 
 
 
 
 
Income from continuing operations
$
0.11

 
$
0.03

 
$
0.24

 
$
0.09

Income (loss) from discontinued operations
 
 
 
 
 
 
 
Operating income (loss), net of taxes
(0.04
)
 
(0.10
)
 
(0.13
)
 
(0.17
)
Gain on disposal, net of taxes
—

 
0.73

 
—

 
0.73

Discontinued operations, net of taxes
(0.04
)
 
0.63

 
(0.13
)
 
0.56

Net income (loss) per common share - diluted
$
0.07

 
$
0.66

 
$
0.11

 
$
0.65

Denominator: Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,121

 
6,020

 
6,089

 
6,004

Diluted
6,331

 
6,248

 
6,310

 
6,171

The effects of 16,000 and 57,000 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the nine months ended September 30, 2015 and 2014, respectively, because these securities would have been anti-dilutive.

8. EQUITY METHOD INVESTMENT
The investment in unconsolidated affiliate reflected on the interim consolidated balance sheet relates to a pharmacy joint venture partnership in which the Company owns 50%. The joint venture was initially funded by the Company and its partner and began operations during 2012. This investment in unconsolidated affiliate is accounted for using the equity method as the Company exerts significant influence, but does not control or otherwise consolidate the entity. The investment in unconsolidated affiliate balance at September 30, 2015, was $744,000 as compared to $463,000 at December 31, 2014. Additionally, the Company's share of the net profits and losses of the unconsolidated affiliate are reported in equity in net earnings or losses of unconsolidated affiliate in our statement of operations. The Company's equity in the net income of unconsolidated affiliate for the quarter ended September 30, 2015, was $97,000 as compared to a net loss of $30,000 for the quarter ended September 30, 2014. For the nine-month period ended September 30, 2015, the equity in the net income of unconsolidated affiliate was $280,000 compared to a net loss of $89,000 for the nine-month period ended September 30, 2014.

9.
BUSINESS DEVELOPMENT
Acquisitions
On February 1, 2015, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Barren County Health Care Center, Inc. to acquire certain land, improvements, furniture, fixtures and equipment, personal property and intangible property, together comprising a 94-bed skilled nursing center in Glasgow, Kentucky, for an aggregate purchase price of $7,000,000 partially financed through a $5,000,000 mortgage loan with The PrivateBank with the balance paid in cash consideration.

As a result of the consummation of the Agreement, the Company allocated the purchase price of $7,000,000 between the assets associated with the transaction based on the fair value of the acquired net assets. The allocation of the purchase price was determined with the assistance of HealthTrust LLC, a third-party real estate valuation firm. The allocation for the net assets acquired is as follows:

16



 
February 1, 2015
Purchase Price
$
7,000,000

 
 
Land
672,000

Buildings
5,778,000

Furniture, Fixtures, and Equipment
550,000

 
$
7,000,000


Lease Agreements
During the the first quarter of 2015 and the year ended December 31, 2014, the Company has completed several transactions to assume the operations of additional nursing centers through the assumption of long-term operating leases. The transactions during these periods are as follows:
•
On February 1, 2015, the Company assumed operations at Diversicare of Hutchinson, an 85-bed skilled nursing center in Hutchinson, Kansas. The facility has an initial lease term of 10 years and includes an option to purchase at a fixed price of $4,250,000, exercisable after the first year of the lease. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
•
On October 1, 2014, the Company assumed operations at Diversicare of Greenville, a 62-bed skilled nursing facility in Greenville, Kentucky. This facility has an initial lease terms of 14 years. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
•
On August 1, 2014, the Company assumed operations of two centers in Ohio. The centers included in this transaction are a 142-bed skilled nursing facility and a 42-bed assisted living center. The lease provides for an initial lease term of 10 years. The centers were already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers.
•
On July 1, 2014, the Company completed a transaction to enter the state of Missouri through the assumption of operations of three facilities totaling 339 skilled nursing beds. The lease provides for an initial 15-year lease term with a 5-year renewal option. The centers were already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers.
•
On June 1, 2014, the Company assumed operations at Diversicare of Nicholasville, an existing 73-bed facility in Nicholasville, Kentucky. The lease provides for an initial 15-year lease term with a 5-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
•
On March 1, 2014, the Company assumed operations at Diversicare of Big Springs, an existing 135-bed facility in Huntsville, Alabama. The nursing center is owned by an unrelated third-party and the lease provides for an initial 10-year lease term with two additional 5-year renewal options. The additional skilled nursing center increases the Company's footprint in Alabama to seven centers, and the third center in the Huntsville market. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.


10.
DISCONTINUED OPERATIONS
West Virginia Disposition
Effective April 3, 2014, the Company entered into an asset purchase agreement with Rose Terrace Acq., LLC (“Purchaser”) to sell its skilled nursing facility in Culloden, West Virginia. The original asset purchase agreement was subject to a number of conditions including an amendment to the Consolidated Amended and Restated Master Lease ("Master Lease") with Omega to terminate the lease only with respect to two other skilled nursing facilities in West Virginia, state licensure and regulatory approval.
Effective July 1, 2014, the Company completed the transaction with Rose Terrace Acq., LLC to sell Rose Terrace, a 90-bed skilled nursing facility in Culloden, West Virginia for a sales price of $16,500,000. The Company also entered into the Fifteenth Amendment to the Master Lease with Omega to terminate the lease only with respect to two other skilled nursing facilities in West Virginia, and concurrently entered into an operations transfer agreement with American Health Care Management, LLC, an affiliate of the

17


purchaser with respect to two other skilled nursing facilities located in Danville and Ivydale, West Virginia. The amendment effectively reduced the annual rent payments due under the Master Lease by $1,900,000. Upon completion of the transaction, Diversicare no longer operates any skilled nursing centers in the state of West Virginia. In conjunction with the closing of the sale, the Company paid the balance of the $8,000,000 mortgage loan outstanding on the Rose Terrace facility.
The transaction resulted in a gain on the disposition of Rose Terrace which, along with the results of operations for these nursing facilities, is presented within Discontinued Operations on the Consolidated Statements of Operations. The pretax gain on the transaction was $7,522,000. The tax expense associated with the gain was $2,793,000 for which the Company plans to apply net operating loss carryforwards from our deferred tax assets to substantially offset and minimize the cash outlay for this transaction.
These centers contributed revenues of $0 and $10,989,000 and net income (loss) of $(159,000) and $165,000 during the nine months ended September 30, 2015 and 2014, respectively.  The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense or any allocation of corporate interest expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations.
Other Discontinued Operations
In addition to the ongoing impact of the West Virginia discontinued operations, the Company also experienced ongoing expense during the quarter as it relates to the exit from our Arkansas operations which occurred in September 2013. The activity within Arkansas primarily relates to the progress as it relates to outstanding professional liability claims and finalizing the collection and/or write-off of remaining accounts receivable. These centers contributed net loss of $(624,000) and $(935,000) during the nine months ended September 30, 2015 and 2014, respectively. 

11. SUBSEQUENT EVENTS
On November 1, 2015, the Company entered into an Asset Purchase Agreement with Haws Fulton Investors, LLC to acquire certain land, improvements, furniture, fixtures and equipment, personal property and intangible property, together comprising a 60-bed skilled nursing center in Fulton, Kentucky, for an aggregate purchase price of $3.9 million. This facility is expected to contribute in excess of $3.5 million in annual revenues.



18



ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in nine states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Missouri, Ohio, Tennessee, and Texas.
As of September 30, 2015, the Company’s continuing operations consist of 54 nursing centers with 6,004 licensed nursing beds. The Company owns 14 and leases 40 of its nursing centers. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 496 licensed assisted living and residential beds.
Strategic Operating Initiatives
During the third quarter of 2010, we identified several key strategic objectives to increase shareholder value through improved operations and business development. These strategic operating initiatives included: improving skilled mix in our nursing centers, improving our average Medicare rate, implementing Electronic Medical Records (“EMR”) to improve Medicaid capture, accelerating center renovations and completing strategic acquisitions. We have experienced success in these initiatives and expect to continue to build on these improvements. We describe each of these below as well as provide metrics for our most recent quarter versus the third quarter of 2010, the quarter before we embarked on our strategic operating initiatives.
Improving skilled mix and average Medicare rate:
Our strategic operating initiatives of improving our skilled mix and our average Medicare rate by accurately capturing the delivery of care required investing in nursing and clinical care to treat more acute patients along with nursing center based sales representatives to attract these patients. These initiatives developed referral and Managed Care relationships that have attracted and are expected to continue to attract patients whose stay in the centers is covered by Medicare and Managed Care. A comparison of our most recent quarter versus the third quarter of 2010, the quarter before we embarked on our strategic operating initiatives, reflects our success with these strategic operating initiatives: 
 
Three Months Ended
 
September 30, 2015
 
September 30,
2010
As a percent of total census:
 
 
 
Medicare census
11.9
%
 
12.3
%
Managed Care census
3.7
%
 
1.3
%
Total skilled mix census
15.6
%
 
13.6
%
As a percent of total revenues:
 
 
 
Medicare revenues
27.9
%
 
29.3
%
Managed Care revenues
6.9
%
 
2.8
%
Total skilled mix revenues
34.8
%
 
32.1
%
Medicare average rate per day:
$
452.48

 
$
394.23

The initiatives have developed positive results in growing our skilled patient population, increasing the Managed Care census to 3.7% of total census in the third quarter of 2015, as compared to 1.3% in the third quarter of 2010, and total skilled mix census to 15.6% from 13.6% over the same period.
Implementing Electronic Medical Records to improve Medicaid capture:
As another part of our strategic operating initiative, we implemented EMR to improve documentation of the delivery of care. We completed the implementation of EMR in all our nursing centers in December 2011, on time and under budget. A comparison of our most recent quarter versus the third quarter of 2010 reflects the increase in our average Medicaid rate per day:

19


 
Three Months Ended
 
September 30, 2015
 
September 30,
2010
Medicaid average rate per day:
$
168.12

 
$
147.93


Completing strategic acquisitions and dispositions:
Our strategic operating initiatives include a renewed focus on completing strategic acquisitions. We continue to pursue and investigate opportunities to acquire, lease or develop new centers, focusing primarily on opportunities within our existing areas of operation. We expect to announce additional development projects in the near future. We have added six skilled nursing centers in Kentucky, three in Missouri, five in Ohio, one in Indiana, one in Alabama, and six in Kansas since the inception of our strategic plan.
As part of our strategic efforts, we have also performed thorough analysis on our existing centers in order to determine whether continuing operations within certain markets or regions was in line with the short-term and long-term strategy of the business. As a result, we disposed of an owned building in Arkansas in 2012, and reached an agreement to terminate our lease for eleven other facilities in Arkansas in 2013. In addition in 2014, the Company disposed of an owned building and two leased facilities in West Virginia. As a result of these transactions, we no longer operate within the states of Arkansas or West Virginia.
Basis of Financial Statements
Our patient revenues consist of the fees charged for the care of patients in the nursing centers we own and lease. Our operating expenses include the costs, other than lease, professional liability, depreciation and amortization expenses, incurred in the operation of the nursing centers we own and lease. Our general and administrative expenses consist of the costs of the corporate office and regional support functions. Our interest, depreciation and amortization expenses include all such expenses across the range of our operations.

Critical Accounting Policies and Judgments
A “critical accounting policy” is one which is both important to the understanding of our financial condition and results of operations and requires management’s most difficult, subjective or complex judgments often involving estimates of the effect of matters that are inherently uncertain. Actual results could differ from those estimates and cause our reported net income or loss to vary significantly from period to period. Our critical accounting policies are more fully described in our 2014 Annual Report on Form 10-K.
Revenue Sources
We classify our revenues from patients and residents into four major categories: Medicaid, Medicare, Managed Care, and Private Pay and other. Medicaid revenues are composed of the traditional Medicaid program established to provide benefits to those in need of financial assistance in the securing of medical services. Medicare revenues include revenues received under both Part A and Part B of the Medicare program. Managed Care revenues include payments for patients who are insured by a third-party entity, typically called a Health Maintenance Organization, often referred to as an HMO plan, or are Medicare beneficiaries who assign their Medicare benefits to a Managed Care replacement plan often referred to as Medicare replacement products. The Private Pay and other revenues are composed primarily of individuals or parties who directly pay for their services. Included in the Private Pay and other are patients who are hospice beneficiaries as well as the recipients of Veterans Administration benefits. Veterans Administration payments are made pursuant to renewable contracts negotiated with these payors.
The following table sets forth net patient and resident revenues related to our continuing operations by payor source for the periods presented (dollar amounts in thousands):
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2015
 
2014
 
2015
 
2014
Medicaid
$
48,958

 
49.9
%
 
$
43,866

 
48.6
%
 
$
140,008

 
48.3
%
 
$
121,376

 
48.5
%
Medicare
27,413

 
27.9

 
26,348

 
29.2

 
84,987

 
29.3

 
74,387

 
29.7

Managed Care
6,743

 
6.9

 
5,926

 
6.6

 
20,230

 
7.0

 
16,643

 
6.6

Private Pay and other
14,991

 
15.3

 
14,191

 
15.6

 
44,393

 
15.4

 
38,037

 
15.2

Total
$
98,105

 
100.0
%
 
$
90,331

 
100.0
%
 
$
289,618

 
100.0
%
 
$
250,443

 
100.0
%

20


The following table sets forth average daily skilled nursing census by payor source for our continuing operations for the periods presented: 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2015
2014
 
2015
 
2014
Medicaid
3,143

 
67.6
%
 
2,949

 
66.8
%
 
3,088

 
66.9
%
 
2,796

 
67.1
%
Medicare
553

 
11.9

 
544

 
12.3

 
583

 
12.6

 
536

 
12.9

Managed Care
171

 
3.7

 
152

 
3.4

 
174

 
3.8

 
147

 
3.5

Private Pay and other
784

 
16.8

 
769

 
17.5

 
769

 
16.7

 
687

 
16.5

Total
4,651

 
100.0
%
 
4,414

 
100.0
%
 
4,614

 
100.0
%
 
4,166

 
100.0
%
Consistent with the nursing home industry in general, changes in the mix of a facility’s patient population among Medicaid, Medicare, Managed Care, and Private Pay and other can significantly affect the profitability of the facility’s operations.

Health Care Industry
The health care industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, quality of resident care and Medicare and Medicaid fraud and abuse. Over the last several years, government activity has increased with respect to investigations and allegations concerning possible violations by health care providers of fraud and abuse laws and regulations as well as laws and regulations governing quality of care issues in the skilled nursing profession in general. Violations of these laws and regulations could result in exclusion from government health care programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Compliance with such laws and regulations is subject to ongoing government review and interpretation, as well as regulatory actions in which government agencies seek to impose fines and penalties. From time to time, the Company, like others in the healthcare industry, may be involved in regulatory actions of this type.
In March 2010, significant legislation concerning health care and health insurance was passed, including the “Patient Protection and Affordable Care Act,” (“Affordable Care Act”) along with the “Health Care and Education Reconciliation Act of 2010” (“Reconciliation Act”) collectively defined as the “Legislation.” The impact of this Legislation remains uncertain to a large degree due to various implementation, timing, cost and regulatory requirements imposed by the Legislation. While much remains uncertain, we expect this Legislation to impact our Company, our employees and our patients and residents in a variety of ways. This Legislation significantly changes the future responsibility of employers with respect to providing health care coverage to employees in the United States. Two of the main provisions of the Legislation became effective in 2014 whereby most individuals are required to either have health insurance or pay a fine and employers with 50 or more employees either have to provide minimum essential coverage or will be subject to additional taxes. On July 2, 2013, the United States Treasury Department announced that it will delay the employer reporting mandate, which was to be effective for 2014, until 2015 to allow additional time for process improvement and system integration. We have not estimated the financial impact of the Legislation and the costs associated with complying with the increased levels of health insurance we will be required to provide our employees and their dependents in future years. We expect the Legislation will result in increased operating expenses.
We also expect for this Legislation to continue to impact our Medicaid and Medicare reimbursement as well, though the exact timing and level of that impact is currently unknown. For example, the Legislation expands the role of home-based and community services, which may place downward pressure on our ability to maintain our population of Medicaid residents. Additional provisions under the Legislation for skilled nursing facilities participating in Medicaid and/or Medicare, including but not limited to, new transparency, reporting, and certification requirements, will likely lead to an increase in the Company's administrative and other costs.
The provisions of the Affordable Care Act discussed above are only examples of federal health reform provisions that we believe may have a material impact on the long-term care industry and on our business. We anticipate that many of the changes and reforms resulting from the Legislation, as well as other similar health care reforms, may be subject to further clarification and modification through promulgation of regulations, executive orders, and judicial review and could have a material adverse impact on our business, financial condition, and results of operations.
Medicare and Medicaid Reimbursement
A significant portion of our revenues are derived from government-sponsored health insurance programs. Our nursing centers derive revenues under Medicaid, Medicare, Managed Care, Private Pay and other third party sources. We employ third-party specialists in reimbursement and also use these services to monitor regulatory developments and other changes to applicable

21


coverage criteria to comply with reporting requirements and to ensure that proper payments are made to our operated nursing centers. It is generally recognized that all government-funded programs have been and will continue to be under cost containment pressures, but the extent to which these pressures will affect our future reimbursement is unknown.
Medicare
Effective October 1, 2011, Medicare rates were reduced by a nationwide average of 11.1%, the net effect of a reduction to restore overall payments to their intended levels on a prospective basis and the application of a 2.7% market basket increase and a negative 1.0% productivity adjustment required by the Affordable Care Act. The final Centers for Medicare and Medicaid Services (“CMS”) rule also adjusts the method by which group therapy is counted for reimbursement purposes and, for patients receiving therapy, changes the timing of reassessment for purposes of determining patient RUG categories. These October 2011 Medicare reimbursement changes decreased our Medicare revenue and our Medicare rate per patient day. The new regulations also resulted in an increase in costs to provide therapy services to our patients.
The Budget Control Act of 2011 (“BCA”), enacted on August 2, 2011, increased the United States debt ceiling and linked the debt ceiling increase to corresponding deficit reductions through 2021. The BCA also established a 12 member joint committee of Congress known as the Joint Select Committee on Deficit Reduction (“Super Committee”). The Super Committee’s objective was to create proposed legislation to reduce the United States federal budget deficit by $1.5 trillion for fiscal years 2012 through 2021. Part of the BCA required this legislation to be enacted by December 23, 2011, or approximately $1.2 trillion in spending reductions would automatically begin through sequestration on January 1, 2013, split between domestic and defense spending. As no legislation was passed that would achieve the targeted savings outlined in the BCA, payments to Medicare providers have been reduced by 2% from planned levels effective April 1, 2013. In April 2015, congressional committees began deliberations on proposed legislation that would extend sequestration and increase the amount cut by $700 million. If the bill were to become law, it would result in a net effect of increasing the sequester in 2024 beyond the 2% in the BCA.
In July 2015, CMS issued Medicare payment rates, effective October 1, 2015, that are expected to increase reimbursement to our skilled nursing centers by approximately 1.2% compared to the fiscal year ending September 30, 2014. The increase is the net effect of a 2.3% inflation increase as measured by the SNF market basket, offset by a 0.6% market basket update factor. The wage index budget neutrality factor resulted in an additional 0.2% downward adjustment in rates for the Company's facilities. This adjustment is further offset by the ongoing sequestration from the BCA as mentioned above. The 2% sequestration is not applied to the payment rate, but rather it is applied to Medicare claims after determining coinsurance, any applicable deductibles, and any applicable Medicare secondary payment adjustments.
Therapy Services. There are annual Medicare Part B reimbursement limits on therapy services that can be provided to an individual. The limits impose a $1,940 per patient annual ceiling on physical and speech therapy services, and a separate $1,940 per patient annual ceiling on occupational therapy services. CMS established an exception process to permit therapy services in certain situations and we provide services that are reimbursed under the exceptions process. The exceptions process has been extended several times, most recently in April 2015 by the Medicare Access and CHIP Reauthorization Act, which extended this exception process through December 31, 2017. This allows Part B providers to continue delivering therapy services above the current $1,940 threshold for therapy services, provided the services were medically necessary. In addition, the legislation replaced the mandatory medical manual review of therapy claims exceeding the cap with a review process targeting providers with high denial rates and outlier billing patterns, new providers and certain medical conditions within group practices.
Related to the exceptions process discussed above, for services provided with dates of service, providers are required to submit a request for an exception for therapy services above the threshold of $3,700 which will then be manually medically reviewed, consistent with the treatment of these services historically. Similar to the therapy cap exceptions process, the threshold process will have a $3,700 per patient threshold on physical and speech therapy services, and a separate $3,700 per patient threshold on occupational therapy services. The exception reviews were conducted by Medicare Administrative Contractors during this period.
On November 2, 2010, CMS released a final proposed rule as part of the Medicare Physician Fee Schedule (“MPFS”) that was effective January 1, 2011. The policy impacts the reimbursement we receive for Medicare Part B therapy services in our facilities. The policy provides that Medicare Part B pay the full rate for the therapy unit of service that has the highest Practice Expense ("PE") component for each patient on each day they receive multiple therapy treatments. Reimbursement for the second and subsequent therapy units for each patient each day they receive multiple therapy treatments is reimbursed at a rate equal to 75% of the applicable PE component through March 31, 2013. Effective April 1, 2013, the rate at which these services are reimbursed was reduced to 50% of the applicable PE component.
Medicare Part B therapy services in our centers are determined according to MPFS. Annually since 1997, the MPFS has been subject to a Sustainable Growth Rate Adjustment (“SGR”) intended to keep spending growth in line with allowable spending. Each year since the SGR was enacted, this adjustment produced a scheduled negative update to payment for physicians, therapists and other healthcare providers paid under the MPFS. In April 2015, as part of the Medicare Access and CHIP Reauthorization

22


Act, Congress passed and the President signed into law the "permanent SGR fix" or "doc fix." Under this legislation, the Medicare formula for establishing physician payment rates was permanently replaced. The permanent fix is expected to remove a substantial annual risk of future payment reductions.
The Medicare Access and CHIP Reauthorization Act also extended several other elements of the Middle Class Tax Relief and Job Creation Act of 2012, including the reduction of bad debt treated as an allowable cost. Prior to this act, Medicare reimbursed providers for beneficiaries’ unpaid coinsurance and deductible amounts after reasonable collection efforts at a rate between 70 and 100 percent of beneficiary bad debt. This provision reduced bad debt reimbursement exposure for all providers to 65 percent. In addition to the provisions above, the legislation sets that for fiscal year 2018 (October 1, 2017 through September 30, 2018), all Medicare Part B providers will receive inflationary market basket increases no greater than 1%. This provision is expected to reduce Medicare payments to all post-acute providers by approximately $15.4 billion over the 2018-2025 period.
Medicaid
Several states in which we operate face budget shortfalls, which could result in reductions in Medicaid funding for nursing centers. The federal government made an effort to address the financial challenges state Medicaid programs are facing by increasing the amount of Medicaid funding available to states. Pressures on state budgets are expected to continue in the future and are expected to result in Medicaid rate reductions.
We receive the majority of our annual Medicaid rate increases during the third quarter of each year. The rate changes received in the third quarter of 2014, along with increased Medicaid acuity in our acuity based states, was the primary contributor to our 4.2% increase in average rate per day for Medicaid patients in 2015 compared to 2014. Based on the rate changes received during the third quarter of 2014, we have experienced a favorable impact to our rate per day for Medicaid patients due to modest rate increases in many of the states within which we operate.
Effective February 1, 2015, the Company began participating in the Upper Payment Limit ("UPL") supplemental payment program in the state of Indiana that provides supplemental Medicaid payments for skilled nursing facilities that are licensed to non-state government entities such as county hospital districts. One skilled nursing facility previously operated by the Company entered into a transaction with one such hospital providing for the transfer of the license from the Company to the hospital district, and providing further for the Company's operating subsidiaries to retain the management of the facility on behalf of the hospital district, which is participating in the UPL program. The affected operating subsidiary therefore retains operations of its skill nursing facility and the agreement between the hospital district and the Company is terminable by either party to fully restore the prior license status.
We are unable to predict what, if any, reform proposals or reimbursement limitations will be implemented in the future, or the effect such changes would have on our operations. For the nine months ended September 30, 2015, we derived 29.3% and 48.3% of our total patient revenues related to continuing operations from the Medicare and Medicaid programs, respectively. Any health care reforms that significantly limit rates of reimbursement under these programs could, therefore, have a material adverse effect on our profitability.
We will attempt to increase revenues from non-governmental sources to the extent capital is available to do so. However, private payors, including Managed Care payors, are increasingly demanding that providers accept discounted fees or assume all or a portion of the financial risk for the delivery of health care services. Such measures may include capitated payments, which can result in significant losses to health care providers if patients require expensive treatment not adequately covered by the capitated rate.
Licensure and Other Health Care Laws
All of our nursing centers must be licensed by the state in which they are located in order to accept patients, regardless of payor source. In most states, nursing centers are subject to certificate of need laws, which require us to obtain government approval for the construction of new nursing centers or the addition of new licensed beds to existing centers. Our nursing centers must comply with detailed statutory and regulatory requirements on an ongoing basis in order to qualify for licensure, as well as for certification as a provider eligible to receive payments from the Medicare and Medicaid programs. Generally, the requirements for licensure and Medicare/Medicaid certification are similar and relate to quality and adequacy of personnel, quality of medical care, record keeping, dietary services, patient rights, and the physical condition of the center and the adequacy of the equipment used therein. Each center is subject to periodic inspections, known as “surveys” by health care regulators, to determine compliance with all applicable licensure and certification standards. Such requirements are both subjective and subject to change. If the survey concludes that there are deficiencies in compliance, the center is subject to various sanctions, including, but not limited to, monetary fines and penalties, suspension of new admissions, non-payment for new admissions and loss of licensure or certification. Generally, however, once a center receives written notice of any compliance deficiencies, it may submit a written plan of correction and is given a reasonable opportunity to correct the deficiencies. There can be no assurance that, in the future, we will be able to maintain

23


such licenses and certifications for our facilities or that we will not be required to expend significant sums in order to comply with regulatory requirements.

Contractual Obligations and Commercial Commitments
We have certain contractual obligations of continuing operations as of September 30, 2015, summarized by the period in which payment is due, as follows (dollar amounts in thousands):
Contractual Obligations
Total
 
Less than
1  year
 
1 to 3
Years
 
3 to 5
Years
 
After
5 Years
Long-term debt obligations (1)
$
64,182

 
$
17,782

 
$
46,398

 
$
2

 
$
—

Settlement obligations (2)
4,807

 
4,807

 
—

 
—

 
—

Elimination of Preferred Stock Conversion feature (3)
2,061

 
687

 
1,374

 
—

 
—

Operating leases (4)
579,235

 
32,067

 
65,103

 
67,698

 
414,367

Required capital expenditures under operating leases (5)
3,362

 
219

 
438

 
438

 
2,267

Total
$
653,647

 
$
55,562

 
$
113,313

 
$
68,138

 
$
416,634

 
(1)
Long-term debt obligations include scheduled future payments of principal and interest of long-term debt and amounts outstanding on our capital lease obligations.
(2)
Settlement obligations relate to professional liability cases that are expected to be paid within the next twelve months. The professional liabilities are included in our current portion of self-insurance reserves.
(3)
Payments to Omega Health Investors ("Omega"), from which we lease 23 nursing centers, for the elimination of the preferred stock conversion feature in connection with restructuring the preferred stock and master lease agreements. Monthly payments of approximately $57,000 will be made through the end of the initial lease period that ends in September 2018.
(4)
Represents lease payments under our operating lease agreements. Assumes all renewal periods are enacted.
(5)
Includes annual expenditure requirements under operating leases.
We have employment agreements with certain members of management that provide for the payment to these members of amounts up to two times their annual salary in the event of a termination without cause, a constructive discharge (as defined therein), or upon a change of control of the Company (as defined therein). The maximum contingent liability under these agreements is approximately $1,767,000 as of September 30, 2015. The terms of such agreements are for one year and automatically renew for one year if not terminated by us or the employee. In addition, upon the occurrence of any triggering event, those certain members of management may elect to require that we purchase equity awards granted to them for a purchase price equal to the difference in the fair market value of our common stock at the date of termination versus the stated equity award exercise price. Based on the closing price of our common stock on September 30, 2015, the potential contingent liability for the repurchase of the equity grants is $429,000.

Results of Operations
The results of operations presented have been reclassified to present the effects of certain divestitures discussed in the overview to "Management's Discussion and Analysis of Financial Condition and Results of Operations."
The following tables present the unaudited interim statements of operations and related data for the three and nine month periods ended September 30, 2015 and 2014:
 

24


(in thousands)
Three Months Ended
September 30,
 
2015
 
2014
 
Change
 
%
PATIENT REVENUES, net
$
98,105

 
$
90,331

 
$
7,774

 
8.6
 %
EXPENSES:
 
 
 
 
 
 
 
Operating
78,501

 
73,006

 
5,495

 
7.5
 %
Lease and rent expense
7,198

 
6,876

 
322

 
4.7
 %
Professional liability
2,069

 
1,743

 
326

 
18.7
 %
General and administrative
6,378

 
5,582

 
796

 
14.3
 %
Depreciation and amortization
1,887

 
1,812

 
75

 
4.1
 %
Total expenses
96,033

 
89,019

 
7,014

 
7.9
 %
OPERATING INCOME
2,072

 
1,312

 
760

 
57.9
 %
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Equity in net income (loss) of unconsolidated affiliate
97

 
(30
)
 
127

 
423.3
 %
Interest expense, net
(998
)
 
(916
)
 
(82
)
 
(9.0
)%
 
(901
)
 
(946
)
 
45

 
4.8
 %
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
1,171

 
366

 
805

 
219.9
 %
PROVISION FOR INCOME TAXES
(502
)
 
(147
)
 
(355
)
 
(241.5
)%
INCOME FROM CONTINUING OPERATIONS
$
669

 
$
219

 
$
450

 
205.5
 %
 
(in thousands)
Nine Months Ended
September 30,
 
2015
 
2014
 
Change
 
%
PATIENT REVENUES, net
$
289,618

 
$
250,443

 
39,175

 
15.6
 %
EXPENSES:
 
 
 
 
 
 
 
Operating
232,298

 
200,517

 
31,781

 
15.8
 %
Lease and rent expense
21,529

 
19,094

 
2,435

 
12.8
 %
Professional liability
6,150

 
5,360

 
790

 
14.7
 %
General and administrative
18,770

 
16,077

 
2,693

 
16.8
 %
Depreciation and amortization
5,629

 
5,252

 
377

 
7.2
 %
Total expenses
284,376

 
246,300

 
38,076

 
15.5
 %
OPERATING INCOME
5,242

 
4,143

 
1,099

 
26.5
 %
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Equity in net income (loss) of unconsolidated affiliate
280

 
(89
)
 
369

 
414.6
 %
Interest expense, net
(2,997
)
 
(2,757
)
 
(240
)
 
(8.7
)%
 
(2,717
)
 
(2,846
)
 
129

 
4.5
 %
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
2,525

 
1,297

 
1,228

 
94.7
 %
PROVISION FOR INCOME TAXES
(1,044
)
 
(538
)
 
(506
)
 
(94.1
)%
INCOME FROM CONTINUING OPERATIONS
$
1,481

 
$
759

 
$
722

 
95.1
 %


25


Percentage of Net Revenues
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2015
 
2014
 
2015
 
2014
PATIENT REVENUES, net
100.0
%
 
100.0
%
 
100.0
 %
 
100.0
 %
EXPENSES:
 
 
 
 
 
 
 
Operating
80.0

 
80.8

 
80.2

 
80.1

Lease and rent expense
7.3

 
7.6

 
7.4

 
7.6

Professional liability
2.1

 
1.9

 
2.1

 
2.1

General and administrative
6.5

 
6.2

 
6.5

 
6.4

Depreciation and amortization
1.9

 
2.0

 
1.9

 
2.1

Total expenses
97.8

 
98.5

 
98.1

 
98.3

OPERATING INCOME (LOSS)
2.2

 
1.5

 
1.9

 
1.7

OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Equity in net losses of unconsolidated affiliate
0.1

 
—

 
0.1

 
—

Interest expense, net
(1.0
)
 
(1.0
)
 
(1.0
)
 
(1.1
)
 
(0.9
)
 
(1.0
)
 
(0.9
)
 
(1.1
)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
1.3

 
0.5

 
1.0

 
0.6

PROVISION FOR INCOME TAXES
(0.5
)
 
(0.2
)
 
(0.4
)
 
(0.2
)
INCOME FROM CONTINUING OPERATIONS
0.8
%
 
0.3
%
 
0.6
 %
 
0.4
 %

26


Three Months Ended September 30, 2015 Compared With Three Months Ended September 30, 2014
Patient Revenues
Patient revenues were $98.1 million and $90.3 million for the three months ended September 30, 2015 and 2014, respectively, an increase of $7.8 million. This increase is primarily attributable to the acquisition of new facilities. The following table summarizes the revenue increases attributable to our portfolio growth (in thousands):
 
Three Months Ended
September 30,
 
2015
 
2014
 
Change
Same-store revenue
$
83,385

 
$
80,302

 
$
3,083

2014 acquisition revenue
11,922

 
10,029

 
1,893

2015 acquisition revenue
2,798

 
—

 
2,798

Total revenue
$
98,105

 
$
90,331

 
$
7,774

The overall increase in revenue of $7.8 million is driven by incremental revenue contributions from acquisition activity in 2014 of $1.9 million, as well as the contribution from the newly acquired nursing centers in Glasgow, Kentucky and Hutchinson, Kansas. These two nursing centers acquired in 2015 contributed $2.8 million in revenues during the third quarter.
The same-store revenues increased by $3.1 million in 2015 compared to the same period in 2014, primarily driven by favorable rates. The average Medicaid rate per patient day at same-store nursing centers for 2015 increased 3.8% compared to 2014, resulting in an increase in revenue of $1.5 million. This average rate per day for Medicaid patients is the result of rate increases in certain states and increasing patient acuity levels. The average Medicare rate per patient day for same-store nursing centers increased 0.8% for 2015 compared to 2014, resulting in an increase in revenue of $0.2 million.
Census results for the quarter provided a mix a favorable and unfavorable variances on the same-store revenue results. Same-store Medicare census decreased 3.2% in 2015 resulting in same-store revenue decrease of $0.6 million compared to 2014. The primary favorable census variance related to Managed Care census which increased 11.3%, resulting in a revenue increase at our same-store nursing centers of $0.6 million. Medicaid census also increased at our same-store centers compared to 2014 resulting in a revenue increase of $0.7 million.
Two other contributing factors affected our same-store revenue for the third quarter of 2015 compared to the same period in 2014. The first is an increase in Ancillary Services revenue of $0.2 million. The second factor is the Company's participation in the UPL supplemental payment program in the state of Indiana that provides supplemental Medicaid payments for skilled nursing facilities that are licensed to non-state government entities such as county hospital districts. Participation in the UPL program produced an additional $0.3 million in revenue during the quarter.
The following table summarizes key revenue and census statistics for continuing operations for each period:
 
 
Three Months Ended
September 30,
 
 
 
2015
 
 
 
2014
 
 
Skilled nursing occupancy
77.5
%
 

 
77.2
%
 

As a percent of total census:
 
 
 
 
 
 
 
Medicare census
11.9
%
 
 
 
12.3
%
 
 
Managed Care census
3.7
%
 
 
 
3.4
%
 
 
As a percent of total revenues:
 
 
 
 
 
 
 
Medicare revenues
27.9
%
 
 
 
29.2
%
 
 
Medicaid revenues
49.9
%
 
 
 
48.6
%
 
 
Managed Care revenues
6.9
%
 
 
 
6.6
%
 
 
Average rate per day:
 
 
 
 
 
 
 
Medicare
$
452.48

 
  
 
$
446.75

 
 
Medicaid
$
168.12

 
  
 
$
161.45

 
 
Managed Care
$
382.52

 
  
 
$
384.45

 
 
Operating Expense

27


Operating expense increased in the third quarter of 2015 to $78.5 million as compared to $73.0 million in the third quarter of 2014, driven by the $1.9 million increase in operating costs attributable to the nursing center operations acquired in 2014, as well as $2.4 million of operating expense associated with the nursing center operations assumed in the first quarter of 2015. The following table summarizes the expense increases attributable to our portfolio growth (in thousands):
 
Three Months Ended
September 30,
 
2015
 
2014
 
Change
Same-store operating expense
$
66,173

 
$
65,019

 
$
1,154

2014 acquisition expense
9,908

 
7,987

 
1,921

2015 acquisition expense
2,420

 
—

 
2,420

Total expense
$
78,501

 
$
73,006

 
$
5,495

Operating expense decreased slightly as a percentage of revenue at 80.0% for the third quarter of 2015 as compared to 80.8% for the third quarter of 2014. The largest component of operating expenses is wages. Considering the aforementioned addition of the new centers, we experienced an increase to $45.4 million in the third quarter of 2015 as compared to $42.9 million in the third quarter of 2014, an increase of $2.5 million, or 5.9%. While wages increased overall, as a percentage of revenue wages decreased in the third quarter of 2015 to 46.3% as compared to 47.5% in the third quarter of 2014, a decrease of 1.2%.
While the majority of the $5.5 million increase in operating expenses is attributable to the $1.9 million of incremental operating expenses from 2014 acquisitions and $2.4 million from 2015 acquisitions, the same-store nursing centers also experienced an increase of $1.2 million in the third quarter of 2015 as compared to the third quarter of 2014. The increase in operating expenses for our same-store nursing centers is primarily driven by a $0.5 million increase in bad debt and bad debt crossover expense year over year. Additionally, we experienced a slight increase of $0.1 million in health insurance expense and $0.1 million in provider taxes in the third quarter of 2015 compared to the third quarter of 2014.
Lease Expense
Lease expense increased in the third quarter of 2015 to $7.2 million as compared to $6.9 million in the third quarter of 2014. The increase in lease expense was primarily attributable to $0.2 million in incremental lease expense for the eight newly leased nursing centers in 2014, as well as, $0.1 million related to the Hutchinson center acquired in 2015.
Professional Liability
Professional liability expense was $2.1 million in the third quarter of 2015 compared to $1.7 million in the third quarter of 2014, an increase of $0.4 million. We were engaged in 50 professional liability lawsuits as of September 30, 2015, compared to 48 as of September 30, 2014. Our quarterly cash expenditures for professional liability costs of continuing operations were $1.7 million and $1.4 million for 2015 and 2014, respectively. Professional liability expense and cash expenditures fluctuate from year to year based respectively on the results of our third-party professional liability actuarial studies and on the costs incurred in defending and settling existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.

General and Administrative Expense
General and administrative expense was $6.4 million in the third quarter of 2015 as compared to $5.6 million in the third quarter of 2014, an increase of $0.8 million, and increased slightly as a percentage of revenue from 6.2% in 2014 to 6.5% in 2015. The increase in general and administrative expense is primarily attributable to an increase in salaries of $0.5 million in the third quarter of 2015 compared to the third quarter of 2014.
Depreciation and Amortization
Depreciation and amortization expense was approximately $1.9 million in the third quarter of 2015 as compared to $1.8 million in 2014. The increase in depreciation expense relates to fixed assets at the newly leased and acquired centers.
Interest Expense, Net
Interest expense was $1.0 million in the third quarter of 2015 and $0.9 million in the third quarter of 2014, an increase of $0.1 million. The increase was primarily attributable to higher debt balances in 2015 as a result of higher outstanding borrowings on the revolving credit facility as a result of the increase in centers undergoing the change in ownership process, as well as the addition of the Glasgow term loan during the first quarter of 2015.

28


Income from Continuing Operations before Income Taxes; Income from Continuing Operations per Common Share
As a result of the above, continuing operations reported $1.2 million income before income taxes for the third quarter of 2015 as compared to a income of $0.4 million for the third quarter of 2014. The tax provision for income taxes was $0.5 million for 2015 as compared to a tax provision of $0.1 million in the third quarter of 2014. The basic and diluted income per common share from continuing operations were both $0.11 for the third quarter of 2015 as compared to both basic and diluted income per common share from continuing operations of $0.03 in the third quarter of 2014.

Nine Months Ended September 30, 2015 Compared With Nine Months Ended September 30, 2014
Patient Revenues
Patient revenues were $289.6 million for the nine months ended September 30, 2015, as compared to $250.4 million in the nine months ended September 30, 2014. This increase is primarily attributable to the acquisition of new facilities during the period. The following table summarizes the revenue increases attributable to our portfolio growth (in thousands):
 
Nine Months Ended
September 30,
 
2015
 
2014
 
Change
Same-store revenue
$
246,696

 
$
236,189

 
$
10,507

2014 acquisition revenue
35,309

 
14,254

 
21,055

2015 acquisition revenue
7,613

 
—

 
7,613

Total revenue
$
289,618

 
$
250,443

 
$
39,175

The overall increase in revenue of $39.2 million is primarily attributable to increased revenue contributions from acquisition activity in 2014 of $21.1 million, as well as the $7.6 million contribution from the two new nursing centers added in 2015.
The same-store revenues increased by $10.5 million in the nine months ended September 30, 2015 compared to the same period in 2014 primarily attributable to improved rates. The largest driver for the increase in same-store revenues is the increase in Medicaid rates which increased 4.8% resulting in a $5.5 million increase in revenues for the nine months ended September 30, 2015, as compared to the same period in 2014. Medicare rates also increased by 2.4% resulting in a $1.5 million increase in revenues in 2015 as compared to 2014. Additionally, Managed Care rates increased 1.9% resulting in a revenue increase at our same-store nursing centers of $0.3 million.
In addition to the effects of favorable rates, same-store Managed care census increased 14.6% compared to the same period in 2014, resulting in an increase in revenue of $2.2 million. Both Medicare and Medicaid census also decreased slightly in 2015 resulting in decreased revenue of $(0.6) million and $(1.0) million, respectively.
Two other contributing factors affected our same-store revenue for 2015 compared to the same period in 2014. The first is an increase in Ancillary Services revenue of $1.8 million for the nine months ended September 30, 2015, as compared to the same period in 2014. The second factor is the Company's participation in the UPL supplemental payment program in the state of Indiana that provides supplemental Medicaid payments for skilled nursing facilities that are licensed to non-state government entities such as county hospital districts. Participation in the UPL program produced an additional $0.8 million in revenue in 2015.
The following table summarizes key revenue and census statistics for continuing operations for each period:

29


 
 
Nine Months Ended
September 30,
 
 
2015
 
 
 
2014
 
Skilled nursing occupancy
77.1
%
 
 
 
77.7
%
 
As a percent of total census:
 
 
 
 
 
 
Medicare census
12.6
%
 
 
 
12.9
%
 
Managed Care census
3.8
%
 
 
 
3.5
%
 
As a percent of total revenues:
 
 
 
 
 
 
Medicare revenues
29.3
%
 
 
 
29.7
%
 
Medicaid revenues
48.3
%
 
 
 
48.5
%
 
Managed Care revenues
7.0
%
 
 
 
6.6
%
 
Average rate per day:
 
 
 
 
 
 
Medicare
$
454.59

 
  
 
$
441.05

 
Medicaid
$
165.97

 
  
 
$
159.33

 
Managed Care
$
386.63

 
  
 
$
380.35

 
Operating Expense
Operating expense increased in 2015 to $232.3 million as compared to $200.5 million in 2014, driven primarily by the $18.2 million increase in operating costs attributable to the nursing center operations acquired in 2014, as well as $6.4 million of operating expense associated with the nursing center operations assumed in 2015. The following table summarizes the expense increases attributable to our portfolio growth (in thousands):
 
Nine Months Ended
September 30,
 
2015
 
2014
 
Change
Same-store operating expense
$
196,817

 
$
189,568

 
$
7,249

2014 acquisitions operating expense
29,122

 
10,949

 
18,173

2015 acquisitions operating expense
6,359

 
—

 
6,359

Total operating expense
232,298

 
200,517

 
$
31,781

Operating expense increased as a percentage of revenue at 80.2% for 2015 as compared to 80.1% for 2014. The largest component of operating expenses is wages. Considering the aforementioned addition of the new centers, we experienced an increase to $134.5 million in 2015 as compared to $116.9 million in 2014, an increase of $17.6 million, or 15.1%. While wages increased overall, wages decreased slightly as a percentage of revenue in 2015 to 46.5% as compared to 46.7% in 2014, a decrease of 0.2%. The increase in operating expenses for our same-store nursing centers other than wages is primarily driven by a $1.0 million increase in bad debt and bad debt crossover expense and along with nursing and ancillary costs of $0.6 million year over year.
Lease Expense
Lease expense increased in 2015 to $21.5 million as compared to $19.1 million in 2014, an increase of $2.4 million. The increase in lease expense was primarily attributable to $2.3 million in combined lease expense for the newly leased nursing centers in 2014.
Professional Liability
Professional liability expense was $6.2 million in 2015 compared to $5.4 million in 2014, a increase of $0.8 million. We were engaged in 50 professional liability lawsuits as of September 30, 2015, compared to 48 as of September 30, 2014. Our cash expenditures for professional liability costs of continuing operations were $3.3 million and $3.6 million for 2015 and 2014, respectively. Professional liability expense and cash expenditures fluctuate from year to year based respectively on the results of our third-party professional liability actuarial studies and on the costs incurred in defending and settling existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.

General and Administrative Expense
General and administrative expense was $18.8 million in 2015 as compared to $16.1 million in 2014, an increase of $2.7 million, and increased slightly as a percentage of revenue from 6.4% in 2014 to 6.5% in 2015. The increase in general and administrative expense is primarily attributable to an increase in salaries of $1.5 million and an increase in share-based compensation expense

30


of $0.8 million. Additionally, the Company's participation in the UPL program at Providence resulted in $0.3 million of general and administrative expense in 2015.
Depreciation and Amortization
Depreciation and amortization expense was $5.6 million in 2015 as compared to $5.3 million in 2014. The increase in depreciation expense relates to fixed assets at the newly leased and acquired centers.
Interest Expense, Net
Interest expense was $3.0 million in 2015 and $2.8 million in 2014, an increase of $0.2 million. The increase was primarily attributable to higher debt balances in 2015 as a result of higher outstanding borrowings on the revolving credit facility as a result of the increase in centers undergoing the change in ownership process, as well as the addition of the Glasgow term loan during the first quarter of 2015.
Income from Continuing Operations before Income Taxes; Income from Continuing Operations per Common Share
As a result of the above, continuing operations reported income before income taxes of $2.5 million for the nine months ended September 30, 2015, as compared to a income of $1.3 million for the same period in 2014. The provision for income taxes was $1.0 million for the nine months ended September 30, 2015, as compared to a provision of $0.5 million for the nine months ended September 30, 2014. The basic and diluted income per common share from continuing operations were both $0.24 for the nine months ended September 30, 2015, as compared to both basic and diluted income per common share from continuing operations of $0.09 for the same period in 2014.

Liquidity and Capital Resources
Liquidity
Our primary source of liquidity is the net cash flow provided by the operating activities of our centers. We believe that these internally generated cash flows will be adequate to service existing debt obligations, fund required capital expenditures as well as provide cash flows for investing opportunities. In determining priorities for our cash flow, we evaluate alternatives available to us and select the ones that we believe will most benefit us over the long-term. Options for our cash include, but are not limited to, capital improvements, dividends, purchase of additional shares of our common stock, acquisitions, payment of existing debt obligations, preferred stock redemptions as well as initiatives to improve nursing center performance. We review these potential uses and align them to our cash flows with a goal of achieving long-term success.
Net cash provided by operating activities of continuing operations totaled $6.7 million in the nine months ended September 30, 2015, compared to $0.7 million in the same period of 2014.
Our cash expenditures related to professional liability claims of continuing operations were $3.3 million and $3.6 million for nine months ended September 30, 2015 and 2014, respectively. Although we work diligently to limit the cash required to settle and defend professional liability claims, a significant judgment entered against us in one or more legal actions could have a material adverse impact on our cash flows and could result in our being unable to meet all of our cash needs as they become due.
Investing activities of continuing operations used cash of $8.1 million and provided cash of $12.2 million in 2015 and 2014, respectively. The use of cash in 2015 is primarily attributable to the $7.0 million of assets purchased in the Glasgow transaction. The cash provided in 2014 was the net result of $16.5 million provided by the sale of the West Virginia operations and $4.2 million used to purchase other property and equipment.
Financing activities of continuing operations provided cash of $6.2 million in 2015 as compared to cash used of $6.2 million in 2014 primarily due to draws on the Company's revolving credit facility and the new debt associated with the Company's purchase of the Glasgow nursing center in 2015. The draws on the revolving credit facility are primarily related to funding the CHOW process for newly acquired and leased nursing centers.

Dividends
On November 4, 2015, the Board of Directors declared a quarterly dividend of $0.055 per common share payable to shareholders of record as of December 31, 2015, to be paid on January 15, 2016. While the Board of Directors intends to pay quarterly dividends, the Board will make the determination of the amount of future cash dividends, if any, to be declared and paid based on, among other things, the Company’s financial condition, funds from operations, the level of its capital expenditures and its future business prospects and opportunities.

31


Redeemable Preferred Stock
Effective August 14, 2014, the Company redeemed all of its outstanding shares of Series C Preferred Stock (“Preferred Stock”) from the holder, Omega. The redemption was affected as a result of Omega’s exercise of its pre-existing option to require the Company to redeem the Preferred Stock as provided in the Company’s Certificate of Designation. Following the redemption, the Company no longer has any Series C Preferred Stock outstanding.
Professional Liability
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. On a per claim basis, coverage for losses in excess of those covered by SHC are maintained through unaffiliated commercial reinsurance carriers. All of the Company's nursing centers in Florida and Tennessee, as well as the Company’s formerly operated Arkansas and West Virginia facilities, are now covered under the captive insurance policies along with most of the nursing centers in Alabama, Kentucky, Ohio, and Texas. The insurance coverage provided for these centers under the SHC policy include coverage limits of $0.5 million per medical incident with a sublimit per center of $1.0 million and total annual aggregate policy limits of $5.0 million. All other centers within the Company’s portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. 
As of September 30, 2015, we have recorded total liabilities for reported and settled professional liability claims and estimates for incurred, but unreported claims of $23.2 million. Our calculation of this estimated liability is based on an assumption that the Company will not incur a severely adverse judgment with respect to any asserted claim; however, a significant judgment could be entered against us in one or more of these legal actions, and such a judgment could have a material adverse impact on our financial position and cash flows.
Capital Resources
As of September 30, 2015, we had $56.2 million of outstanding long-term debt and capital lease obligations. The $56.2 million total includes $0.5 million in capital lease obligations, $8.0 million currently outstanding on the revolving credit facility, and $5.0 million in a note payable for the asset purchase of the Glasgow nursing center in Kentucky. The balance of the long-term debt is comprised of $42.7 million owed on our mortgage loan.
On May 1, 2013, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated February 28, 2011. The Credit Agreement increases the Company's borrowing capacity to $65.0 million allocated between a $45.0 million Mortgage Loan ("Amended Mortgage Loan") and a $20.0 million Revolver ("Amended Revolver"). Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $1.3 million and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of $45.0 million with a five-year maturity through April 30, 2018, and a $20.0 million Amended Revolver through April 30, 2018. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest is based on LIBOR plus 4.5%, which was 4.70% at September 30, 2015, but a portion of the outstanding principal balance under the Amended Mortgage Loan is effectively fixed at 6.87% as a result of the interest rate swap described below. The Amended Mortgage Loan is secured by thirteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.5%.
Effective March 31, 2014, the Company entered into the Second Amendment to the Amended and Restated Revolver ("Second Amendment"). The Second Amendment temporarily increased the Amended Revolver capacity from the $20.0 million in the original Amended Revolver to $27.5 million through September 30, 2014, as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process. Effective July 1, 2014, the Company entered into the Third Amendment to the Amended and Restated Revolver ("Third Amendment"). The Third Amendment makes the previously temporary increase to the Amended Revolver capacity from the $20.0 million in the original Amended Revolver to $27.5 million, a permanent change to the borrowing capacity as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process.
As of September 30, 2015, the Company had $8.0 million borrowings outstanding under the revolving credit facility compared to $4.5 million outstanding as of December 31, 2014. The outstanding borrowings on the revolver primarily reflect the Company's approach to accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under this Revolver are 3.0% of the amount

32


outstanding. The Company has eleven letters of credit with a total value of $8.1 million outstanding as of September 30, 2015. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $27.5 million, the balance available for borrowing under the revolving credit center is $9.0 million at September 30, 2015.
Our lending agreements contain various financial covenants, the most restrictive of which relate to minimum cash deposits, cash flow and debt service coverage ratios. We are in compliance with all such covenants at September 30, 2015.
Our calculated compliance with financial covenants is presented below:
 
 
Requirement
  
Level at
September 30, 2015
Minimum fixed charge coverage ratio
1.00:1.00
 
1.07:1.00
Minimum adjusted EBITDA
$10.0 million
 
$10.9 million
EBITDAR (mortgaged centers)
$6.15 million
 
$10.34 million
As part of the debt agreements entered into in March 2011, we entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and carries a notional equivalent to half of the outstanding principal on the Amended Mortgage Loan. The interest rate swap agreement requires us to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 6.87% while the bank is obligated to make payments to us based on LIBOR on the same notional amounts. We entered into the interest rate swap agreement to mitigate the variable interest rate risk on our outstanding mortgage borrowings.
On February 1, 2015, in conjunction with the acquisition of Diversicare of Glasgow, a 94-bed skilled nursing facility in Glasgow, Kentucky, the Company entered into the $5.0 million Glasgow term loan with The PrivateBank in order to finance the purchase of the assets. The Glasgow term loan is an interest-only loan and has an 18-month maturity dated August 1, 2016, and a variable interest rate based on LIBOR, with a minimum base rate of 4.75%.
Receivables
Our operations could be adversely affected if we experience significant delays in reimbursement from Medicare, Medicaid or other third-party revenue sources. Our future liquidity will continue to be dependent upon the relative amounts of current assets (principally cash, accounts receivable and inventories) and current liabilities (principally accounts payable and accrued expenses). In that regard, accounts receivable can have a significant impact on our liquidity. Continued efforts by governmental and third-party payors to contain or reduce the acceleration of costs by monitoring reimbursement rates, by increasing medical review of bills for services, or by negotiating reduced contract rates, as well as any delay by us in the processing of our invoices, could adversely affect our liquidity and results of operations.
Accounts receivable attributable to patient services of continuing operations totaled $52.0 million at September 30, 2015 compared to $47.5 million at December 31, 2014, representing approximately 45 days and 43 days revenue in accounts receivable, respectively. The increase in accounts receivable is due to increases in payor sources with longer payment cycles, including Managed Care payors, as well as an increase in Medicaid patients undergoing the initial qualification process.
Our accounts receivable included approximately $6.4 million and $5.5 million at September 30, 2015 and December 31, 2014, respectively of unbilled accounts, primarily attributable to newly acquired facilities.  During the change of ownership process, we were required to hold these accounts while waiting for final Medicare and Medicaid approvals.
The allowance for bad debt was $7.7 million at September 30, 2015 as compared to $6.0 million at December 31, 2014. We continually evaluate the adequacy of our bad debt reserves based on patient mix trends, aging of older balances, payment terms and delays with regard to third-party payors, collateral and deposit resources, as well as other factors. We continue to evaluate and implement additional procedures to strengthen our collection efforts and reduce the incidence of uncollectible accounts.
Off-Balance Sheet Arrangements
We have eleven letters of credit outstanding with an aggregate value of approximately $8.1 million as of September 30, 2015, the first of which serves as a security deposit for our facility lease with Omega in the amount of $4.6 million. The second letter of credit serves our initial funding of insurance policies with a captive insurance company in the amount of $1.0 million. The balance of the outstanding letters of credit relate to deposits at various leased facilities where the Company opted to issue letters of credit

33


as a deposit in lieu of cash. These letters of credit were issued under our revolving credit facility. Our accounts receivable serve as the collateral for this revolving credit facility.


34


Forward-Looking Statements
The foregoing discussion and analysis provides information deemed by management to be relevant to an assessment and understanding of our consolidated results of operations and financial condition. This discussion and analysis should be read in conjunction with our consolidated financial statements included herein. Certain statements made by or on behalf of us, including those contained in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere, are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those contemplated by the forward-looking statements made herein. In addition to any assumptions and other factors referred to specifically in connection with such statements, other factors, many of which are beyond our ability to control or predict, could cause our actual results to differ materially from the results expressed or implied in any forward-looking statements including, but not limited to, our ability to successfully operate the new nursing centers in Alabama, Kansas, Kentucky, Missouri, Ohio, and Indiana, our ability to increase census at our renovated centers, changes in governmental reimbursement, including the impact of the CMS final rule that has resulted in a reduction in Medicare reimbursement as of October 2012 and our ability to mitigate the impact of the revenue reduction, government regulation, the impact of the recently adopted federal health care reform or any future health care reform, any increases in the cost of borrowing under our credit agreements, our ability to comply with covenants contained in those credit agreements, the outcome of professional liability lawsuits and claims, our ability to control ultimate professional liability costs, the accuracy of our estimate of our anticipated professional liability expense, the impact of future licensing surveys, the outcome of proceedings alleging violations of state or Federal False Claims Acts, laws and regulations governing quality of care or other laws and regulations applicable to our business including laws governing reimbursement from government payors, impacts associated with the implementation of our electronic medical records plan, the costs of investing in our business initiatives and development, our ability to control costs, changes to our valuation of deferred tax assets, changes in occupancy rates in our centers, changing economic and competitive conditions, changes in anticipated revenue and cost growth, changes in the anticipated results of operations, the effect of changes in accounting policies as well as others. Investors also should refer to the risks identified in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as risks identified in “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2014, for a discussion of various risk factors of the Company and that are inherent in the health care industry. Given these risks and uncertainties, we can give no assurances that these forward-looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from anticipated results. These risks and uncertainties also may result in changes to the Company’s business plans and prospects. Such cautionary statements identify important factors that could cause our actual results to materially differ from those projected in forward-looking statements. In addition, we disclaim any intent or obligation to update these forward-looking statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The chief market risk factor affecting our financial condition and operating results is interest rate risk. As of September 30, 2015, we had outstanding borrowings of approximately $55.7 million, $29.3 million of which was subject to variable interest rates. In connection with our May 2013 financing agreement, we entered into an interest rate swap with respect to one half of the Amended Mortgage Loan to mitigate the floating interest rate risk of a portion of such borrowing. In the event that interest rates were to change 1%, the impact on future pre-tax cash flows would be approximately $293,000 annually, representing the impact of increased or decreased interest expense on variable rate debt.

ITEM 4. CONTROLS AND PROCEDURES
As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), our management, including our chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of September 30, 2015. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is properly recorded, processed, summarized and reported within the time periods required by the Securities and Exchange Commission’s rules and forms. Management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures that, by their nature, can provide only reasonable assurance regarding management’s control objectives. Management does not expect that its disclosure controls and procedures will prevent all errors and fraud. A control system, irrespective of how well it is designed and operated, can only provide reasonable assurance, and cannot guarantee that it will succeed in its stated objectives.
Based on an evaluation of the effectiveness of the design and operation of disclosure controls and procedures, our chief executive officer and chief financial officer concluded that, as of September 30, 2015, our disclosure controls and procedures were effective in reaching a reasonable level of assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission’s rules and forms.

35



PART II — OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
The provision of health care services entails an inherent risk of liability. Participants in the health care industry are frequently subject to lawsuits, many of which involve large claims and significant defense costs. Like many other companies engaged in the long-term care profession in the United States, we have numerous pending claims, disputes and legal actions for professional liability, negligence and other related issues. It is expected that we will continue to be subject to such suits as a result of the nature of our business. Further, as with all health care providers, we are periodically subject to state and federal regulatory investigations, proceedings, and actions related to our compliance with laws governing health care fraud, reimbursement for services provided, patient care standards, elder abuse, employment, and other issues related to the operation of our business. Like other health care providers, in the ordinary course of our business, we are also subject to claims made by employees and other disputes and litigation arising from the conduct of our business.
As of September 30, 2015, we are engaged in 50 professional liability lawsuits. Five lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The ultimate results of any of our professional liability claims and disputes cannot be predicted with certainty. A significant judgment entered against us in one or more of these legal actions could have a material adverse impact on our financial position and cash flows.
Some of the professional liability lawsuits are pending in Arkansas state courts and relate to claims arising prior to the cessation of our operations in that state on September 1, 2013. On June 4, 2015, the Supreme Court of Arkansas issued a ruling in a lawsuit against another provider that may impact the pending and any future lawsuits filed against us in Arkansas. The Arkansas Supreme Court ruled that a lawsuit against several facilities formerly operated by Golden Living could proceed as a class action. The class certified by the Court includes all residents of defendants’ facilities over a several year period, and the class is certified for a determination of whether the defendants’ facilities were chronically understaffed and, if so, whether this understaffing violated the residents’ admissions agreements and constituted a violation of the Arkansas Deceptive Trade Practices Act. According to the opinion, if plaintiffs prevail on either legal theory, then each member of the class will be entitled to a hearing to determine the amount of damages sustained as a result of the breach or violation. This decision could impact a purported class action complaint filed against the Company in 2009 that is still pending in the Circuit Court of Garland County, Arkansas, in which the plaintiff asserts similar claims against a single facility formerly operated by the Company. This lawsuit remains in its early stages and has not yet been certified by the court as a class action. The Company currently intends to defend this lawsuit and any other similar ones vigorously, but this action could be expensive to defend, and a negative outcome could have a material adverse impact on our financial position and cash flows.
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee (DOJ) had commenced a civil investigation of potential violations of the False Claims Act (FCA) at two of the Company's facilities. Notice to the Company came in the form of a civil investigative demand (CID), a form of subpoena, to produce certain documents relating to our practices and policies for rehabilitation and other services since 2010 at those two facilities. The Company responded to this limited CID and has cooperated with the DOJ in connection with its investigation. In October 2014, the Company received a second CID indicating that the DOJ’s investigation now covers all of the Company’s facilities, but only directing the Company to produce material related to a total of six of the Company's facilities. The Company also received from the OIG requests for the medical records of certain patients and has produced the requested records. The Company believes that some of the records were requested in connection with an investigation of its practices regarding the preadmission evaluation forms required by the TennCare program. The Company intends to provide additional information and to continue cooperating with the DOJ and the OIG in the investigation. The Company cannot predict the outcome of this investigation or any possible related proceedings, and the outcome could have a materially adverse effect on the Company, including the imposition of damages, fines, penalties and/or a corporate integrity agreement, but the Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.
In November 2012, a purported stockholder class action complaint was filed in the Chancery Court for Williamson County, Tennessee (21st Judicial District) against the Company's Board of Directors. This action alleges that the Board of Directors breached its fiduciary duties to stockholders related to its response to certain expressions of interest in a potential strategic transaction from Covington Investments, LLC (“Covington”). The complaint asserts that the Board failed to negotiate or otherwise appropriately consider Covington's proposals. Plaintiff has filed a motion seeking to certify the action as a class action, which is not currently set for hearing. On May 23, 2014, the plaintiff and defendants entered into a memorandum of understanding outlining the terms of a settlement subject to the execution of definitive documentation and court approval. The agreement provides that the Company will adopt and maintain certain corporate governance procedures for a period of at least three years. An Agreed Order approving this settlement was entered into on August 19, 2015, and no appeal was filed, so this matter is concluded.

36


In June 2012, a collective action complaint was filed in the U.S. District Court for the U.S. District Court for the Western District of Arkansas against us and certain of our subsidiaries.  The complaint alleges that the defendants violated the Fair Labor Standards Act (FLSA) and seeks unpaid overtime wages as well as liquidated damages.   The Court conditionally certified a nationwide class of all of the Company's hourly employees, but recently decertified the class.  After the class was decertified, the law firm initiating the action filed three new separate actions in federal courts in Arkansas, Tennessee, and Texas, naming as plaintiffs many of the individuals who had filed claims in the first Arkansas action.  The new actions assert the same claim as was asserted in the original Arkansas action.  All four actions, the original action and the three addition actions, have been settled and dismissed with prejudice, so these lawsuits are concluded.
In April 2015, the Company contested and requested a hearing on sanctions totaling approximately $900,000 imposed by CMS for alleged survey deficiencies related to an outbreak of a contagious skin ailment at one of its Kentucky centers. The Company has specifically challenged both the amount and duration of the civil monetary penalty imposed against the facility. The Company believes that the evidence presented at the hearing will show that the sanctions were inappropriate, but cannot predict with certainty the outcome of this matter.
We cannot currently predict with certainty the ultimate impact of any of the above cases on our financial condition, cash flows, or results of operations. An unfavorable outcome in any of these lawsuits, any of our professional liability actions, any regulatory action, or any investigation or lawsuit alleging violations of fraud and abuse laws of elder abuse laws, of any state or Federal False Claims Act, or of any other material laws governing the operation of our business could subject us to fines, penalties and damages, including exclusion from the Medicare or Medicaid programs, and could have a material adverse impact on our financial condition, cash flows or results of operations.

ITEM 6. EXHIBITS
The exhibits filed as part of this report on Form 10-Q are listed in the Exhibit Index immediately following the signature page.

37


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
 
Diversicare Healthcare Services, Inc.
 
 
 
November 5, 2015
 
 
 
 
 
 
 
By:
 
/s/ Kelly J. Gill
 
 
 
Kelly J. Gill
 
 
 
President and Chief Executive Officer, Principal Executive Officer and
 
 
 
An Officer Duly Authorized to Sign on Behalf of the Registrant
 
 
 
 
By:
 
/s/ James R. McKnight, Jr.
 
 
 
James R. McKnight, Jr.
 
 
 
Executive Vice President and Chief Financial Officer and
 
 
 
An Officer Duly Authorized to Sign on Behalf of the Registrant

38


 
 
 
Exhibit
Number
  
Description of Exhibits
3.1

  
Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement No. 33-76150 on Form S-1).
 
 
3.2

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.5 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2006).
 
 
3.3

  
Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement No. 33-76150 on Form S-1).
 
 
3.4

  
Bylaw Amendment adopted November 5, 2007 (incorporated by reference to Exhibit 3.4 to the Company’s annual report on Form 10-K for the year ended December 31, 2007).
 
 
3.5

  
Amendment to Certificate of Incorporation dated March 23, 1995 (incorporated by reference to Exhibit A of Exhibit 1 to the Company’s Form 8-A filed March 30, 1995).
 
 
3.6

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.4 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2001).
 
 
3.7

 
Certificate of Ownership and Merger of Diversicare Healthcare Services, Inc. with and into Advocat Inc. (incorporated by reference to Exhibit 3.1 to the Company's current report on Form 8-K filed March 14, 2013).
 
 
 
4.1

 
Form of Common Stock Certificate (incorporated by reference to Exhibit 4 to the Company's Registration Statement No. 33-76150 on Form S-1).
 
 
 
31.1

  
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
 
 
31.2

  
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
 
 
32

  
Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).
 
 
101.INS

  
XBRL Instance Document
 
 
101.SCH

  
XBRL Taxonomy Extension Schema Document
 
 
101.CAL

  
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
101.LAB

  
XBRL Taxonomy Extension Labels Linkbase Document
 
 
101.PRE

  
XBRL Taxonomy Extension Presentation Linkbase Document
 
 


39
 EX-31.1 2 dvcr-ex311x93015certificat.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(i) CERTIFICATION
I, Kelly J. Gill, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 5, 2015
 
 
/s/ Kelly J. Gill
Kelly J. Gill
Chief Executive Officer



 EX-31.2 3 dvcr-ex312x93015certificat.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(ii) CERTIFICATION
I, James Reed McKnight, Jr., certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:  November 5, 2015
 
/s/ James Reed McKnight, Jr.
James Reed McKnight, Jr.
Executive Vice President and Chief Financial Officer



 EX-32 4 dvcr-ex32x93015certificati.htm EXHIBIT 32 Exhibit


Exhibit 32
CERTIFICATION OF QUARTERLY REPORT ON FORM 10-Q
OF DIVERSICARE HEALTHCARE SERVICES, INC.
FOR THE QUARTER ENDED SEPTEMBER 30, 2015
The undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the undersigned’s best knowledge and belief, the Quarterly Report on Form 10-Q for Diversicare Healthcare Services, Inc. (the “Company”) for the period ending September 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”):
(a)
fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(b)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
This Certification is executed as of November 5, 2015.

 
 
/s/ Kelly J. Gill
Kelly J. Gill
Chief Executive Officer
 
/s/ James Reed McKnight, Jr.
James Reed McKnight, Jr.
Executive Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-101.INS 5 avca-20150930.xml XBRL INSTANCE DOCUMENT 0000919956 2015-01-01 2015-09-30 0000919956 2015-10-30 0000919956 2015-09-30 0000919956 2014-12-31 0000919956 2015-07-01 2015-09-30 0000919956 2014-07-01 2014-09-30 0000919956 2014-01-01 2014-09-30 0000919956 2013-12-31 0000919956 2014-09-30 0000919956 us-gaap:MaximumMember 2015-09-30 0000919956 us-gaap:MinimumMember 2015-09-30 0000919956 us-gaap:RevolvingCreditFacilityMember 2015-09-30 0000919956 avca:GlasgowTermLoanMember avca:ThePrivateBankMember us-gaap:LoansPayableMember 2015-02-01 0000919956 us-gaap:InterestRateSwapMember 2015-09-30 0000919956 2013-05-01 2013-05-01 0000919956 avca:GlasgowKentuckyMember 2015-02-01 0000919956 us-gaap:RevolvingCreditFacilityMember 2014-03-31 0000919956 avca:LondonInterbankOfferedRateMember 2015-09-30 0000919956 us-gaap:LoansPayableMember 2015-09-30 0000919956 avca:RevolvingCreditFacilityInterestAtFourPointFivePercentAboveLiborMember us-gaap:LetterOfCreditMember 2015-09-30 0000919956 avca:GlasgowTermLoanMember avca:ThePrivateBankMember us-gaap:LoansPayableMember 2015-02-01 2015-02-01 0000919956 avca:CreditAgreementMember 2015-01-01 2015-09-30 0000919956 avca:RevolvingCreditFacilityInterestAtFourPointFivePercentAboveLiborMember us-gaap:RevolvingCreditFacilityMember 2015-09-30 0000919956 avca:CreditAgreementMember 2013-05-01 2013-05-01 0000919956 us-gaap:RevolvingCreditFacilityMember 2013-05-01 0000919956 avca:CreditAgreementMember 2013-05-01 0000919956 avca:RevolvingCreditFacilityInterestAtFourPointFivePercentAboveLiborMember us-gaap:RevolvingCreditFacilityMember 2014-12-31 0000919956 avca:SHCRiskCarriersIncMember us-gaap:ProfessionalMalpracticeLiabilityMember 2015-01-01 2015-09-30 0000919956 avca:UnaffiliatedEntitiesMember us-gaap:ProfessionalMalpracticeLiabilityMember 2015-09-30 0000919956 avca:PrefundedDeductiblePolicyMember 2015-01-01 2015-09-30 0000919956 avca:TrialOrArbitrationScheduleTimeframeMember 2015-09-30 0000919956 us-gaap:ProfessionalMalpracticeLiabilityMember 2015-09-30 0000919956 avca:UnaffiliatedEntitiesMember us-gaap:ProfessionalMalpracticeLiabilityMember 2015-01-01 2015-09-30 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2015-09-30 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2014-12-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-09-30 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2015-01-01 2015-09-30 0000919956 avca:TwoThousandAndFiveLongTermIncentivePlanMember 2015-01-01 2015-09-30 0000919956 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2015-09-30 0000919956 us-gaap:StockAppreciationRightsSARSMember avca:TwoThousandAndTenLongTermIncentivePlanMember 2015-09-30 0000919956 avca:TwoThousandAndFiveLongTermIncentivePlanMember 2015-09-30 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-01-01 2015-09-30 0000919956 us-gaap:RestrictedStockMember 2014-01-01 2014-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2015-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2015-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2015-09-30 0000919956 us-gaap:EmployeeStockMember 2015-01-01 2015-09-30 0000919956 us-gaap:EmployeeStockMember 2015-09-30 0000919956 us-gaap:EmployeeStockMember 2014-12-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2015-01-01 2015-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2014-12-31 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2015-01-01 2015-09-30 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2015-01-01 2015-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2015-01-01 2015-09-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2015-01-01 2015-09-30 0000919956 avca:SkilledNursingCenterMember avca:BarrenCountyHealthCareCenterIncMember avca:GlasgowKentuckyMember 2015-02-01 2015-02-01 0000919956 avca:SkilledNursingCenterMember avca:BarrenCountyHealthCareCenterIncMember avca:GlasgowKentuckyMember 2015-02-01 0000919956 avca:HuntsvilleAlabamaMember 2014-03-01 2014-03-01 0000919956 stpr:MO 2014-07-01 0000919956 avca:HutchinsonKansasMember 2015-02-01 2015-02-01 0000919956 avca:GreenvilleKentuckyMember 2014-10-01 2014-10-01 0000919956 avca:HutchinsonKansasMember 2015-02-01 0000919956 avca:HutchinsonKansasMember us-gaap:LandAndBuildingMember us-gaap:PropertySubjectToOperatingLeaseMember 2015-02-01 2015-02-01 0000919956 stpr:OH 2014-08-01 2014-08-01 0000919956 avca:HuntsvilleAlabamaMember 2014-03-01 0000919956 avca:NicholasvilleKentuckyMember 2014-06-01 0000919956 avca:GreenvilleKentuckyMember 2014-10-01 0000919956 avca:NicholasvilleKentuckyMember 2014-06-01 2014-06-01 0000919956 avca:OntarioCommonsMember stpr:OH 2014-08-01 0000919956 stpr:MO 2014-07-01 2014-07-01 0000919956 stpr:OH 2014-08-01 0000919956 avca:AvonPlaceMember stpr:OH 2014-08-01 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2014-01-01 2014-09-30 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2014-01-01 2014-12-31 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2014-07-01 0000919956 avca:LeasedSkilledNursingCentersMember stpr:AR 2014-01-01 2014-09-30 0000919956 avca:RoseTerraceNoteMember avca:RoseTerraceNursingCenterMember us-gaap:LoansPayableMember 2014-07-01 2014-07-01 0000919956 avca:CullodenWestVirginiaMember avca:RoseTerraceNursingCenterMember 2014-07-01 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2015-01-01 2015-09-30 0000919956 stpr:WV avca:RoseTerraceNursingCenterMember 2014-04-03 0000919956 avca:DanvilleandIvydaleWestVirginiaMember avca:RoseTerraceNursingCenterMember 2014-07-01 0000919956 avca:RoseTerraceNursingCenterMember 2014-07-01 2014-07-01 0000919956 avca:LeasedSkilledNursingCentersMember stpr:AR 2015-01-01 2015-09-30 0000919956 avca:HawsFultonInvestorsLLCMember avca:FultonKentuckyMember us-gaap:SubsequentEventMember 2015-11-01 2015-11-01 0000919956 avca:HawsFultonInvestorsLLCMember avca:FultonKentuckyMember us-gaap:SubsequentEventMember 2015-11-01 iso4217:USD avca:State avca:Lawsuit avca:Facility avca:Option xbrli:pure avca:Center iso4217:USD xbrli:shares avca:Bed avca:Letter_Of_Credit xbrli:shares avca:Insurance_Policy 7844000 7556000 13 P5Y 175000 171000 564000 669000 1481000 -0.10 -0.18 -0.04 -0.13 -0.10 -0.17 -0.04 -0.13 -88000 281000 0.03 P5Y 45000000 3000000 1000000 3000000 3641000 3306000 2 P25Y 326000 6004 135 73 142 42 90 339 62 85 94 94 60 54 7 2 2 2 2 3 40 14 50 5 7 11 496 320 50 4250000 779000 1203000 0 893000 243000 6.61 28000 0 0.00 0 0 893000 271000 243000 6.67 6.61 11.09 5.50 7.21 0.00 243000 48000 195000 243000 48000 195000 12.05 12.09 P2Y 1139000 false --12-31 Q3 2015 2015-09-30 10-Q 0000919956 6259152 Smaller Reporting Company Diversicare Healthcare Services, Inc. 21333333 8121000 8335000 41272000 44276000 55014000 60338000 -495000 -532000 -532000 19970000 20615000 6044000 7736000 57000 16000 129089000 135212000 55939000 60582000 29295000 25484000 73000 67000 3500000 7000000 3900000 5778000 550000 672000 7000000 3781000 3855000 3818000 3710000 74000 -108000 -5952000 0 -61000 0 -600000 -4896000 0.055 0.165 0.055 0.165 0.01 0.01 20000000 20000000 6388000 6491000 6156000 6259000 64000 65000 4330000 718000 4273000 4305000 473000 718000 73006000 200517000 78501000 232298000 89019000 246300000 96033000 284376000 5000000 0.0470 0.0475 P18M 8987000 1341000 1692000 1532000 -467000 204000 7016000 8176000 12885000 11544000 1812000 5252000 1887000 5629000 858000 7522000 4513000 4513000 0 0 0.75 0.75 0.00 0.00 0.73 0.73 0.00 0.00 -585000 -1069000 -238000 -800000 -384000 -732000 -237000 -628000 3009000 3009000 2793000 0 0 16500000 10989000 0 48000 220000 0 0 0.68 0.66 0.07 0.11 0.66 0.65 0.07 0.11 14642000 15788000 0.50 463000 744000 8000000 5582000 16077000 6378000 18770000 90331000 250443000 98105000 289618000 219000 759000 669000 1481000 366000 1297000 1171000 2525000 219000 784000 669000 1481000 0.03 0.09 0.11 0.24 0.03 0.09 0.11 0.24 3928000 3444000 165000 -935000 -238000 -800000 -159000 -624000 0.65 0.57 -0.04 -0.13 0.63 0.56 -0.04 -0.13 -30000 -89000 97000 280000 147000 538000 502000 1044000 66000 216000 559000 559000 4131000 1136000 323000 507000 13775000 8302000 -33000 -2490000 815000 2063000 246000 0 916000 2757000 998000 2997000 2496000 2711000 P5Y P5Y P5Y P10Y P15Y P10Y P15Y P14Y P10Y 129089000 135212000 47142000 56930000 70193000 66281000 482000 365000 864000 27500000 20000000 65000000 4500000 8106000 8000000 42559000 41828000 5705000 14375000 0.0687 0.0687 0.045 0.045 5000000 500000 1000000 500000 23242000 1743000 5360000 2069000 6150000 -12194000 6246000 -6242000 6246000 12180000 -8143000 12241000 -8143000 88000 1789000 688000 6685000 4228000 681000 0 -25000 0 0 4099000 4008000 431000 681000 -946000 -2846000 -901000 -2717000 9 1312000 4143000 2072000 5242000 1900000 6876000 19094000 7198000 21529000 6411000 4108000 126000 102000 42000 37000 128000 376000 109000 345000 254000 478000 151000 382000 6359000 6232000 13366000 11822000 -311000 -116000 64000 9000 4918000 0 993000 1008000 220000 0 180000 192000 448000 462000 0 7000000 4228000 3624000 1411000 0 0.10 0.1 200000 200000 0 0 0 0 0 0 2339000 2441000 16500000 0 16808000 21941000 -30000 -31000 4147000 4203000 431000 681000 98869000 109484000 43855000 49146000 4235000 5425000 862000 1353000 14850000 14002000 -5285000 -5647000 11833000 11835000 14268000 12631000 441000 924000 0 3000 0.00 8.93 68000 36000 74000 74000 12.31 12.31 46000 130000 61000 140000 5.35 5.45 9.58 9.07 1000 2000 22000 63000 5.09 5.50 380000 150000 700000 10.4 2.37 11.59 6.21 0.33 0.33 0.33 P10Y 0.85 11754000 12001000 232000 232000 2500000 2500000 6248000 6171000 6331000 6310000 6020000 6004000 6121000 6089000 361000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">LONG-TERM DEBT AND INTEREST RATE SWAP</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company&#8217;s revolving credit agreement ("Original Revolver"). On May 1, 2013, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated February 28, 2011. The Credit Agreement increases the Company's borrowing capacity to </font><font style="font-family:inherit;font-size:10pt;">$65,000,000</font><font style="font-family:inherit;font-size:10pt;"> allocated between a </font><font style="font-family:inherit;font-size:10pt;">$45,000,000</font><font style="font-family:inherit;font-size:10pt;"> Mortgage Loan ("Amended Mortgage Loan") and a </font><font style="font-family:inherit;font-size:10pt;">$20,000,000</font><font style="font-family:inherit;font-size:10pt;"> Revolver ("Amended Revolver"). Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1,341,000</font><font style="font-family:inherit;font-size:10pt;"> and are being amortized over the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year term of the agreements.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of </font><font style="font-family:inherit;font-size:10pt;">$45,000,000</font><font style="font-family:inherit;font-size:10pt;"> with a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year maturity through April 30, 2018, and a </font><font style="font-family:inherit;font-size:10pt;">$20,000,000</font><font style="font-family:inherit;font-size:10pt;"> Amended Revolver through April 30, 2018. The Amended Mortgage Loan has a term of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years, with principal and interest payable monthly based on a </font><font style="font-family:inherit;font-size:10pt;">25</font><font style="font-family:inherit;font-size:10pt;">-year amortization. Interest is based on LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">4.5%</font><font style="font-family:inherit;font-size:10pt;">. A portion of the Amended Mortgage Loan is effectively fixed at </font><font style="font-family:inherit;font-size:10pt;">6.87%</font><font style="font-family:inherit;font-size:10pt;"> pursuant to an interest rate swap with a notional amount of </font><font style="font-family:inherit;font-size:10pt;">$21,333,333</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the interest rate related to the Amended Mortgage Loan was </font><font style="font-family:inherit;font-size:10pt;">4.70%</font><font style="font-family:inherit;font-size:10pt;">. The Amended Mortgage Loan is secured by </font><font style="font-family:inherit;font-size:10pt;">thirteen</font><font style="font-family:inherit;font-size:10pt;"> owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized. The Company&#8217;s Amended Revolver has an interest rate of LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">4.5%</font><font style="font-family:inherit;font-size:10pt;"> and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective March 31, 2014, the Company entered into the Second Amendment to the Amended and Restated Revolver ("Second Amendment"). The Second Amendment temporarily increased the Amended Revolver capacity from the </font><font style="font-family:inherit;font-size:10pt;">$20,000,000</font><font style="font-family:inherit;font-size:10pt;"> in the original Amended Revolver to </font><font style="font-family:inherit;font-size:10pt;">$27,500,000</font><font style="font-family:inherit;font-size:10pt;"> through September 30, 2014, as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process. Effective July 1, 2014, the Company entered into the Third Amendment to the Amended and Restated Revolver ("Third Amendment"). The Third Amendment makes the previously temporary increase to the Amended Revolver capacity from the </font><font style="font-family:inherit;font-size:10pt;">$20,000,000</font><font style="font-family:inherit;font-size:10pt;"> in the original Amended Revolver to </font><font style="font-family:inherit;font-size:10pt;">$27,500,000</font><font style="font-family:inherit;font-size:10pt;">, a permanent change to the borrowing capacity as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$8,000,000</font><font style="font-family:inherit;font-size:10pt;"> borrowings outstanding under the revolving credit facility compared to </font><font style="font-family:inherit;font-size:10pt;">$4,500,000</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. The outstanding borrowings on the revolver primarily reflect the Company's approach to accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under this Revolver are </font><font style="font-family:inherit;font-size:10pt;">3.00%</font><font style="font-family:inherit;font-size:10pt;"> of the amount outstanding. The Company has </font><font style="font-family:inherit;font-size:10pt;">eleven</font><font style="font-family:inherit;font-size:10pt;"> letters of credit with a total value of </font><font style="font-family:inherit;font-size:10pt;">$8,106,000</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of </font><font style="font-family:inherit;font-size:10pt;">$27,500,000</font><font style="font-family:inherit;font-size:10pt;">, the balance available for borrowing under the revolving credit center is </font><font style="font-family:inherit;font-size:10pt;">$8,987,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s debt agreements contain various financial covenants, the most restrictive of which relate to minimum cash deposits, cash flow and debt service coverage ratios. The Company is in compliance with all such covenants at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Rate Swap Transaction</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the debt agreements entered into in March 2011, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income. In conjunction with the amendment to the credit facility, the Company retained the previously agreed upon interest rate swap terms, and redesignated the interest rate swap as a cash flow hedge. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount of </font><font style="font-family:inherit;font-size:10pt;">$21,333,333</font><font style="font-family:inherit;font-size:10pt;"> at an annual fixed rate of </font><font style="font-family:inherit;font-size:10pt;">6.87%</font><font style="font-family:inherit;font-size:10pt;"> while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that the interest rate swap was effective. The interest rate swap valuation model indicated a net liability of </font><font style="font-family:inherit;font-size:10pt;">$858,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the interest rate swap is included in &#8220;other noncurrent liabilities&#8221; on the Company&#8217;s interim consolidated balance sheet. The balance of accumulated other comprehensive loss at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$532,000</font><font style="font-family:inherit;font-size:10pt;"> and reflects the liability related to the interest rate swap, net of the income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$326,000</font><font style="font-family:inherit;font-size:10pt;">. As the Company&#8217;s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Glasgow Term Loan</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 1, 2015, in conjunction with the acquisition of Diversicare of Glasgow, a </font><font style="font-family:inherit;font-size:10pt;">94</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility in Glasgow, Kentucky, the Company entered into a </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;"> Term Loan and Security Agreement (the "Glasgow term loan") with The PrivateBank in order to finance the purchase of the assets. The Glasgow term loan is an interest-only loan that has an </font><font style="font-family:inherit;font-size:10pt;">18</font><font style="font-family:inherit;font-size:10pt;">-month maturity dated August 1, 2016, and a variable interest rate based on LIBOR, with a minimum base rate of </font><font style="font-family:inherit;font-size:10pt;">4.75%</font><font style="font-family:inherit;font-size:10pt;">. See Note 9 for further information regarding the acquisition of the Glasgow facility.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements for the three and nine month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and the results of operations for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, and cash flows for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s balance sheet information at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, was derived from its audited consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The investment in an unconsolidated affiliate (a </font><font style="font-family:inherit;font-size:10pt;">50 percent</font><font style="font-family:inherit;font-size:10pt;">-owned joint venture partnership) is accounted for using the equity method and is described in Note&#160;8.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements for the three and nine month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and the results of operations for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, and cash flows for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s balance sheet information at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, was derived from its audited consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The investment in an unconsolidated affiliate (a </font><font style="font-family:inherit;font-size:10pt;">50 percent</font><font style="font-family:inherit;font-size:10pt;">-owned joint venture partnership) is accounted for using the equity method and is described in Note&#160;8.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview of Plans</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2005, the Compensation Committee of the Board of Directors adopted the 2005 Long-Term Incentive Plan (&#8220;2005 Plan&#8221;). The 2005 Plan allows the Company to issue stock options and other share and cash based awards. Under the 2005 Plan, </font><font style="font-family:inherit;font-size:10pt;">700,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted thereunder. All grants under this plan expire </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the date the grants were authorized by the Board of Directors.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (&#8220;Stock Purchase Plan&#8221;). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers and </font><font style="font-family:inherit;font-size:10pt;">150,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock has been reserved for issuance under the Stock Purchase Plan. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (&#8220;RSU's&#8221;) at </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. No grants can be made under the Stock Purchase Plan after April 25, 2018. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (&#8220;2010 Plan&#8221;), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. Under the 2010 Plan, </font><font style="font-family:inherit;font-size:10pt;">380,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Grants and Valuations</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors approved grants totaling approximately </font><font style="font-family:inherit;font-size:10pt;">74,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">68,000</font><font style="font-family:inherit;font-size:10pt;"> shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares are determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest </font><font style="font-family:inherit;font-size:10pt;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="240px" rowspan="1" colspan="1"></td><td width="108px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="99px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options/</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOSARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="240px" rowspan="1" colspan="1"></td><td width="108px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="99px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="50%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.58</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (&#8220;SOSARs&#8221;) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date, and expire </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the grant date. The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> SOSARs or Options were granted during </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, previously granted SOSARs and Options remain outstanding as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.28125%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.40 to $11.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.37 to $6.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">893,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">893,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;">$924,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$441,000</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="240px" rowspan="1" colspan="1"></td><td width="108px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="99px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options/</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOSARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">271,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">DISCONTINUED OPERATIONS</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">West Virginia Disposition</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective April 3, 2014, the Company entered into an asset purchase agreement with Rose Terrace Acq., LLC (&#8220;Purchaser&#8221;) to sell its skilled nursing facility in Culloden, West Virginia. The original asset purchase agreement was subject to a number of conditions including an amendment to the Consolidated Amended and Restated Master Lease ("Master Lease") with Omega to terminate the lease only with respect to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> other skilled nursing facilities in West Virginia, state licensure and regulatory approval. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective July 1, 2014, the Company completed the transaction with Rose Terrace Acq., LLC to sell Rose Terrace, a </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility in Culloden, West Virginia for a sales price of </font><font style="font-family:inherit;font-size:10pt;">$16,500,000</font><font style="font-family:inherit;font-size:10pt;">. The Company also entered into the Fifteenth Amendment to the Master Lease with Omega to terminate the lease only with respect to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> other skilled nursing facilities in West Virginia, and concurrently entered into an operations transfer agreement with American Health Care Management, LLC, an affiliate of the purchaser with respect to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> other skilled nursing facilities located in Danville and Ivydale, West Virginia. The amendment effectively reduced the annual rent payments due under the Master Lease by </font><font style="font-family:inherit;font-size:10pt;">$1,900,000</font><font style="font-family:inherit;font-size:10pt;">. Upon completion of the transaction, Diversicare no longer operates any skilled nursing centers in the state of West Virginia. In conjunction with the closing of the sale, the Company paid the balance of the </font><font style="font-family:inherit;font-size:10pt;">$8,000,000</font><font style="font-family:inherit;font-size:10pt;"> mortgage loan outstanding on the Rose Terrace facility. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transaction resulted in a gain on the disposition of Rose Terrace which, along with the results of operations for these nursing facilities, is presented within Discontinued Operations on the Consolidated Statements of Operations. The pretax gain on the transaction was </font><font style="font-family:inherit;font-size:10pt;">$7,522,000</font><font style="font-family:inherit;font-size:10pt;">. The tax expense associated with the gain was </font><font style="font-family:inherit;font-size:10pt;">$2,793,000</font><font style="font-family:inherit;font-size:10pt;"> for which the Company plans to apply net operating loss carryforwards from our deferred tax assets to substantially offset and minimize the cash outlay for this transaction.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These centers contributed revenues of </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$10,989,000</font><font style="font-family:inherit;font-size:10pt;"> and net income (loss) of </font><font style="font-family:inherit;font-size:10pt;">$(159,000)</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$165,000</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160; The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense or any allocation of corporate interest expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Discontinued Operations</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the ongoing impact of the West Virginia discontinued operations, the Company also experienced ongoing expense during the quarter as it relates to the exit from our Arkansas operations which occurred in September 2013. The activity within Arkansas primarily relates to the progress as it relates to outstanding professional liability claims and finalizing the collection and/or write-off of remaining accounts receivable. These centers contributed net loss of </font><font style="font-family:inherit;font-size:10pt;">$(624,000)</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$(935,000)</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EARNINGS (LOSS) PER COMMON SHARE</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator: Income amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">669</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: loss attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Diversicare Healthcare Services, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">669</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock dividends</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(220</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">669</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,928</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,444</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to Diversicare Healthcare Services, Inc. common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">681</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss), net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on disposal, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.68</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.66</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss), net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on disposal, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.73</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.73</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.63</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.56</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.66</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator: Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,089</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,331</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,310</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effects of </font><font style="font-family:inherit;font-size:10pt;">16,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">57,000</font><font style="font-family:inherit;font-size:10pt;"> SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, because these securities would have been anti-dilutive.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EQUITY METHOD INVESTMENT</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The investment in unconsolidated affiliate reflected on the interim consolidated balance sheet relates to a pharmacy joint venture partnership in which the Company owns </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">. The joint venture was initially funded by the Company and its partner and began operations during 2012. This investment in unconsolidated affiliate is accounted for using the equity method as the Company exerts significant influence, but does not control or otherwise consolidate the entity. The investment in unconsolidated affiliate balance at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;">$744,000</font><font style="font-family:inherit;font-size:10pt;"> as compared to </font><font style="font-family:inherit;font-size:10pt;">$463,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">. Additionally, the Company's share of the net profits and losses of the unconsolidated affiliate are reported in equity in net earnings or losses of unconsolidated affiliate in our statement of operations. The Company's equity in the net income of unconsolidated affiliate for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;">$97,000</font><font style="font-family:inherit;font-size:10pt;"> as compared to a net loss of </font><font style="font-family:inherit;font-size:10pt;">$30,000</font><font style="font-family:inherit;font-size:10pt;"> for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">. For the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-month period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the equity in the net income of unconsolidated affiliate was </font><font style="font-family:inherit;font-size:10pt;">$280,000</font><font style="font-family:inherit;font-size:10pt;"> compared to a net loss of </font><font style="font-family:inherit;font-size:10pt;">$89,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-month period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">INSURANCE MATTERS</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Professional Liability and Other Liability Insurance</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, consolidated offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (&#8220;SHC&#8221;) which has issued a policy insuring claims made against all of the Company's nursing centers in Florida and Tennessee, as well as the Company&#8217;s formerly operated Arkansas and West Virginia facilities. Several of the Company&#8217;s nursing centers in Alabama, Kentucky, Ohio, and Texas</font><font style="font-family:inherit;font-size:10pt;color:#1f497d;"> </font><font style="font-family:inherit;font-size:10pt;">are also covered under this policy. The SHC policy provides coverage limits of either </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> per medical incident with a sublimit per center of </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> and total annual aggregate policy limits of </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;">. The remaining nursing centers are covered by one of </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> claims made professional liability insurance policies purchased from entities unaffiliated with the Company. These policies provide coverage limits of </font><font style="font-family:inherit;font-size:10pt;">$1,000,000</font><font style="font-family:inherit;font-size:10pt;"> per claim and have sublimits of </font><font style="font-family:inherit;font-size:10pt;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;"> per center, with varying aggregate policy limits.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reserve for Estimated Self-Insured Professional Liability Claims</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the Company&#8217;s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company&#8217;s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of </font><font style="font-family:inherit;font-size:10pt;">$23,242,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of the current portion of this reserve. Merlinos&#160;&amp; Associates, Inc. (&#8220;Merlinos&#8221;) assisted management in the preparation of an estimate of the appropriate accrual for the current claims period and for incurred, but not reported general and professional liability claims based on data furnished as of May 31, 2015.&#160; The Company used this estimate from Merlinos in the preparation of its estimate of liability for incurred, but unreported professional liability claims as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company&#8217;s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator&#8217;s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company&#8217;s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company is engaged in </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;"> professional liability lawsuits. </font><font style="font-family:inherit;font-size:10pt;">Five</font><font style="font-family:inherit;font-size:10pt;"> lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company&#8217;s cash expenditures for self-insured professional liability costs from continuing operations were </font><font style="font-family:inherit;font-size:10pt;">$3,306,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3,641,000</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company&#8217;s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company&#8217;s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company&#8217;s reported earnings and financial position for the period in which the change in accrual is made.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Insurance</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to workers&#8217; compensation insurance, substantially all of the Company&#8217;s employees became covered under either an indemnity insurance plan or state-sponsored programs in May 1997. The Company is completely self-insured for workers&#8217; compensation exposures prior to May 1997. The Company has been and remains a non-subscriber to the Texas workers&#8217; compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June&#160;30, 2003 until June&#160;30, 2007, the Company&#8217;s workers&#8217; compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July&#160;1, 2008 through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> per claim, subject to an aggregate maximum of </font><font style="font-family:inherit;font-size:10pt;">$3,000,000</font><font style="font-family:inherit;font-size:10pt;">. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers&#8217; compensation claims is </font><font style="font-family:inherit;font-size:10pt;">$361,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The Company has a non-current receivable for workers&#8217; compensation policies covering previous years of </font><font style="font-family:inherit;font-size:10pt;">$1,139,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The non-current receivable is a function of payments paid to the Company&#8217;s insurance carrier in excess of the estimated level of claims expected to be incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to </font><font style="font-family:inherit;font-size:10pt;">$175,000</font><font style="font-family:inherit;font-size:10pt;"> per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is </font><font style="font-family:inherit;font-size:10pt;">$864,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The differences between actual settlements and reserves are included in expense in the period finalized.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows current accounting guidance set forth in FASB ASU 2010-24, &#8220;Presentation of Insurance Claims and Related Insurance Recoveries,&#8221; that clarifies that a health care entity should not net insurance recoveries against a related claim, and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the Company has recorded assets and equal liabilities of </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$246,000</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diversicare Healthcare Services, Inc. (together with its subsidiaries, &#8220;Diversicare Healthcare Services&#8221; or the &#8220;Company&#8221;) provides long-term care services to nursing center patients in </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> states, primarily in the Southeast, Midwest, and Southwest. The Company&#8217;s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company&#8217;s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Missouri, Ohio, Tennessee, and Texas.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s continuing operations consist of </font><font style="font-family:inherit;font-size:10pt;">54</font><font style="font-family:inherit;font-size:10pt;"> nursing centers with </font><font style="font-family:inherit;font-size:10pt;">6,004</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds. The Company owns </font><font style="font-family:inherit;font-size:10pt;">14</font><font style="font-family:inherit;font-size:10pt;"> and leases </font><font style="font-family:inherit;font-size:10pt;">40</font><font style="font-family:inherit;font-size:10pt;"> of its nursing centers. Our nursing centers range in size from </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">320</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds. The licensed nursing bed count does not include </font><font style="font-family:inherit;font-size:10pt;">496</font><font style="font-family:inherit;font-size:10pt;"> licensed assisted and residential living beds.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS DEVELOPMENT</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Acquisitions</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 1, 2015, the Company entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Barren County Health Care Center, Inc. to acquire certain land, improvements, furniture, fixtures and equipment, personal property and intangible property, together comprising a </font><font style="font-family:inherit;font-size:10pt;">94</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center in Glasgow, Kentucky, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$7,000,000</font><font style="font-family:inherit;font-size:10pt;"> partially financed through a </font><font style="font-family:inherit;font-size:10pt;">$5,000,000</font><font style="font-family:inherit;font-size:10pt;"> mortgage loan with The PrivateBank with the balance paid in cash consideration. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the consummation of the Agreement, the Company allocated the purchase price of </font><font style="font-family:inherit;font-size:10pt;">$7,000,000</font><font style="font-family:inherit;font-size:10pt;"> between the assets associated with the transaction based on the fair value of the acquired net assets. The allocation of the purchase price was determined with the assistance of HealthTrust LLC, a third-party real estate valuation firm. The allocation for the net assets acquired is as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:52.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="63%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="35%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">February 1, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">672,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, Fixtures, and Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lease Agreements</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the the first quarter of 2015 and the year ended December 31, 2014, the Company has completed several transactions to assume the operations of additional nursing centers through the assumption of long-term operating leases. The transactions during these periods are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 1, 2015, the Company assumed operations at Diversicare of Hutchinson, an </font><font style="font-family:inherit;font-size:10pt;">85</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center in Hutchinson, Kansas. The facility has an initial lease term of </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years and includes an option to purchase at a fixed price of </font><font style="font-family:inherit;font-size:10pt;">$4,250,000</font><font style="font-family:inherit;font-size:10pt;">, exercisable after the first year of the lease. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 1, 2014, the Company assumed operations at Diversicare of Greenville, a </font><font style="font-family:inherit;font-size:10pt;">62</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility in Greenville, Kentucky. This facility has an initial lease terms of </font><font style="font-family:inherit;font-size:10pt;">14</font><font style="font-family:inherit;font-size:10pt;"> years. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 1, 2014, the Company assumed operations of </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> centers in Ohio. The centers included in this transaction are a </font><font style="font-family:inherit;font-size:10pt;">142</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing facility and a </font><font style="font-family:inherit;font-size:10pt;">42</font><font style="font-family:inherit;font-size:10pt;">-bed assisted living center. The lease provides for an initial lease term of </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years. The centers were already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 1, 2014, the Company completed a transaction to enter the state of Missouri through the assumption of operations of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> facilities totaling </font><font style="font-family:inherit;font-size:10pt;">339</font><font style="font-family:inherit;font-size:10pt;"> skilled nursing beds. The lease provides for an initial </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;">-year lease term with a </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">-year renewal option. The centers were already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 1, 2014, the Company assumed operations at Diversicare of Nicholasville, an existing </font><font style="font-family:inherit;font-size:10pt;">73</font><font style="font-family:inherit;font-size:10pt;">-bed facility in Nicholasville, Kentucky. The lease provides for an initial </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;">-year lease term with a </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 1, 2014, the Company assumed operations at Diversicare of Big Springs, an existing </font><font style="font-family:inherit;font-size:10pt;">135</font><font style="font-family:inherit;font-size:10pt;">-bed facility in Huntsville, Alabama. The nursing center is owned by an unrelated third-party and the lease provides for an initial </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">-year lease term with </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> additional </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">-year renewal options. The additional skilled nursing center increases the Company's footprint in Alabama to </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> centers, and the third center in the Huntsville market. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">RECENT ACCOUNTING GUIDANCE</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the FASB issued ASU 2014-08,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity</font><font style="font-family:inherit;font-size:10pt;">&#160;changing the criteria for reporting discontinued operations. The ASU states that only those disposed components (or components held-for-sale) representing a strategic shift that have a significant effect on operations and financial results will be reported in discontinued operations. The ASU also required expanded disclosures about discontinued operations in the financial statement notes. The ASU is effective for disposals (or classifications as held-for-sale) that occur within annual periods beginning on or after December&#160;15, 2014 and interim periods within those annual periods. Early application is permitted, but only for those disposals that have not been reported in financial statements previously issued or available for issuance. We chose to early adopt this ASU and applied the new criteria in determining the accounting treatment for the nursing centers exited during 2014. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No.&#160;2014-09,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In July 2015, the FASB announced the deferral of the effective date by one year from the originally stated effective date in ASU 2014-09. The new standard is now effective for the Company on January&#160;1, 2018, but can be adopted as of the original effective date of January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures, as well as the time frame for adoption. The Company has not yet selected an effective date or transition method nor has it determined the effect of the standard on its ongoing financial reporting.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the FASB issued ASU No.&#160;2015-03,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Presentation of Debt Issuance Costs (Topic 835)</font><font style="font-family:inherit;font-size:10pt;">, which amends and simplifies the presentation of debt issuance costs. The main provisions of the standard require that debt issuance costs related to a recognized liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, and amortization of the debt issuance costs must be reported as interest expense. ASU 2015-03 will be effective for the interim and annual periods beginning after December&#160;15, 2015 with early adoption permitted. The new standard must be applied on a retroactive basis, and the Company will be required to comply with the applicable disclosures for a change in accounting principle. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2014, the FASB issued ASU 2014-08,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity</font><font style="font-family:inherit;font-size:10pt;">&#160;changing the criteria for reporting discontinued operations. The ASU states that only those disposed components (or components held-for-sale) representing a strategic shift that have a significant effect on operations and financial results will be reported in discontinued operations. The ASU also required expanded disclosures about discontinued operations in the financial statement notes. The ASU is effective for disposals (or classifications as held-for-sale) that occur within annual periods beginning on or after December&#160;15, 2014 and interim periods within those annual periods. Early application is permitted, but only for those disposals that have not been reported in financial statements previously issued or available for issuance. We chose to early adopt this ASU and applied the new criteria in determining the accounting treatment for the nursing centers exited during 2014. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No.&#160;2014-09,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In July 2015, the FASB announced the deferral of the effective date by one year from the originally stated effective date in ASU 2014-09. The new standard is now effective for the Company on January&#160;1, 2018, but can be adopted as of the original effective date of January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures, as well as the time frame for adoption. The Company has not yet selected an effective date or transition method nor has it determined the effect of the standard on its ongoing financial reporting.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the FASB issued ASU No.&#160;2015-03,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Presentation of Debt Issuance Costs (Topic 835)</font><font style="font-family:inherit;font-size:10pt;">, which amends and simplifies the presentation of debt issuance costs. The main provisions of the standard require that debt issuance costs related to a recognized liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, and amortization of the debt issuance costs must be reported as interest expense. ASU 2015-03 will be effective for the interim and annual periods beginning after December&#160;15, 2015 with early adoption permitted. The new standard must be applied on a retroactive basis, and the Company will be required to comply with the applicable disclosures for a change in accounting principle. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator: Income amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">669</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: loss attributable to noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Diversicare Healthcare Services, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">669</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">784</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock dividends</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(220</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">669</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,481</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,928</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,444</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) attributable to Diversicare Healthcare Services, Inc. common shareholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,099</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">681</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended <br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2014</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss), net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on disposal, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.75</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.68</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.66</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss), net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:108px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on disposal, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.73</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.73</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discontinued operations, net of taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.63</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.56</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.66</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator: Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,020</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,089</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,331</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,310</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allocation for the net assets acquired is as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:52.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="63%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="35%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">February 1, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">672,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, Fixtures, and Equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">550,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.28125%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$10.40 to $11.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.37 to $6.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">893,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">893,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:474px;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="240px" rowspan="1" colspan="1"></td><td width="108px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="99px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.7265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td width="50%" rowspan="1" colspan="1"></td><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="2%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="22%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.09</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding September 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.58</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">SUBSEQUENT EVENTS</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 1, 2015, the Company entered into an Asset Purchase Agreement with Haws Fulton Investors, LLC to acquire certain land, improvements, furniture, fixtures and equipment, personal property and intangible property, together comprising a </font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center in Fulton, Kentucky, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">. This facility is expected to contribute in excess of </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;"> in annual revenues.</font></div></div> EX-101.SCH 6 avca-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Business (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Business Development link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Business Development (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Business Development (Schedule of Assets Acquired) (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Business Development (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Consolidation and Basis of Presentation of Financial Statements link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Consolidation and Basis of Presentation of Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Consolidation and Basis of Presentation of Financial Statements (Policies) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Earnings (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Earnings (Loss) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Earnings (Loss) Per Common Share (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Earnings (Loss) Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Equity Method Investment link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Equity Method Investment (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Insurance Matters link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Insurance Matters (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Interim Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Interim Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Interim Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Interim Consolidated Statements of Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Interim Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - Interim Consolidated Statements of Operations (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Long-Term Debt and Interest Rate Swap link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Long-Term Debt and Interest Rate Swap (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Recent Accounting Guidance link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable) (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 avca-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 avca-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 avca-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of allocation for net assets acquired Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Discontinued Operations and Disposal Groups [Abstract] DISCONTINUED OPERATIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock Options and Stock Appreciation Rights (SARs) Stock Options and Stock Appreciation Rights (SARs) [Member] Stock Options and Stock Appreciation Rights (SARs) [Member] Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $10.40 to $11.59 Stock Options Exercise Price Range One [Member] Stock Options Exercise Price Range One [Member] $2.37 to $6.21 Stock Options Exercise Price Range Two [Member] Stock Options Exercise Price Range Two [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Range of Exercise Prices, Maximum Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Range of Exercise Prices, Maximum Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Weighted Average Exercise Prices Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Grants Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Intrinsic Value-Grants Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Grants Exercisable Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Intrinsic Value- Grants Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value BUSINESS Nature of Operations [Text Block] Insurance [Abstract] Schedule of Malpractice Insurance [Table] Schedule of Malpractice Insurance [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] SHC Risk Carriers, Inc SHC Risk Carriers, Inc [Member] SHC Risk Carriers, Inc [Member] Unaffiliated Entities Unaffiliated Entities [Member] Unaffiliated Entities [Member] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Professional malpractice liability insurance Professional Malpractice Liability Insurance [Member] Prefunded deductible policy Prefunded Deductible Policy [Member] Prefunded deductible policy. Trial or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Trial or Arbitration Schedule Timeframe [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months Scheduled for trial or arbitration over next 12 months Trial Or Arbitration Schedule Timeframe [Member] Trial Or Arbitration Schedule Timeframe [Member] Malpractice Insurance [Line Items] Malpractice Insurance [Line Items] Insurance policy coverage limits per claim Malpractice Insurance, Maximum Coverage Per Incident Annual sublimit per center Malpractice Insurance Annual Sublimit Per Center Malpractice Insurance Annual Sublimit Per Center Maximum annual coverage Malpractice Insurance, Annual Coverage Limit Number of types of professional liability insurance policies Number Of Types Of Professional Liability Insurance Policies Number Of Types Of Professional Liability Insurance Policies Liability for reported and estimated future claims Malpractice Loss Contingency, Accrual, Undiscounted Number of professional liability lawsuits Number Of Professional Liability Lawsuits Number Of Professional Liability Lawsuits Cash expenditures for self-insured professional liability costs Malpractice Insurance Self Insured Costs Paid During Period Malpractice Insurance Self Insured Costs Paid During Period Other Insurance Industry Disclosures [Abstract] Other Insurance Industry Disclosures [Abstract] Professional liability insurance, annual coverage limit per facility Malpractice Insurance Annual Coverage Limit Per Facility Malpractice Insurance Annual Coverage Limit Per Facility Liability for workers compensation claims Workers' Compensation Liability Workers compensation insurance, non current receivable for excess premiums paid Workers Compensation Receivable For Excess Premiums Paid Workers Compensation Receivable For Excess Premiums Paid Health insurance, maximum self-insured annual amount per individual Employee Health Insurance Maximum Payable Per Individual Annually Employee Health Insurance Maximum Payable Per Individual Annually Liability for reported claims and estimates for incurred but unreported claims Liability for Future Policy Benefits Non-current receivables for workers' compensation policy Insurance Receivable for Malpractice Earnings Per Share [Abstract] Earnings (Loss) Per Common Share (Textual) [Abstract] Earnings Loss Per Common Share (Textual) [Abstract] Earnings loss per common share. Antidilutive shares excluded from computation of diluted earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Subsequent Events [Abstract] EQUITY METHOD INVESTMENT Subsequent Events [Text Block] EARNINGS (LOSS) PER COMMON SHARE Earnings Per Share [Text Block] Accounting Changes and Error Corrections [Abstract] RECENT ACCOUNTING GUIDANCE New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Income Statement [Abstract] PATIENT REVENUES, net Health Care Organization, Revenue Net of Patient Service Revenue Provisions EXPENSES: Costs and Expenses [Abstract] Operating Cost of Services Lease and rent expense Operating Leases, Rent Expense, Net Professional liability Malpractice Loss Contingency, Premium Costs General and administrative General and Administrative Expense Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Total expenses Costs and Expenses OPERATING INCOME Operating Income (Loss) OTHER EXPENSE: Nonoperating Income (Expense) [Abstract] Equity in net income (loss) of unconsolidated affiliate Income (Loss) from Equity Method Investments Interest expense, net Interest Expense Total other expense Nonoperating Income (Expense) INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest PROVISION FOR INCOME TAXES Income Tax Expense (Benefit) Income from continuing operations Income (Loss) from Continuing Operations Attributable to Parent INCOME (LOSS) FROM DISCONTINUED OPERATIONS: Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent [Abstract] Operating loss, net of tax benefit Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Gain on disposal, net of tax Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Income (loss) from discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest NET INCOME Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Less: loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest NET INCOME ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC. Net Income (Loss) Attributable to Parent PREFERRED STOCK DIVIDENDS Dividends, Preferred Stock NET INCOME FOR DIVERSICARE HEALTHCARE SERVICES, INC. COMMON SHAREHOLDERS Net Income (Loss) Available to Common Stockholders, Basic Per common share – basic Earnings Per Share, Basic [Abstract] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Net income (loss) per common share – basic Earnings Per Share, Basic Per common share – diluted Earnings Per Share, Diluted [Abstract] Continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Discontinued operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Net income (loss) per common share – diluted Earnings Per Share, Diluted COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK Common Stock, Dividends, Per Share, Declared WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Debt Disclosure [Abstract] Line of Credit Facility [Table] Line of Credit Facility [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Revolving credit facility Revolving Credit Facility [Member] Loans Payable Loans Payable [Member] Letter of Credit Letter of Credit [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Revolving Credit Facility Interest at 4.5% Percent Above LIBOR Revolving Credit Facility Interest At Four Point Five Percent Above LIBOR [Member] Revolving Credit Facility Interest At Four Point Five Percent Above LIBOR [Member] Glasgow Term Loan Glasgow Term Loan [Member] Glasgow Term Loan [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Interest rate swap Interest Rate Swap [Member] LIBOR London Interbank Offered Rate [Member] London interbank offered rate. Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Glasgow, Kentucky Glasgow, Kentucky [Member] Glasgow, Kentucky [Member] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] The PrivateBank The PrivateBank [Member] The PrivateBank [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Long-Term Debt and Interest Rate Swap (Textual) [Abstract] Long-Term Debt and Interest Rate Swap (Textual) [Abstract] Long-term debt and interest rate swap. Revolving credit facility and the maximum loan Line of Credit Facility, Maximum Borrowing Capacity Long-term debt for syndicate of banks mortgage debt Long-Term Debt for Syndicate of Banks Mortgage Debt Long-term debt for syndicate of banks mortgage debt . Long-term debt revolving credit facility Long-term Line of Credit Loan acquisition costs Debt Issuance Cost Term of debt agreement Debt Instrument, Term of Debt Agreement Debt Instrument, Term of Debt Agreement Long-term debt five year maturity Long Term Debt Five Year Maturity Long-term debt five year maturity. Mortgage loan with principal and interest payable monthly based Mortgage Loan With Principal and Interest Payable Monthly Based Mortgage loan with principal and interest payable monthly based. Long-term debt interest based on LIBOR Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate Long-term debt fixed based on the interest rate swap Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate Notional amount of interest rate derivatives Derivative, Notional Amount Debt interest rate at period end Debt Instrument, Interest Rate, Effective Percentage Number of owned nursing centers secured Debt Instrument Collateral Number Of Owned Nursing Centers Debt Instrument Collateral Number Of Owned Nursing Centers Borrowings outstanding Long-term Debt Letters of credit issued under Revolver outstanding Letters of Credit Issued Under Revolver Outstanding Letters of credit issued under this revolver outstanding. Number of letters of credit Number of Letters of Credit Number of Letters of Credit Borrowing under the revolving credit facility Debt Instrument, Unused Borrowing Capacity, Amount Liability at fair value Derivative Liability, Fair Value, Gross Liability Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Net of the income tax benefit, interest rate swap Net Income Tax Benefit Net income tax benefit. Number of licensed nursing beds Number of Licensed Nursing Beds Number of licensed nursing beds. Amount of term loan Debt Instrument, Face Amount Term loan maturity period Debt Instrument, Term Minimum base rate percentage Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2005 Long Term Incentive Plan Two Thousand And Five Long Term Incentive Plan [Member] Two Thousand And Five Long Term Incentive Plan [Member] 2008 Stock Purchase Plan Two Thousand And Eight Stock Purchase Plan [Member] Two Thousand And Eight Stock Purchase Plan [Member] 2010 Long Term Incentive Plan Two Thousand And Ten Long Term Incentive Plan [Member] Two Thousand And Ten Long Term Incentive Plan [Member] Stock Only Stock Appreciation Rights (SOSARS) Stock Appreciation Rights (SARs) [Member] Restricted Stock Restricted Stock [Member] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] Share-based Compensation Award, Tranche One Share-based Compensation Award, Tranche One [Member] Share-based Compensation Award, Tranche Two Share-based Compensation Award, Tranche Two [Member] Share-based Compensation Award, Tranche Three Share-based Compensation Award, Tranche Three [Member] Number of shares reserved for future issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Percentage of quoted market price offering rate Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Restriction period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Grant of restricted common stock (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vest of restricted stock on each year (percentage) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Stock-based compensation Share-based Compensation Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Haws Fulton Investors, LLC Haws Fulton Investors, LLC [Member] Haws Fulton Investors, LLC [Member] Fulton, Kentucky Fulton, Kentucky [Member] Fulton, Kentucky [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Purchase Price Business Combination, Consideration Transferred Expected annual revenues of nursing center Business Acquisition, Revenue Reported by Acquired Entity for Last Annual Period Per common share – basic and diluted Earnings Per Share, Basic and Diluted [Abstract] Numerator: Income amounts attributable to Diversicare Healthcare Services, Inc. common shareholders: Income Amounts Attributable to Parent, Disclosures [Abstract] Income from continuing operations Less: loss attributable to noncontrolling interests Income from continuing operations attributable to Diversicare Healthcare Services, Inc. Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest Preferred stock dividends Income from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders Income (Loss) from Continuing Operations Attributable to parent Shareholders income loss from continuing operations attributable to parent shareholders. Income (loss) from discontinued operations Per common share – basic Income (loss) from continuing operations (in dollars per share) Operating income (loss) from discontinued operations, net of taxes (in dollars per share) Income Loss from Discontinued Operations Operating Income Loss Net of Taxes Basic Income (loss) from discontinued operations Operating income (loss), net of taxes, basic. Gain on disposal, net of taxes (in dollars per share) Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Per Basic Share Discontinued operations, net of taxes (in dollars per share) Income from continuing operations (in dollars per share) Income (loss) from discontinued operations, Operating income (loss), net of taxes (in dollars per share) Income Loss from Discontinued Operations Operating Income Loss Net of Taxes Diluted Income (loss) from discontinued operations Operating income (loss), net of taxes, diluted. Gain on disposal, net of taxes (in dollars per share) Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Per Diluted Share Discontinued operations, net of taxes (in dollars per share) Denominator: Weighted Average Common Shares Outstanding: Equity Method Investments and Joint Ventures [Abstract] Percentage of owned joint venture Investment in nonconsolidated affiliate Equity Method Investment, Ownership Percentage Investment in unconsolidated affiliate Equity Method Investments Statement of Financial Position [Abstract] Allowance for doubtful accounts receivable Allowance for Doubtful Accounts Receivable, Current Preferred stock, par value (dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (shares) Preferred Stock, Shares Outstanding Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (shares) Common Stock, Shares Authorized Common stock, shares issued (shares) Common Stock, Shares, Issued Common stock, shares outstanding (shares) Common Stock, Shares, Outstanding Treasury stock, shares (shares) Treasury Stock, Shares INSURANCE MATTERS Insurance Disclosure [Text Block] Summarized activity of equity compensation plans Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of summarized activity of Restricted Share Units Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule of summarized information regarding stock options and SOSAR grants outstanding Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Tax effect on operating income Discontinued Operation, Tax Effect of Discontinued Operation Tax expense associated with the gain Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation Basic and diluted net income (loss) per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Skilled Nursing Center Skilled Nursing Center [Member] Skilled Nursing Center [Member] Barren County Health Care Center Inc Barren County Health Care Center Inc [Member] Barren County Health Care Center Inc [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Land Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Buildings Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Buildings Furniture, Fixtures, and Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Total purchase price Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, December 31, 2014 Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number Granted Share-based Compensation Arrangement by Share-based Payment Award, Awards, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Awards, Grants in Period, Gross Exercised Share-based Compensation Arrangement By Share Based Payment Award Awards Exercises In Period Share-based Compensation Arrangement By Share Based Payment Award Awards Exercises In Period Expired or cancelled Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Outstanding, September 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, December 31, 2014 Granted Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Exercised Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Expired or cancelled Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Outstanding, September 30, 2015 Exercisable, shares Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Number Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Number Exercisable, Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Accounting Policies [Line Items] Accounting Policies [Line Items] [Line Items] for Accounting Policies [Table] Number of states in which entity operates Number of States in which Entity Operates Number of nursing centers Number Of Nursing Center Facilities Number Of Nursing Center Facilities Number of nursing center facilities owned Number Of Nursing Center Facilities Owned Number Of Nursing Center Facilities Owned Number of nursing center facilities leased Number Of Nursing Center Facilities Leased Number Of Nursing Center Facilities Leased Number of licensed nursing beds per center Number of Licensed Nursing Beds per Nursing Center Number of Licensed Nursing Beds per Nursing Center Number of licensed assisted living beds Number of Licensed Assisted Living Beds Number of Licensed Assisted Living Beds Entity Location [Table] Entity Location [Table] Ohio OHIO Missouri MISSOURI Nicholasville, Kentucky Nicholasville, Kentucky [Member] Nicholasville, Kentucky [Member] Avon Place Avon Place [Member] Avon Place [Member] Ontario Commons Ontario Commons [Member] Ontario Commons [Member] Entity by Location [Axis] Entity by Location [Axis] Location [Domain] Location [Domain] Hutchinson, Kansas Hutchinson, Kansas [Member] Hutchinson, Kansas [Member] Greenville, Kentucky Greenville, Kentucky [Member] Greenville, Kentucky [Member] Huntsville, Alabama Huntsville, Alabama [Member] Huntsville, Alabama [Member] Property Subject to or Available for Operating Lease [Axis] Property Subject to or Available for Operating Lease [Axis] Property Subject to or Available for Operating Lease [Domain] Property Subject to or Available for Operating Lease [Domain] Property Subject to Operating Lease Property Subject to Operating Lease [Member] Major Property Class [Axis] Major Property Class [Axis] Major Property Class [Domain] Major Property Class [Domain] Skilled nursing center Land and Building [Member] Entity Location [Line Items] Entity Location [Line Items] Lease agreement term Lessee Leasing Arrangements, Operating Leases, Term of Contract Option to purchase at fixed price Operating Lease, Option to Purchase, Purchase Price Operating Lease, Option to Purchase, Purchase Price Lease renewal period Lessee Leasing Arrangements, Operating Leases, Renewal Term Maximum number of capital lease renewal periods Maximum Number Of Lease Renewal Periods Maximum Number Of Lease Renewal Periods Statement of Comprehensive Income [Abstract] NET INCOME OTHER COMPREHENSIVE INCOME: Other Comprehensive Income (Loss), Net of Tax [Abstract] Change in fair value of cash flow hedge, net of tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Less: reclassification adjustment for amounts recognized in net income Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Total other comprehensive income Other Comprehensive Income (Loss), Net of Tax COMPREHENSIVE INCOME Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest COMPREHENSIVE INCOME ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Discontinued operations Adjustments to reconcile income from continuing operations to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Provision for doubtful accounts Provision for Doubtful Accounts Deferred income tax benefit Deferred Income Tax Expense (Benefit) Provision for self-insured professional liability, net of cash payments Increase (Decrease) in Self Insurance Reserve Equity in net (income) losses of unconsolidated affiliate, net of investment Income (Loss) from Equity Method Investments, Net of Contributions Paid Income (Loss) from Equity Method Investments, Net of Contributions Paid Provision for leases in excess of cash payments Provision For Leases In Excess Of Cash Payments Provision For Leases In Excess Of Cash Payments Other Other Noncash Income (Expense) Changes in assets and liabilities affecting operating activities: Increase (Decrease) in Operating Capital [Abstract] Receivables, net Increase (Decrease) in Receivables Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Trade accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Net cash provided by continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Acquisition of property and equipment through business combination Payments to Acquire Businesses, Net of Cash Acquired Proceeds from sale of discontinued operations Proceeds from Divestiture of Businesses Change in restricted cash Increase (Decrease) in Restricted Cash Deposits and other deferred balances Payments for (Proceeds from) Other Investing Activities Net cash provided by (used in) continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Repayment of debt obligations Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Proceeds from issuance of debt Proceeds from Issuance of Long-term Debt and Capital Securities, Net Financing costs Payments of Financing Costs Issuance and redemption of employee equity awards Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Redemption of preferred stock Payments for Repurchase of Redeemable Preferred Stock Payment of common stock dividends Payments of Ordinary Dividends, Common Stock Payment of preferred stock dividends Payments of Ordinary Dividends, Preferred Stock and Preference Stock Distributions to noncontrolling interest Payments to Noncontrolling Interests Payment for preferred stock restructuring Payments of Stock Issuance Costs Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Financing Activities, Discontinued Operations Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, beginning of period Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL INFORMATION: Supplemental Cash Flow Information [Abstract] Cash payments of interest, net of amounts capitalized Interest Paid, Net Cash payments of income taxes Income Taxes Paid, Net EQUITY METHOD INVESTMENT Equity Method Investments and Joint Ventures Disclosure [Text Block] Document and Entity Information [Abstract] Document and entity information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Business Description and Basis of Presentation [Text Block] BUSINESS DEVELOPMENT Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Employee Stock Employee Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding, December 31, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted Dividend Equivalents Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Cancelled Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Outstanding September 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Outstanding, December 31, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Dividend Equivalents Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cancelled Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Outstanding September 30, 2015 CURRENT ASSETS: Assets, Current [Abstract] Cash and cash equivalents Receivables, less allowance for doubtful accounts of $7,736 and $6,044, respectively Accounts Receivable, Net, Current Other receivables Receivables, Net, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Income tax refundable Income Taxes Receivable, Current Current assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Current Deferred income taxes Deferred Tax Assets, Net of Valuation Allowance, Current Total current assets Assets, Current PROPERTY AND EQUIPMENT, at cost Property, Plant and Equipment, Gross Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net OTHER ASSETS: Other Assets, Noncurrent [Abstract] Deferred income taxes Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred financing and other costs, net Deferred Costs Other noncurrent assets Other Assets, Noncurrent Other noncurrent assets Acquired leasehold interest, net Acquired Leasehold Interest, Net Noncurrent Acquired leasehold interest, net. Total other assets Assets, Noncurrent Total assets Assets CURRENT LIABILITIES: Liabilities, Current [Abstract] Current portion of long-term debt and capitalized lease obligations Long-term Debt and Capital Lease Obligations, Current Trade accounts payable Accounts Payable, Trade, Current Current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Current Accrued expenses: Accrued Liabilities, Current [Abstract] Payroll and employee benefits Employee-related Liabilities, Current Self-insurance reserves, current portion Self Insurance Reserve, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current NONCURRENT LIABILITIES: Liabilities, Noncurrent [Abstract] Long-term debt and capitalized lease obligations, less current portion Long-term Debt and Capital Lease Obligations Self-insurance reserves, noncurrent portion Self Insurance Reserve, Noncurrent Other noncurrent liabilities Other Liabilities, Noncurrent Total noncurrent liabilities Liabilities, Noncurrent COMMITMENTS AND CONTINGENCIES Commitments and Contingencies SHAREHOLDERS’ EQUITY: Stockholders' Equity Attributable to Parent [Abstract] Series A preferred stock, authorized 200,000 shares, $.10 par value, none issued and outstanding Preferred Stock, Value, Issued Common stock, authorized 20,000,000 shares, $.01 par value, 6,491,000 and 6,388,000 shares issued, and 6,259,000 and 6,156,000 shares outstanding, respectively Common Stock, Value, Issued Treasury stock at cost, 232,000 shares of common stock Treasury Stock, Value Paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Total shareholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and shareholder's equity Liabilities and Equity LONG-TERM DEBT AND INTEREST RATE SWAP Long Term Debt And Derivative Instruments [Text Block] Long Term Debt And Derivative Instruments [Text Block] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Groups, Including Discontinued Operations, Name [Domain] Disposal Group Name [Domain] Rose Terrace Nursing Center Rose Terrace Nursing Center [Member] Rose Terrace Nursing Center [Member] Leased Skilled Nursing Centers Leased Skilled Nursing Centers [Member] Leased Skilled Nursing Centers [Member] West Virginia WEST VIRGINIA Culloden West Virginia Culloden West Virginia [Member] Culloden West Virginia [Member] Danville and Ivydale, West Virginia Danville and Ivydale, West Virginia [Member] Danville and Ivydale, West Virginia [Member] Rose Terrace Note Rose Terrace Note [Member] Rose Terrace Note [Member] Arkansas ARKANSAS Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Sales price of Rose Terrace Disposal Group, Including Discontinued Operation, Consideration Reduction in annual rent payments Operating Leases, Rent Expense, Minimum Rentals Amount of mortgage loan paid Extinguishment of Debt, Amount Pretax gain on disposition Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Tax expense associated with the gain Revenue Disposal Group, Including Discontinued Operation, Revenue Consolidation and Basis of Presentation of Financial Statements (Textual) [Abstract] Consolidation and Basis of Presentation of Financial Statements (Textual) [Abstract] Consolidation and basis of presentation of financial statements. Consolidation Consolidation, Policy [Policy Text Block] Basis of Accounting Basis of Accounting, Policy [Policy Text Block] Recent Accounting Guidance New Accounting Pronouncements, Policy [Policy Text Block] EX-101.PRE 10 avca-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`#",94>)6B0\O`$``"88```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[#,!"$7Z7*%36N;?Y%>P&N@`0O8))M8S6.+=N4\O;8*2"H"FJ! M2G/)3V>],\DZWZ47#R^.PF!IVBZ,BR9&=\Y8J!HR*I3649>4J?5&Q73K9\RI M:JYFQ,1H=,PJVT7JXC#F'L7DXG9!WNN:!I%\JY5EO=1W: MZ5175-OJR:0E94S6=)#T8G"G?+Q1)K5@RY;UPNK(RZRS_S$,SI.J0T,435N& M^-)2V.2_4MZ=KVBJGMJXD_';NRL]M7U-:+1[L[I>IBXA_38NDAJV]89>DXKND!I9:_\G[?:=4UM-6AKEPCQ]%HSS5]]&G^6[^-CX7 M["]'GFM__=W0>S&P_K1'2.R40X#DD"`Y#D%R'('D.`;)<0*2XQ0DQQE(#CY" M"8)"5(Z"5(["5(X"58Y"58Z"58["58X"5HY"5H%"5H%"5H%"5H%"5H%"5H%" M5H%"5H%"5H%"5H%"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5OE!5M;_/3!Y!5!+ M`P04````"``PC&5'2'4%[L4````K`@``"P```%]R96QS+RYR96QSK9++;L)` M#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL M#C2B]AQ2U\=43'X,JQW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6: ME((C-Z."N[_8_`)02P,$%`````@`,(QE1\3+)$.4`0``/!<``!H```!X;"]? M&?/ODKC;671NJN@^S]^;: MANWP?Y]5,?9;8T)1N<:&AZYW[;!Z[GQCX_#I2]/;XF)+9SC/E\9/YV2'W<_9 ML^-IG_GCB;+9B_6EB_OLK?.74#D7@QE?]#!L,"S?>O>?[;OSN2[<8U>\-JZ- M?U28KPTRDP[B=!!#@B0=))"@>3IH#@E:I(,6D*!E.F@)"5JE@U:0H'4Z:`T) MVJ2#-I`@RA49C-&;%;T9HSC-&;U;T M9HS>K.C-&+U9T9LQ>K.B-V/T%D5OP>@MBMZ"T5L4O05T5Z)=EF#T%D5OP>@M MBMZ"T5L4O06CMRAZ"T9OF>@=*NO=Z3GZNBW#O6N^#5>+)GB'>+NZ^Z>,4]7[ MR(G6<=C)F?%Y=Q3'J9\AYM=%^>$#4$L#!!0````(`#",94?R,T.IM@(``&\* M```0````9&]C4')O<',O87!P+GAM;+U634_C,!#]*U9.<("4E@5M52)!6^TB M@:C:+GMVG6EKD=C!XT2POW['#BTI)%G:P_929_S>?+P9.QDH[/0G1F=@K`1D M+VFBL$_&JV!M;=8/0Q1K2#F>$D31[E*;E%MZ-*M0+Y=2P$B+/`5EPVZGK=Z#%#G69]2X^@U2XRW%86OSS*5- M`!^6$V[L?Y+"U[01HG<95*K?N&!59+MZE99,#)E0ZU0 M)S*F(8O9#4^X$L!FZP,XO:]S9I;^7,9X`.?;`9R+`SB7M9R;'*4"K$_\W1') M[KMQPU$BTTLV,5#/F8)PK;L60N?4.K5B/W+R0)+6PN^T6IW,P:1L!(NRX[X, M0,NFW#;4B;GQ3;KGEK#UB/9]+^W8T9PODOI.MDK8/?NR*F\Q\+B=<30"RV72`&LM MNGN^_RAVFX[IAU'\1U[-PGI:/<>]$6LY?F?/.%,JIWZ>FSDSNO3C_9O>JV]Z M.Z>[UUEKTZU^N%K;4T_QY><)L'T.[";2EPYN?5J?7MP?7M/A[N=E]!=02P,$ M%`````@`,(QE1PQ+G8(^`0``:0,``!$```!D;V-0-R8PX>;9!M$Q0H+8@.9A$BM,3*ZLUQQCZ-?$ M<;'E:R#3HK@D&I!+CIP<@+D;B%E=2<&$!X[6]W@I!KS;^2;!I"#0@`:#@=`) M)5G];+;&MJ8BH[ZNHN.&!UQ8J58*Y$TWEOU.QC'.30/OW]TT/*D*RO MW`S);TBI4EFUZ_'2;[YF\TK/LA_JWCD\&T7538P)F[31J9EIL^$TA"$%XY M5-:621 MA'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_> MX%#BVR]*+41B1%G\@MNN01.+5)#3(3 M/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8: MXIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7`\:V@S&L%&KQMUAVC2 M/'K^!?F<-0HACA*FNVB M<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y`\FIS_I,C0'HYI9";V$5FJ? MJH,@H%\;D>/N5Z>`HWEL:\4*Z">P'_T=HWPJOX@L`Y?RY]SZ7ON?0] MH=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[ M9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^`VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X M&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90 M-!1M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q6\8#*Y"B?$R,1>APYY=< M7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9 MKF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E M.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5'`86%S+D4.Z2D`83``>LX=SFWJXPD6L_UC6'ODRWSEPVSK>`U[F$RQ#I'[!?8J* M@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\U*M:I60K$3]+!WP?D@9CC%OT M-%^/%&*MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8- M-!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0````(`#",94=L#\\L M60(``&X+```-````>&POY-V1OQ*5<]RHMH*])M^E\-@MOZ6FTY]:KT:7X'L?S]')+71? MLP3+F?UK/%S2Y^O]5V:_3CB0^;Y5IJ9.4>TWYZK, MO$7^3YK7]JR-QKC5%CL4)#6ABO"U!F0>,O=&-]WJ6'U+U)Q9TW=#NZI0HA^_ M6UDT689S5%/U0)9"V<4(]O9/(S^8=E[SCB*"O?T+9Z1F-U9!_\*._P%02P,$ M%`````@`,(QE1[%E'8"@`P``R@P```\```!X;"]W;W)K8F]O:RYX;6R5EM]/ MVS`0@/\5*T_L@;5QVC*J==*@'4."#5&T/;O)E5@X=K"=POCK=T[HN+8N6I_: M_/!G^^[SY3Z[\9.Q#PMC'MASI;0;VTE2>E^/>SV7EU`)]]'4H/'9TMA*>+RT M]SVS7,H/--*@]V*CQ<6-/44M\C*V%+:9V?A^VV;U92RTJ^A'7C ME2O-TW=CY8O17JAY;HU2[:CPH!V$,[A_=W"-7N8;+WJQN`V9F"2C/@)7TLF% M5-+_F23M?P5A)[VMK;3A?_O'=!N<=8J9T`6;:8\4=JF[Y&%HPAKPY#(JB=:43/>;-P\-@$3V:KK>FII^FAHJ:G%$5-32.J[DLN.\)2K:BO MG/K*([Z^FV.>4A3UE4=\C>7G=47N`P5M%-R(N_]`1U/P0JK-T=1:'K'VW3CS M`451:WG$VG%EE-Y>;34;AWF^.:HPSSB\/[,MS2*HB[SF,MXA"&*:I]0 M%%6;1]3>OZI;#!4M%)RJS0]2>X[]7$&_ME3M[%"U,ZIV1M7.(FJ_C^(41>7. M(G+OJX2[&&PO=V]R:W-H965T&ULA97+;J,P%(9?Q>(! M"C:7A(@@-1E5G<5(51L@]> M$B+`9U.W?.^50G0[W^=%21K,GVA'6OGE0EF#A>RRJ\\[1O!9FYK:1T&0^`VN M6B_/]-@;RS-Z$W75DC<&^*UI,/MW(#7M]Q[T'@/OU;44:L#/,W_PG:N&M+RB M+6#DLO>>X>X(0R71BM\5Z?FH#53R)TH_5.?G>>\%*@=2DT*H$%B^[N1(ZEI% MDN2_-N@74QG'[4?T%SU=F?X)"!,[G@6RW>:?]*[!QB%;"@ M-==/4-RXH,W#XH$&?YIWU>IW;[Y$H;6Y#<@:T&`(MXN&T!K"P0`C/5.3F9[7 M#RQPGC':`V86H\-JS>$NE'^N`%P/RBEQ3PGDG\JS>QYD_EV%L0HT4AR,`@X* M7\8>`,@%F-B1MJ-YP-$H0C<@=`'"\0Q";8_<]LAEC\;V2-OC:7YCQ<$H$C<@ M7@7$VKZ9`F*M:`W`*%*8IO$,)5FE)#K&=F$:1I&Z`9M5P,9L@V"!8"4S6V6[ MBM@:/UI`6,G,9DE7$:GQ1PNK820H@+$;HDZ(%0H,#.;;KDHF964U,RL.G:4[ MI=C*W"S\KX=F.T-QUN^48LH3IDL46^3!#,59Q%.*J6($YQ?F:#4)BE,8HV\H M?W3X-81=]:7`04%OK;Z#1J/#Q?.,].'Y)<^S#E_)+\RN5C4Y")4G4]]ZU=KYK7OCJ>W+=VT;W6==G^MW%5 M[ZPY`V72YV;E^^5OWWYO+541OT6.&VJ;KKW\7VM>N;VA=9 M+NKR)WX>3]?/"_['IE1LOH"@`N)6`!1;0%(!^:Y`@LFN[?JC[,OUJFTNBQ8? MQKD30I&XY`L.=6J_>UD*LDK>Q'D+$';(A)$P41,@;D@S7 MOX403E77MV7EUA>3R-F5^2$C4!$9I"&H8(@"W8^B8HF49C$ M3"^B[Y,@HI3(&*H@"D0FYK/H:!:-63(F"R(@M62B(&1-((B)!C$8Q#)!"%$* MF"`$29G/)\FB23*L(6>2(*(UPQ2_,Y,<-IK#8D=+F1R(&.;I%8AD@6&71U/D MF(*YY1M$++!]%:$L!3.?9'1J)`JDF$4P68@QJ;8,5A`V/)U0/X%9+4[SH-(D M,RXVQ$":*ZNX0,CEUII0H%E%3@.A(R5SH0TQ#R:5DAELA>>T3B'@7(A+%\B6 MFDN$C,I!<1W(8])J'<@SJ][)2P10F3+4">/"!!T?$,0`:,4^<\*$M:$6Q;T) MAEY:7!YD0'-#I_"4R0,2A[@[(:.W(Y<&F8R_-P@I$Q`7Q/T))%!.Y,0H2-FQ M0)Y5`($T<8]"_H$T^8?2Y)$T(JY2@?Y3W,N%F$QK;EAZRJJ`)41RT4>&%,B[E&![E/G4Y^O?P"-<0G MG<)/*;DV(0-*9HRP"\)TEH9N<5RC`MVGN!<#,59RKX_"4R!"PR$N46'(-EP: M$JUAPU!%-J!0,:O0Z:,F\V6!&N+B$R0U3L+$@,XLYQJ/*:-"+8JK3Y#6./41 M`V#YA_T+"PP%&9>?I,D?)S]BC&!?F9Z2H5F^C,M/HK$T)S_/F)Q;#A2$J0Q" M3TO&U]D2A:5#-7Q@I8VRXM:+&V(46&[)5WA,!-=1,JX^2;[BU$<,",/-[`J/ M*6$"RW\9=Y_4M/C@\O@II'V_[3+-XQ?GT@2FM#)N/VFH=W%;(\@8(RR$L8*P M89F7A\9G?!(I:>G\;DI[SVP\8\-,\3LS33)KTNE80/T%^U[A4\YWL]@T3WRRIP0Y MG,M#FX^I`?;FT%POS[-0GK@]E7Q_AV?R2%J<&\7M_=PP$5I@J@_L5JIHK]@0 M\\`O,#VE0E-S%7>GTN0A+HU?5ZS)CQ3]-/0S(,K=[>#RNW[\6LV M?&_QQPH\Z)NS_^WE]@/0^G]02P,$%`````@`,(QE1]KT^@A9`@``HP@``!@` M``!X;"]W;W)K?;3AVUE/VSDM"A/71U"W? MVZ40W8OM".M?'*AK,%"-MG5X1TC^#R8FMI!KALY#:Y:.\^&OE>6 M9_0FZJHEK\SBMZ;![.^!U+3?VY[]Z'BKKJ50'4Z>.:/O7#6DY15M+48N>_N+ MMRL\I"2#XE=%>CZI6PK^2.F[:OPX[VU7,9":G(0*@65Q)P6I:Q5)COQ'!_T_ MIC).ZX_HWX;I2OPCYJ2@]>_J+$I)Z]K6F5SPK19OM/].]!Q"%?!$:S[\6Z<; M%[1Y6&RKP1]05NU0]O`DCK5MV8"T`8T&+S`:?&WPGPP.D`WS^HH%SC-&>XO! M9G18[;FW\^7*G2P^=,HI<5L)Y$KEV3V/DLRYJSA:@B:2`TC0NJ+0"G^4.'+\ M$0(M0?A3"`00Z;+?7_('4[\_^&-WCA@/DA8FH26Q'ZV+"A!%;A`LDP2;)`$, MX\T'2:8D('%?GC3I%.2S9L81;G*$P/&T:>&4`R3RVY:_=5FQ*)O11)LT$=#X M!AJ0F$">%3.&>),A!H;`P!!O,CPK9@S))D,"#.'ZSA\2O?.NZ?58$,U(TDV2 M%$@BPVJDDXTWOB$KPAF12JL;2)ZK/U$#D]9$0>J9F1Y"/TG6F1:SXYP),EN< MF)AT"D5ANL&DA5X8K3,M)LLY$V3+.#4Q(9V1T0;2H@Z(G,EQTN$K^8G9M6JY M=:1"GDS#,7*A5!`9QWV144MY8Q@;-;D(58UEG<$9"@U!N\>58+R7Y/\`4$L# M!!0````(`#",94?,8Q@&\@4``'8@```8````>&PO=V]R:W-H965T&ULE9I-2?0KP6P_Z^9G^UI5W>K7\7!J[]>O7?=VM]FTCZ_5 ML6QOZ[?JU/_EN6Z.9==_;5XV[5M3E4_GH.-APQG3FV.Y/ZUWV_.U[\UN6[]W MA_VI^MZLVO?CL6S^3:M#_7F_AK6]\&/_\MH-%S:[[6:,>]H?JU.[KT^KIGJ^ M7W^#NT*R`3D3?^VKSW;R>35T_J&N?PY?_GBZ7[.A#]6A>NR&%&7_ZZ/*JL-A MR-2W_`\F_6IS")Q^MME_.\OMN_]0ME56'_[>/W6O?6_9>O54/9?OA^Y'_?E[ MA1K4D/"Q/K3GGZO'][:KCS9DO3J6O\SO_>G\^]/\)688MAS`,8"/`6,[RP$" M`\17@"0#)`;(:UM0&*!F+6R,]O/(Y657[K9-_;EJS'2_E<.J@CO5S\WCJCU? M[`>M70]`/Q>[[<N]U4TY$Q2!0K!GXJ M0TKT-=%/Y8;B@O,D]F,%8HPIB):514%ED5$6$)KH2F8@B"8K[U*5@30H1H@RD!*:+6M*@IH2 MHXGH;FH0+2)JI@RDU+Q8.9H,!'$44:*0TBSRK+_!#P.R@&&Q('0A`S&U3K.1 M`DH94DJ3:]!27'FJ,2Q:EZO,N$Y"U(/4,KJOE90T]+B$`='K'#$>2T'=AX7E MI.X+D4??HBNZ^HQ?)<1HI\AP%A%4AA0(>N8XSHDDJ`(I"3ZW@+"1@G'2Q)--R*E36.O28L?*4EJT[;30&JS6#S)YFH+>SQ$ MP866(@,0D=H,)30I#6V^+YZ4,FR0)[Y)"]L\Q+@=I809YD8QL@(A!9(8I'RD M^KTH)A^C'!DA5Y;`7'8VIF&^R%IW8M2ST M1N8IZR)\QA7H>C";A&0Z-@BQ6P`_E8W4O)I.J7RDN/13Q5H(*YXA(Q>[;-[$?9$(9<7^VS`Y#6:LA&;+_?9 M"$G/>I^-D`PM^+`S"G75@E=7+GAEYXS6IZY<\#:=TIY5Z,H-&Z=`XP1*1HK4 M_UW^^G+!+HG7URU_?5D[7+5A8Q;V%#PO/^"HC:Q:17'9E5P^OMQQIEN+D[FS,-2^7CC1+39_.&&F;R4O58]6\G%]GMZO'^OW4 M#3,_N3J^,O_&AY>RL^LIW&6P<#V'N\*\$/]*O]N^E2_5GV7SLC^UJX>ZZ^KC M^;WM9$6(`A^,-G+M54JU*PAE41&&Y0-O2:/?'+A@ M6.FM**%L!<%[2V(4(M]_A`S7C9X%W M#KS69:5,`*8)''C[FI%&UKP!@AS6WG.PVL8&80&_:]+)T1H8[SO.W\SFYW[M M^<8"H:101@'KQXEDA%(CI!._]YJ7E(8X7I_5O]MJM?L=EB3C]$^]5Y4VZWM@ M3P[X2-4K[WZ0O@3KL.!4VE]0'*7B[$SQ`,,?[EDW]MFY-TN_ITT34$]``V'( M,TT(>T)X(40W"5%/B+Z:(>X)\:<,T-5N.Y=CA=-$\`X(=]HM-G^J8!7KLRF` MM$'=-.D9@#Z+-#FE0?"4P),1ZC%HA-DXS#*8A^2]S("`VL#@`DVYN,J`+!W- M)\@<8GD#DM\5V?XG:@`.B&R.)[Q[=5Y_'=B=8% M?V!GVL@W!];6A9#=]NCQ%WV?4'!0^A$MRQBNM?9W?A@M6W$->IBP_S M+!O]O)HWL0]AXP$8`G`7T,TS'A!`0/`90*P!!`+(_\X00D!X-X-GO.O*984H MTJ1E5Z%5J%PRP%$@L"_R\;KG9DU;8_Z MML*=';LT0FUTO='N1O2(U9E[-[Y!JRT:&<_4#4J?T9_R:7(NCO17T1[+ACNO M3,B37A_+!\8$E0G[#[*4)WG'ZSH5/0C5C&2[-;<>TQ'L?+O$=3?)]!]02P,$ M%`````@`,(QE1WB*I6PX!0``41P``!@```!X;"]W;W)KR_ M7SY>IZ'B'/>F^>AC\]K@QX>POE;UK^90%.WB=WDZ-X_+0]M>'E:K9G?YZHN\[;[6+^LFDM=Y/NA47E:Z3",5F5^/"\WZ^&['_5F7;VVI^.Y M^%$OFM>RS.O_ML6INCXNU=)]\?/XK6;G\LBW-SK,Z+NGA^7'Y5 M#YD->V0@_CX6U^;N_:(/_U15O_H/?^X?EV&?H3@5N[;O(N]>WHJL.)WZGKHC M_XM.WX_9-[Q_[WK_-@RWB_^4-T56G?XY[MM#ES9<+O;%<_YZ:G]6U^\%QF#[ M#G?5J1G^+G:O35N5KLER4>:_Q]?C>7B]CO])0C2;;Z#10-\:W(XSW\"@@7EO M0,-(QV3#N/[(VWRSKJOKHAY/QB7OS[EZ,-W,[1;-\&4WI&;9`]U,;=9O&V7" M]>JM[PB,OF.V8&[$JNO]=@@]=XA)AS$R4:)X)AL9TJ&93V*]22R2F.E1['V2D0F2,.2A;(0, M$TQMC3IB1)-Z1).-(A.G:CHB- MM##<#)"VS)6:>I.D&(H5HHR,)2U`68HK[:ZG293>8YXL*D282`@#2(-7I8(K25I-@`)U;\*9-,#BF'&#\@M3P9@D#'OK M("5H8FXM^.VI M$B02+O,MH,"&POK-'&4TLT$JOT(5'$J20QTDRBT#16SEH/T6U;`H218%%$6) MY'1'<:M3^RVJG46EJP=00$DJS8[#HKLZ8YK'[U$-CY)D=0?%B;3Y@F(GQU\F M:N/*%:8+O_VTLY^D8D"!B<2=P6&D-1?(KS\-LUE)QX"".!1+1F#0=)J`!!$7Q>]/`W]::7,! MY)L;UY=6"7,5FUF!3F]MX48;,5WXRT<#[5G)P8""KJX32XIW+K'SD]RB0;HUSMT+D-RDIMX=+85PE*IW.[$9Q MA1OY"U&"1R.I3`?4E6U270PJZ##F-H_\4B9W3R]=-X#$4(EE?AV@62%/"A2"D&/.6WZ'$AP:2QL,(!TK:;MS M%*5,O63]&K70:"P]#0"D/_ZB-'D<8-UM_XU^/3[S&#VUU<0_P;D\1-_\#4$L#!!0````( M`#",94=8J;LLI`$``+$#```8````>&PO=V]R:W-H965T&UL M;5/;;J0P#/V5*!_0,`S35B,&J=-JM?NP4M6']CD#!J(F,9N$H?OW3<*EM.*% MV.:<8SMV\@'-NVT!'/E04ML3;9WKCHS9L@7%[0UVH/V?&HWBSKNF8;8SP*M( M4I*E27++%!>:%GF,/9LBQ]Y)H>'9$-LKQU7_%;GWU%V[A$>6;J%SKBTTHJ:#FO70O./R&J85#$"Q1 MVO@E96\=JIE"B>(?XRET/(?QSWTRT;8)Z41(?Q#8F"B6^<0=+W*#`S'CU78\ M3'!W3/U%E,3&H*_0T@#PC1?YM=C=[7-V#4(3)EUASA-F03"OOJ1(MU)\HZ>1 MGF[3]UOT_;K"_51AMBV0;0ED:X%L$CA\;W&-.<^8VQ])V.I.%9@FKHXE)?8Z M+NHJNFSG0QIG\@4O\HXW\)>;1FA++NC\9.,8:D0'/GUR]G<234+IAW MWC;C2HV.PVY^(,LK+3X!4$L#!!0````(`#",94>"6TH_I`$``+$#```8```` M>&PO=V]R:W-H965T&UL;5/;;J0P#/V5*!_0,!FZTXX8I$Y7 MJ]V'E:H^M,\9,!`UP6P2AN[?-PF7THH78IMSCNW8R08T;[8!<.1=J]:>:.-< M=V3,%@UH86^P@];_J=!HX;QK:F8[`Z*,)*T83Y(?3`O9TCR+L2>39]@[)5MX M,L3V6@OS_PP*AQ/=T3GP+.O&A0#+,[;P2JFAM1);8J`ZT8?=\9P&1`2\2!CL MRB:A]@OB6W#^E">:A!)`0>&"@O#'%1Y!J2#D$_^;-#]3!N+:GM5_Q6Y]]1=A MX1'5JRQ=XXM-*"FA$KURSSC\AJF%VR!8H++Q2XK>.M0SA1(MWL=3MO$Z7R;OM^B[]<5[J<*TVV!=$L@70ND MD\#=UQ;7F/.,N?^6A*WN5(.IX^I84F#?QD5=19?M?.!Q)I_P/.M$#7^%J65K MR06=GVP<0X7HP*=/;FXI:?S[61P%E0OFP=MF7*G1<=C-#V1YI?D'4$L#!!0` M```(`#",94?L5XNHI@$``+$#```9````>&PO=V]R:W-H965T+;$]5H+^^<""H*91H\3ZNTJ1U&/\<^43;)O")P!?"?9:,CXV2S2?A19%; M'(@=M[83\01W)QXVHB0N%8-#1R,@#%[DMV)WG^7L%H4F#%]A+A-F0;"@OK3@ M6RT^T7FB\VWZ?HN^7SO<3P[_T_^P)7!8"QPF`?YYQ#7F,F/V_S1AJSW58)MT M=1PIL3?IHJZJR^U\2(?(/N!%WHD&?@K;2./(%7TXV70,-:*'T#Z[.U+2AO>S M)`IJ'\.O(;;CE1H3C]W\0)976OP%4$L#!!0````(`#",94=^@\RFI@$``+$# M```9````>&PO=V]R:W-H965T[#2E4?=I\=&,"J[:&V"=V_7]M<2BM>\,QPSIDSON0#FC?;`CCR MH:2V9]HZUYT8LV4+BML[[$#[/S4:Q9U/3<-L9X!7D:0D2Y/DGBDN-"WR6'LQ M18Z]DT+#BR&V5XJ;?Q>0.)SICLZ%5]&T+A18D;.%5PD%V@K4Q$!]IH^[TR4+ MB`CX(V"PJY@$[U?$MY#\JLXT"19`0NF"`O?+#9Y`RB#D&[]/FI\M`W$=S^H_ MXK3>_95;>$+Y5U2N]6832BJH>2_=*PX_81KA$`1+E#9^2=E;AVJF4*+XQ[@* M'==A_+,_3K1M0CH1TH5P3*+QL5&T^_0 MT@#P@Q?YK=@=LYS=@M"$25>8RX19$,RK+RW2K19?Z&FDI]OT_19]OW:XGQP> MM@6R+8%L+9!-`O=?1UQC+C/FX5L3MMI3!::)5\>2$GL=+^JJNMS.QS2>R2>\ MR#O>P&]N&J$MN:+S)QN/H49TX-LG=P=*6O]^ED1"[4+XX&,S7JDQ<=C-#V1Y MI<5_4$L#!!0````(`#",94=XD5W4I@$``+$#```9````>&PO=V]R:W-H965T MD<>)%UXT*`Y1E;>*74T%J)+3%0G>A]>CSO`R("_DH8[&I/@O<+XFLX/)4G MF@0+H*!P04'XY0H/H%00\HG_3YJ?*0-QO9_5?\=JO?N+L/"`ZI\L7>/-)I24 M4(E>N1<<'F$JX38(%JAL_)*BMP[U3*%$B[=QE6U+6="!U,C]Q?1$%L#'J'E@:`+SS/KGEZ.&3L&H0F#%]A MSA-F03"OOJ3@6RF^T'FD\VWZ;HN^6SO<30[OM@7V6P+[MI.-9@ZCHXE!?9M'-15=)G.>QY[\@G/LT[4\$>86K:67-#YSL8V5(@. M?/KDYI:2QK^?Y:"@8?4$L#!!0````(`#",94?< M10C[I@$``+$#```9````>&PO=V]R:W-H965T8:]DZV&9T-LKY0P'V>0.)SHCLZ%E[9N7"BP/&,+KVP5:-NB M)@:J$[W?'<]I0$3`WQ8&NXI)\'Y!?`W)[_)$DV`!)!0N*`B_7.$!I`Q"OO'; MI/G5,A#7\:S^&*?U[B_"P@/*?VWI&F\VH:2$2O32O>#P!-,(AR!8H+3Q2XK> M.E0SA1(EWL>UU7$=QC]WZ43;)O")P!?"CR0:'QM%F[^$$WEF<"!FW-I.A!/< M';G?B(+86/0.+0T`/WB>7?/=3YZQ:Q":,'R%.4^8!<&\^M*";[7X1N>1SK?I M^RWZ?NUP/SG<;PND6P+I6B"=!-+O(ZXQYQES^*\)6^VI`E/'JV-)@;V.%W55 M76[G/8]G\@7/LT[4\$>8NM667-#YDXW'4"$Z\.V3FP,EC7\_2R*A&PO M=V]R:W-H965T8T8I$Q6J]W# M2E$.R=D##5BQW:QMAN3O8YM'2,0%=S=5U=5^Y`.:-]L"./*NI+9'VCK7'1BS M90N*VROL0/L_-1K%G4]-PVQG@%>1I"1+D^2&*2XT+?)8>S)%CKV30L.3(;97 MBIN/$T@/6=CR&PO=V]R:W-H965TK%=DWL8QL5."[@N'O[`?ZI M.WDW!HZ_/SB0#VA?70O@R;M6QIUIZWUW8LR5+6CA[K`#$_[4:+7P86D;YCH+ MHDHDK1C/LGNFA32TR%/MV18Y]EY)`\^6N%YK8?]<0.%PICLZ%UYDT_I88$7. M%EXE-1@GT1`+]9D^[$Z70T0DP"\)@UO-2/J'[+RK5V/O#4DP]XD7>B@9_"-M(X*7&A<=N?B#+*RW^`E!+`P04````"``PC&5'4[KU/*4!``"Q`P`` M&0```'AL+W=OL?EI"("[:'[V?&,RXG-&^V!W#D74EM M3[1W;C@R9NL>%+=W.(#V?UHTBCM_-!VS@P'>1)*2+,^R>Z:XT+0J8^S%5"6. M3@H-+X;842EN_IU!XG2B.WH+O(JN=R'`JI(MO$8HT%:@)@;:$WW<'<]%0$3` M;P&37>U)R/V"^!8./YL3S4(*(*%V08'[Y0I/(&40\L9_9\T/RT!<[V_JWV.U M/OL+M_"$\H]H7.^3S2AIH.6C=*\X_8"YA$,0K%':^"7U:!VJ&X42Q=_3*G1< MI_3G6S;3M@GY3,B_$%@RBFD^<\>KTN!$3+K:@8<.[HZYOXB:V!CT&5H:`+[P MJKQ6>5:4[!J$9DR^PIP39K<@F%=?+/(MBT_T/%ELT_=;]/TZPWUR?RBV!8HM M@6(M4,PE'CZ7N,:V#WYLT4NG@<+@]D.655O\! M4$L#!!0````(`#",94?[^K$]I@$``+$#```9````>&PO=V]R:W-H965T%;_EJ8-[J_"P3.JW[+R;3";45)!+7KE M7W'X#M,(QRA8HG+I2\K>>=0SA1(MWL=5FK0.XY_C3-LF\(G`%\)CEHR/C9+- MK\*+(KY./&Q$25PJ!H>.1D`8O,AO!<_N\R#O1P$]A&VD&PO=V]R:W-H965TVF6C@@C+!>Y!J2@4&O^=-3]: M1N(ZOJK_3-,&]V?AX![5'UG[+IC-**FA$8/RSS@^P#S";12L4+GT)=7@/.HK MA1(M7J=5FK2.TQ_^?:9M$_A,X`OA6Y:,3XV2S1_"B[*P.!([;6TOX@GF!QXV MHB(N%8-#1R,@#%X6EY+G6<$N46C&\!7F-&'R!<&"^M*";[7X1.=3BVWZ;HN^ M6SO\+'K1PB]A6VD<.:,/)YN.H4'T$-IG-[>4=.']+(F"QL?P:XCM=*6F MQ&-_?2#+*RW?`5!+`P04````"``PC&5'$@(8[\,!``![!```&0```'AL+W=O M=O"LD!Z$ M8.K?!;@,#O%D:]FB.7 M^U7*5[?X69YQY%(`#H5Q"LP.-W@`SIV0-?X[:;Y;.N)Z/JL_^FIM]E>FX4'R M/VUI&IMLA%$)%1NX>9'C$TPE[)U@(;GV7U0,VD@Q4S`2["V,;>?',>PDPM'VS/W!^$3M011(^Z#-4&,'L(7GV2VG\2XC M-R@*$$0J[Y8T"V+#W0:++;INRWZ;IWA+K@?DFV!9$L@60LD4XG) MQQ+7F,N,V6^;[+\UV4\"Z147^A*BD-6/OHSAY58U^" M9<&A,FYZL',5FB,LC.SG5E_>F_P_4$L#!!0````(`#",94=*:XYNP`$``'L$ M```9````>&PO=V]R:W-H965TEW.:?T-!^4?C8M@$6O M@DMS3%IKNP/&IFQ!4'.E.I!NIU9:4.N6NL&FTT"K0!(] M1P3`'P:#6@7JA@O<`>=>R!F_C)IOEIZXG$_J M/T.U+OLS-7"G^%]6V=8EFR:H@IKVW#ZIX1>,)>R\8*FX"5]4]L8J,5$2).AK M')D,XQ!W?J0C;9U`1@+Y0,#1**1Y3RTMQ`W$&4R(2@R]`D M'N`*+_)+0;*;'%^\T(@A"\PI8K(9@9WZ;$'6+-[12;18IV_6Z)MEAIOH?K-9 M%]BN"6R7`MOH3]+W)2XQIPGS29&[;TUVHP#YPF3"?%+)_EN3_2BP_<)DPNP^ MF.#%[1"@F]`$!I6JEZ'E%M&YSVY)N%UO\"+O:`._J6Z8-.BLK+NCX4+52EEP M]NF5.ZK6O03S@D-M_?3:S75LCKBPJIM:?7YOBO]02P,$%`````@`,(QE1SGD M?=6G`0``L0,``!D```!X;"]W;W)K&UL;5/;;J,P M$/T5RQ]0$R=INA%!:KJJVH>5JCYTGQT8P*HOU#:A^_?U!2A=\8+MX5QF/.-\ MT.;=M@`.?4JA[`FWSG5'0FS9@F3V1G>@_)]:&\FR>X@A>#;"\E,__.(/1PPAL\!5YYT[H0($5.9E[%)2C+M4(& MZA.^WQS/NX"(@#<.@UWL4L$.A+H3+C+8N+)**;YFSE6Y$8/R*2K[5CHX.9( M_464R,:@S]#B`/"%%_FUH/0V)]<@-&+H`G-.F,V,(%Y]MJ!K%C_H-%FLT[=K M].TRPVUR_W58%]BM">R6`KNQQ,//$I>8\X2Y^\^$+.Y4@FGBZ%A4ZE[%05U$ MY^F\I[$GW_`B[U@#?YAIN++HHIWO;&Q#K;4#;Y_=[#%J_?N9#P)J%[8'OS=I MI-+!Z6YZ(/,K+;X`4$L#!!0````(`#",94=@>'ETHP$``+$#```9````>&PO M=V]R:W-H965T*'MX;NE/_3:".9\T?3$ML;8'4D24%HEMT0R;C"91%CSZ8L].`$5_!LD!VD M9.;C!$*/1[S#<^"%MYT+`5(69.'57(*R7"MDH#GBN]WAE`=$!/SC,-K5'H7< MSUJ_AL.?^HBSD`((J%Q08'ZYP#T($82\\=ND^649B.O]K/X8J_79GYF%>RW^ M\]IU/MD,HQH:-@CWHL!)*.8Y@-SK"R,'I%)5]NST,'=@?J+J)"-09^AQ0'@"R^+2TGI[X)< M@M"$H2O,*6%V"X)X]<6";EE\H]-DL4W?;]'WZPSWR?TVWQ;(MP3RM4">_/?9 M]Q+7F-.,^5DD6=VI!-/&T;&HTH.*@[J*+M-Y1V-/ON!ET;,6_C+3^KU)(Y4.3O?S`UE>:?D)4$L#!!0````( M`#",94&PO=V]R:W-H965TU%I=5>M-<.F(#68&H[8?OV]2F4;`WT M)C[PS__-$,;.1\K>>(.Q\-X[TO.CWP@Q'(*`EPWN$'^B`^[EDYJR#@FY9)>` M#PRC2@=U)(!AF`8=:GN_R/7>"RMR>A6D[?$+\_BUZQ#[?<*$CD-U_;2 M"+41%'DPQ55MAWO>TMYCN#[ZG\#A!&(ET8H?+1[Y;.ZIY,^4OJG%M^KHARH' M3'`IE`62PPT_8T*4DR3_LJ9_F2IP/K^[?]'ERO3/B.-G2GZVE6ADMJ'O5;A& M5R)>Z?@5VQH295A2PO6O5UZYH-T]Q/Q6&$:3AN$")=VDI):R7Z$8#5A@[#89.\O(5AA&$X=NQGZ3 ML3>,F<&_#*.)L]0-R38AF84`MX'J[HV/&X3K7S=P-N%#$L!V6`Q72K6B9.%] M`F<;/F)L'\8+C0R>V:4H&E2?@D+1MY+4T+@FNAICLY9^:@-@M!A_N],UU^Q1]02P,$%``` M``@`,(QE1Y7X#JN#`0``-P,``!D```!X;"]W;W)K&UL;5/+;L,@$/P5Q`<4Q\ZCBAQ+3:JJ/52*0L@(;=>@;OE"CN0 MT@NYQE^]YF]+3YS&@_I+.*US?^0&=B@_16$K9S:BI("27Z0]8/L*_1$67C!' M:<*7Y!=C40T42A2_=:NHP]IV.X]13[M/B'M"/!)F\V"\:Q1L/G/+LU1C2W0W MVH;[&YRM8S>(G)A0=`X-]0!W\"R]9O%\GK*K%^HQ\02S[3$C@CGUL45\KT4R M;1'W+1;W!9)[`O.I0-(++/]ZG&*V`V;UKPF;#*7A)WCG^B1J0XYHW7S#,$I$ M"TXC>EA04KE7/"822NO#E8MU=[%=8K$9GNGXKV0_4$L#!!0````(`#",94&PO=V]R:W-H965T*9VDFD/G2;`ZJ_JE.4K9>N]E436W_K%M3S=!T.R.LLR::W625??/0=5EUG:G]7/0 MG&J9[8>@L@AH&,9!F>65OUX-UQ[K]4J]MD5>RTO!.M5,,7M\U)63:XJKY:'6_\;N7G@HI<,BM^Y/#>S8Z^_^2>E7OJ3 M'_M;/^SO019RU_8ILN[G36YE4?29.N>_D/3#LP^<'^OL#T.YW>T_98W7A^RU:'^I\W<)-41]PITJFN';V[TVK2IUB.^5V?OXFU?#[WG\ M1X009@Z@$$"G`,J=`0P"V$<`<09P".!3`(^=`1$$1)<`,&)K6.,""^+39!B<4")N&`:F$061@D.*0$"$^(:V"`B;/A8UBR< M50JL)M0Q8$%T)2)AA8/BP%(SL$LK,[!+*YQ#"APFS.4UBEBW>EBM#Q_I'/L,BI-+-;FQ8RR#2*0BL7OA MJS0%Q!/+CH4:$5]VA$`Z`J>7:GI=VYY)9)F]&0XN`W"%I<&8D<=%M8RXJV4X M9TRO=Z[]UR2RK/7L@JTQ0"9L*7#(&`(9PR%C0(5P3)9;$,7.+3K#T6&`CF!V M=+8@(HP3NQ>.#@-T!'=UHUY"+7PQ?`EEP)>(+"F,?"V[,75W(\?1X1H=UZ0$ M(H%-E?<@Y*Z9DN.+(P<8A:5U.?X`RI$G4(YSQC5GPE[Q!D3N9]`+'D(!2)': M!]U&BU*;#TXM!VI3XO+1(FKQP8'E`&QJV8UQ?)?*D5TJQQ'CXI+!/8H$"0U; MGV#VQN>4/P2A===\Q]EMI]."GEH^\.D.Z[' M-V_C2:M.^D7B]#9S_1]02P,$%`````@`,(QE1UK\"[\C`P``A0X``!D```!X M;"]W;W)K&ULC5==;YLP%/TKB!]0_`4)$4%J$TW; MPZ2J#]LS39P$%7`&3M/]^]GXPJ#"=E\"=LX]YUZ;8[C97;1OW85S&7S45=-M MPXN4UTT4=8<+KXON05QYH_XYB;8NI!JVYZB[MKPX]D%U%1&$DJ@NRB;,LW[N MN[;$(?#Q$MYOD@]$>59-,8=RYHW72F:H.6G M;?B(-WM*-*1'_"KYO9O].#'<1LBG0.O^$%JBD)=WOF.5Y5F4LI_ M@/2_I@Z,#%93H0N)4*GM5(062T3L"4" M-B5@0+">9QGWF,94:S`Q6M:(O1HQ:*1SC=54PV`H10E"R([;`2YA>(J;)91X M5RTQ)#:"E;>B%1!@QZH!)K$GNO;JK$&'.'0,!F.:6H52KU`*0M0A9#!X%5MU M]-'D$<((E)A#"4#KA-FE%L^!N10&J=CQW`'(\N_3<@0@DC]NWU M.Q4/5DTM%(L>G)>ZB]Z9:U'0LKQJR:)WYA4SS_[XC4'BK^Q/[-^?10/-I>`EAUU'.H"P M^Z[GBXXB%LC]7?O9';LK![[QNK3 M_!/>[$P3\)\FSZ[%F?\LVG/9=,&KD*J5Z+_[3T)(KK)"#RK'B^H)QT'%3U+? MKM1]:[HD,Y#B.C1]8^>9_P-02P,$%`````@`,(QE1]\C_>77`@``(@P``!D` M``!X;"]W;W)K&ULC5?;CILP$/T5Q`&9R7`.;,S#EC#DR*.^W>V9D0[GTT M=/:?XF>MY!+2(_X79$[FYQ[DOR.TG=Y\?.P]D/)@=1DSV4*+`XWLB5U+3.) MRG]UTL^:,G!Z/F3_WLL5]'>8D2VM_U0'?A9L0]\[D".^UOR-WG\0K2&1"?>T M9OVOM[\R3ILAQ/<:_*&.5=L?[^I.MM)A]@#0`3`&C'7L`4@'H,^`N%>JF/6Z MOF&.RZ*C=Z]3FW'!%*-0&0`81FZEB-:-;1 M3IP\7V8*J]$,L1$XU%J=9+)`CZA%#K5NPT6Q3I',I+!:Q52;.-1:S6*R2!]1 MFSK4NCT5#:9*9U)8G6"JS1UJK5XP66@S0+9@;0W*PG#6MN`V#0Q^R!<:.X)F M7G;@-@UHTZ`YJF[3@,,TX#8-H`<:JT%1LM!8MV]`^P9%2XT=0#,?5'!_AT"; M"Z&E.@-HYI4%;@>"-A>:>0^`U5SF!F:.#71_9B!_9`,U*+=L8#`9O1K2G?J1 ME'E[>FVYG'4FJ^/8^P)R=/NROA'CL!I>/].4Q06?R"_3O*Q6#83W%' M2CD1U,(G0?0L!O;QHB9'+D\S<=ZI$59=<'H9)O+Q;T'Y'U!+`P04````"``P MC&5'5@@\LEX"``!>"```&0```'AL+W=O/EF=E[XWG&;K*N&O+&@;A1BOF_(ZE9=_"@]]AXKZZEU!M^ MGOE]W+FBI!$5:P`GEX/W!/='F&B(0?RI2"<&_S@FWI@X@CQ`,4?]FQ:LS8V2?;P(5-!R`7@/J`T`3X5LBD M^8(ESC/..L#MV;987R'<(W40!1!F4V4H/`U0A>?9/0_#)//OFLAAT`!SM!C8 M(WS%WDN@*8E1.'(2Z31!.$40#G,,'<%VFB":(HB&!)$CV(V+C`VFL5E:#$IG MRHQ716(K$@4+(A833$LDJQ*)DX`+$A;S`\T<5KHJDCH1M""2+M6Q7978.HEP M0<)BT``S$MFMOC4[)Q)-$VC?KJ0)`T<1C_/<#?-TH&23S+S?<-*$8R'GPBA9 M.!`'FCET..G#L8HS8I2.5?1)#&0L*MV@&2?`2<..E9QCH^U2/>%B/>NNAL[6 MT6[I>J+'][?2M]0J9_?,/SK,57\AOS:]4(<&)2=2'3,BZ,2:(2"#:J[%(U^WY1 MDXO4TU3-N6U_=B%9^^CF_5^*_#]02P,$%`````@`,(QE1V-#*(8J`P``50X` M`!D```!X;"]W;W)K&ULC5=-;Z,P$/TKB'L!C_D( M%4%JNUKM'E:J>M@]T\1)4`%GP6FZ_WXQ'E*H;,RE@/-FWOCC/7>R*V_?NA-C MPOFHJZ;;NB^W^U.K"XZCY]9T_]RX&U=B/ZS/?K=N67%?@BJ*Q^"(/;K MHFS^;>X?5FS MIBMYX[3LL'4?R/TC!0D9$+]+=NTF[XXL_I7S-_GQ<[]U`UD#J]A.R!1%_WAG M3ZRJ9*:>^2\F_>24@=/W,?OW8;I]^:]%QYYX]:?`Z>W8H+I5XX=<1I#Y[S(18F"">508 M@H9N&@*&BB3T!U"<)IC11KI/H$H2X!G28(,4&H3Q!9*XAP"NE\ ME:(!TZAI*@RA@9XDMI+$BB0,%D@4)C%,)+%R)+@2T0*'PH">8F.EV"!%O$"A M,'>Q84=3*TF*),D"B<+<&3BD;BTD)$"6S0(+@DAHV'>BU>#L>))1A*DAA59C M\U)19.&7C4UGI2I0Y$U0/\NN36"#"X*=@U#M,*M$12; M%DVKX-E9A7C9K,$N34A6F#6"(H\:W`;LTH3-&K-&U()9@_U"AG2-62-*FK5A M5M0N=1JL,6M$1<9K@=K53D"LB?_)O?\W: MX]#==,Z.7YJAF9J,WCJHAZ&!\C_A>78NCNQ7T1[+IG->N>B;CZ%3.'`N6%]` MX/63/O4]WNVC8@&PO=V]R:W-H965TL28>1]=V].5?V3L]!2&='O$':(!.>&>O]F3H4.,3X=#2$\#1CL9 MU+4AC*(L[%#3^W4EUUZ'NB)GUC8]?AT\>NXZ-/Q[P2VYKGS@WQ;>FL.1B86P MKL(Q;M=TN*<-Z;T![U?^,WA:PT1`).)W@Z]T,O9$\1M"WL7DYV[E1Z(&W.(M M$RD0?USP&K>MR,29_^JD=TX1.!W?LG^78%X4!(R+DV4<*:**8A4,9#NT$:XV(S0RQB2&>BHB5"%"8$R2F M!,DT0:)W(9L764I,KV0H3!9DP`Y:CZ#<7$KJ+"75I>1SEG1:BL+`Q+)AF9,D MTR3%`Y+L,4GN),DU26E.4#B/M7A\K*6S@E(ER*.YS&(J4V%`%"1F%O%!<-"` MR,PC0N]$&@5`D%IV!!CM.J<""VZJ!G&FR,9D=.V<"2ZXB!J46$X(&*T[I]'> MS3^Y*I_1*%!D87'[&R0++KP&6<6XO0NT>7/X2$SZ4(S;O$"[-[ M<-(>=7@XR+:1>EMR[F67.ED=6]-G*-NK.[RN3NB`?Z'AT/34VQ#&FS394>T) M89CS1P%7?>3-\SAI\9Z)8<['@VHGU821TZT['EOT^C]02P,$%`````@`,(QE M1X#;Q&)'!```J14``!D```!X;"]W;W)K&ULC9C+ MDILZ$(9?A6(?@P0(<'E<%0.I9'&J4EF)V\?0`U&'-1B%L/% M7[?TJZ5NI-VSK'[65\X;XW>>%?6;>6V:^]:RZN.5YVF]*>^\:'\YEU6>-NUC M=;'J>\734V^49Q:U;6;EZ:TP][O^W?=JORL?378K^/?*J!]YGE9_#CPKGV\F M,8<7/VZ7:].]L/8[:[0[W7)>U+>R,"I^?C,_DVU"O0[IB7]O_%E/[HVN\^]E M^;-[^'9Z,^VN#SSCQZ9SD;:7#Q[Q+.L\M2W_`J>O-CO#Z?W@_4LOM^W^>UKS MJ,S^NYV::]M;VS1._)P^LN9'^?S*04/?PV.9U?U_X_BHFS(?3$PC3W^+ZZWH MKT_Q2V"#V;(!!0,Z&HSM+!LX8."\#%S4P`4#=VT+'AAXLQ8LH;T?N3AMTOVN M*I]&)<)]3[M91;9>&YNC4?P=W]U9'YTC8.B$.0@F(&HD M%LB+L-H.C+V@2[V06J"].54W$`DB0)!8ZR3YGQ.IF\Y2-YWI8#DP6-ZR`W?) M@3MUX/8.PE#NH]\CA1@*@3"&,)%@*$&86##$G8=M"B4"\KUP69"G%>2)5FQ/ M;L2;*A*,K28B+1%KB4005!$:IE7"(+8,4<*68R-I8DG`"Z7VLII`JR8`-4@_#L&*^`B&^,C0Q\&: M^`C(8XKXA%I%(:P=!U$4PK@YB.Q(0$Y(L1B!I\#&P@2>7%RL!!H=XP#PVJ9V],84:A>+OIRE?%#K*%SH*RV!4AM@H3D`I=$4C=@\3\U&*%`DJMD( M!;I,I2^[!(I<@+5T`$H_X<-UF2I<.>%?G&+&4WT)IO:*3`40FJD&9N,CWRCQ M"D_)DB=9UF(!EF61-9D**&W@@&L7&SHQ7^[PP(WN/*9('[)<_<<"I;"2D=)] MH'1=VI*^'48CQM143-=\AR0O7XH21/7;:CI\.ZATNP38[`#%"D841 M#91-L0WI2`7(9B,9*5OQ04WU!9K"'IM@.Q^`F#/_HI:E`471W=SHBV!;A8&: M[J2$-&MR#I7SZM*?`-;&L7P431?YR=OQE/$S[Y+!O>=KA=F:9QY>EI?,CXN>EN_?:^$B>) MXJ$I[\/!Z'@ZN_\+4$L#!!0````(`#",94<^OK0GQP$``#\$```9````>&PO M=V]R:W-H965TWS.F3,>FWR4ZE-W``9]<2;T,>J,Z0\8 MZZH#3O2=[$'8G48J3HQ=JA;K7@&I/8DSG,;Q#G-"153D/O:JBEP.AE$!KPKI M@7.B_IV`R?$8)=$U\$;;SK@`+G(\\VK*06@J!5+0'*.'Y%!N',(#WBF,>C%' MSOM9RD^W>*Z/4>PL`(/*.`5BAPN4P)@3LHG_3IJWE(ZXG%_5'WVUUOV9:"@E M^Z"UZ:S9.$(U-&1@YDV.3S"5L'6"E63:?U$U:"/YE1(A3K["2(4?Q["SCR?: M.B&=".E,F/.L$[*)D-T(_NAP<.;K^D,,*7(E1Z1"+WKB6IX<,GMR%=(^:$O2 MD0/8DRKR2Y'M=SF^.*$)DRXPIX!)9@2VZG.*="W%-WKJZ>GO"36X\1H8R`27:_0\H`V?ZT@1>-X:!:?V$U MJN0@C#N)171^$P^I:^R/^,F^E7"U;S)%WI,67HAJJ=#H+(V]-K['C90&K*OX MSGKL[&N>%PP:XZ;W=J["!0\+(_OK&PO=V]R:W-H965TN^%+,PFQ":!*7[;]OOD3<@OH"R>6<<\\-R4W6 M,?XN*HPE^*2D$4NODK)=0"C*"E,DGEB+&_7EP#A%4DWY$8J68[0W)$I@Z/L) MI*ANO#PSL5>>9^PD2=W@5P[$B5+$_ZXP8=W2"[QSX*T^5E('8)[!GK>O*6Y$ MS1K`\6'IO02+;:(1!O"KQIT8C('VOF/L74]^[)>>KRU@@DNI%9!Z?>`U)D0+ MJ<1_G.8EI28.QV?UK:E6N=\A@=>,_*[WLE)F?0_L\0&=B'QCW7?L2IAIP9(1 M89Z@/`G)Z)GB`8H^[;MNS+NS7]+8T<8)H2.$/:'/,TZ('"&Z$&YGB!TA?C3# MS!%FCV9('"'Y0H!VLLU,0+/-W*L'"2=AJPMY%OD MWRC'8L+Y#JD`)3LU4F^C0;1OUR^A/N!?XJM@L0Y& MXD6PV-AN?)'/LQ8=\4_$CW4CP(Y)U59,#S@P)K&RZS^IO5"I"ZB?$'R0>IBJ M,;<]V4XD:\\W3'_-Y?\`4$L#!!0````(`#",94>K#0XP]@,````6```9```` M>&PO=V]R:W-H965T0O;K);CM6_-:FG>N[*H];O27!X7;&$O?"_>3MUP(5PMPZO= MH:ATW1:F#AI]?%S\Q1Y>E!@DH^*?0E_:F^-@6/RK,3^'DZ^'QT4TK$&7>M\- M+O+^XT-O=%D.GOK(O\#I9\S!\/;8>M^-Z?;+?\U;O3'EC^+0G?K51HO@H(_Y M>]E]-Y<7#3FHP>'>E.WX/]B_MYVIK,DBJ/+?TV=1CY^7Z9LT`C.W`0<#?C7@ MTFL@P$!<#5CB-9!@(#\C"*^!`@/U::"\!C$8Q/#H&^/U?)C);)H&7X, MCD##;S3K2<-EAFLVU@_#-5NKX;CFR6H$KME9C<0USU:C<,V+U<173=C7[5H\ M[BJ>N"T>!P>)VX%P.9"W#L1469',5ZE&33VM0L]T!,.)(/9B3HWD<#G$8XL)) MTJRF3!!%I3%A$E;!/1UD15SA+<1H7)B"6`)Q00/#"&(8C0Q+Z#;:@"CF2!@: M&);2;;2YBI`MB#FYFL?)P`72\=P)UGQ'C_Q%Y30TG-%%?081$]A2:6@XIZOZ M#"(43D[/*&Z'E&=\/(,(JQH-'[?PQ;YL8)(I+`X-'K?@>>\.3#,DBI/->92) M31YC97>R.>_$A.A$FCN>WC$E0)0AV'$:.VZQ2]TN!(V=(+`3-';B#NS6(,*2 M%31UPE*7>88$B!+?'$:E[3E*@IC8S(Z&;=@HA))%M)/R?*"++%7#BY MFF4KF3];23,C^1W9@@A-EL9%6ER09RI)XR()7"2-BU1TLD\@$@+!1=*XR)C& M\LF*&/;;D09&6F"4+Q\85D@4>E1)^_3G&?]/($+'OZ3!DS"K&/*;7]&S2A&S M2M&S2MTQJW8@2I"B*IH[=<<3XLZ*L!91-'A*T#=O!Z+_W[SPYK75.7_3?^?- M6U&WP:OI.E.-KZN.QG2Z=Q)]Z2MTTOGA>E+J8S<<)OUQ,[V@G$XZ<[;O6Z\O M?5?_`5!+`P04````"``PC&5'('")(LAKEHFJ'Z0 M`^OMET8J08T=JA/4@V*T]D6"0XS0%@K:]4E9^+DW51;R;'C7LS<%]%D(JOX> M&)?C/DF3:>*].[7&3<"R@'-=W0G6ZT[V0+%FGSRENP-Q"B_XU;%1+_K`93]* M^>$&/^I]@EP$QEEEG`.US84],\Z=D07_B9[_D:YPV9_<7_QJ;?HCU>Q9\M]= M;5H;%B6@9@T]<_,NQU<6EY`[PTIR[7]!==9&BJDD`8)^AK;K?3N&+X\HEJT7 MX%B`YP(<@@>0C_F=&EH62HY`A:T=J#O!=(?M1E1`^TF;4"=.8!=>%I6Q`4OO'Z]J%_+FIQ$]5[O.6^< MSR(OZZF[;YK#@^?5ZSTOTOI>''@I_]F*JD@;^5CMO/I0\733&16Y!X2$7I%F MI3N;=.]>JME$')L\*_E+Y=3'HDBK?W.>B]/4I6[_XC7;[9OVA3>;>&>[35;P MLLY$Z51\.W5_T(<5)"VD0_S.^*F^NG?:X-^$>&\??FZF+FECX#E?-RU%*B\? M_)'G>%:Y'7WZZR/=2.*WL1UBO137;.RNY[4/S%!LW$#0`,X&S`P&C`T8!<# MLP0C0(;_40H4%TJT&,!O'%H*N2IY:C6\RGM$EGDTJ< MG$IUX"%M&YT^Q+)=UD[=O93K6+LM0+;';/(Q\R&8>!\M$6+@"C/O,:$>\]AC M(CWF26$@,?`L;N!9WL#SC)@`])A5[RL^8SQ9MW/Q8*QX[+IX@`3).`$;(_"O M"9B*DGW)).@PI:JLP@2^'K+X!AF$X5O#\%4886P(0V%"0DR!C(`&H0364(*. M@0(=>HFN0U$8HD<\*00C)-&#%E::Y0C-()W0FDZHTB',D(["W`&+#1DI$$O` ML$8+9(H)T8.6R.3[FC6*K$E%JNT9&2>(K;J)S;I)K!$D&(&A2^8*0Q.B";/= MWBQN*$$_H*$8G:^#5"DUYTI'I\PP"APSS-!$E:Y]&E*$C36?0T4DR M3->WI&N?`%2ISJ>!OHGG"`(]9/4-,@S$KET:8CD"?=V?$10%H'-DUQ.-[$/O M&4$0)4SC:%1W0TI`J# M\6C`+G7HI1YI*.Q2!XO4P2YU`/M./$=0HA$ZV(4.O=`-.\X<0;*HNI$"]B\+ MP'G`=#49G0?#L@:6LMJ5#.$-(P5!&AF#7<:`^Z*O*Y=]8P3+S@AV68%&5H-/ M'P3=A>#K4E;"ONO*NCAJ'=,=_I=4N*VOG333RU-(=,;9"-%RRD'M9Y;T\ M0I\?&G'HS\CG@_KL/U!+`P04````"``PC&5'\B%?==8! M```_!0``&0```'AL+W=O"=T5X>@U:IX0"AK%K"L-SQ@?3Z3<,%PTHOQ17*01!<6Q*C$(5A!AGN^J`L M[-ZS*`M^4[3KR;,`\L88%G].A/+Q&$3!M/'275ME-F!9P)E7=XSTLN,]$*0Y M!E^CPSDW"`OXU9%1+N;`9+]P_FH6/^IC$)H(A))*&06LASLY$TJ-D#9^\YK_ M+`UQ.9_4O]EJ=?H+EN3,Z>^N5JT.&P:@)@V^4?7"Q^_$EY`:P8I3:9^@NDG% MV40)`,/O;NQZ.X[N33;1U@G($]!,0,E#0NP)\4R(]K92E\S6]805+@O!1R#< MMQBP^>31(=:=JX"TF[HD&1B`[E19W,LDB0IX-T(>@Q:8TX1!GV/.$R:>,5!G MF(.@M2#Q,@CR`LFZ0+PFD"P%8BN`LOQCRM1B>I?28;(P_,0EV71)?,QT72#= MK#-]7&>VF2#;KO.4^3K7/?:;'GL7$H4?/?*EA\/$NR_K)OFF2>X[D3TPR;W) M_^V&BW]]P%?R$XMKUTMPX4H?&_N/-YPKHC7"G6Y-JV^S>4%)H\QTK^?"'7"W M4'R8KJOYSBS_`E!+`P04````"``PC&5'F_Z<"IU$``#8%`$`%````'AL+W-H M87)E9%-T&UL[7W9;B-7EN!SSU=<)%1C":!H;=3BJ3)`252FRDI) M)2K376@,&B$R)$5E,((504JIAA_\#STO#?2\S*?5E\S9[A;W!DEEVH4JP`]V MBF3$7S/[P9F_OX(WZ/,F+^@]O'F>SZ7???EN/ M'M-)4G?+:5K`+_=E-4EF\+%Z^+:>5FDRKA_3=#;)O]W9VMK_=I)DQ9OO?U]G MW_]^]OUI.9I/TF*FDF*L!L4LF[VH\X)'R,I";:KZ,:G2^O??SK[__;?X#K]W MI-Z7Q>RQAG?&Z;CYZS"==M7N5D?M;&WWFC]>C6;M/RY;S[_U[^I9E8QF_[OY MICQ\DSYD^`0,<9E,TF#\["FMZFP$>U+OTB2?/=*?P[1ZRD9IW8')1MV6H4]@ M7562PR/C]+/Z(7UI7?SMRS28>7MK\T^M+URG55;BAL?J-)D%[VIX_H]_^9<8 MT/HPQIC&.AW#0,Y]E]0CV].`>+!Z\W7SHL9['L"[Q5UF6=C6,98 M'2=Y4HP`>Y"\:J"5#\-3M;ZVH=945JC;QW)>PV@A1-,1G.8V$`+`/-S># MRUO5'PX'M\/O@I^3^I%H8X1_I'^=9T])#@`.)KE)1RG\=IP10%[9F9H/7%?I-,G&*OT,G*D&"./();TU$L1(ZCH-5P]46$Y2-4L^P_#W M\V*,P[?A%@^!ZQ\#E@%;RHHYG`YPPXJ81N0`[E-X=0RGI*<)UWY;S@!A%R_S M^N;J>G!S^V?5OSQ5@S]].+]^#V?74_^#O@B!B3L"W,4'\>2G2)8=5:3!1%>W[P8W;2AD=G^?%8`.2"O. ML<"RZ^B8Y\536L^($P!RSP%R#B4D]_=9GD5HFE&D*(O%@.R/8#^XICQ-ZO2Q MS/%L@.)@QNAB^'!XR?$1^8GX;YK&+L[[Q^<7Y[?G@PBAR7J)G<#I`';E9?&P M"8N:P+G=S80*IQG,D_V'7KHJ[_+L(8YVMU4R3BV]39.715@-X+P#F,ZR]#6H MW1^-*GQ"4URPK^ODI2KSG)%H,LW+ES15=VF1WF$\MQ08JSU[ M#=U<7IX&;XMY__B_C9[9\#$(.JA"C95S"4,)*:I6@RGSV6%0$:%,W.UM:6 M*(\=M=;=W@*$KQ1(JWE*@$M55M>(JL1\VB6O2.K8'#A%8YJM;7>:_<[>T38] M@9/L=W8/#YWG90$=^7&G=^0\NMW;=Q]U%KA8)MZ"O@V(\L(+UI(`9/WNCC?> M/7QO-Q92:38&C-/(&Z%R1X;<9Z,LX)#N(YJU3^#('H$MP,*!F=4M"$@K1!8, MBC+B`8J:6;A/>M9E4@@WY]UOZI8W5U&EUJ\3I(#'=`:J>KZQLFHUG,%H)*,` MP&MLB?G07Z(=62TGHN3X=&`04*V/@=4F%?!Z@#_!9F/IVX(@#J*O M\U@[J^S/IU[S:MOC450V.$A4 M?F5$M5K_4"3S<0;/N`BM=^1@=6<)EN^N;'P'YH4HUI9.VBGBN@\B%N3MS>#C MX/+#8!A5Q`;_>CVX'$8DL>P[Y.<7)(.169",$T4EHNS>@V0&N#E<)F`E;T%O M08N<5.?Q)"O(]$?&'"J]K]"TF;=I%2K8&:C\?12VZOP2Q/`@KGP+8`*X#(@G MXO$"-+4!LH[<>`/1956]^ERT8[W*I5IR"YQY"^KLYNJ]Z!`?<&>RQZO+H3H> MG%W=#&2OZK;_KX%^@6;0Q_,A/*W@T85/"OK=5^5$B3J+Y-BNS\I@ZQ=7P^$& M+_/T?"@K'9PZ"VW'0))U!""$,-J4HN\&Z)3`L0!^@*X]+>LD=]]IV8F<'&UH M117]-HP>"J?WM[GR!YPWN!Z^OZ9G`V`+W[ M5`UOKTY^P$'.3P>7I\').A,C$JPTF4(M%K#&U3R#!;#F0NP<.:7ZV\__J>Z2 M.AN%3#^"3VH=CG2Y<#J-']V*;U\&E#Q=>=71_8VS?#X+.?N*\[2\K8'MGZ,Z M'9Q<]/&`@9+X)-35F7(?;@[TX^#\[;M;>*,/9]Q_._".<:BN/MP.;\$F`3X2 MT.0Q@J!5G)[RPG\%0+I>$H?`K1IYG/HN>A1'D#*WS. M9H\*YE8/P%^^8$\GGN*N&<\%(4!B[O0=M6C^GX(5W$9)DA@N#.`9P9V#DBO\=_F8LK M"I5U$.5:12\?"E(F/?&Z2"SZ1E'\^=AN5WGFE^'`JR`(0O0,(-JF8R[&AY/^ M\)TZN[CZ<<@"UBHX_9-;X!-13\ME*WA;>&E@<)E#K%'`X>&!L9;K0UB@(Y`\ MA.D)D:95^92!%JSN7M3ZO*:SWW`H-4$[G0S4T!6&KZ**&3?Y5O`:MRD2_LBU M<1_!R].H8FN(@/>4O$QB/GV*5FR"&(%Q$'$!:Z/ZJZ]CKO-Z-TBQ8-=#FY9I MEI$99^_BK9%#C8R7]/,(/6G+MD#^L#BGH&'$EX\:NN=;(![LH,'BD_6"'Q'% M>$%OL+W;04. MJL95-D+<1@!&C$%T"+G'/M;$?<>.J-4.PS*<+S]0.P83W>N.]NS\LG]YLN1H M;U(A1P(F.L871"G\(T!'"WG%Y,WFTV>\T!BZ_9U3]#&@:69$4=PT:YL+ MV69S,L+7^6@VKR(.DR58XT3Q6K%&C+.;07\(MC1H_/37!GRG"*$H@H!_H,__ M8_\"PPI1S(L]V`$I^)`5!>'^/9HD61D:'^UOITB$;>\-/UQ?7PPPSM&_@.6" M:?F>S/UX8%Q+'19A3OP0O]!JHA,06F&0]@#QL?"S0,15#TDAGJ6.H[9IS],U MAF"*6:*1VKJI':VN70,__C`\OQP,@_/1WZN54ES4^JQ\2(GUD7F"W+">W]79 M.$LPOM,!2_*_EXSTMY__KP)D1LL&'I9\"_AR0V-J[81,Z47EI23/H-S#MUZ4259&H`.@_TK["Y<$4F;,JYE\UL@345Q\3TG[S.0PF M&^D@!M>DUN%@O":R`7,S<%?UQV.2ETF>@](W:ZS3APFF;-0E+/(>]1(PH.!@ M@%$R=W.L%OB+-25&J=H<=%*KYQ1CO3@R,"V>&,YYBM%*9U4.O+ZI6Y1NO5V] M-CB-?I[<)9.D@[9'!2B.J`7X4\`?/R2@F\(2?H"GYZ-/+WA68!$#@^NHJ\>L M[*C;M$#J2052M^GG!.%#9#=,IT`(=[!MG2>F0F#%EXF*+7!H'*6W%P"4WN@7HY07QN;9^Y`Z'F@4.4S#+B]Q]HH:[I[6\069L%9==75O`KFJ[1&4@.[ M88G:VT+TVMW96K2"V$^*E$^P4V`916GQ;^]HWSZ/=G(]DZBJ1MB,3(TG.X7E M%8./@XLKREI1CC97JZM"G:5WU3RI7A1G*O6\$U"T01)!L)L$<`'U9J652-5_ MJ%+V,:P+?PA_(E9!)W*<8,!;48;CB[`:L&J!)$]H'N%9.!,GB@"`JQEZ:T%9 M&W=4-D'*9M;94??SJLA`E@)FW6>?\8^ZF3-C2-7366$O<%X9:O;Z>]BTYI-$ M=!F=1J*.]M0FGDG]*.T<<+S#(; MD56)WR[TY39NK:[HMXS3"9LT;=!N9FV[?D=WRW$HVBTXA0Y/.03$^R M*F?YC94]`X\!//Z@6`AF$C M$ERT+I[P/JLFP2KN17#:A=K%9P@'>`(CTO5W`1U:(KNFI:\I"](+2EXXX%2# MXWF68[2S5KW.P0%G/IQ9VC@3VF#^.S#V6J_'8WGCIA[EUNJ45%4^'SR*K`*0 M_!66B=@/D**%XKCXZPMF?:88JU2G8)DS8Y?\1Q][8%M$9WF**%"G3Q3>D:X!)]:D(XB?VMY__WW(&RIOPH@V@5+@J%R+YT= MP1[0ZS^GU2BKV5%RC^NSF$(8(91(2^!5RCZ0&),<$]<]?P=B$WQ)'XQB)KR` M#HD]$>C3HN$J)NNB;!([<3_8BX8:JWL"B\1(+J91H,8XN+OZG*]&LQ)1.HK1 M*QWS6YBR>,))D*7L[\1/V9PA2A?G#2U@<-.PVN5'3;0">@V=]3\SY/OS!V3% MJP(>$>ZY=#585$5=`!@U=\S6!BS!%3]$Z`"Y90=$?D&E'S,ZF>A@>A.W9N?& M7A(-83%U^@M^1FC_PYP9LL7XH=7FU/XXSU_B9V99?^+!W.@)@B;N[1\&R'6U\X2&!H-LD?N:<%ND/B=*_@'*;/F/, M:![M,,2ZG:SSN,KM?]63^V7CA M^P1&_XIC.U'"*VDWM'\KV;B\\E7?H2I,C$3<``Z^IDM1H1;//,L&R@2K- MQ3JP>K/6$Y>T[<,B"]:B>@17F+YM$4F"IPS=U]E!0 M9@0A)BQTI(E>3\@8Y-@PC\D3EGP`UJ9Y-L%('*L[(_L) M>K9@SX@FBE>H_E(BO3PARZY2OM4$I`:%).GLL MV9&5H7%>CZKLCE=Z6<*,A]U7GHZVN5D-P'')T3S!7%ICR[&9&G%`XO/(6L&R M,3HB4ALLQP)TBH'EBMF=PSXZQ*C*.9A,F)S10=+$P-A,/,VJFN>I=C(_8-:^ M55D0+T;SRN;8#SZ/.-")6'C@E-R<$1"B.-??[4&0F M=87VUI\`S$>)`SXXPS'[,>&HRDDVPQ=<6-5SD'%18'75>2%T!P*#^V) MI-)T'VUGH9<(EL,>N@I8YUA"T\C;.-=IA5-+F/,&`_/*%H-R]7TB&T??O#YY M#EN-*7'MR;@IK737\U)`:9*\`!E0(LE(<\5$W<\!SU"AH976KV%X-;"E:^NG#KB M@C06SH@W^:AEH4/DH!1(33V))2W$05@CFB9TUI69LR65AZD0`<%A7R:(LB!& M6=:II.1+WIM,OEY6[L?'-!]OPFR;F#:T@7,R*#E@0X4AZ0.``?2/^QE/0)(G M\72H(-M70\12A";:9]"/F;AP=TP$2_='(=TJ%5<_T'I">.^*Y^0.-866D32E M10B4:=-.!5H3[P99#Z4XFE,DT'E)M<0A&R#D0QB!:"-N01H@T;1FB$[B1X$B MF]V\AH;1Y/UQNVJ0H(Q,IM-JY#)HAD@&%.=9\X@9W$A.89-$\9UW]1=*@E(V7H/XJJ=H5V676%J M1QW@.6`#S"4`CG4:R&LE&G\"ZE(YP8T)F]K?VM]`>?^8H:['E$*.[)39C"0+ M4Z8W0X\2>W#;E5:6NU\8SE;IH M_"3,WG&CL-'IIX$@'Y5PKK90Y3UD-`Z8&!^(RI!CS5:@)#%CI)3;"@$O>8?P M-*.<^&3"D-;$[J_T,>'4D)<4LWMR5B.1"@I^.'(1Y'V74_SZ2UD%+W-K=V.&@)+RK/[%PWHIC9TBLFK)JGT!%-. M-=LXW.U9MI%@1R0I2>)55%L+(LT"[' M*2YH%KSJS<26/<&(FJO5($XTJDV[&NOQU(P>%/("+?-I_C;5(:XT]%@Z..(5 MUVU4@`A'T@O7@A=-2:;^A%>%]7>.AU83C57C1"E#7H^!J!?'1F)-!%4!5U-C M"VUD\LYC+I%EPCECDC56'\S^R\GIH*`*PR6[J;X,%J9)):=0]K+MDB=-K"F%W9 ME]PS8E`X-2S,`&,Y:-$Y#1B;@W-,UVT\),S=LNFU[<[NGFU-@WZCNU0X.;)I MY%]/)F4&V`''M'0J``UFCJJK/L#\57C\B<8N\RAC8H143'%!^W:9S@JKJ&E9 M19D_]L"$'IUE`R=##_:+B=2S4B#^L\-.Y.P"F,9?%5T\NEYB$P9DM!S*GV!O MO.;0TC["B#A=VT4N3I`!)N4P43LZM.C*TJ[EH%EMG[XX/[ZZ4=-\7JN];N]W MJHL=DVPOL78HNU8[Y7YBAA7(]/WNX<'O/&LMUD"0#)0-HG@-NW M8R:VY62,*B#A"RT0(SUZ!,1U:I,7VE?42L9(E2,P'NK-$?8`F&%@`TDS]&8' MKYK<*Q>*L*@F6DATRX%(;#?ZJ?G=7\CN*!4&[FP<>))\SB;SB7/6*.7$$R(& ME]O^9F[81:47;!#7,FS\RI32L1=K8%0\3C>(9W%ZN>$2P2IA"[9/:0.//.GG M<.WF>\BU;Z/CI1,@+NUO9TG4&Q\\Y%7:VU%Z2X)0+8E<]%_%JOA]V=03L/A53,4]GY,'%"BX&K?A!-/"! MQWO"9[>[!=+4*'/,W"T,0^=/FE,V4CB1:`64\&AK)@`MMK?V6PXQ@EA=*F?$ M6A'MH'%4P#3/N'8F(L$8(X-E=9R-O1X=M=S6TH\L.U?=<2G<7:SOU[<4OF!2 MF\X&,#LZ/&#-/1J@#[4#[D5J+2LD>_0N844?L#['=!^!T@]_:SV=7,I&`G,` M6?O%$>61`#",@+NG4/U8*ML[3I<5!!.M0)S9-$F%V@^%E.K`V4EQ8G2:.;D> MF&F$N1=F@:V;#_T)ZM9)Y>W7E`?D>:`H@^8<8IA0LZ5FM71"5$N-+K;&"0%LZ$@9F-./\35G>H"MJ.U`3%7)7C+0`:H583/2:*>76PAS/?)3D M(]T8M6AZ]Y:835CT8J*@SD3P&-MG0)UY:N?"/$ANM0,-VE,75 MZ/)O+,O'3*P?J[7GQ=B.A;1C:4%6,FBE8(NM7.T;;4L[FGG$X$0(DEG;\:)% MZ(2S6L[5ELI-RG&:ZX091'RB"NLP)Y'5.US*?,/*P,BTF5_L\;>?_YNI*MZ` MF8K=PR27:#*.Y\/G%3ER,EFA,V_+[E#\]*21,),8L0@^>0NFAK4>[MURFT?3 M;\EI9T1PWMUAQ8#TS.BV`W"B'WN&G7+$7\))SM@:B-0E1B'G;#*OYG(NI;46 M'1S7"V5#<+*H*]F2_`7P5@J?]$LZQA1P&H3NG9CAW*#;9(T3; MD?Y+63&=HYQE%,*58^^6";OBYY3ORF3L35.O0`2P`9V:P9AY`3I=KG;TNAT` M/F8@R$%`OG1B"9HFVF9B#5BB#2H/]GO`^.Z).@2K29WA@!]IP/?4_I9!T-4E MS(H"!N0JB58U9FT"QV\/U*QYT_71[<747L%;6$[=K@^XY=%V\=0D@G-I7P+G MNMZKB1&\V8C74J/.7XW9B)3";):1.MM>J^M.^7$P.*4_6P&Z2;DL](,DK]#/ MVX=JDS,MC0.5&8Q7][:OW:>H3A*B^NCEBY6.T89$;V0OCPBQO>X!^2J':D(M_/*V)4;IHFEK!78YO!XIWUS-FT/L5(9SO=4?]]0H9!^P/M(:?SR^&' M&\JR>]^_O8TT$`T>4%YOX0O#-1&(W*[??F=7T+2TXGWN$24AL;FCQCO@]BK=QBV.H&:RJL0=M!J(,4=N8LN>`Q-0S`/$.WYVHFZS^A&T>8).5Z4L#L.3';S_?^)H0^D+%T+9'V([8;B9]XX25I`_:3NL3Y>$B) MU2>JLJ9!?D2:^YA5#T!:B>-"0'KB2G9_6=&>+VY?%*:93"E:B82DAH MYKL0&$;B*04P"\Q,797!3.U$-ODR:\:E4V&$RG2B@)\FY$Y!Y6Q$/45,U'5^ M1\-P*UJVDCF^9>)[:`'Q;2RL-SO]+WAE=AT.W]:)V9B'@?`)>N-4J=F\Y#C! M`%*-Y6#%4D*E19"C1SBXY)=3JAA^/R],F8L3$I0SU%G9=A3I,12!<@.DM$H" M#P7\-23YT5W_T93;H-#LP.7Q,JD2<;^7(*!E#.!VVE$S# M8+SF+R&K#7M)8-I-15'-X+H*FYEQZSP>=9L64&(?:LUD0S]U9]+)Y%E_&PLH:'8?VU<9A9;X[&I236:YC MPE:)=;X6<4%E@QR+SB;2K,E?%>!@'N8\2?B-%L.E:M)_%`D74.,O+)-**2MS M%'RR14U8W&9(Z1HJUCPX`@IL#=04;G'DWM!#*$&LMR_>1>*8X[$UB_1!$0Z[ M&W)QV`>Y8(0Y-LG!3=$7S8E-)M?*S,EI6YJI-"=VX59T59J_^93*;_"YM)<0J&JQ7H9T@U,#T5G!HO MF9YKULS\F/XHIVM45UEA9ULI[)MFS2I7;&S-T M5J#,DZXV/BKKV>S=(675,?YYW]S)`:^M\U2XJVGW+H7;AC5(]B*ZS%G,-])Y M77IR9Z<5!PCK<"269,AN#77A!")]W"43@3UEZ7,`%N=X!%TE]\?9&UZ"XW*& M+M9U6Y^I"^"0X`4ZO'5W37STB&[DV[03."R8PT8NQPRYSXL?.IKJJ!_V?>6R MT29WQ:"3Q:VR\"9T3=EB3AC-HS&4G:X!9@Q[(KHB9\Y]M3A^Q!J8)53*1*26 M;NA\KC1CD9H_/*>:W.K/E%J-[;U.+VX,9S/[XL/9EEA&.JT8F49.5F`>#L$0R\?C/$IY@MD M`C"_QD*&$3#1N:GM(`&%4*_NLIEP0V>I1?H9:!E(\DE2O<3[34%9QV0F(]HY M?@*$3AD6?YJ=[#%-JF9@EIM5TG6MR"S&V6OA'18AD.5]S:OW+%T&IFD+M/0JF2M M0%%]4>,,3,P19I1@39EPC:YOICEK(2R4-''L7Z=&+Z,\M0Q3%\Z0CU$,=F'N M]!,%W5*6$&PV=$R18VZ<\AY+7VH'-I5C*A=\40\8B]+,!D_7)$IPY(@R@:2O ME=-Z,NSW&K%GD'L^D:2R%9SY2Z!IV[-QZR0LAWL4_PT.YZ;DW.?8DUN*J)Q\ M?!DELD&L7$21;])#FI,Z!B(Q$:[M0#FL2XJ:F>>BCIGXL5^+:IH%^+7J.#4K M1S,O6\7P=':.=,7A:=V"NE3&5U9?9)[(-T;)ZRMU6FX(D/G&ZL(TNT= M"S]&&-'T_5;B?R)T':>3HN&AR2GKF`L;-NLINAV%8SY4">$<9]L?'1T$V0RZ MIQA*")?=(L#:=@>,6BH\@%&4Y.J/CX^80P6FS+,FPK.*LMA$L%#'DDI3'GON MVN:L7\">F4BJ)V%_E<(:T\["'9@N^EGQESE=S/K<.$%DSCRS6XY\AB1"C;R8 M]V_M*BQ]Z.=F)O':K6Q,R($N*X$1/JS3_GFFS6B*@=L+A4/S2]K,%8P0F1 M:DA-+XUWU3C_.FY*K]<96.&SZ M+L4(*@D$L\U&6H%.XY(;"^B$M+T3N)NM5=NT-TDF4@C3JN#.MND4>0B[DKH] M:''KB=A%5&Q%[-KN_O:J&5M2-H`DK'T!3B;VHOF,"YB=3U0$QGDSTE657<#; MNT?+'8EIVP)(@M[K6"L6+>ML$MW?*VK^LI^40RW*NZZ'/#;&]=D\J-9C6%W% M#RA"6N[;=>GKQQD_I9.1E1B+".:U-C--'[AB/I MBD$YA.Z";!QI3DUD/`^!4A2DGG1K/KIYH%OY:#>7$`NQ&O,WVQQOC^.U@ MP@XG68.YK>M_J6FQ>^6#]!203CG>1K-Q]&M[?=C)C(RH#6W(?-S9V]>8 M%>O%Y-F&\5O*V%ETLN"6,J>B5)K*&$ZJ#Y8*O#MJB-=!2M[-M69W[2D!=&GE MYG%_.#BEFPH'ET-J\K?J<^KJ"3-ETV=<%S;4J3>L`!U`NGE;=9\XEXGHS, M.R[)?8.)+ZCCE^B`E*8'^#,.HVP][GF!,3YT;^",Y/"F)_`3>KR9R,Q75#7Y M'"1`4IQ<+A62OI?L[B+UFJ\(-7V]&*!\[Y);0F@FZ:@#43SLK?5^5-V[9LGV M<1-.,O;ZIG#.J'0%YXQQ]^8G!5IC(<"I4M(O.&Q$W]>>QI%3?](IEM^;EN6^ M[8M_R(O<8-=>-"ZNT/!XI-]&01`X;+10=4ZN/W["@E6.3)"R22CO].7']>'6 M?TA?U#5=-5&`5*74AO!)>[JQ8;QNJ&97FN2B-ZUNG:/"V4%\(;E0;; MGQ';YL9(QYF&52]VFEIW@D##-CLAC[=!17'?VQO4.NJQ?,8$&.,;]T&(&A_W MH=*CT4Y2JX+ M.`1?5UV6FFU(V23ED"R&*C>PD#XG/5V7[+8^V?I%Y`6PNB7R`I[0'*4CBIB8 MM>CT?,*2[9<&MCD@)3^*\+_M+2UP9,P5!`Y.DJ*_D^)EA`^=KY=%,G]'[1[^ MW6515\E5JF\9)W"Y'W6LRUR"TO2MZ>F'SV08`-$>[!D? M__YA`QSNK9<-;A\WJK@@IFY?53,*@!CAY]:'3))S'HQR*_'.%B:(/Q%QY931 M-'*N,B?+RF5*1OCYS,_./'N98HH:0`F;%JO=W=^9FX+0_]+!*NNR&`OGP()4 MX!F4E$P=EKTYI)_V!^I_;*=`#['#9DPG);[-L>M>BZ/O\M1Y(88=RHVQMNJQ ML0^.Q%-06VYI&]?3(VE[*TVH?YJM,%=^ M_X54]:QV4H;(R_6=^C'%1:78Y9*F^5;UQ24YO!KV;VHUT)R`KU2ZLJ9_)V(` M[1QLRPU)^]W]`V8.,/C??OX_])\>;*S6=YA&-]1!=V<;?IA2P2EJ'A(NKES^N(&`WOB-/5A:OSJEMW>ECHQ(%K7 MWQ]VCW;=%<4VOKVG5W34W3I8A$,."&C?U*':*MHM"I1[T=-KH"JCKPY:,<$1 MLKL6LKO[RR"[;2#;,Y#=V3&0!7B?+$*^&$SWMPU(>X=((QP3^2IYA\G+3:&' M'D6"^A760_"??5>KN&'F0I8442[KVUC8P>]I/8-%1TS<+%:T7>9/Q@GS!ZH- MD+%_(>$BF91M5NP*"R'#EB2QONY1?#^94SDX@66@YHT/.&D+Q+WYYE?GAF?N MIX;@T$1@W8?>=7T^8'T;Q6A5IO15?T&/-W(7C><9G^3<)J=7'I5A%-"%5`EB,,[48AHI323J9SDSS@*#_6 M6[MDBL:HOE]A5I:?N&C)]_Z%<&M(O@>KD2[']*@MZ>A27H8A^U;8Z_]48J?, MG%LW`5&1*Y$U.J=>Q7G*-*V2TG5JU2VV*?LA164P4^39?7QOHH!@C2_@J]5/%YKGUO'I1+UD*VMEH7E%=M.Y@*5R!6FDN`("W/*VVR9`-G92& MZ.B"0XT&)HCBNAZL_F=3EKCEE\[[Y8:AEB=UU8]435P8]`:B](A?N\S&<4/$ M*=O63T;8"(>M5VT`028`R3_:+<6D:BUC_?Q#FU87&H&T#L/V5YDZ(FW/"Q"V M0#4CYZ\;?;&S4>G$=B.9NRD?8M_Y.F"M_W%%H_NWHX!Y?Z^!Z;RWQ6&I[6[O M"*0F_`M2=^]0A"@*7._#&@CS`VZ+AVKB&NL_VT<]>>;PB!6@\!NMY>E_V??. MA-',:.`03LV!1<1(Z2IE(CUAFP$WI]G)4J76N3(@7M1AKC/07_("R"B1*(C3 M:9R,%[YWUE7>G>BE:?JEK56?2!M%'?6R/6.TXVC'&LYK>Y(:)W+R"^_'6!@$ M&>ATG?6+LJXWT`M,:A$LB[3!UN?Q0=87VP,<@_[-Y?GEVR$,?C4/K.>UNVK#S(D88 M`QN844(>08P_3[EHC-[X#DX8F?Q[3E`<$/PO\6"\;]BT(1O,_'4YGZ24.OT= M.L5P5:;\8@9<`8QIHDO8RI)[EZ36P-V(.,;,R`O2,,'0VD=BW]D^`A5\[W!; M'0#Q7Z0UO"TE_?YJL,\`UJ8#,S47T*283JF5RV MS(X,8=A69.%2UO<.P8"@OW9VT);XM186.0!:[/;!MBRVM[^G9Q<,I$6T7)E@ MNAW83@?`U]=W=G$_NYVCG4.U?DC6T6YG;P\0*L#O7VX?:VIO%SD\<*,CQ);] M0_FT=?@5%+"4(+\CON*1Z-]^_D^A[0@DVU!\J[N]3?]L[=(_.WO\Z>@5QZ&O M&B&<=U[R6^"H=1AV#\X$_MW>DG]WY5\\N+>DM!3FWH?&ZXBG6]V#GOWC=`EV M^--N=?=[9LZM;N]@!2@[,"6H'-`_^XAF>LJC.8?Y!0.5CZ%7?O' MJT]AUSV%_55.8=,`TSV%?>\4`!W2HJ0<9Q0<@6KIRFI/!_R.KC<]M?`H9&"HR;([P+#)3;5=[687)&@XE=%/W>;W2TZ%<7JD3QH"KO:?N MF=)<;!`&0]:;M"AL!!3H)VSVO>>+",[-G8.K/L?0^B-=-OB1+QM#VW=7V&O\XV!XB[<]KOIZ<7KO_U,/?TS2=F6=-=&B1@7P]1Z)OI\!Q9=$:G] M`>38,05H*\%E]>L?_9`C^D3P9C/OULM[L.(H%1T#)^,RY4Y$HER1A8*1B&>T M[9SE\&24_Q6[[+)UZ::+8$N?+`3NVL'>GD[R''E=,\7''4VLZJJ^B?0TDKMT MI%9[2@IR]I24-4FUDEQ;;>(Z+6OG\(J]"TE@#7_A@(9;8*]*,V#[&:+3H'+N MG_+JPCR;#99OI]+K%S:^:`KMAI02H786)6`_.HA!7=J(E;6T5MCR"J.6C(W' MHK/-B5MNNJ;BHA4YR/RZ7=-6=B3,!(@IP:?HO"JG M,?Y[_&%X?CD8#M7IX./@XNHZQC1;+I5;\3'"97W9G'I;E?/I(DY^>CX\N<++ M]CX,3M45F+64OQ>T`&IYK-&OA:?E:AK;&4?:S2_MF8P9$IARZ>3.^/TG;[`7 MSBW>U`2\HS_Z:[>C+BY.*)2A8TP513.H.4.>\PW`"SIBG]4FBY8#:DG4/M&J$`F]!N^^S[![;\,/*@Y;?WA'^?4^,:[`+ZS!ODIRCBIB+W!IT)[<, M%V*H8[\IW).N$*5SH0OO+?\5*:J)IOJR[>A;36!;ITG!U[[CALZ?7L8)1NTC M9&LIS+T#@DJS!=,DI,#M-'0N]'CNYJAY!P9:W=IVY\B@`N5?"/(ZU9T.`G<\ M]T914H%IJMV\E#KTTG(YO*DM9U*#L1M[;.M-BXG@DM/*D^.1!HX) M+5B-:_:U\%[A.HV@3>WT)&%`H`,OF$87D=MQ:#!66CH'$IF@0JG`*N$4G1E%_@&QR>8W?@C2:^A* M,WB9\_#(OD4EE8WV/HZF9P/C!]E;G2'0O_!SZP_'9]>T>/;(A[_"-1UX+ M@J^JR+]MZ).5U`&VW!KJUO.TN82,Z62N."=Y08Q,!V[*"N]H`.)>+3:T:(3P M5KE;3\!R/)SY7IUZ71CXHB:?UF2GW^CV75.Y]K%VPU$6VSA^_<+7;S8O9#48 MX+#(-I8G-;:NY<-5U6U$>VXS^K2,U9>$9?SK=ZMSVKG:2[:1PY-B/K M,W'P3QL^?.FCXW7@`#BV!M?D9]HF`I][?HBWTD1:+II"OA9&8D M]Y(';V9S$4:P+I>G+VE/5)CZ-'ND>2Y7G\.OWR)[PAMY-X%I<"*K;C08N;Y@ M$8/P+++U?8XS"M&O'^WV^.,O1?9!#1,P0+`Q41L8/$5,MN;O"^NF/AP/!W_Z M@!XNL.\N;X?8RNFR?))[&76[WT4F4)^L#9,SU_=5L7?)CL MR2IF>#DYU7*;R])GY4,Z,PVX,^D_O=^BB^LK(`K9@MN>DW1PMW[;&%Q6(]_M M'H%8RG/$0'&66?7>K[2U^.77ZL(8/3.&O8Y;RZ@`.ZQ>(&A/SFL::K5[YJ^E MI'ECX44SO&*;>@H)52/^?#T/&C,:)O"G6_[CS-S=H4SB0%Z$< M`7>X"WS6'5-*F\SI=AGWMCQ2Q^=Y6KMVOYL,/[3A"WQB(%WK.9N5)$U7G0AO M(>NU/6+>."W].ITX8,TXRU M%<#GR@:P`S[T[Z`R0)GHI?1+<-C^^ M3JU<:,-]/9:;$JA[JJ\*VW6]8K2P[Y@?6?+0-E[:C68ZIAJB_JQ!Z0(A2)MWH:P.@P+ZD3`_5S!7"\]!M+$:+ED[(:B.FC2 MG\$1J^VMS1^<]C,UING2U:4,W,@!AAB65LR8$@;FGD]Y?'=_:^,[V1T>Y9+`@6&^I#%P'*'6_04HKU%:_*H! M=WX@)F]L!+0(*O&IFFOLVRPON5,4`%'/I/UN,F/_)TBA.K5UIR,[^;J4',O' MQS0?;\)LF^CRVL`Y&92LBI)%G3X`&$#^W\^47`Y!;=]<'4;RF\NBJ4!9_-(D M8&\[MU'`I?LCJ]+R1W*W3;/@FZ1&:([8[J=RKW^EHYA;$YQ MG;L7.:FDQ&\:(.1#0*M4FYRM-\^7U%4L?O_\GC8;B`GH=V5$/EY_7&S]1@U5 M^3(IW8'5W%C/T6G"#J9+BR&<4J^/ENL+J7+5'E&;VJ#SNX4J<3O>Y7:ZNJ.K M?L0^<"7?J9GR2K&ZF)UA=,BH<./BQ=.,Q2"&(++01^(H)IAWSPIOF_L)W0FI MFZB^)^Z!,2>YF.YXID?,..-^+(+NIOF>=I%XG)"J>9;P55)=L(U;.T.[++O" MU(XZ>!,C6E4L!4_D%B%]O2,H'^4$-R9L:G]K?T-US.5\*YB M8>B9/C%BO5&W/7H]FXEPTBW83;FE43ITK`-K]6%Y5&SX4"*&4E=1,8G0DM0+ MM11&'`!P*T>W-95IF(;C>BFR5#H8`@(SUN?/"QW&8'^NO1'#TOQ8^BWBA0XDL4R.DXYI8A\\CBXVWJ)+C;18 M.M(N4BQI`MS&"C3*?G]N,!@O:P;6GA3.]4:'3+;2#$#7XR?&:#!QUL92X&=_ M(&D<:);"?(&36^92@LY-$%GGG(GWDO09X'M\91AY5Z53).(`'Q$;?4'G0]V6 M65N(NL,D,!H'3$X?!U.#LHJ&HI/T'2$0W)U"E3;W%=:AD98EQ![V6T-"?TGQ MBDI]Y6$10+0*MXR&`=\/,_.OI#.[U;Y;#7;9HO:*NO)1I+W?N:&WD%'T-K=V M.VJ8X669]R\:T$UMZ!3ON#S797;4TTBSC,K.7)'LCTJV9 MIG"/O.$,4ZKD">N\S?:%,S$21$9Q2^H2MQ#/>ECOW"L91*[[5@;5D7!_%=W2 M#QN4FE1%C/"0?N.TRM++,?.8BQ3@4/[#:T0;6_8$K\-RM9K$N:/.A!<$Z_'4 MC!X4\@(M\[DQ=HOJ$%<:>KKMNQ&OTEN$58`(1](+UX*7&B(3]2>\*N=B1I=1 M635.E#+R&DZF.O9.(L9>:^EJ:FSO>#UA`P?#,N$LE_VY/LM?3DZOVE`,B(AN M=0ZE=\82'V>Y-_5@&#I M']Y,I#%3'W:^M=5\)KY,6_U=S^H];;=-(C M42DOR(/"S;LY(VH)[E8])J>IV#`U:DSFPRUIDD8S6#>+V>-E/,N*UP6S_%.Y_R"+#2:=?HI!10 M/*&HPG$(&9O#HG3JDOJW"V2]YZ#;UD'*VZ6I>9$0GJFE%+^]27K_B4.9[0,T M(QX_*5YE^QM)DF-VEX\`7T3:!6VG`>4/+)VP?@4HW5AG"K-E!<>!P,R+>B_.)I;FV8]]4#WZ:?\:J%C059E]><_96P!15+`3OW M\LE8V8QDDS4'[@''W/I=\UO;09C$>'X:G M:GUM(T*'[Y,7\]BN/+:0K.490]@7Z0S^^/>K^W\_`3:6!7FMIRFH9=J)T#+! M>TSF6/+,BN!8X1QI)`Q!L(.:KO=[X9P4.MF[I/A4VR(5?&C9$.C_I1`8&'28 MFO82'#%W#0PV[E7"R`U+Y-F5?'WC&I\F+Z0)4Z)1+I?X-(?;:9FFL5PSJ.G+ M=G%^?'73?&L/[.PX5KH[_YR._?YN?O>W&DZE.<9^]_`@&-CR&J:L)I>FG@4+ M.!_C(3?<)43442`NM[I)G_#VO&J!2^?[W1@9.CPPF.$GM0S[EW'0GU2$)M_F M2?U0/MNTY=!WL`S$EZ448-C0C7\NE#E&80ZERF@W]LO"VMS2]3YCEK:;QB^2^X%M_S2C_3@I^0&#NJ^V*03Y%&8X6 MCUW5:G;"DBN*D7GSGP$)?MT-P,WAFA=WGA?C.6@F+UX2Y`)M)7:#7NSZO.:+ M/\8>=6X#+?#-^+UY4L M"T5B[)J^V@7K-Y%K`D.\77Y[-?76I7NKMW=:N(!W7_#$07.+30:T*\+)!=!8 MUU;&87'=?G5F.S.0NQ_-):%873.K[1V9"[<8V9:]\,<;D09LD\K#=R?J!AL- MG_`-B>SW!5K^&GA*8G8]O[,+6&C6-A?>?.Q#86R],:YER MVG0+%\K\$^.IEW+CUM0-S?K5IA(NK=;0O+W5D:5@*.<2.&^H?E5A_)'LX[N7 MV&5QJH_5Y`L9O!LEQS4'RC/%NG:CYLA7K/+VN?PE1\/(26"`ZJOR5.3J MHP4N/7;Y>A<`"?_2Z6-![!8S91*=M173O[;BMG#;-7"+O3WQ6W'N^?+8*N+3 M.>PM.KWV9>^TK5KNE(H!EER>JUS&0'D%PU")HR./T?Y7DW)')U1U=.X'5^S9 M;#3\NN/E#O`3)F=@PV-!C=LCS'T2\?WV;^`EP:Z%+,M58]?4M_(.__\7YV\. M4-Q]_]M-F>=8%(3/!'QO27;.3RJ^6)VGT_:[345K?R*2D];V\+(ZPYCW M)2>>]27[S27O%2BU9;3UF^&'B'7Z]5@EG4Q!?9I5@W-@7/#] M8QUEQ9I$,A?3=31GKNW8A(>V_7SR&OK\.Y/GZP$9H*63PNBD+2YH.A@!;1RB MK8!\'?P"*I-K$>*::CL=N4%G7^#]FG+2U>^_=6B1**P3(\[.$DM@"6.)"RMO MDRU/.-MN/M',,`P82)`"R6OIJ):8I]!(B%RRR^89:8=5>DF.`1TL3%:-& MVB]SB'^/7+\0@K]*FEO,#1)-OOL[K2<&BY:IEV>*K6/E)T@:O)S,Y'@&(K$E M!6FU9#Y)%%IIHB592JL-LF+FTDIC+3_#5XVS$MQ63/A:#19?F#SUQRV MR(D7";2![KD6Q!CFL]$C2%)JX47-Z,)8F-\K&8=;/@J[8KGGV-!V5K;4RL/^ MI(;1SF(A3]4=`FWW9IT:P:ZBR-[>PI*YUVQ[G!_L^J@WZ!V*7WFWGR=WR22) M`Z9*B_39E$6V>;.=?M+)-,.;NO+(VP@UWFFPE6:^@@.Y2X$<^1J!Y]9@%SDW\#I[M/\'97&,-?1)G42_`ASG!<:Z'/6:5]R2IMV`3Q,]E< MZ4S@L?"<%_/'6`I:ZY;Z3E;"(M;AXT*`]DF8?&$R8H/U+4V+;;YQ2_?8^2T# M%^HL3M\;>Q*+H>9Q>(':`D:_,#DOX+M3Y/J[OO1H47!,=F0'\(.KQH=<-0X0 MLM=?>&'LNY?FG0"DZ$IC^C;(+`SWN*V;?<0-74.Z@MUMN.ATWW[%V)@=T,@G M\9\N0Y>_%6I^@^M8]'SQU%X[V8C1XO:%=EI=AP"A)B&OFULWKU^\B*'?Q-X= M\G73K=!P/2K:QBW<#+FL[EP;++K18K5)DN^Y7VG7X3W MP<,_+6K*^E/0Z33B;];].KQ.I*&S[_\_4$L!`A0#%`````@`,(QE M1XE:)#R\`0``)A@``!,``````````````(`!`````%M#;VYT96YT7U1Y<&5S M72YX;6Q02P$"%`,4````"``PC&5'2'4%[L4````K`@``"P`````````````` M@`'M`0``7W)E;',O+G)E;'-02P$"%`,4````"``PC&5'Q,LD0Y0!```\%P`` M&@``````````````@`';`@``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"%`,4````"``PC&5'\C-#J;8"``!O"@``$```````````````@`&G!``` M9&]C4')O<',O87!P+GAM;%!+`0(4`Q0````(`#",94<,2YV"/@$``&D#```1 M``````````````"``8L'``!D;V-097)PC$`8``)PG```3``````````````"``?@(``!X;"]T:&5M92]T M:&5M93$N>&UL4$L!`A0#%`````@`,(QE1VP/SRQ9`@``;@L```T````````` M`````(`!.0\``'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L!`A0# M%`````@`,(QE1\/9$'M(`@``C`<``!@``````````````(`!BA4``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`A0#%`````@`,(QE1\QC&`;R M!0``=B```!@``````````````(`!H1\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`,(QE1WB*I6PX!0``41P``!@````````` M`````(`!#2L``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0# M%`````@`,(QE1^Q7BZBF`0``L0,``!D``````````````(`!+S0``'AL+W=O M&PO=V]R:W-H965TDW M``!X;"]W;W)K&UL4$L!`A0#%`````@`,(QE1]Q% M"/NF`0``L0,``!D``````````````(`!QCD``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`,(QE1U.Z]3RE`0``L0,``!D` M`````````````(`!6S\``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`,(QE1Q("&._#`0``>P0``!D``````````````(`! M\D0``'AL+W=O&PO=V]R:W-H965T-(``!X;"]W;W)K&UL4$L!`A0#%``` M``@`,(QE1V!X>72C`0``L0,``!D``````````````(`!P4H``'AL+W=O&PO=V]R:W-H965T5^`ZK@P$``#<#```9``````````````"``>9.``!X M;"]W;W)K&UL4$L!`A0#%`````@`,(QE1R>M#/CQ M`P``V10``!D``````````````(`!H%```'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`,(QE1U8(/+)>`@``7@@``!D````` M`````````(`!,%L``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`,(QE1X#;Q&)'!```J14``!D``````````````(`!)60` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M,(QE1ZL-#C#V`P```!8``!D``````````````(`!"VT``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`,(QE1_(A7W76`0`` M/P4``!D``````````````(`!P'8``'AL+W=O```>&PO XML 12 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814
Equity Method Investment (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Equity Method Investments and Joint Ventures [Abstract]          
Percentage of owned joint venture Investment in nonconsolidated affiliate 50.00%   50.00%    
Investment in unconsolidated affiliate $ 744   $ 744   $ 463
Equity in net income (loss) of unconsolidated affiliate $ 97 $ (30) $ 280 $ (89)  
XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814
Long-Term Debt and Interest Rate Swap (Details)
 9 Months Ended
Feb. 01, 2015
USD ($)
Bed
May. 01, 2013
USD ($)
Sep. 30, 2015
USD ($)
Center
Bed
Letter_Of_Credit
Dec. 31, 2014
USD ($)
Mar. 31, 2014
USD ($)
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]          
Long-term debt for syndicate of banks mortgage debt   $ 45,000,000      
Long-term debt five year maturity     5 years    
Mortgage loan with principal and interest payable monthly based     25 years    
Long-term debt interest based on LIBOR     4.50%    
Long-term debt fixed based on the interest rate swap     6.87%    
Number of owned nursing centers secured | Center     13    
Letters of credit issued under Revolver outstanding     3.00%    
Number of letters of credit | Letter_Of_Credit     11    
Accumulated other comprehensive loss     $ (532,000) $ (495,000)  
Number of licensed nursing beds | Bed     6,004    
Glasgow, Kentucky          
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]          
Number of licensed nursing beds | Bed 94        
Interest rate swap          
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]          
Long-term debt fixed based on the interest rate swap     6.87%    
Notional amount of interest rate derivatives     $ 21,333,333    
Liability at fair value     (858,000)    
Accumulated other comprehensive loss     (532,000)    
Net of the income tax benefit, interest rate swap     326,000    
Revolving credit facility          
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]          
Long-term debt revolving credit facility   20,000,000     $ 27,500,000
Borrowing under the revolving credit facility     $ 8,987,000    
Loans Payable          
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]          
Debt interest rate at period end     4.70%    
LIBOR          
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]          
Long-term debt interest based on LIBOR     4.50%    
Credit Agreement          
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]          
Revolving credit facility and the maximum loan   65,000,000      
Loan acquisition costs   $ 1,341,000      
Term of debt agreement     5 years    
Revolving credit facility | Revolving Credit Facility Interest at 4.5% Percent Above LIBOR          
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]          
Borrowings outstanding     $ 8,000,000 $ 4,500,000  
Loans Payable | Glasgow Term Loan | The PrivateBank          
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]          
Amount of term loan $ 5,000,000        
Term loan maturity period 18 months        
Minimum base rate percentage 4.75%        
Letter of Credit | Revolving Credit Facility Interest at 4.5% Percent Above LIBOR          
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]          
Borrowings outstanding     $ 8,106,000    
XML 15 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814
Subsequent Event (Details)
$ in Millions
Nov. 01, 2015
USD ($)
Bed
Sep. 30, 2015
Bed
Subsequent Event [Line Items]    
Number of licensed nursing beds | Bed   6,004
Subsequent Event | Haws Fulton Investors, LLC | Fulton, Kentucky    
Subsequent Event [Line Items]    
Number of licensed nursing beds | Bed 60  
Purchase Price $ 3.9  
Expected annual revenues of nursing center $ 3.5  
XML 16 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidation and Basis of Presentation of Financial Statements
 9 Months Ended
Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The investment in an unconsolidated affiliate (a 50 percent-owned joint venture partnership) is accounted for using the equity method and is described in Note 8.
The interim consolidated financial statements for the three and nine month periods ended September 30, 2015 and 2014, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at September 30, 2015, and the results of operations for the three and nine month periods ended September 30, 2015 and 2014, and cash flows for the nine month periods ended September 30, 2015 and 2014. The Company’s balance sheet information at December 31, 2014, was derived from its audited consolidated financial statements as of December 31, 2014.
The results of operations for the periods ended September 30, 2015 and 2014 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
XML 17 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details)
shares in Thousands
 9 Months Ended
Sep. 30, 2015
$ / shares
shares
Restricted Stock Units (RSUs)  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, December 31, 2014 | shares 130
Granted | shares 74
Dividend Equivalents | shares 2
Vested | shares (63)
Cancelled | shares (3)
Outstanding September 30, 2015 | shares 140
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, December 31, 2014 $ 5.45
Granted 12.31
Dividend Equivalents 12.09
Vested 5.50
Cancelled 8.93
Outstanding September 30, 2015 $ 9.07
Employee Stock  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, December 31, 2014 | shares 46
Granted | shares 36
Dividend Equivalents | shares 1
Vested | shares (22)
Cancelled | shares 0
Outstanding September 30, 2015 | shares 61
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, December 31, 2014 $ 5.35
Granted 12.31
Dividend Equivalents 12.05
Vested 5.09
Cancelled 0.00
Outstanding September 30, 2015 $ 9.58
XML 18 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814
Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable) (Details) - Stock Options and Stock Appreciation Rights (SARs)
shares in Thousands
 9 Months Ended
Sep. 30, 2015
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Outstanding, December 31, 2014 | shares 271
Granted | shares 0
Exercised | shares (28)
Expired or cancelled | shares 0
Outstanding, September 30, 2015 | shares 243
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]  
Outstanding, December 31, 2014 $ 6.67
Granted 0.00
Exercised 7.21
Expired or cancelled 0.00
Outstanding, September 30, 2015 $ 6.61
Exercisable, shares | shares 243
Exercisable, Weighted Average Exercise Price $ 6.61
XML 19 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) - Stock Options and Stock Appreciation Rights (SARs) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 9 Months Ended
Sep. 30, 2015
Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted Average Exercise Prices $ 6.61 $ 6.67
Grants Outstanding 243  
Grants Exercisable 243  
$10.40 to $11.59    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Range of Exercise Prices, Maximum $ 10.4  
Range of Exercise Prices, Maximum 11.59  
Weighted Average Exercise Prices $ 11.09  
Grants Outstanding 48  
Intrinsic Value-Grants Outstanding $ 0  
Grants Exercisable 48  
Intrinsic Value- Grants Exercisable $ 0  
$2.37 to $6.21    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Range of Exercise Prices, Maximum $ 2.37  
Range of Exercise Prices, Maximum 6.21  
Weighted Average Exercise Prices $ 5.50  
Grants Outstanding 195  
Intrinsic Value-Grants Outstanding $ 893  
Grants Exercisable 195  
Intrinsic Value- Grants Exercisable $ 893  
XML 20 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814
Earnings (Loss) Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Numerator: Income amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:        
Income from continuing operations $ 669 $ 219 $ 1,481 $ 759
Less: loss attributable to noncontrolling interests 0 0 0 25
Income from continuing operations attributable to Diversicare Healthcare Services, Inc. 669 219 1,481 784
Preferred stock dividends 0 (48) 0 (220)
Income from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders 669 171 1,481 564
Income (loss) from discontinued operations (238) 3,928 (800) 3,444
NET INCOME FOR DIVERSICARE HEALTHCARE SERVICES, INC. COMMON SHAREHOLDERS $ 431 $ 4,099 $ 681 $ 4,008
Per common share – basic        
Income (loss) from continuing operations (in dollars per share) $ 0.11 $ 0.03 $ 0.24 $ 0.09
Operating income (loss) from discontinued operations, net of taxes (in dollars per share) (0.04) (0.10) (0.13) (0.18)
Gain on disposal, net of taxes (in dollars per share) 0.00 0.75 0.00 0.75
Discontinued operations, net of taxes (in dollars per share) (0.04) 0.65 (0.13) 0.57
Net income (loss) per common share – basic 0.07 0.68 0.11 0.66
Per common share – diluted        
Income from continuing operations (in dollars per share) 0.11 0.03 0.24 0.09
Income (loss) from discontinued operations, Operating income (loss), net of taxes (in dollars per share) (0.04) (0.10) (0.13) (0.17)
Gain on disposal, net of taxes (in dollars per share) 0.00 0.73 0.00 0.73
Discontinued operations, net of taxes (in dollars per share) (0.04) 0.63 (0.13) 0.56
Net income (loss) per common share – diluted $ 0.07 $ 0.66 $ 0.11 $ 0.65
Denominator: Weighted Average Common Shares Outstanding:        
Basic (shares) 6,121 6,020 6,089 6,004
Diluted (shares) 6,331 6,248 6,310 6,171
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814
Business
 9 Months Ended
Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare Healthcare Services” or the “Company”) provides long-term care services to nursing center patients in nine states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Missouri, Ohio, Tennessee, and Texas.
As of September 30, 2015, the Company’s continuing operations consist of 54 nursing centers with 6,004 licensed nursing beds. The Company owns 14 and leases 40 of its nursing centers. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 496 licensed assisted and residential living beds.
BUSINESS DEVELOPMENT
Acquisitions
On February 1, 2015, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Barren County Health Care Center, Inc. to acquire certain land, improvements, furniture, fixtures and equipment, personal property and intangible property, together comprising a 94-bed skilled nursing center in Glasgow, Kentucky, for an aggregate purchase price of $7,000,000 partially financed through a $5,000,000 mortgage loan with The PrivateBank with the balance paid in cash consideration.

As a result of the consummation of the Agreement, the Company allocated the purchase price of $7,000,000 between the assets associated with the transaction based on the fair value of the acquired net assets. The allocation of the purchase price was determined with the assistance of HealthTrust LLC, a third-party real estate valuation firm. The allocation for the net assets acquired is as follows:

 
February 1, 2015
Purchase Price
$
7,000,000

 
 
Land
672,000

Buildings
5,778,000

Furniture, Fixtures, and Equipment
550,000

 
$
7,000,000



Lease Agreements
During the the first quarter of 2015 and the year ended December 31, 2014, the Company has completed several transactions to assume the operations of additional nursing centers through the assumption of long-term operating leases. The transactions during these periods are as follows:
•
On February 1, 2015, the Company assumed operations at Diversicare of Hutchinson, an 85-bed skilled nursing center in Hutchinson, Kansas. The facility has an initial lease term of 10 years and includes an option to purchase at a fixed price of $4,250,000, exercisable after the first year of the lease. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
•
On October 1, 2014, the Company assumed operations at Diversicare of Greenville, a 62-bed skilled nursing facility in Greenville, Kentucky. This facility has an initial lease terms of 14 years. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
•
On August 1, 2014, the Company assumed operations of two centers in Ohio. The centers included in this transaction are a 142-bed skilled nursing facility and a 42-bed assisted living center. The lease provides for an initial lease term of 10 years. The centers were already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers.
•
On July 1, 2014, the Company completed a transaction to enter the state of Missouri through the assumption of operations of three facilities totaling 339 skilled nursing beds. The lease provides for an initial 15-year lease term with a 5-year renewal option. The centers were already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers.
•
On June 1, 2014, the Company assumed operations at Diversicare of Nicholasville, an existing 73-bed facility in Nicholasville, Kentucky. The lease provides for an initial 15-year lease term with a 5-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
•
On March 1, 2014, the Company assumed operations at Diversicare of Big Springs, an existing 135-bed facility in Huntsville, Alabama. The nursing center is owned by an unrelated third-party and the lease provides for an initial 10-year lease term with two additional 5-year renewal options. The additional skilled nursing center increases the Company's footprint in Alabama to seven centers, and the third center in the Huntsville market. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
XML 22 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814
Earnings (Loss) Per Common Share (Details Textual) - shares
shares in Thousands
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Earnings (Loss) Per Common Share (Textual) [Abstract]    
Antidilutive shares excluded from computation of diluted earnings per share 16 57
XML 23 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814
Interim Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
CURRENT ASSETS:    
Cash and cash equivalents $ 3,710 $ 3,818
Receivables, less allowance for doubtful accounts of $7,736 and $6,044, respectively 44,276 41,272
Other receivables 1,353 862
Prepaid expenses and other current assets 2,441 2,339
Income tax refundable 559 559
Current assets of discontinued operations 67 73
Deferred income taxes 8,176 7,016
Total current assets 60,582 55,939
PROPERTY AND EQUIPMENT, at cost 109,484 98,869
Less accumulated depreciation and amortization (60,338) (55,014)
Property and equipment, net 49,146 43,855
OTHER ASSETS:    
Deferred income taxes 11,544 12,885
Deferred financing and other costs, net 1,532 1,692
Investment in unconsolidated affiliate 744 463
Other noncurrent assets 4,108 6,411
Other noncurrent assets 4,108 6,411
Acquired leasehold interest, net 7,556 7,844
Total other assets 25,484 29,295
Total assets 135,212 129,089
CURRENT LIABILITIES:    
Current portion of long-term debt and capitalized lease obligations 14,375 5,705
Trade accounts payable 8,335 8,121
Current liabilities of discontinued operations 365 482
Accrued expenses:    
Payroll and employee benefits 15,788 14,642
Self-insurance reserves, current portion 11,835 11,833
Other current liabilities 6,232 6,359
Total current liabilities 56,930 47,142
NONCURRENT LIABILITIES:    
Long-term debt and capitalized lease obligations, less current portion 41,828 42,559
Self-insurance reserves, noncurrent portion 12,631 14,268
Other noncurrent liabilities 11,822 13,366
Total noncurrent liabilities $ 66,281 $ 70,193
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:    
Series A preferred stock, authorized 200,000 shares, $.10 par value, none issued and outstanding $ 0 $ 0
Common stock, authorized 20,000,000 shares, $.01 par value, 6,491,000 and 6,388,000 shares issued, and 6,259,000 and 6,156,000 shares outstanding, respectively 65 64
Treasury stock at cost, 232,000 shares of common stock (2,500) (2,500)
Paid-in capital 20,615 19,970
Accumulated deficit (5,647) (5,285)
Accumulated other comprehensive loss (532) (495)
Total shareholders’ equity 12,001 11,754
Total liabilities and shareholder's equity $ 135,212 $ 129,089
XML 24 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814
Interim Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Statement of Comprehensive Income [Abstract]        
NET INCOME $ 431 $ 4,147 $ 681 $ 4,203
OTHER COMPREHENSIVE INCOME:        
Change in fair value of cash flow hedge, net of tax 151 254 382 478
Less: reclassification adjustment for amounts recognized in net income (109) (128) (345) (376)
Total other comprehensive income 42 126 37 102
COMPREHENSIVE INCOME 473 4,273 718 4,305
Less: loss attributable to noncontrolling interests $ 0 $ 0 0 25
COMPREHENSIVE INCOME ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC.     $ 718 $ 4,330
XML 25 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814
Business Development (Schedule of Assets Acquired) (Details) - Skilled Nursing Center - Barren County Health Care Center Inc - Glasgow, Kentucky
$ in Thousands
Feb. 01, 2015
USD ($)
Business Acquisition [Line Items]  
Purchase Price $ 7,000
Land 672
Buildings 5,778
Furniture, Fixtures, and Equipment 550
Total purchase price $ 7,000
XML 26 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814
Business Development (Tables)
 9 Months Ended
Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of allocation for net assets acquired
The allocation for the net assets acquired is as follows:

 
February 1, 2015
Purchase Price
$
7,000,000

 
 
Land
672,000

Buildings
5,778,000

Furniture, Fixtures, and Equipment
550,000

 
$
7,000,000
XML 27 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814
Discontinued Operations (Details)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 01, 2014
USD ($)
Facility
Bed
Sep. 30, 2015
USD ($)
Center
Bed
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
Center
Bed
Sep. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
Apr. 03, 2014
Facility
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Number of nursing centers | Center   54   54      
Number of licensed nursing beds | Bed   6,004   6,004      
Tax expense associated with the gain   $ 0 $ 3,009 $ 0 $ 3,009    
Income (loss) from discontinued operations   $ (238) $ 3,928 (800) 3,444    
Rose Terrace Nursing Center              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Reduction in annual rent payments $ 1,900            
Rose Terrace Nursing Center | Loans Payable | Rose Terrace Note              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Amount of mortgage loan paid $ 8,000            
Rose Terrace Nursing Center | West Virginia              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Number of nursing centers | Facility 2           2
Pretax gain on disposition           $ 7,522  
Tax expense associated with the gain           $ 2,793  
Revenue       0 10,989    
Income (loss) from discontinued operations       (159) 165    
Rose Terrace Nursing Center | Culloden West Virginia              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Number of licensed nursing beds | Bed 90            
Sales price of Rose Terrace $ 16,500            
Rose Terrace Nursing Center | Danville and Ivydale, West Virginia              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Number of nursing centers | Facility 2            
Leased Skilled Nursing Centers | Arkansas              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Income (loss) from discontinued operations       $ (624) $ (935)    
XML 28 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidation and Basis of Presentation of Financial Statements (Details)
Sep. 30, 2015
Consolidation and Basis of Presentation of Financial Statements (Textual) [Abstract]  
Percentage of owned joint venture Investment in nonconsolidated affiliate 50.00%
XML 29 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 30 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814
Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 681 $ 4,203
Discontinued operations (800) 3,444
Income from continuing operations 1,481 759
Adjustments to reconcile income from continuing operations to net cash provided by (used in) operating activities:    
Depreciation and amortization 5,629 5,252
Provision for doubtful accounts 5,425 4,235
Deferred income tax benefit 204 (467)
Provision for self-insured professional liability, net of cash payments 2,063 815
Stock-based compensation 924 441
Equity in net (income) losses of unconsolidated affiliate, net of investment (281) 88
Provision for leases in excess of cash payments (1,203) (779)
Other 116 311
Changes in assets and liabilities affecting operating activities:    
Receivables, net (8,302) (13,775)
Prepaid expenses and other assets (507) (323)
Trade accounts payable and accrued expenses 1,136 4,131
Net cash provided by continuing operations 6,685 688
Discontinued operations (4,896) (600)
Net cash provided by operating activities 1,789 88
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (3,624) (4,228)
Acquisition of property and equipment through business combination (7,000) 0
Proceeds from sale of discontinued operations 0 16,500
Change in restricted cash 2,490 33
Deposits and other deferred balances (9) (64)
Net cash provided by (used in) continuing operations (8,143) 12,241
Discontinued operations 0 (61)
Net cash provided by (used in) investing activities (8,143) 12,180
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repayment of debt obligations (14,002) (14,850)
Proceeds from issuance of debt 21,941 16,808
Financing costs (192) (180)
Issuance and redemption of employee equity awards (31) (30)
Redemption of preferred stock 0 (4,918)
Payment of common stock dividends (1,008) (993)
Payment of preferred stock dividends 0 (220)
Distributions to noncontrolling interest 0 (1,411)
Payment for preferred stock restructuring (462) (448)
Net cash provided by (used in) financing activities 6,246 (6,242)
Discontinued operations 0 (5,952)
Net cash provided by (used in) financing activities 6,246 (12,194)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (108) 74
CASH AND CASH EQUIVALENTS, beginning of period 3,818 3,781
CASH AND CASH EQUIVALENTS, end of period 3,710 3,855
SUPPLEMENTAL INFORMATION:    
Cash payments of interest, net of amounts capitalized 2,711 2,496
Cash payments of income taxes $ 216 $ 66
XML 31 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814
Interim Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts receivable $ 7,736 $ 6,044
Preferred stock, par value (dollars per share) $ 0.1 $ 0.10
Preferred stock, shares authorized (shares) 200,000 200,000
Preferred stock, shares issued (shares) 0 0
Preferred stock, shares outstanding (shares) 0 0
Common stock, par value (dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (shares) 20,000,000 20,000,000
Common stock, shares issued (shares) 6,491,000 6,388,000
Common stock, shares outstanding (shares) 6,259,000 6,156,000
Treasury stock, shares (shares) 232,000 232,000
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814
Discontinued Operations
 9 Months Ended
Sep. 30, 2015
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS
DISCONTINUED OPERATIONS
West Virginia Disposition
Effective April 3, 2014, the Company entered into an asset purchase agreement with Rose Terrace Acq., LLC (“Purchaser”) to sell its skilled nursing facility in Culloden, West Virginia. The original asset purchase agreement was subject to a number of conditions including an amendment to the Consolidated Amended and Restated Master Lease ("Master Lease") with Omega to terminate the lease only with respect to two other skilled nursing facilities in West Virginia, state licensure and regulatory approval.
Effective July 1, 2014, the Company completed the transaction with Rose Terrace Acq., LLC to sell Rose Terrace, a 90-bed skilled nursing facility in Culloden, West Virginia for a sales price of $16,500,000. The Company also entered into the Fifteenth Amendment to the Master Lease with Omega to terminate the lease only with respect to two other skilled nursing facilities in West Virginia, and concurrently entered into an operations transfer agreement with American Health Care Management, LLC, an affiliate of the purchaser with respect to two other skilled nursing facilities located in Danville and Ivydale, West Virginia. The amendment effectively reduced the annual rent payments due under the Master Lease by $1,900,000. Upon completion of the transaction, Diversicare no longer operates any skilled nursing centers in the state of West Virginia. In conjunction with the closing of the sale, the Company paid the balance of the $8,000,000 mortgage loan outstanding on the Rose Terrace facility.
The transaction resulted in a gain on the disposition of Rose Terrace which, along with the results of operations for these nursing facilities, is presented within Discontinued Operations on the Consolidated Statements of Operations. The pretax gain on the transaction was $7,522,000. The tax expense associated with the gain was $2,793,000 for which the Company plans to apply net operating loss carryforwards from our deferred tax assets to substantially offset and minimize the cash outlay for this transaction.
These centers contributed revenues of $0 and $10,989,000 and net income (loss) of $(159,000) and $165,000 during the nine months ended September 30, 2015 and 2014, respectively.  The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense or any allocation of corporate interest expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations.
Other Discontinued Operations
In addition to the ongoing impact of the West Virginia discontinued operations, the Company also experienced ongoing expense during the quarter as it relates to the exit from our Arkansas operations which occurred in September 2013. The activity within Arkansas primarily relates to the progress as it relates to outstanding professional liability claims and finalizing the collection and/or write-off of remaining accounts receivable. These centers contributed net loss of $(624,000) and $(935,000) during the nine months ended September 30, 2015 and 2014, respectively.
XML 33 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2015
Oct. 30, 2015
Document and Entity Information [Abstract]    
Entity Registrant Name Diversicare Healthcare Services, Inc.  
Entity Central Index Key 0000919956  
Document Type 10-Q  
Document Period End Date Sep. 30, 2015  
Amendment Flag false  
Document Fiscal Year Focus 2015  
Document Fiscal Period Focus Q3  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   6,259,152
XML 34 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814
Subsequent Event
 9 Months Ended
Sep. 30, 2015
Subsequent Events [Abstract]  
EQUITY METHOD INVESTMENT
SUBSEQUENT EVENTS
On November 1, 2015, the Company entered into an Asset Purchase Agreement with Haws Fulton Investors, LLC to acquire certain land, improvements, furniture, fixtures and equipment, personal property and intangible property, together comprising a 60-bed skilled nursing center in Fulton, Kentucky, for an aggregate purchase price of $3.9 million. This facility is expected to contribute in excess of $3.5 million in annual revenues.
XML 35 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814
Interim Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Income Statement [Abstract]        
PATIENT REVENUES, net $ 98,105 $ 90,331 $ 289,618 $ 250,443
EXPENSES:        
Operating 78,501 73,006 232,298 200,517
Lease and rent expense 7,198 6,876 21,529 19,094
Professional liability 2,069 1,743 6,150 5,360
General and administrative 6,378 5,582 18,770 16,077
Depreciation and amortization 1,887 1,812 5,629 5,252
Total expenses 96,033 89,019 284,376 246,300
OPERATING INCOME 2,072 1,312 5,242 4,143
OTHER EXPENSE:        
Equity in net income (loss) of unconsolidated affiliate 97 (30) 280 (89)
Interest expense, net (998) (916) (2,997) (2,757)
Total other expense (901) (946) (2,717) (2,846)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 1,171 366 2,525 1,297
PROVISION FOR INCOME TAXES (502) (147) (1,044) (538)
Income from continuing operations 669 219 1,481 759
INCOME (LOSS) FROM DISCONTINUED OPERATIONS:        
Operating loss, net of tax benefit (238) (585) (800) (1,069)
Gain on disposal, net of tax 0 4,513 0 4,513
Income (loss) from discontinued operations (238) 3,928 (800) 3,444
NET INCOME 431 4,147 681 4,203
Less: loss attributable to noncontrolling interests 0 0 0 25
NET INCOME ATTRIBUTABLE TO DIVERSICARE HEALTHCARE SERVICES, INC.     681 4,228
PREFERRED STOCK DIVIDENDS 0 (48) 0 (220)
NET INCOME FOR DIVERSICARE HEALTHCARE SERVICES, INC. COMMON SHAREHOLDERS $ 431 $ 4,099 $ 681 $ 4,008
Per common share – basic        
Continuing operations (in dollars per share) $ 0.11 $ 0.03 $ 0.24 $ 0.09
Discontinued operations (in dollars per share) (0.04) 0.65 (0.13) 0.57
Net income (loss) per common share – basic 0.07 0.68 0.11 0.66
Per common share – diluted        
Continuing operations (in dollars per share) 0.11 0.03 0.24 0.09
Discontinued operations (in dollars per share) (0.04) 0.63 (0.13) 0.56
Net income (loss) per common share – diluted 0.07 0.66 0.11 0.65
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK $ 0.055 $ 0.055 $ 0.165 $ 0.165
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic (shares) 6,121 6,020 6,089 6,004
Diluted (shares) 6,331 6,248 6,310 6,171
XML 36 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814
Insurance Matters
 9 Months Ended
Sep. 30, 2015
Insurance [Abstract]  
INSURANCE MATTERS
INSURANCE MATTERS
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, consolidated offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”) which has issued a policy insuring claims made against all of the Company's nursing centers in Florida and Tennessee, as well as the Company’s formerly operated Arkansas and West Virginia facilities. Several of the Company’s nursing centers in Alabama, Kentucky, Ohio, and Texas are also covered under this policy. The SHC policy provides coverage limits of either $500,000 or $1,000,000 per medical incident with a sublimit per center of $1,000,000 and total annual aggregate policy limits of $5,000,000. The remaining nursing centers are covered by one of seven claims made professional liability insurance policies purchased from entities unaffiliated with the Company. These policies provide coverage limits of $1,000,000 per claim and have sublimits of $3,000,000 per center, with varying aggregate policy limits. 
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $23,242,000 as of September 30, 2015. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of the current portion of this reserve. Merlinos & Associates, Inc. (“Merlinos”) assisted management in the preparation of an estimate of the appropriate accrual for the current claims period and for incurred, but not reported general and professional liability claims based on data furnished as of May 31, 2015.  The Company used this estimate from Merlinos in the preparation of its estimate of liability for incurred, but unreported professional liability claims as of September 30, 2015.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of September 30, 2015, the Company is engaged in 50 professional liability lawsuits. Five lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $3,306,000 and $3,641,000 for the nine months ended September 30, 2015 and 2014, respectively.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.
Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either an indemnity insurance plan or state-sponsored programs in May 1997. The Company is completely self-insured for workers’ compensation exposures prior to May 1997. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2008 through September 30, 2015, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500,000 per claim, subject to an aggregate maximum of $3,000,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $361,000 at September 30, 2015. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,139,000 as of September 30, 2015. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of September 30, 2015, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $175,000 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $864,000 at September 30, 2015. The differences between actual settlements and reserves are included in expense in the period finalized.
The Company follows current accounting guidance set forth in FASB ASU 2010-24, “Presentation of Insurance Claims and Related Insurance Recoveries,” that clarifies that a health care entity should not net insurance recoveries against a related claim, and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the Company has recorded assets and equal liabilities of $0 at September 30, 2015 and $246,000 at December 31, 2014, respectively.
XML 37 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814
Long-Term Debt and Interest Rate Swap
 9 Months Ended
Sep. 30, 2015
Debt Disclosure [Abstract]  
LONG-TERM DEBT AND INTEREST RATE SWAP
LONG-TERM DEBT AND INTEREST RATE SWAP
The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On May 1, 2013, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated February 28, 2011. The Credit Agreement increases the Company's borrowing capacity to $65,000,000 allocated between a $45,000,000 Mortgage Loan ("Amended Mortgage Loan") and a $20,000,000 Revolver ("Amended Revolver"). Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $1,341,000 and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of $45,000,000 with a five-year maturity through April 30, 2018, and a $20,000,000 Amended Revolver through April 30, 2018. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest is based on LIBOR plus 4.5%. A portion of the Amended Mortgage Loan is effectively fixed at 6.87% pursuant to an interest rate swap with a notional amount of $21,333,333. As of September 30, 2015, the interest rate related to the Amended Mortgage Loan was 4.70%. The Amended Mortgage Loan is secured by thirteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.5% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective March 31, 2014, the Company entered into the Second Amendment to the Amended and Restated Revolver ("Second Amendment"). The Second Amendment temporarily increased the Amended Revolver capacity from the $20,000,000 in the original Amended Revolver to $27,500,000 through September 30, 2014, as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process. Effective July 1, 2014, the Company entered into the Third Amendment to the Amended and Restated Revolver ("Third Amendment"). The Third Amendment makes the previously temporary increase to the Amended Revolver capacity from the $20,000,000 in the original Amended Revolver to $27,500,000, a permanent change to the borrowing capacity as a result of the increase in receivables related to new facilities that continue to progress through the change in ownership process.
As of September 30, 2015, the Company had $8,000,000 borrowings outstanding under the revolving credit facility compared to $4,500,000 outstanding as of December 31, 2014. The outstanding borrowings on the revolver primarily reflect the Company's approach to accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under this Revolver are 3.00% of the amount outstanding. The Company has eleven letters of credit with a total value of $8,106,000 outstanding as of September 30, 2015. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $27,500,000, the balance available for borrowing under the revolving credit center is $8,987,000 at September 30, 2015.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relate to minimum cash deposits, cash flow and debt service coverage ratios. The Company is in compliance with all such covenants at September 30, 2015.
Interest Rate Swap Transaction
As part of the debt agreements entered into in March 2011, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income. In conjunction with the amendment to the credit facility, the Company retained the previously agreed upon interest rate swap terms, and redesignated the interest rate swap as a cash flow hedge. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount of $21,333,333 at an annual fixed rate of 6.87% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at September 30, 2015, the Company determined that the interest rate swap was effective. The interest rate swap valuation model indicated a net liability of $858,000 at September 30, 2015. The fair value of the interest rate swap is included in “other noncurrent liabilities” on the Company’s interim consolidated balance sheet. The balance of accumulated other comprehensive loss at September 30, 2015 is $532,000 and reflects the liability related to the interest rate swap, net of the income tax benefit of $326,000. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.
Glasgow Term Loan
On February 1, 2015, in conjunction with the acquisition of Diversicare of Glasgow, a 94-bed skilled nursing facility in Glasgow, Kentucky, the Company entered into a $5,000,000 Term Loan and Security Agreement (the "Glasgow term loan") with The PrivateBank in order to finance the purchase of the assets. The Glasgow term loan is an interest-only loan that has an 18-month maturity dated August 1, 2016, and a variable interest rate based on LIBOR, with a minimum base rate of 4.75%. See Note 9 for further information regarding the acquisition of the Glasgow facility.
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814
Business (Details)
Sep. 30, 2015
State
Center
Bed
Accounting Policies [Line Items]  
Number of states in which entity operates | State 9
Number of nursing centers | Center 54
Number of licensed nursing beds 6,004
Number of nursing center facilities owned | Center 14
Number of nursing center facilities leased | Center 40
Number of licensed assisted living beds 496
Minimum  
Accounting Policies [Line Items]  
Number of licensed nursing beds per center 50
Maximum  
Accounting Policies [Line Items]  
Number of licensed nursing beds per center 320
XML 39 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidation and Basis of Presentation of Financial Statements (Policies)
 9 Months Ended
Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Consolidation
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The investment in an unconsolidated affiliate (a 50 percent-owned joint venture partnership) is accounted for using the equity method and is described in Note 8.
Basis of Accounting
The interim consolidated financial statements for the three and nine month periods ended September 30, 2015 and 2014, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at September 30, 2015, and the results of operations for the three and nine month periods ended September 30, 2015 and 2014, and cash flows for the nine month periods ended September 30, 2015 and 2014. The Company’s balance sheet information at December 31, 2014, was derived from its audited consolidated financial statements as of December 31, 2014.
The results of operations for the periods ended September 30, 2015 and 2014 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
Recent Accounting Guidance
In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity changing the criteria for reporting discontinued operations. The ASU states that only those disposed components (or components held-for-sale) representing a strategic shift that have a significant effect on operations and financial results will be reported in discontinued operations. The ASU also required expanded disclosures about discontinued operations in the financial statement notes. The ASU is effective for disposals (or classifications as held-for-sale) that occur within annual periods beginning on or after December 15, 2014 and interim periods within those annual periods. Early application is permitted, but only for those disposals that have not been reported in financial statements previously issued or available for issuance. We chose to early adopt this ASU and applied the new criteria in determining the accounting treatment for the nursing centers exited during 2014. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In July 2015, the FASB announced the deferral of the effective date by one year from the originally stated effective date in ASU 2014-09. The new standard is now effective for the Company on January 1, 2018, but can be adopted as of the original effective date of January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures, as well as the time frame for adoption. The Company has not yet selected an effective date or transition method nor has it determined the effect of the standard on its ongoing financial reporting.
In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs (Topic 835), which amends and simplifies the presentation of debt issuance costs. The main provisions of the standard require that debt issuance costs related to a recognized liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, and amortization of the debt issuance costs must be reported as interest expense. ASU 2015-03 will be effective for the interim and annual periods beginning after December 15, 2015 with early adoption permitted. The new standard must be applied on a retroactive basis, and the Company will be required to comply with the applicable disclosures for a change in accounting principle. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.
XML 40 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814
Equity Method Investment
 9 Months Ended
Sep. 30, 2015
Equity Method Investments and Joint Ventures [Abstract]  
EQUITY METHOD INVESTMENT
EQUITY METHOD INVESTMENT
The investment in unconsolidated affiliate reflected on the interim consolidated balance sheet relates to a pharmacy joint venture partnership in which the Company owns 50%. The joint venture was initially funded by the Company and its partner and began operations during 2012. This investment in unconsolidated affiliate is accounted for using the equity method as the Company exerts significant influence, but does not control or otherwise consolidate the entity. The investment in unconsolidated affiliate balance at September 30, 2015, was $744,000 as compared to $463,000 at December 31, 2014. Additionally, the Company's share of the net profits and losses of the unconsolidated affiliate are reported in equity in net earnings or losses of unconsolidated affiliate in our statement of operations. The Company's equity in the net income of unconsolidated affiliate for the quarter ended September 30, 2015, was $97,000 as compared to a net loss of $30,000 for the quarter ended September 30, 2014. For the nine-month period ended September 30, 2015, the equity in the net income of unconsolidated affiliate was $280,000 compared to a net loss of $89,000 for the nine-month period ended September 30, 2014.
XML 41 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-Based Compensation
 9 Months Ended
Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION

Overview of Plans
In December 2005, the Compensation Committee of the Board of Directors adopted the 2005 Long-Term Incentive Plan (“2005 Plan”). The 2005 Plan allows the Company to issue stock options and other share and cash based awards. Under the 2005 Plan, 700,000 shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted thereunder. All grants under this plan expire 10 years from the date the grants were authorized by the Board of Directors.
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers and 150,000 shares of the Company's common stock has been reserved for issuance under the Stock Purchase Plan. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. No grants can be made under the Stock Purchase Plan after April 25, 2018.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. Under the 2010 Plan, 380,000 shares of the Company's common stock have been reserved for issuance upon exercise of equity awards granted.

Equity Grants and Valuations
During 2015 and 2014, the Compensation Committee of the Board of Directors approved grants totaling approximately 74,000 and 68,000 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares are determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed.
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2014
271,000

 
$
6.67

Granted
—

 
—

Exercised
(28,000
)
 
7.21

Expired or cancelled
—

 
—

Outstanding, September 30, 2015
243,000

 
$
6.61

 
 
 
 
Exercisable, September 30, 2015
243,000

 
$
6.61


 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2014
130,000

 
$
5.45

Granted
74,000

 
12.31

Dividend Equivalents
2,000

 
12.09

Vested
(63,000
)
 
5.50

Cancelled
(3,000
)
 
8.93

Outstanding September 30, 2015
140,000

 
$
9.07



Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2014
46,000

 
$
5.35

Granted
36,000

 
12.31

Dividend Equivalents
1,000

 
12.05

Vested
(22,000
)
 
5.09

Cancelled
—

 
—

Outstanding September 30, 2015
61,000

 
$
9.58




Prior to 2014, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date. The SOSARs and Options were valued and recorded in the same manner, and will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.

In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.

While no SOSARs or Options were granted during 2015 and 2014, previously granted SOSARs and Options remain outstanding as of September 30, 2015. The following table summarizes information regarding stock options and SOSAR grants outstanding as of September 30, 2015:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$10.40 to $11.59
 
$
11.09

 
48,000

 
$
—

 
48,000

 
$
—

$2.37 to $6.21
 
$
5.50

 
195,000

 
$
893,000

 
195,000

 
$
893,000

 
 
 
 
243,000

 
 
 
243,000

 
 

Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $924,000 and $441,000 in the nine month periods ended September 30, 2015 and 2014, respectively.
XML 42 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814
Earnings (Loss) Per Common Share
 9 Months Ended
Sep. 30, 2015
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER COMMON SHARE
EARNINGS (LOSS) PER COMMON SHARE
Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
 
 
 
 
 
 
2015
 
2014
 
2015
 
2014
Numerator: Income amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:
 
 
 
 
 
 
 
Income from continuing operations
$
669

 
$
219

 
1,481

 
759

Less: loss attributable to noncontrolling interests
—

 
—

 
—

 
25

Income from continuing operations attributable to Diversicare Healthcare Services, Inc.
669

 
219

 
1,481

 
784

Preferred stock dividends
—

 
(48
)
 
—

 
(220
)
Income from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders
669

 
171

 
1,481

 
564

Income (loss) from discontinued operations, net of income taxes
(238
)
 
3,928

 
(800
)
 
3,444

Net income (loss) attributable to Diversicare Healthcare Services, Inc. common shareholders
$
431

 
$
4,099

 
$
681

 
$
4,008

 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2015
 
2014
 
2015
 
2014
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.11

 
$
0.03

 
$
0.24

 
$
0.09

Income (loss) from discontinued operations
 
 
 
 
 
 
 
Operating income (loss), net of taxes
(0.04
)
 
(0.10
)
 
(0.13
)
 
(0.18
)
Gain on disposal, net of taxes
—

 
0.75

 
—

 
0.75

Discontinued operations, net of taxes
(0.04
)
 
0.65

 
(0.13
)
 
0.57

Net income (loss) per common share – basic
$
0.07

 
$
0.68

 
$
0.11

 
$
0.66

Per common share – diluted
 
 
 
 
 
 
 
Income from continuing operations
$
0.11

 
$
0.03

 
$
0.24

 
$
0.09

Income (loss) from discontinued operations
 
 
 
 
 
 
 
Operating income (loss), net of taxes
(0.04
)
 
(0.10
)
 
(0.13
)
 
(0.17
)
Gain on disposal, net of taxes
—

 
0.73

 
—

 
0.73

Discontinued operations, net of taxes
(0.04
)
 
0.63

 
(0.13
)
 
0.56

Net income (loss) per common share - diluted
$
0.07

 
$
0.66

 
$
0.11

 
$
0.65

Denominator: Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,121

 
6,020

 
6,089

 
6,004

Diluted
6,331

 
6,248

 
6,310

 
6,171


The effects of 16,000 and 57,000 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the nine months ended September 30, 2015 and 2014, respectively, because these securities would have been anti-dilutive.
XML 43 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814
Business Development
 9 Months Ended
Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS DEVELOPMENT
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare Healthcare Services” or the “Company”) provides long-term care services to nursing center patients in nine states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Missouri, Ohio, Tennessee, and Texas.
As of September 30, 2015, the Company’s continuing operations consist of 54 nursing centers with 6,004 licensed nursing beds. The Company owns 14 and leases 40 of its nursing centers. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 496 licensed assisted and residential living beds.
BUSINESS DEVELOPMENT
Acquisitions
On February 1, 2015, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Barren County Health Care Center, Inc. to acquire certain land, improvements, furniture, fixtures and equipment, personal property and intangible property, together comprising a 94-bed skilled nursing center in Glasgow, Kentucky, for an aggregate purchase price of $7,000,000 partially financed through a $5,000,000 mortgage loan with The PrivateBank with the balance paid in cash consideration.

As a result of the consummation of the Agreement, the Company allocated the purchase price of $7,000,000 between the assets associated with the transaction based on the fair value of the acquired net assets. The allocation of the purchase price was determined with the assistance of HealthTrust LLC, a third-party real estate valuation firm. The allocation for the net assets acquired is as follows:

 
February 1, 2015
Purchase Price
$
7,000,000

 
 
Land
672,000

Buildings
5,778,000

Furniture, Fixtures, and Equipment
550,000

 
$
7,000,000



Lease Agreements
During the the first quarter of 2015 and the year ended December 31, 2014, the Company has completed several transactions to assume the operations of additional nursing centers through the assumption of long-term operating leases. The transactions during these periods are as follows:
•
On February 1, 2015, the Company assumed operations at Diversicare of Hutchinson, an 85-bed skilled nursing center in Hutchinson, Kansas. The facility has an initial lease term of 10 years and includes an option to purchase at a fixed price of $4,250,000, exercisable after the first year of the lease. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
•
On October 1, 2014, the Company assumed operations at Diversicare of Greenville, a 62-bed skilled nursing facility in Greenville, Kentucky. This facility has an initial lease terms of 14 years. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
•
On August 1, 2014, the Company assumed operations of two centers in Ohio. The centers included in this transaction are a 142-bed skilled nursing facility and a 42-bed assisted living center. The lease provides for an initial lease term of 10 years. The centers were already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers.
•
On July 1, 2014, the Company completed a transaction to enter the state of Missouri through the assumption of operations of three facilities totaling 339 skilled nursing beds. The lease provides for an initial 15-year lease term with a 5-year renewal option. The centers were already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for these skilled nursing centers.
•
On June 1, 2014, the Company assumed operations at Diversicare of Nicholasville, an existing 73-bed facility in Nicholasville, Kentucky. The lease provides for an initial 15-year lease term with a 5-year renewal option. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
•
On March 1, 2014, the Company assumed operations at Diversicare of Big Springs, an existing 135-bed facility in Huntsville, Alabama. The nursing center is owned by an unrelated third-party and the lease provides for an initial 10-year lease term with two additional 5-year renewal options. The additional skilled nursing center increases the Company's footprint in Alabama to seven centers, and the third center in the Huntsville market. The center was already operating and treating patients on the transition date. There was no purchase price paid to enter into the lease agreement for this skilled nursing center.
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814
Business Development (Details)
Feb. 01, 2015
USD ($)
Bed
Oct. 01, 2014
Bed
Aug. 01, 2014
Center
Bed
Jul. 01, 2014
Facility
Bed
Jun. 01, 2014
Bed
Mar. 01, 2014
Option
Center
Bed
Sep. 30, 2015
Center
Bed
Entity Location [Line Items]              
Number of licensed nursing beds             6,004
Number of nursing centers | Center             54
Loans Payable | Glasgow Term Loan | The PrivateBank              
Entity Location [Line Items]              
Amount of term loan | $ $ 5,000,000            
Hutchinson, Kansas              
Entity Location [Line Items]              
Number of licensed nursing beds 85            
Lease agreement term 10 years            
Hutchinson, Kansas | Property Subject to Operating Lease | Skilled nursing center              
Entity Location [Line Items]              
Option to purchase at fixed price | $ $ 4,250,000            
Greenville, Kentucky              
Entity Location [Line Items]              
Number of licensed nursing beds   62          
Lease agreement term   14 years          
Huntsville, Alabama              
Entity Location [Line Items]              
Number of licensed nursing beds           135  
Lease agreement term           10 years  
Number of nursing centers | Center           7  
Lease renewal period           5 years  
Maximum number of capital lease renewal periods | Option           2  
Glasgow, Kentucky              
Entity Location [Line Items]              
Number of licensed nursing beds 94            
Glasgow, Kentucky | Skilled Nursing Center | Barren County Health Care Center Inc              
Entity Location [Line Items]              
Number of licensed nursing beds 94            
Purchase Price | $ $ 7,000,000            
Ohio              
Entity Location [Line Items]              
Lease agreement term     10 years        
Number of nursing centers | Center     2        
Ohio | Avon Place              
Entity Location [Line Items]              
Number of licensed nursing beds     142        
Ohio | Ontario Commons              
Entity Location [Line Items]              
Number of licensed nursing beds     42        
Missouri              
Entity Location [Line Items]              
Number of licensed nursing beds       339      
Lease agreement term       15 years      
Number of nursing centers | Facility       3      
Lease renewal period       5 years      
Nicholasville, Kentucky              
Entity Location [Line Items]              
Number of licensed nursing beds         73    
Lease agreement term         15 years    
Lease renewal period         5 years    
XML 45 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814
Earnings (Loss) Per Common Share (Tables)
 9 Months Ended
Sep. 30, 2015
Earnings Per Share [Abstract]  
Basic and diluted net income (loss) per common share
Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share:
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
 
 
 
 
 
 
2015
 
2014
 
2015
 
2014
Numerator: Income amounts attributable to Diversicare Healthcare Services, Inc. common shareholders:
 
 
 
 
 
 
 
Income from continuing operations
$
669

 
$
219

 
1,481

 
759

Less: loss attributable to noncontrolling interests
—

 
—

 
—

 
25

Income from continuing operations attributable to Diversicare Healthcare Services, Inc.
669

 
219

 
1,481

 
784

Preferred stock dividends
—

 
(48
)
 
—

 
(220
)
Income from continuing operations attributable to Diversicare Healthcare Services, Inc. common shareholders
669

 
171

 
1,481

 
564

Income (loss) from discontinued operations, net of income taxes
(238
)
 
3,928

 
(800
)
 
3,444

Net income (loss) attributable to Diversicare Healthcare Services, Inc. common shareholders
$
431

 
$
4,099

 
$
681

 
$
4,008

 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2015
 
2014
 
2015
 
2014
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
0.11

 
$
0.03

 
$
0.24

 
$
0.09

Income (loss) from discontinued operations
 
 
 
 
 
 
 
Operating income (loss), net of taxes
(0.04
)
 
(0.10
)
 
(0.13
)
 
(0.18
)
Gain on disposal, net of taxes
—

 
0.75

 
—

 
0.75

Discontinued operations, net of taxes
(0.04
)
 
0.65

 
(0.13
)
 
0.57

Net income (loss) per common share – basic
$
0.07

 
$
0.68

 
$
0.11

 
$
0.66

Per common share – diluted
 
 
 
 
 
 
 
Income from continuing operations
$
0.11

 
$
0.03

 
$
0.24

 
$
0.09

Income (loss) from discontinued operations
 
 
 
 
 
 
 
Operating income (loss), net of taxes
(0.04
)
 
(0.10
)
 
(0.13
)
 
(0.17
)
Gain on disposal, net of taxes
—

 
0.73

 
—

 
0.73

Discontinued operations, net of taxes
(0.04
)
 
0.63

 
(0.13
)
 
0.56

Net income (loss) per common share - diluted
$
0.07

 
$
0.66

 
$
0.11

 
$
0.65

Denominator: Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,121

 
6,020

 
6,089

 
6,004

Diluted
6,331

 
6,248

 
6,310

 
6,171
XML 46 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814
Insurance Matters (Details)
 9 Months Ended
Sep. 30, 2015
USD ($)
Lawsuit
Insurance_Policy
Sep. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
Malpractice Insurance [Line Items]      
Number of professional liability lawsuits | Lawsuit 50    
Cash expenditures for self-insured professional liability costs $ 3,306,000 $ 3,641,000  
Other Insurance Industry Disclosures [Abstract]      
Liability for workers compensation claims 361,000    
Workers compensation insurance, non current receivable for excess premiums paid 1,139,000    
Health insurance, maximum self-insured annual amount per individual 175,000    
Liability for reported claims and estimates for incurred but unreported claims 864,000    
Non-current receivables for workers' compensation policy $ 0   $ 246,000
Scheduled for trial or arbitration over next 12 months      
Malpractice Insurance [Line Items]      
Number of professional liability lawsuits | Lawsuit 5    
Professional malpractice liability insurance      
Malpractice Insurance [Line Items]      
Liability for reported and estimated future claims $ 23,242,000    
Prefunded deductible policy      
Malpractice Insurance [Line Items]      
Insurance policy coverage limits per claim 500,000    
Other Insurance Industry Disclosures [Abstract]      
Professional liability insurance, annual coverage limit per facility 3,000,000    
SHC Risk Carriers, Inc | Professional malpractice liability insurance      
Malpractice Insurance [Line Items]      
Insurance policy coverage limits per claim 500,000    
Annual sublimit per center 1,000,000    
Maximum annual coverage 5,000,000    
Unaffiliated Entities | Professional malpractice liability insurance      
Malpractice Insurance [Line Items]      
Insurance policy coverage limits per claim 1,000,000    
Annual sublimit per center $ 3,000,000    
Number of types of professional liability insurance policies | Insurance_Policy 7    
XML 47 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814
Interim Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Income Statement [Abstract]        
Tax effect on operating income $ 237 $ 384 $ 628 $ 732
Tax expense associated with the gain $ 0 $ (3,009) $ 0 $ (3,009)
XML 48 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814
Recent Accounting Guidance
 9 Months Ended
Sep. 30, 2015
Accounting Changes and Error Corrections [Abstract]  
RECENT ACCOUNTING GUIDANCE
RECENT ACCOUNTING GUIDANCE
In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity changing the criteria for reporting discontinued operations. The ASU states that only those disposed components (or components held-for-sale) representing a strategic shift that have a significant effect on operations and financial results will be reported in discontinued operations. The ASU also required expanded disclosures about discontinued operations in the financial statement notes. The ASU is effective for disposals (or classifications as held-for-sale) that occur within annual periods beginning on or after December 15, 2014 and interim periods within those annual periods. Early application is permitted, but only for those disposals that have not been reported in financial statements previously issued or available for issuance. We chose to early adopt this ASU and applied the new criteria in determining the accounting treatment for the nursing centers exited during 2014. The adoption of this guidance did not have a material impact on the Company's consolidated financial statements.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In July 2015, the FASB announced the deferral of the effective date by one year from the originally stated effective date in ASU 2014-09. The new standard is now effective for the Company on January 1, 2018, but can be adopted as of the original effective date of January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures, as well as the time frame for adoption. The Company has not yet selected an effective date or transition method nor has it determined the effect of the standard on its ongoing financial reporting.
In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs (Topic 835), which amends and simplifies the presentation of debt issuance costs. The main provisions of the standard require that debt issuance costs related to a recognized liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, and amortization of the debt issuance costs must be reported as interest expense. ASU 2015-03 will be effective for the interim and annual periods beginning after December 15, 2015 with early adoption permitted. The new standard must be applied on a retroactive basis, and the Company will be required to comply with the applicable disclosures for a change in accounting principle. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.
ZIP 49 0001628280-15-008338-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-15-008338-xbrl.zip M4$L#!!0````(`.6`94=4W?H'(KL``"(L"@`1`!P`879C82TR,#$U,#DS,"YX M;6Q55`D``_[$.U;^Q#M6=7@+``$$)0X```0Y`0``[%U9<]M(DGZ>C=C_H-7S MRJH""I?"[0F<;VOWRR```D2X"62(B1T1SAL MUIF97V9E9A6J/O_]>>B?C&D4>V'PVRG^A$Y/:."$KA<\_G;ZX^Y,O=,O+T__ M_N6__^OS_YR=_4N[O3HQ0B<=TB`YT2-J)]0]>?*2PC"1)K,:9RFR<00.$-1">&08!)%(Y9(%/R_SQ>.[/)41(1(LDL4 M7I0=^8':CB1AI>_T79SW]OP0^=X%^_,$)A[$%_;8L7\['23)Z.+\_.GIZ9/M MCD/'3KS`^>2$PW,.80$I/)"5UW?"-$BBE[()Z^I33)U/C^'X?%+(&O%G")_Q MN&R61A'PI:G=I)0U)-6&+O7JVT!!377Z[`SJZ[.2C)IJ`R\8TSBI;Y*7U5#C MQ2'AL%3A6]8RC!ZA.N+/)S6*!KX7_%I2FQ4_V#$MJ@>VY\3U<\J*V)1P=4I! M&`3IL'X,-XG.DY<1/8=*9U"+1IY3MEO=J-H@HOU&2L1S*"TJQIY33P(4U!`0 M)Z.HH3Z4U#1(X[-'VQZ5;?IV_)!-9%)0(VPHB4*?QK5MLI+Z1HP/]8VRDKI& M240?&_FDG$-Y4945N',@+_F9%U:J)K55A;QJ,EO56P;0($[LP"DA][P`T2<^ MJXT513G/2LNJL5M7$;K%Y_^ZOKIS!G1H3RM[JRN?E;,!&_6WSVRPBS@KN:7] MDVSPBT$&/&:NS@J;]`EFP(QKWTH1)BBUO1\O`'$Q)S@Z,9MA1E+R&'=:$ M'^T@OX*&G9%/OI,VD$_.,`:?D3PS(]Q89$.F-#4C&,](BGI$->4;VQ[/6 M+%1DPX5J'SQCIHEOAVGB]V":J/GMQ^P-T^$U'3[0Z)!L*C6&/K+`/_\M_]&%P9]'ON=X23ZO$]>#.GDZ83+QBY*4 MTR_%3Q5:/I_7=C49^WQQ\&-S*%;(S0O>C]QF:7E7#W.K"/"6 MCD-_##%#M4[[!+I(XU2R2XELLZ1S06.+/N!2H@9]2"ZA[RC+9&;"9J'YS]]] M.WX,G^YI-+P*[2"GLFQUY06TUZ\!2M;V?D!O(F\,;H!F![_FFX;!8P*]LH'O M(=:OX(L-%=_8+_:#3]L'JD5>GGYA#+FH9>92)&TP:I,L)F/7"6-G0]?(F,ZE?FM%_^J`/H2.HAHG-P"_^^>[%$;0=U,YE36 M]72VV5@:60S"7=LO^&@=\4K@QI\A89/`;:[^[C*,U07F+H%>F8!_I^%C9(\& MGF/["^O,/Z%"ZOQJH2?12%_5]E<);+TA)-]QYR\>E;\(D3B_CT3$BL@@4V+P M`]PPR-:`!W`R>OT^+`8N6PO>AZ0S15Y%9)L7NTUBP';[Z,L4^6T=UKW+M"G4 M:[!?A4NG)E:81C>A%R06>($W-')8\X=P3*^\AS#:*+ZC"905T4K[T-,8X>V$ MAP<*RVIDT&:<&UU6H\MJO-^LQOPF,+?A)C"WXQAOYN3-2G7+Q:<^1C2+D-X1 M]FLI.RP0WOHXT3'Z%^\FWGP/CL9QQ,7[30UV)O#-3."1Y#OG@=!EPXY!Z^>$ MO:O=TT[KWT#K]RO6XAQLY\9T;LP1NS%[/`(]&\GI[,,O&HU@+7WY9@_I%/YW M7W6V[:O;403HB"\#9P[1[`L0-_4A:K^V_5%D.XGGL#WC-&(?A&1\#=Q[:'M9 M8JP"^ILH[-.82<;V9WJX\NR'EJ*_CID3_#=Q0WE(84]2O)XT/'O$V:\N/ MP.[W@5'LLU"3T>K1N-.7[?6EF9^=QAQN1ZEFP=@6Q9F6W$2TGP8N=0WH`UH^ M^/0F!*ZT$+M;PR>#]PI&?%`SFV^[1)[M]R(U>O"2R$Z`Z06K[T$*_:AB=M>H MW!YHY1L=ZY%?;(NL2W^KS=#\,MRMI-UBMN?HI_/G.G^NBX`63:_Z9$=N3?XJ M3B+/`=G>):'SZT?@)?'MW8_V(;A"WFQ*:`E]K3:*\\G03KYO)]\#I?PZ$1]8 MQ$=GU&M`<>/;0=4#NG\*[P=A&MN!"PNGZ3T.DHQS-VGD#.R8LA;M0\SAL-^=](F4%K1U8UEIHV@>,]1:8#PF"^6BA M6U7>?%4Y<&JN7N"?K2X,965+5F)V.:O?%6H[M^9(W)K#IX`W<%+*TC^@U`L>JR:.W;*I@6%W]7`X`JYG MRIOWSC*0`]H+6K07M7-G9X,Q9]@[8Q?7Y^\'<[JF%PYVGO>;>-[';'`T[BEN/C/S(W8;TMGIEVX/\5RQM^;72:IH,PLC[/^K^ M"%P:S8S!7(98>S&?:>1X,?MZTZ'3&P(79K18[SVLE[L'XB8[HKN76PU%2P37 M:=1Q:10X^IU&M5&C2L&U6J/6CK[,X<@/7RA]7VYJ#54?+%)9+UG82;\-RKS> MP9%.EKN6Y9L<$NGBQS>/'X_2F#<;@`XQ;XZ8MS8:^\REWP\BVO[LP#%GTVC>>0Y?0ZM2PVZGIU/!H=FJ.30WK;A#6 MTM@+:!RKSG]2+_8ROV$*_U^>[U/W6QK%[%X@RKYRG%.]YD])-9N]D9Z5OWRE MMI\,=)!KWDG-K3KO_/F,!CX7<&UD]*Y4;N:MM7$$`\9D!0??O!'MKM M03D0=E%'V$2H#90=]D@AO^&10GX/UI=\Y_^1^B_K/.X5)Z/HYW6O#=)?0[<9 M-1?7O0,FZ"L/E^_ZF8Q5BIPX`Q@R#/X)`87=HLV8E7I<1]C'TYZ3K(* M!K]'E`:9U6N?V[(""$VD'=2B8[291:_4W[4_W5F$@UF$_?MKKQ'J]*UV^]]A M=!.%,('D10>W-JZ^:91_'::E'C`J>)QK7+2[2Q_^39WD/NQ%ZMCV?/9HCA5& M/2BTV7;-%;7CZB;:8LM*W8^,O`U]70V^L?`K=VZMEOY'7+!Y M-7U^'C;0DC<,M.2]!%I=Q'WPB'O^,=W=/Q]"OG/_2`.Z M]N/8WSQG$(+U;JD7OF[2;`F9AY2XN!>)=Z'6&X1:U;..:"\YT4Z5CTF5YU=Q M<<-57-Q/NK3BMBW=K.H%,$LOU,/A,`P6#G*\)X=O^5Y2'1\.L'MS$%>SNM[( M>S%+78;^<$9&VM#(2`T9(QF^^SB_+L!I8D:N*KK9J*Q?<.+'3^,TXC&V@O\ M8Q3&MO][%*8C]JR9G[($(ZL#\_&"E+J3E!X[4ED"^S:,Z3V-(I!KS2&2-J"W M.0S*\//G'[M"ZF'$4CS3N%0NAUULW_Q.IKP)>E?R^%"!C'I[U`O.7K[M M64B*-3[Q/F-CPF0^RCZ>56B]5^2O0CN(;^P7=NZB/:M7`>3FI^/KA/31EK0- M2%K^NOTB2#YD"G6%0YKII)[Z?@@@_Y/&R1]>].@%GGVT)J(-JKYBZ[B9WQ]- MV]O@P`I=>K&+Z5JD$L?V$?KD?)@Z6G;LKU.B3HF.28FJZPH[-;F'_=%U?#/# MS@^9V8%[.7YQ;9]V7MIAO+1U.-_IU5'Y:[4YD4XICCZ)>#3NTA'$[7579W5) M\_>%]X^9-#^"6"37+?(M'*]Y,.VK_11;J9^$P64PAN4_C.*K*WUM1?ZW=*V2GE!U;*RN4)%17;-C!*`R_7KS1V*]@<@OT_?BWTS/^M#`KR9FDJ@+'RX;,\9+.(XXC MO*A(@B6)/,8J,D]/V!RROC)S+,F$P"+_^7R#&;V>`N$[WT@!,E7,ZX;)RXI" MD&AAV;(*"GA-Y!8H$`1Q>PJJAV#TT/=AN8AL_UMF[7K]WE,P'QFO).?RFS4K M$5G`,B9$T)".B`)D(:ZDARAXAI["%&)^0LT6LVLBC;TN'_;9;^IC1#./ITI( M3;JGZ117KJYE/Q.W%0SW,X(..9)$Z21-Y#FK#. M[L,;FZ$Z6^H8YA=`.LE'?[\W&M5.LU3=-##F+NBJ+2*]F5RYT315$1%4"TB$$G%(I+T@G93TM`"YHE\ M$-#7YVW+F[JFE6%1Z_7O[6<::W;L.>LH/3X'35$V6=$O1,5(XS22%SF-% MY<4J_5-G^@Q]PO5H:UOF#6(S#F*(IJYPJ&BIX5"(RE((;B"RUG[NS&DNX MT8<>38B1DY=KF@Q"-\^LLT"+M0_[S(_)G!8VR(WMK:4<%:_*$!5#,BU>$35> M$#$Q94LL\6!JQKQ7=2;+=4[5QA/=$[4K?$A=-04(<=EB@3CV%][0"FHA"M;F MJ>7J7)>/P_++^,XG3Q==4O'H3^F42]-6.J>'0G8,!+F!3#NG(H% M59)E3;&07B9C-)YH^@QU17X8M+K`\48SFR$H#![O)]_36-Z8_D7MZ-I.T@BX MTRR?J09:V#`Y$YM8,115,"51D(LY:X179[,/RX9JF%`8W;W`A!T[H;V^9@>_ MXNLP2A[M1\J**_-CT^._<]?V"VYFL<@IO&7RBLGIEJF+ABQPJ'2X!',A""$L MUS"%T`9SFQ)T;?NC"`;W'%HF*/(LA!Z"5*#^E3?T$K!.Q4[$RES1G3.@;NK# MN'6=9UM;@7OOT>BRW$&<)I1N(MI/`1>N`7U`2Y8AR7*I16JIB7D$*:II0L@J M\APFB.-,3BB3:Q:W$+GS%=YMSH9U6'B7/OB39GE.;B7OFM](NONJWWKQ+]V. M(F!87/,LTI9LG[D-O$_C.#M2--/#E6<_9`2O$H!JJL24,"=PV`3OT!1$4H;0 M2%K,UN(U!;#`Q$-S_D=@]_O``E`E-SN6,)>=U=V(WPM02,RTA`S%"JV3$'G MRLPC$I59^!:;VES)@E5$S!`\60'9=[A_>LG@!KCB>".6=B\WAXK/_4;:S.[-Y$W!B&-Z71_A2TF%1M4#'T+=N[NR1XM"JV:+;8DS9(-9.FRJ>FB MBI$QS0Y)ZJ)JU MQ)7!2S-SS+:_889%&+ID$IO/]/77S"\A45$5$Q%>LF0)_H9EK4`>AK"3GR<1 M4+H_"G=W37.SEP%.+]8,3D4:$3G=5$U<[FJ;*E+FZ97X_9%[D-LDFR7/&1HO MJH8F2BSM8AJ652J@;JG<@N0)=Q2L>.7ER\V+B"KK2)$-T5!,F8=(7!.FIP5D M@N;YL5=VO+\[#IH3`\A4-(47B"S)!M9U12R-K*XAP9SGNX+VSO?U+V1NI`J` M9!(+*1R@"7F>*IY7]D?6J]XU:"01BTBV$*>80"B1#0'II!2< M@56\L#KN36%>]3):(WT"CPC692(2083_>8M3IQD!"9-Y^N2]K8SOZB7E9CQI M`!H3&Q#[Z]@T5`V+Y5Z(I"@+_%;VYFO-\WNW=$H\IQHBTE256!KBP/$JG7U= MD2K1RM[I;/\G"LWK"@>QH($4"^)_3"2".4DW(,+B,#BVAKY@@<6MUI6*FDUR M>Q[=--#@B"`ILBD9)LQ1%F`1!,1/3(V@H=E`HSC9)\RCHF$FVTUYCQ&'K+,T MGVI(!/'@BX.O)4T/2.B\54.KM']2VWN91[.#;UH"YG6P,@`N`+Y@JK@\DR-K MLZ":?D3.PM??ZXF9'R>!XCL>2($*LA$1!`[4N ML_4F_]:\WD7TQ*FZS([#Z`)6B(E48I8)74-0K5H*YS,UKZ4P_Z1]PY74D314U21`C<>%[5N.D. MHJ7/HJ;\)D^89_[2">UB_KGNWT>>[?%S+F]>QACGP<4.K>V@<2/UUE4X4ZE]+SZ2[*O]2$LCFQ6)=)&28[^_?AM#$4,2P^$A4G;L)*G( MIDA.'T"C?XT^VLOY;0[S-W*Y"CX1;161#`_(1#GU95,Y1E9#['6IV*;K>Y!0 M-W4RO;K/HYG>Y]$-P]CG",@R)HB3W$##G`EDL.B)"JT*Z1F[1N)64[V2NX$0__ M-;,XO-K?C";OUJ'O_2WEKI5F$"M:Y@-CX`6)-C)9(E;2VNIR@U&RA<\!VA^' M872#]V`XEYO$8+VR'NU;\.!$P9(\Z0KCBP?QNS[@?'&3?#M]=3>[>(]_+S]G M^)W5S?=#0I0KRZ!O5'S71+QO4ORJ&?MPT*CW@4^NO7?'12]1PADFJ57>IQR, MP5-H:31`T:H?0)X^?+M!@OKSRH_G[5Z// M;3[DP?DD%#P-TE%A<'5YZG64W6VIJ_-DE%HI<=J7JE/PL2-M)`1BI27HYSGF M<`<)+0MR1@-9I9H")>PAC+29R6T6@I_>?,`=MUCW"'UPX[M MTO[5?O@P0S&U)+T9OWM_._]U5'<&Z^6@?75N[V[?3V?C_]QGI*X\XQ6B1\2' M]_0OEFEG["J*ZO>]G.S:7E:@,@$D>NY"6$&=$V;%9:_R*)9*/)=*_E;Z@Y7^ MVY_3'4H/(D8.EE`A<0OK(*GOR@TA5KF2VJQLW[^2YA?G]-DUOKT)@N)")BL< M!*.3YD&:+H;JS*K'NVP@0?E99+V0Q#ED_.\F2P-]VT6B\MIZ?%3)KQ:_!"T! ML3QWDBNF"%M3K_M.%B>3,KHL5\WX-L=M43[QTX?Q?5CVJY`Z2"^D MM.A)"N\=NLO*=I%=%72/U$\D\9UR>3P-[&^/SJ^=59/D$+`$CH@Z>0A2ZR!D M.0ND4FJ;22+/3[4M'B2ZDRGP)WS?;7GD3[/I?"L`>91-PW.(/2'Z-PC/5&Y" MT(5]`WH^Y]LT/9(XF917ZMF^,_=W#\S#(HG:!46,)2[XA$=/"?L85X443J3N MK2KY6^F/@'ELU)[8R`FUG@(D$71WNV.4/R?F>53-;\,\_#5_%'NJO>)>)BJ9 M\3+D6R-KNV2DM5XVQ?5;;>%T:DD\IHP?"U=2;R/"&$5!:ZZ[T?0"BU@*) MY\"5CR+CPW#E&5?WJA/'G;+:V$@Y-P222F`+KG1N+;-@$U>JD\O^4=RUHS7R M2$C?2.U2XH1`0-\-?6I-2P"3<+:UZ;W.GIK2R.&2*Q."80Q MW@CFW++_@@_4\&U+`^`Y,7^OC;_RVNCU!]>ZX]`0@5.N`N+QR(*67>4ST7YK M'RGQ7)S^$#W1TI@?&!7[6B,ETBK!)!544D:-5-'KDKX'AIIMNE'/Z=XF_92R M.IV*UB,"7ZM^K'5M5TIC`$3D`J@HU[_.VZWZ.222=3)![5+.7J:H-C#+A*J5 M,/^"LB\'"@QS/&>P0S((3YH3CQX&"4\OGF]/'ES[J=L>[@D!PF#P7 M,8&DBJI4^J"!\"3U+`R^\S+F[W7QE:^+W2$Q\"8DFF+42CJNM7;N1 M6*X+,.(;6Q@K;MB7-N`N>K3;^;)41G1_0I"I&'"F?>^EZ=D->"6?;TX?7WJC M[C;@*3@$*S'Q2(S2.F=#EHWJ0?>%5,]NP/]>%U_>@*L\TH+0E"CU^#,$%LO! M;GWOU>7Y#?BNA?%VP.M_^[E[RZK3OVA(VG6/FK^\?=_,;M^/)O?2"^V@H4G[ MQH^CZ_R6#5#0(H8\F2^-QK.>2[&=$&KYZG*L1BN1'5?^7'BFC>6*F,1I8(87 M_?``6]LS`WU.Q*J.OAJ9?6.Z?-,@%>,+_.96F[^C-N9O?OU]6*O"1200XY!6S=>NU2R&8V):2TEF^[!?(E0V(^O%6&CP?GL_O9LOZA!B M)KJEIZ3IXR?J$3\^*::D,BTC\-1+E"GM4VD/Z*7.6EF=:KWU214=V9#O\?A$"8W*(G:R MP;((DG5-(BUPD;L`/WN]_N#\U>5YBU*K7,@U&UW_C'[0I_]I]NG\S7E2(MKD M4/U`@@FV5#I"L%&O#[3=^J1-.MJ>=:T16_AHV]JIW]N4ZDU#W?QTC+G,U$/R M*G+MNN%+N)_[0D2(4`T(ND;^`($;O*3Q=3/SJ-MWT]D^$A4$"6)11,Y`".9S ME^VB2ES@3U_\BGSA=SYYTWR8SG+)UY-L]4:3SZL4KCUV@Z0WS;LQFGD\'/.Q MM$_;55!<2N^X5@P=;NJC*\7ZQ.75C8)6MS)3PN7<*$T5XF MC8:WLVZ1;D;_<8<#:__YQP\[.&FY70X3?3=S5V>F7D9FB[B@'^^;EH7%#W> MFVRU_M.^OJR8S0YO[AN3??D/]:#,75KAN;:/$BD9PM`@F`*IRNE+ZI1'=!&` M;S)X$KH?21B#VD:7C'#CF-/@J,B3@DJM-V6I:G4N"6/Z4871(KE\9LV:]WE` M>[;9FQ-U#EL`Z`LSCX=C%%8X9@)T`W!`)E7Q_(R;RI(<0MUI.1O2I@01K89'/!*OLS1?E[*S-T9T6WI'HM$.'A'IET7`MP9!(FW&G M4TNG-+G*=:.#`1!Z!IP3WI%@Q2&RMT?0"`*,1 M)^O<[*3HP0P,K56A@@65W54;`2%93+(,MP343^4P$5S=#V+@^GKZ9V[D@@`_ M3._>WE[=7=='U5$'O?5,AV!]SJ1C22H6;.'%R52=F9+PC1/E$-I.R=60AB`9 M"D;@0D/)6T:YZ/HR)$XK:Z(4DZ?B"MW^RSPD#3?6K\U%GO?+B[;8^4EU=Q-)L@M)DOHXI]&&"/1A32:H8^6Y0Q$6N?X%'0_AB1VM++0SJ`LDG,>CSZ*RP"/$Y=;6MED$6[V56B#/+L<1>EU[!TCE:U&`*WY MH<2]O%KKR3G>*Y@=!UUP5EZB.']?!P#)EGXW;P$D-S M*:4/UH*,Q(/5JD3O8JB!B%3GX+:G/_F;YF.#GUO$#)M+][G]W>R^&>#GW*%H M-+]=3"/KN=<*WUX7]&=B#68A=H2@";.*NQRZ]KD)NA04S3ILSF5_^H()LNYZ MGT3DO4K$0_7M>++0]11QR>6]XG^;C2;SJP:U?PE;VZA]:Y,0UBTD")JH_TL[%S8$-9G-Y?$TN!05`DWF9"DK,(B> M*^=#Z?4;\+UH.@47?`!"^NBHBBH1GR1Z3)IIMKP5=R:J&HIH(;X4%]MU(9EE M/#IA(I#DC-;0C1I62==CXC7H+\/%$)S70B7/E(C!(!.11E)20`"W5:Q7%)"S M<+'`AV@W9KF/<&@6/P\.AWLEN'`"D2ZWQBJ29U4L+0/Z`+5EX'MPTT_;"9G: M$=EVQ`D2O32Y1@"8]])V[JJQE0/S#,@^2VU/MMHFSY<9WO\^1^,X26@P)Q>Y M)N#B=ORQM8#]\VT.5A['E2B%H<*#XH'09%R7&:9BSU6P$;1B]&AZS\GYKNGM MW!N`:`0@RTFAKG77WT+$*E'HT5A>8/)S*-MYPI*E/$H@W"<2HUS>;'OCH;*? M.8*U2]5[4WM.OG>HVBJ;2>D_$=NB;>T#R$PZ$+(QE1$5BYR@N@:L/- MM9'GXGQZ=XSIZQ41@E!6K)CW=VL.* M/"="K*A]#^).P\W_#7$C$T??4$ETFI2+@"81$(>N$3D&Y2+`MF8*6= M3#>O1K.7LQ;87[9N_O)S.X'4!B=,HK?'69*$:B+QI%!=MQ--MW;B0[U`+R/; MZ'HX'X/#I6P2P'%)>?"!1,:D%+0@0BD'=LN)^-@L]SU0#]QID5CP8"SQFD2&AMB7\'+"3Z_ MVT/2&RWUG0P*Z4-41YE`;TB7KDL&>@4MF=;#!"\(.8[8P1H&T)XY/`F\CYYQ M$*1;%=3$V$51.T4KT:H[W)F*94LDB!Q.W;#S[3JZ[$@0TC0D07*70(K@Q,R1:"N&^7";%_+_URX]6"RCXA]Y>%"BNF4@B4(6PGN MOA+[2II50%WR;53VA(=V4C8D1.IRF:11Q$`R1J,\38EG4=^3U2H.HFPS=;H_ M,7R?4`=Q$3>4,8:P0$3VKXH)8$Y4F6R*)WQ:$L0Z\/B*4R>@G* MV-C5!4M?X3BU&?%\.,TE5>A5+L^83NSM[6S\]NZVK8Z:YDPPY&DVO;Y>-.AN M4^WW\>+7=Z*A+$CMG:,@3*X5*FD7@+Y*%43$=[!]&3V&@4<7SF"H"FC^ST/4 M`OT=-%&R+`(\#JHJ=LY(MXB%B5)7N`]3B!;.;X3O1>I11:C:7["!Q][-[\MS9P]><)#D9/GKJ<%?%[/#&DNV`FJYK MBPV!36=QG83#Z1L27U1$&>ZL<2)JGE-/NPGR$%RUW2F7K`)E#R)PQ]J+%#&8 ME2X%B4;;$.5U-WE!5]'$%R;7D9Z8OD%O*_*,MYS$/QB):]!"%S47=9DKU9RI MVJIL)3`T;V^[0D5\9%_A35]*R?H'JQR.WYK9S3^GR_X^W4SB\:1Y>3_A&Q_6 MSBE?:1CT/O3=VBT;_*#J_3-_*AE??S.`>R1NA@5;A#$ M*Z1P'X8$9RB$QJJ4LIY,R<=5MG[2=W]J0%%=;^=[!TI["6`2VNH_EU]KV M<_F?/]UUV%RC#'0RC,9M-:.^G*1X:E=*QE9TXC81R.[Y#J@GBRR;T#L M735H-(+C:+@/;^DWS<7K],7_?VGMV-0S7,4%,24C&M0*)[DE)J8K)]XP! MUFK`L`VR5HMD/K_+%;/M:5,M'_::_FOT>??R6?!KW\V:-DUP5P:WH=YHKXWR MG!/TIVU:[B!GG:_B)X`G:X^BD!695HF"< MES*ZHAX`5S7:03^8;E"[@YZ'4C\8F#0&73:BK1+:I$"B6;D7Z.D]`9L]"(ZC M?@'Q$-W=>R^NF317X\,#%@[0SJ;_9^]:>]L\CO5_R7<#.[/W+P'VFJ9-:C11 M19>&\A*'\:*G4H17X[O1)>@XXB>50 M$%XI.,^U48.EME'#@#X=Q0=;%019>H?(KCCOBU&IP3,%\*JU@6B,G*1ZXE;N M2GA/VIE$G8U4&"4*"EZ%8[7280)KW'``*3:K]4Z$#P`_(UR?O6-N--E+22^L M$=F:'+BT%860?.D6P,3`V!)N)>8HHOM=E3)X!!]21E1DRD7=G04FCA>H4]"# M\@F(G@C.>5+%ZCG'L\I)AX2R-D0&RUOH`=,X-.Z#GPBI(5@7GE92IP=ZB5U!5( MD1ZRUA&59B2!W3A[+(Y-W6\_S!97!=FHP'8\3)NOYL[;C_KYA^OEO#Z1FVZ8 M*'C'[^>+?]V--ONO/UU?S.HPS/O:T(K7U5'7OSLLKB9OWZ:SXO? M,V``%6HNKV]N2<#^ZZ.1^)O^3/S-X#?_GLH/!9&YS)LT5D9QS M,(HKU!Y%D[(4$OCN,MF9[J<21;=+F=P>CI8KGS,FEPLT!XG"!)=(#_!5B6+B M*M"*B;9ZB;U8(W2#*<^NS9CDJ&U!Y5S+3*WV`C+HM MU'P+0G@W7_K9S>)B0Z_?9F.!CU+)3&ODP07P7EHOH9;5?+3C-O[U9K]'6;S3 M,_(L@OKG=D&1\P:D,1@@NK)PV=C:%>D-B/1_2%"MH7FTD-I14.04!404V8L4 MC.-FJ#>.7^3Q+L;7)JB.1F5C1,&"U@K)W281,3[,+/KQ_.@W+ZA8$.GF[P^S M4B)*C]J16^XEO>(&:B8FR&ABY_+Q,XAJG95G$E9'KX0R6HJDT`N?H@XNIUJQ MEFZ,$_'JA=6W5L"%"U%SL#P:IX7FME:GN9#ZB2_A"Q!6[PT47@>1I-':.W*5 MI+_PX.`I31KH@@.6$#KD3 MJYU;#UD4&39,`8^SFF?@XGG$U*T,<,>R%0JL(+\JRDCQ26VGDZ:I*;T!INQK ME--$^&:"<)F>/0?<8U"IA+0UDZC:"LH;'('%OQXQ];O=7!)&114XA7?6*2EY MY!3;`41&/VK$9,:M,<\BIE+16G6@;+%Z>UL?SQ-CCLRT]#&ZLFY$U"$NSC<` MKO,1)NE!9)Z)T6Y_GI(945,]#S6/;/WT:%B5%TR`*J3-=5DT#`^#(Z9X-HL1G+]J-]!+`7^4\LF+YF4$SC M!)FJ9$N3NI6BI#"3U"EXSYJ[_IH$\^HJ-YHIZ8/U+C-T$DW26,-43C]I6D*T MW2$U_RT7S'MY>?U^?O6/ M^ZU>E5$N$5/6*SPG+BD61\MJHC7HV"`SD@MJFB=V3\&>_%SDZSN7 MR"0Z9C3/@J(;BNR]K:UFV?&F1^Z4!_*`IK*\;U;;L'!J!Z>6H>%:ELVMUGL3 M@\%8\SP95#M2.O;I-Y)Q,*G=_J?(,2MAO0YE_-72N\.'!#IO)^9P;*!.2.N$ ML^!\H$>1(B8E@\B,NV'9N*<`L`S(2Y\AQ:!UL%?D<;OO>G9;F8'H$=*\`VW@J9HJ-W MH>Z,U<)WR.TIPCTQ!Q/`"18=@>2:"^]KK9':! M.V-"=-DYX5/%8@F9CV$#=]7>8PGN2+A$TV40+TXZ9S7@](%#V3;4"R4>)W,G"3J6 M_-X\@,\LRN3!"@ODK($4K"8N=6BAM$'J$1K6GN3_S^UJI.[+IP)_7/!3B_OZ M]H^K^?+FT^+SN_YP[C;MT;P8%*E,9A0)V"!4J.B4%!RLMTP.0YURG8E=R=J! MF3UW#M++PO/*(\;$4Z(()M4=9N0CM>V>ZG%*:0L1AQ':Q7?*)@.$0.9$!6VT MRFI8:">@'2T:#8[L1.A_"R3I[>+FTTK^'\JHX(:ISKB>@9B:;EP/7ZZ_S%]L M^N$4L\Z/PQ>?M%*JO%G6Q$R/;JC.H>9M4<*,1^ZWG\:C0_MA3M=D=KD2UV^+ MJP4=P6IBX'[>;>^PRY"#Q6*23/J"N^!8Q&$+9\A-RER.5SI.$'0T\5VH'7)@ MRL`KN0R&8C+DK/HV4'9`MKDBIO7343\%S)')'U/1E&5G94EQHG!R;32AQ7#C MH^U,YR:^VY9!P9IBGH?2;I>=+_NZZR0AV:YV<$F/=ESO0_VP=^7M\N/LZGY6 MZ#X=L:JBOZ._H7MSCT%S_Y,5HO3-8AN6=Q>Q)ZJRKS/2/8X4W2<9AG8*(]K[ M;!GGCR>OCZ;Y"230[93`LB*C]`DH*UR.QO/Z5I86KW9M*1."?ULBF()M`BL1 MZ5_MM(@*"YC]@Q*4G:>-$A@8@ZM7QR#B9N&G.,[*UF$%`@A?PZ\8H4 M4S#3FK=0/0<'W3-@8H5NHR!CYM:;$E@_X(")%F8+Q&AGUSF]^7EQ= M+RDL>)AUI:?W\;?L%+KL7I1, M>_IELE0V8DJ!KCKYN:S4>![>(C5&CR\H"%;_OU`GS`[D'+)Q222129X8DQT6 MES!H`6M`[WMI7Z=0NT`,AH.WWML8M/?.!39@/MNP`D#_BT["_@_S0MO%I;W_D:!S9)Y143],H9,:H`#586P9UA(DUD>T-;SPW M/>IA?D62FC)T/I1P[NM M0Z6G8+`WIQ:-\ED:6R*E&*,UK!;'I36=XCBS+X3!?DDR^\`!,_G@F"V'9$1M MIPB2FTY)V6-D2*6=2V@DXY#M"5`A>T,HGA"!H^9:=;.R2R` MO"/G3%).&5\AAJSJEI7WO85;!R5/PV2OV(\VA,R3!Y:954RJ-`"C"]W;5;;O M33PGD_W;F,J(BDO:99Z9@4"1<4TC)CE.,!UU&\_,9.2+(WD%D`GE04 M=4^;=&.<]J-NY(Y,;JX0'CROJZ7R`$:!C0)YUI:)`:*RZ?OY[GMN1V-'^U!W M6K:ZG7>)ZZ0R>84I&1N53Z9B_8D\WN9&;`G1E=,\1E:V MQ>M0T[@2XX9R9B]N?NJ3>`Y!_U0V>;__]3^+R\OY^T>BOAG5^2L]/\RO/RYG MGS\M+F:7@Z*X7SI#9=8)AD:8@$)E,M[#')(U[:JM-Y:_B&.9FB*2U@! M`.0T=.:-86$9K[[6=EZ5>:, M<\NX4L4AP(`4JIC^*UVC.9.4-O?$C6!>T@RHI*7%"E M6J`(A<_PX!^5P(A,F$P/*2\6.TG%DJOQO7*B$SJMMQ`?3.X9F>YU_#NI8B07 MPF<4/)<]*+5?(\LQ^/XZTU*_8*8G)@>T(%7F*FF=B=V<@ZL8:65GYS:FWY0] M(R^;Z\Y11Y^$Y"Q'5M:2"@JZU'#4G0W,Q#5LS0T\$=?'I$2LE730QNDRTP&B&!]3J)VD7HV/MZ"0M1SUO>O\9ZJ.4-+9U&# M+UBY@%$G+FMSAH-Q&K-$'3U/]XQ\3#4\(IF3##JP*`NP#O0NU>-TLN-"803T3I5 M_PXBVF`HZE3)T2OBN!NVB*:VT47HNQ ML#$CNR.Q\YMWLT5!HMM_X8JWLIAI:7Q9?DIWKHZSA02^.?^-37[K%.Q-X(0@ M&3VAY#AH+LN(0O)E;K<.E=O0KF:%0RG\97XQ7_Q>ZO?[S:/9LD`%Z-%P2F?/ M61"B-K!0--=N4MF8(1F1<`B1O5DT6RBT4C/-G$E18@P50@!R:JSI040N2^8C MSN_^^^.5N[@HHT\/PU:W.MF M^@]XT]IQ`)UG875"]3,J(0SSTF*,)INR`+9&B%:T.[.`-[I_>E;?+>>?Z2(] M;+6Z-T_T36^_?)HO[S9<[7VJF2$IG,W>,.ZS\@[<`&>MQD'A=]]SY!.<[D+F M63B=RFUS&;,BG34\6;*WU@V5"(\MR(MDC7-P>DZ'*[W_T1$[LBBI,*B4<"FJ M`9P$L9VO`:YU4UO93L\QE$\!CCGF+4\94S8.O5C!"SZ`%.2V&&QXZU`<0?C- ME^7B@N*T,+OYM+\99,YQG9+),:FRI]-6,U@V1S;/XAL^=6$>$W0D]9,%GJ0M M2AW)WRQ#(BH/=2O.V\U;;[#XT2>D_]?YY8E7@-3>K^)K)-P,C7WDA@Z8;2,7A0,L.!L[>!)J2VX M(5-3ZK0#*_6'#W]/670/FHN%<"K2)7%R3N785;D$E:$(NU'+\ MM!Y!W-1B+BTA%2030Z^,L\C*9M^'.7'N&^*L'0VMR&6;5)&T\0=&J`FBQ:(%'"1XOU45MO5AX[\XA:G3=C-*K[+1-O!SV_7 M)MG`/[`#V'Y-_'@F<0_N)^XQ1,Y-#HG`/DL]UW8U/N9@!.$0=GD(>W-U^ MW/D.O/W3>K3"K(\IVNBT$EF"5Z'6+TD&_"5KP1%7GT>FG`SFT8`40GB$U.((0>O#?BUO%Q$/(?J#YE(=W4' M`TN6Z?U\>7-7P]LO+`SDG$1R6DK/11(:4X:Z^LUNJ"("6C:JZTX1="3UO;B0 M0TK19:FDY\P$\$(.;1N0D,\%KU1ZVBTA;+N76:NM`YI(#!!$^I(94?="KL36&9`#Q$BUSXA M2HJL47E3D'2QIOT3RTU:4C,8+1GO MG23+Q@GCH@BE7"G)Q@0[)$Y86WP9C:R<@_&O^7J9;[_<+N?OKB\7%U_OR]][ M(G""3%DS963@)B%=)A35?AKFV@R_$ALYVT;-B/2K.;UIR_G[<;_`G>8-7MC= M9XC"U7<_0JO\9?[[]>7OI6/\T6?:+OT?_YK7TTM9).0A"M$\@LC$HYTZ< M57)F_UW\=ON;OUXNK_\HQ,X^TT]&[_8FSK>!J=Y]O?M(SF;YP12[X&+)8#+, M(3!;DL&U//B_[%U9#%($\JO*HS/S2BZBJ$_NT.&4/NV-<[8KC;O7G M'T\HJKV6) MIPE"Y((S8H.GTC/&;2P(KUR8JMT%JFNR):0CI(=&ZFN2WJ^+>_S=\RD9&0$" MAP%(2D%9O(O&>VA"N:=&/!HJ*!OT\O([E-G!)VYG$Y+P)C`MO31)83B1>"@O M)C2%;@=P#Z3P0<+#R!ZO]/)^=MND5U?O;I=_]D'@C;8R.8NACV8I^)"\<)+0 M,HE!JAT.>#U8MT_H,*K.PLB0XQ<9ZE)CD`_<6`JY#[G$^2G54(1`=6?0^V*, M3(I-9;0A666]CI!<]-&%TD[(0PW')50'P_0HVL[)U2"6?@@Q4!5E\"YWD1.O M6Q1ZHJN]-A2XN@1;KPM:O5O,\H;?M/R_Q?S9B+R9W8^7/#J=N#%<&>XR MS(`/Q63F#>"]\/H8IZI^SL;I.S=K6X9WO?PTRY#.K?E]L]S\:\ M?1SUPL8X:825X(PA+C!9GM6\3HI]0?'\'?^;:^@G*%\#XS(Y)9G2W!$JA2Q% M@XQMWL\=B`.9ZZ/P`OP-A?2/8ZYWJWE>FHV?\VZV^M?5S0U^X#Q_WICZT23[ MO/M#00"NN7`BE9H2UWZ/^L\GH*WFB-(]85>KA]FMQ\!@C9_TZ_+#_I[O5C*Y ME7*Q_CA;WW_^;?9ATA\Q3>RQ MFO^!?_O+''E;WN#_[=RXU^N[F\5FT\PL;WU"R5?'5&!D7G<6DU39Y7NM?!FN M16]9KP"LLHP#93@J]Z?,Y/F/4)DHK+P*[+L6/V@G\T9C^]<8P*TB8"V&=PT4;`BN,C; MEJMDJDFGRYSC/./EF]?%/Q>KZ\]-1_OL]NUJGA\=\_&<#WNXES^&NTE7<%JC MYPO12X?VF(,K47#$(*)ZX>*L4S0Y2A8'2A'/Q(=E5L-FPD@H`V*D`AIH$LD[ MZ@DOKUC4]>QT49VE$X?1=2Y6!@>D2'*0J_]*.Y6H`=MFDF!E!;HJFAF,+\/* MV&`HMXY)9X7.4$%)V=!VJT5#ZFXUT@&0?5E6!H<.\G91ET3`Y#$C:#E?1BQI M1)M4/9,VK=>GL?+;XCYWEC<[+=!6NL]O-SG+2,L5FHE<[L9/^S1MJ,D$9"@Z M(M``8(;(\DQ(V3M@;#U"31F>Q!V&#J?N;$R-C4"*A->&M7[BW@XOHO5),VF9R+%$(JF\F7$(U9M9AN)A$_GL(_BBO(_- M:!L?`%-=/*X0O-,"2`F@DK#5`\X)*I[*^N.P]VG7TSI#&!,Q`-&8T-M$5>F$ MLJ16<>X()H?PV4/2RO5O=*TXZ,OSM-9 MKJ>($FV04)[QE-OX"%?%4UB,5FO=H40F\GG&,WJ6ZYEX2L$J8XTC3`#%LUK@ M1YAA57A^BHZG\EX:PTZXGR$:+JC(VRJLUGCY7`&0RNM\JK/<6XLX9C8%#FXXQ0]6(^U>E9NSA+9[F;1F,`ASI+P$SP0E"\GZ4] M@XHJ_Y:3%7?&TWDFQPE.^)11.WG"TYO10HKC5*GJ-9)2BPNRWF*E'#^Y'2"# MM=L\$L%5!B0LI0[JA*B[IABKE-A^_3&$C6V]4]1BS(EGBP7,TXA5OO2J)U(_ M[DA=F?U#Z+K(]AC*N+0R-V`;%*_,&]^?FUZ<)O5$UCZRCUY*<1[6AO-I$X4P MR;#DA,)DE.J2%4"H0\97K#KX7Y:_,4A>+K4%)I3*A=J\\(L4_A3Q5;_25\;: MX(TRH!58IH/65H/PQI9>!H^F^858^S1;WC[^J;_[\.%NM=W3W,`;'GW=/'BM M&'H@C.89E2;7H\MS5:SC^[SR?>!0CA)X=N8&9^U-(M1)EFQDPH!BCI3\%*UU M]>H#A`P8Z)=F;N2V9>0`)0`(!P;!H,,1!216N7HE$O`!(_\%>!O,.L$KG2PX MJS'Q3*!E:->C2%M9DD$'=BQO=ZN[YU#B\4.F3HQC=AF,1S:(28*G(,&46K\W MM(9Z,-TG@GVDG$#P8&+,?%0&6(@L>HYI4BQ%H;RUL<=!Z4M3/(:+%@D0CV)6 MX`T'%T/<`BZL(65>&4(O3O"@2<*TU.>W,L(X\=1@=M/N2#"D1\2*JBD4-]T# M5S?-U-OFE]4_WB^OWS].0SW&PMW4;+2W(Z.L)$G0IK+L!V,"61I[D)/M:+?Y MTO_Z[ZT--P>0LT/^U2Z'>\/SP;,!5J<0&`99#-,--"BBX`Y80^NG*]Z9'^HA M8A*1@V\TA$@K.%..`]7">U%`YO/:F2JP@.XSQ5F('+EE(3=RBL28#5RATBTK M:$%Y$KK>B$G4!20Y MAY\Q=&PQ$/+)V0`&H[^@J6>@"5AQ/^&"VD1_;<]=TH`JD MPOBA+8O34/E#"1;*D-3`5T$[^=2"5&-9_7"_> MHZR;9MUGZSUY51I+N7Q`T+,%SJ5)UJ;RD.&BJ5(KRF1-]@A1Y^%B.(D2X)*& MO/!)"8U&L$7P$#Q4`S^T`_'W0ER,I;F8LZ/,.0%K,.BT7D.;PR=3Q1Y=I_YB M3`S"3$7\1R:CJ&0P!1*8B*6*&O!Z5&.FZG),O%EKMO7]A$MD-88,5D>;C`^:H?,MT%H6;,4S93UW_[P\?!$9#>.V M\8!W$>-\\)Q$)F,[X8E_7IEQW@U0O@<9C<''&8;I&MI?/$KH0IA*L04B":(' M3MQ\ES(:S"*YP4R7HU5X(HQPW[8X!U_,4H0XSV-^0A,9,$&9XRE4@O,V5B5>W'1XY%&P'0.IG0P_R)@B(@*\B)+[ZCPY0&$ M&B_J+)'Q'G4<2>G4E-8Z3UC`Y)6@?19@*6F3+M_3UTPQ->N)AL:1=8XA>!"A MR@#J/R43I90^>.K+JE:J"*OS*YJ#X*D$Y]_--N]/*_!0`E$[ZC4-VBG,R'D9 M3J!X(NH]3[SOV:"/E*D$C]@33)3`RR0Q@3*`_MM:6@AF'.HMOY3VG(E1@E_/ M/C=0;>EN_7I]=[U8S)O-2+#X^K*_?Y]'WFS>+^6+Q(==[ M\VQ7LQ>B*?@>_PIKP>%=B9X%3,:2D<)S#*N%8:`XB_7+@Z%Z'W.'$'A>YL;: M+"$(D36\TW6S7YXQL\O`S:&[1I5FA% MI;2\#N#2K@Z+&$PZS,T;C^7DX)N8$JL?2-L&(-QG0/:\<9\RV:Q"\3G5/-LA] M`B5M&SGU\.,J-W4^_F1]_MGEBN0,UD@A*"FJ9?3XM M3O-Z]+:'@4/H.B-#8\U"!C-HDJR*Z":H$)A6MY=5JJI92'6'],_'%D9G'Q?K M^\^O;V>KW*20$70_?N@=SQ\;&B2Y-`S!2&MBW@46VM)E"K+J+*BZY@^G[6PL MC>C)FWR+E<9P-P()LAEF?SIX1*BJ7L@EZP_P)[/TM^7J;KV\_]PL/GYJ;3Q> M,\YA\IT[";1`!3G'"]@[C0#UZ'JWJ#Q,STFDC[IFPH*2&'EP'C4Q&!@6`V8T M.^SJCQ.]X[)?S]97ZZ:)9_[WV>W#XGF']>BS1P>_%*7L/*:MBKG=%^22M8Z4+2]%!;L[(3//[C7VX M?X\*_4\?",:@2EABQK.4!X^T\$&IF-I`C^QL-]LTW_2,O;J/A2X])Y$^*'^N M/:6,1:$P(HV18);7+O9S6EV>].S\CY8X99[)B!D<%T%D?'+3+NX.F*+VD#U" M\2,9DZD=%#*&2!@6&::38+FP'PDM?EF[G5;8\U)[]7"_N9^M^ELOOMXVH;A)AF&CI9`Q!S/2^NM M*@#OBI'J'?4XVO(.UM[=J],`/[F(#K-31Q(82J4DHH6]IJH'%(B;K@$;H^AT M#@8A6',OB^7*T62=P6.KRF-(WJ52-Q-"9^[^>`[:M].P;)Y-,V+[U4T;[Q^? MR2;K:48S,B:/[&IN;<)3S!UW>0E]E1-2V86X.H"JT[D82Z%4\!HLR3UP@&?= M.=#/7`1=H^&>B?SG#/CJIA^F]??%]8SH3^8R:`M1B:8$4:B)4FJ#))Z M!_7F>BIU]_5P*JV7XGBLRF!$()#0M":&/E=+&I_K0,[[>O5YQ@CJ7JG+YZ9_)*5W;OM\8U:N/TT`$`E"16+(& M';MP1FHTZ\6I9-DCGCK(%#!A;"^16'5OIXQ?\4/ M.4L7DMO-\G[2^%,TB6#RZP+7:/1H%($7-^I$K!Z/@(+J0--SN"%PX M#$*4,!R#)1%:P`3J=,_3#^&GDC32T@-12LZM<@'#8NU,X+1L#Z&L/@K=*=II M%`V/FC,,?B0%_'HT]"&%TBM,*;?58U)W]G4_1?TO2C^O*RI'US0QP;F/>*`T M#0H3?EDFZVB".D(S6LMNB#9$S4F$#P5F0)2-SG"OC"$Z.A_B\PNQCT1552I* M#&@X.^65!QS=\,WREALT6)'EPD?.@IXOCE,0ZKO,M1"'D=WCX8X@>K`_1F#N M+KV@`21+`9,/5::)F4KU@+JAG6GB8XC^M,PHI.EN'>X>WMW?/-S:ZP;U2=D:_1LI@RD/<7I@@A>;0O96;:XYFN,U.TX-WC,YFO^QGF M?O,X6Z\P;MO@_7CX\'";WZ;#XF9YW;_^;*#ID;K,`@O1(N>:F="^)!KIJKK% M*\$Z:%CC%)W,P-`=R0WC7KF\)-4E*J03K,4SZ$'S>B5D)\P\DH'?%[(&4ZR4/"CICI&J0Z M:5",R&8M3LGW/*FRX$RR.!O)4QM[8[+6\13`6J)2#JM+B(WQ0<]K1?9@HU3O MZ94]EO#!LZVB3WF'KK541P5Q:SFD<'5/4]X23R<3WILF'FWS.<'`160,_V#Q M0AK?.E8:B:Z;%CO/)/UD3*)T;.+:4XN!.$:&`0-R0U6;A%,)LCH6IE,SGTSI MUFYF][G])T]U8/OOV7K^N!^X7?NS:=Y?_W@_6STEZ1@BW2R6]QEW\''<8'1+ M0?.YU6:U^.'C[=WGQ6/'URA8OK?HH3%WUTI`"!@O%X%A#KB=!/240EY0%M^8 M#O!>WJ^7U_=/%8ZW*,3-F]_?CFBCP36P5'@6HQ;24BY+Q5*IG>#P61O\@//[ M'2CD`9G]QV+YYWNDP#YNLO@9/_P^H$M/L^6ZIWQUKOO"=BJ>,CJ%&3Z@@T^6 MT"#*=5&TB[ZUW8GPHEHZ2%K?CP(/OFS;JF0J8*PC<_$2'4:`H*`%[,8KN$^5 M^B?#?U!5-E^\V6\988*R1BQBKGI*C.XLA82Q1G#.0QN=*M=C$;MQW@N)XRO1 MP=DC!!Z5M9:!Y40K)6WNE2COLHF3/I\D_]+`66\!&,T$Q.1=4BD'"2&4C)[& MU*<#=4A@^Y<.CH_1\`Y$%VGNH@[:*I2^*7Y#BYT)KA]1%U]!D.:3$IK91)3Q M>5@<0[-VQ90,=)]GI^PG3E]>35^G=_^J8C4!`C\^41DL4S)PD5+I@L/K"']I MM)>JW^Z::=?%_!$IM?>%[8R1@O361`GY,9&!%\I&W_8JP@Z\X[-EA)>*%#JB M^'84,,U):6.!!RM=\,D;ZFPL$,8T$-WWD$`[?3P_G"ZV5UB>?AGP(@"HC&NL M)2B9I(&VG3MJV9>X'/)J^D,K8-IE2(XEG?<:.IW;`:PFOEU9I7;P0\ME@!_D M,ASIYL_B-'9B-;G/LXN?N'A1]7QU/OTBFIL6G27` M0)LDK1P7$#0GK$4$$G)O=/;_[#UI<]M&EG\%I=W)424IN`][,U4XLY[8DDO4 MS-9^A,BFB!@$.``HF?OK][W7N$B"U.&6(L;\$$8U.V MJ6DI;8J6&ECR;AC*UG<)0VZC?IB([M^($A1X&+N;N.HBA=$KD+<-I1X?J7!\V_ MB')?,=H0&JX91AYVVU#A_V"TZEZGJT?:$"!>"Q+KAW%($'BNW>0%1N0[JJL: MJJ?+NJQV3H0H&"J3-5\K'>$-P.(->+IERP*@A+[MRDY@.!HV:FXAI&W6OO0U M;]EY?2B]%07@=<#X+&5.``JO"_:8E'`\=/[KW`+Y2:94V6=UN9A_=L`WACY)D.(LYT=2^T33F(]$"-@BZ%R!W*:-!L0=ZH M72?Y9\+IH7,.$4"\9TO=%O(QIZQKIFP%?F`%CJJ'IBI'7CLZIIF1C:Q6S5$H;?F7% M.`&$`S[.KG`U'_-[5O"_DOEF6<.#HH'.O5^6BY6\.QA27)0;#.D;-N*MMK,#"0@UXF8,9[8ZA6E8[*<)3-SLJ]L*S\KG^$!J(`=01(P1B M!'".AS`B\%S3\LU(!AY@1Z'FA6Y7#"]'.QV+ZKGVH%/JK6/$/Q>+[PTC'L$C M`IK;%MEA9(,QZT<%D55M#Z\,M+, ML.Y!VTR6%WV"WQ6,KF<%>P!*1J`;F@Z4I"B6%06:9IB^I[N&K@6*&ZSYA(Y0 M>B$H#?&^/HQ"UW=-!:"D1Y$9JKX6ZA["2-,4VPK<\)!A%'Y=)'Q@]"-=UM]L MFG;N4.I6Y1JVIV'.F^W+7:]AWW>CD[]_5N3_%7"*FWL46T-WFA MAM$W'^7S?"F:$ZB:8H6FBBVN5$?%JMJF_:MLN8/8:F^F=KS(B:P?//Y0MUCF MGLRGU90;H>'+IB>KV`;"M#P+^Q`TQ<.VLSV)3;$VYOEMK^#)"]Q7.RZ;CF&X MCN<8MF]AQ#@RVL1V,["V>U2HLJP\98'7&%M<%JM>9].G=CEVL$>E#;J^+FN6 MY?JFUL7O/'VH4F5S/MC`(IZ^R+W]7WVP3"U+E4/DOZX5*E$7[?6T8,@Y^$V+ M?$;?5R6*`B`TV955PU<-3%IL69DC;T^+5C?[9&XOX,GKVXN*(3:F]4,[L@S3 M\&S/Z+IU^4&TU3SJJ>O;""TTGKX@29&>I9L_!I`^U)#W]9-H`+?#W4C;8=H*&I0]GFIBSK;V-O#U"= MK`3`4T+/-SS/5E7L%QBTCGY?'>JH;RKJHZCN5?:V=XQE:`2@404@75TG"K70 MC-K&9K*YUJ&O@YOMB-I;7GP!G:RO'S79'`-^_#2OTV]E\G_LG2(OJO3GR4@+JGJ7O9# M/%^\_P];5:SWI52PNSR](U%3 M9)HPO@'<;8EG@1^&M]MN=FOMW<-+:4)KB=A-L8R+E:3:M!<%-D=`V5QC4F>9 MEOV]_EA*-WE1Y/=T>/$B'J/A6N72%OX]!SG^TS1.@=?@?T*>)\4IL!+:]@VK M[AF#DQ*T4EWP2M?A^=-)@T=#:"UJ#ZHL=@\MTG7+7Z,ACJHX?ZQ,D-$!B\=9 M@G%9YABX@LN)!2"Z#6Z_1?/-ITOW#.=(\<::E/^29'1A/,?FLD@\8DY,.=5T M12!Z(C!AY3<,R2E&!D>KSW%/N'XAKYF"A!7RH+,5BPO.?6MVU''O\T,10!3\ MVV:L<<.WVQUQ'C\@C1;8QGC")GL0E8NR3,H;?GP3I]BA41PFBN8_M?!]BP@W MCROLE`MB9E;DR]N9Y"Z*))4TF>072+&WS!.W6-7P)LY)!@\C$ZE)+=F]+0A) M""$@%4(?V%$V3A:`[@B1!-1WL'0J:1&OL$,U:#59-4M7$GGVI5R8+%8-@DK);]L,X#(-/F*K*\2LQ_SW+;$;$A:+`LR M'#>-F"=8XJL@\C4-_Q,&HE+8ZD9L45&\CELWBBF_KQF*&)+@(G#]U`M&G;,1 M(GOD7RR,-BQ9&''L9K%`#R7V8T=#825FY=4L*2JP.,000GZ?P=HR(`@I0U,>`PG<@/'T(L8+%NEM6B.KA5'G3V.7TE%G<."F7CG MVZ?W1K7RL)%&TJ>X&,\DC3M:]`U'"^$)J1:<^XS8.(>C)KPB]-_@2FM>F)YY MNGD?F:?7@P]DAJJ]8CLH,>6G?(M,CGXLPWX2II;1NWMLFVBBK*G:-: MIX;(E3>ZD*5&/>`%$'H,FAI9W-S!)^L30'9IPD<0_%&R-X0!3P8]9E:ZXLQ\AW6,[<5G; M'KWO%GS>Z6,9#[?Z_4\C-*>S;`FO MF3!"SEX[EP79J9U#FIL&'3C7["HRG82\D*7L3I29NGWXM7^FRBL`TAWE%@KS MS=BGBFR^>:I_:7EQ#BB1E0D@-RZ<%(8NV,!`HB9DD6Y;J5S0;('LM(=^3^?M MC;>@L7`I3"_<*2=:^>J?6GP7)RE9\&[<1AGG.3J_ M&L_-'9$N3P7AZCM*X7F2$46-XW(&;UKD98*WT\=IFM\3Z=$*<`I<,F;T$DP] MDRBOJ%R7'X"L24:J6)H0WG-.G:92N83WM@O\SK!'45\4??A'O/P=Y2J,^9/: M.-,5`GN$@0TL'RMC\N,="EF`D05Z?6N1;E+#FM,CR6I/'Z8@[7&.#$=]NGRM M6K^8#N2&W&)K>L ME76L'BQ*U)23!5\OA*X[!<.;?Q-_94"Q2=GHW.C9H0?W[\NQS1)]5;`9`\E^ M1\9]/F>@[7Z@,8A_+#-"C"Y?)M[T'&W(Y?43+NJ)J)L>(3I6T)1A,4.'0`D3 M/-P.3^_.;#M(M//,^+GOA6C!R&982SLC_A=_876DDFYK!NRV;A($^CA.Q[6E MTH0_%L#@QB3/#R5(B"R7`B_(6&#)NCV@GFT`+DD^#G><3EL(EG,=C MT!.Y;-IDH@NT,@W[.U3%"0#3."DZHWT'X$B1'*?+"4^[;!1B57[/)5G6U2DT MT$E8V5ZFO&\(?TBCIOFESDZ3D MRNQDS?R+TQ7("B2(I&P_KL,)+=("K`I4+-;R7_>J9`CN)+IS-1A-FGZZ`LE`;+.]M=MP=/6 MKU,[/7EJFT@;6#^WQ*5=`^XPZ2*'Y3D4-9@N"](\DPP^S;DD*]AM7$R:&,T& M3ZAZB-`0V7Z^WOS]7[\\O;9VK=H8ZX_+RZG+`T2POL^@:(]7_-^GE.-ZOJU[ M9A1$ONO:KNX;2M>FQ%-\[<7+Q#-V)KG588L`[5Y,$J7Z//,\)*4YYJV)O4@.K7[&=!UXY:6FYH< MW,,M&%@%/1Q^1^1HRR1Q'@%\&N'3:6_N',YX'/>.#]-BP8!&'EU(^3RI\(;^ M65'4:/"PL(R&I^4M@)MS?@!C*D),@%^9<8PCP2U-\I[8R6N!&V)=+73S.M>2;$W@N.!N!%.VU@%3QHD M(.?`=&ITWN9-0EZ+#$X,KSER29%<$M?4.@XZZ!]A_I>%^>Z:G#5GZKJ0$L3< M7CCM\91"!YC^=(=R`1/4,;)"XIQ/PGA`:AQ2AN=!A<'VRYHC88M94D'1TE:C MX85*%!6K$XFXZD7G#UI0`Q3R)AMLUI;E>V_2*?[B\ MH$9=GCOZ,)(N(^GS53@*+Z[Y+_`Y^G#A7O@?W(_2"+X,/\%OHT-Q?C_-[U$3 M;)\-H1@@;V"3E+SA%?]O%J?5C/X<\5Q&?CW*]7)Y4R:3!!@=YE*AI7<_R\&H M/:,2Z7/)Q0Q&V'DRA6=E%5_HN$G(:%Y(YE"785?V+%V&I;IU,EC6VQ\9\WSK M.,.X[I&%KMAEMG8*\72:I-C/2/I)D-_;D%%:CD4%C/A127_D<#;2'7KO"T:9 M>W69Q<_D@1XW(49DF3P<26DLO%?UG%6S?-(4.D^(6=SP(T,_:,?_[(/(RSSZ M\]ZB4=_WDX7SM&?=^221W_>=PGSHS_OZ,\[^O/^@H1]].<=_7E[ M_'E/=LZM^?;\OC/CZ0D^H>P;CA/8GN9'GAKIINPWR'IGWI$$:=JCZOA*&@>YJ MFND;H>ZT[OG`]_2_B'M^='WI_W[FN:,PD/S+3Y_#BQ'YXY^MA+TP_\'[;@II MG()0^_4DRS-V\DN[Q+>U7OYQ*[__\@[9&J`&,#Z:LGPP^NZ'3&ID/XA[V>B2 MVQORXT[!JF*M4N;E<3'A/+X`%2DO@+M,\D53(HV/D3!/]XSRSMOQI70RTD^] MPCFZ$K_M5P623\?-&)(%X)1\.*.G2YUG?';EWQ[.0P=IB4R:9\/7-IP,_Y(Q?=S@`K?>B?F4"DJ[FKVCJ=#UC&5 MN+-ZY#JT:=#`66F> M+4%/AR4VH*"RXU98](':-/K!`JOZ*(JM+VD*6[F&=5>C?_[8+YS^69A+SQ;5 M'KN&Z;^7.6ZD+GE=X,1F*LVNM[8?\G4Y^*2N]FF.#41RCN)`+>_@#=XP#(F< M)IL`5L[R>P::V&D3,5I'-.`4%5F15?-4]#_=8`.?%(W5KIB;KN<3H]L`5+T: ML$'KN\"HF6`[9C1.>7AQDI2+G$*-TV8WU2`@`<07>2.@ZC;H\WCR`+6#(8K= MU_A`%=5H!JH%F1A2B:BOQ811.NW)1>I\!ID4O6[>VQ$>@=CC!: M;1!M#QNHEU@M>Q6Y9K_MPQ^AJN);&`X!HTHYPN73YVFQ:VILO0!!:JQF'Z8: M^WP-[FC@/F#@AOR\?^,L"U'R7TWK`C&V[BNX.0/.DD7%0?ZRH9GGC MJ[]`0&:#>C#`_P;3!BE&D/`\/.##=1^Z#O'6L(T$UBPM8SS'?#&A:$>5Z4]A1Q[Y=WE/!#,+0#,?JCJKE<=>L&)KJT4XTG]24$2 M[^(^1T9U.%.#1LLY-K%']Q7&M^[JOF^]\,V:#8ZNNA+-P3I!$!5DC]^>F!'#CIVR3CBXR75=Y\07C'O[E/)M7LG6[IL)X;ZH3R_^U]Z7/; M2)+OY]V(_1\J_-IOW1$4S?M0=T\$=?5XGVUY)/5,S$<(+(IH@P`;AV3M7_\R MJPH@P$,BJ0)9(',BQDU2.*JR,G]Y5%:F;`TV#?EI\B%+(GQ69N!!^@DQ'8?K M_?:N^XX%X#R(S_7TVH_1G_M)TZTWCN>VGG;%5&;"F M4^UT"6@.R]?2*,,;*3GA1M:$-<4Y:Y:)5,FK?8L.4&_A7)A>D: MQ"#[M4C:)DZX-N5RF-[AA\;RK+:BB#1CE.*HI)V7?C:2AXY5@Q4GB+L6OFZU M42=WB=RE]74:'L\56:,VGIO`GF;:^*>`2+TQ6JX`&_(U>IG",^1[&:2YBI8Q MDJO2R!7Y;FMN]Z7%\]C*FGE:6*T)K#;T8TPZ3WA-*[G5VT2BNRZN+F"WL-74 MZ@]N3>(BR&4<")1(WHW3NF_C.ZV;D:7@57T[E6^&S=*C9*?:T>>X$T0>@-L_ M#X_)X;H>/&?O4&E83KO1M"*^VH*OS$AM-Y=6Y.R]NE&'IWT/Q]DSQE(QQI\S MA=W(93-4M^[693.%'F$[3K3..YC:HP9>]K5UOZTJ9,7_JW`DU)_!RJ MPK2C(_G+.T\=>:$9\^3!.*5[N`68ZHUJ4UO2U:%(!/F)+S1B5)W*&':5?+1< M`,$MWR M:K[#<30X>V5=$I8>P?K5FKY&8P1?>;MC=2V(G0WLI5H.&2K^&8>1,WK>/R'W M.-[;>#*Q`OAMR"P[ZICST=;7Z/2KW4:GW6FTWQM39:-=>[]=#8E& M<\L;Z]N^<-?OV\T+2^+>&6?R3BFL02IE`'^(?0BDJ MKF$*DYD!4E19K&)`>F$K2K3..YC0ILY'/\FU1@X\!\'2JPL1O9:6I5TZ:L<-': MF)3N`1\9HP(;Y"9N1%LJL+&QB)%O2+ZA66KJ<,YW88$-\H?('Z("&UN<6VYH MK?VTN.;%$DA@[86VIKK.9D"N>3LT0%-@Q75!*%>HUZ0Y\;L2TA36$M M\K-*H.#V)ZXDHN474?+6J!Q'T7+;T1N=I./L1HJH<1KT,,31X%27(ZK&T>X1 M?!UG-8XL$W>`8_=.12H=LO9XOP4.E@+QV<(`-WR:LOV5$(I1#[GM!U;D^-XI M$D*^<&D6\S8CKX@")N?^9,J]4+P%OTR<*.(\J7YRYEO!$+]<.`&W(S\(F>6& M/K.FTP"4\9`]8%I6B%?(2BC7GONL/@[@&FX[\LDWN"`A^Y#X5XW:+[?7MX.; M,/VA_LO/#"SDY#E3O`W>%HEQ3*S@.X_8-'#L=&PX$XD[X M@'\5`V-#*^)5QNZP4HMXG7A%\O!''D8[6[=F\[V694LF.'*",*JP$-X%4\)I M16,GP$^>`VHAM`*'APFM9M2HB$OYCRDLZ)OG+K;U#!(?LE'@3]9> MP"<.DWC$DQ.2`@$2?@A?'$FCT)H@[W@>#^2\GQS79??P!QY%+L?OT9@Y81AC M@!.)Y?$GQ4=)A9^A,QK!:_#O]SQZXMQ;PI'R-QPL/H3_X('MA%RM"I_]("ZO MBNDH]F7`@\[$POI">&7D1Y8KYO'@R7I$\(C8R_Q@9P4VX*Z\U<^21PF"(E(< MHM2W$A+^>2)/^1NU534+9N6^.2) M=8NC9"E&>.9'<&[*`*^NU-SB5+(H"!S@?P>V!T8`/`@=,._DI8OLEV!"=N'# ME%5?1MH'>Z"S,7!(]['.&"!'25:"=;M10+D MAC=,$L[D(]4CL('+'[F+?P8(PRG;5CA.'Q3BL`"8(M"X]QQO MF5J.F`86*,OJ1!)C3>/]U]AQ-6E-S]>C-17L@[+**<4'F2[/AG&`G+%#XW0Q MFKG5O!"/2FA2@\G[Z/AQZ#ZG2[#$;@GXQ`(T\3-184O8:EI&D0:89R&ME9'F M;9XOD4[6-Q1():H$ADD-Q1"`,/>+Y)+D4@M#7:HT3V*H0S44]M&4A?I@$#[I82?1XN*$F(HPBC"J!.Q$ M&%6D>[.'3D=FN3^)M8YP;K4Y)^KL$,\1SAG*O5MK8*X0:1SS@!UPZ` MQE>3I3:8N>))=8VE^(U?>[R/BGT;B#2'66^_U:.6921=^Y+Z!M@ M.@<0WAB*-Z3-2;I(NDB;DS8G;4Y=?G8H1(UJLROBIYUJ0ULW>L)C_?0QAF-T M$Z$,Z-JNMK69<:8L9-'6&H&`,2!0P"9`OZW3M2&9()D@Q5A"Q=CK-PD'"`=* MC`.D&TDF2"9(-Y)N-#GJ1J%_VC/98ZKR#HE8!L(90ZRR<=S+A'NU![).RI:C MQW2CI56';D_BH^@_3:)-RL0P3"2.(V5"RH24R7&)-BF3;0B7B2Q\%'TBEUV_ M,U'(D&FAD69V,>I(Z(*[`-]B(],3V30ZUXT=>SU[H6@I#=,Z$=V:L<^I@RU1 M;3?&SO16R"QQ%\P;7HVMG[G'`\L55UK#B>,Y880M:A]Y^D`_8/Y4=/3V'M(? MY0#BJ>I;;;M6&#HCX&HQ%GBP>']N@*)!M.J;G;2.YY.IZS]S'N8;6&/'^6`H M6LMC1_KPM3GKZM?Z4[_16JI7MGF8EB["YH$XZ!G5!'X< MJQ[K(>,>KKZ6)Q?=@U??,FOL!!WP$#N_@QB[SR\W8$\^__HQ#D\>+&MZ>N&$ MMNN'<<"O1^<9:;N1,GONAU%X.[8"?H8"^V,;9\\)S!T]6,$R?#=+O(;[>\-%O[ZXN<`W_T?SWW<4[ MY@SA!\N.3OJMJUKC_*+5[M?Z@T&KWC[KU_O=]E6WTZQ?GE^VWOUM#M&S1'VE ML_`RO?FB0NCL0!\DG:\!OW'!G>@9X1`EG/\5X[<\"+N6%Z).F`*+<-$B_)ZC MVE]DX6TTX-R$C[:U=*O;FOE2]EO;2G??V%6ZT0+J;-F:MM;;]M;6MC?V=W_C MUG=N.,F2Y*F;Y0R85V;6./H0_VCRPG?#/X;W-B:4.@B4VG7AORE:F.%'@BV" M+2T,M6$S1$(M*BVIGPEOKV\'-U2Q>1\;(L?(;OG"](5"GT&[=D5N?F;J$5?8 M!;=%+)@UZR($O!AO-6$+U)QM]N[R?0*NA:^KL<@?N4MF6(;% MZK2I$_`A9G/;EH>IF.T7!'E6%^AERD\0[Z709JK:!DCN2J-7)'O MMN9V7WKV@ZT\\D&'=(/(`W/YY>$P.U_7@.7N'2L-RVHVF%?'5%GQE1FJ[N;0B9^_5C3H\[7LX MSIXQEHHQ_IPI[$8NFZ&Z=;[$*CH;*-?-5<:9^:+F_`X-,PT^B.A=(#;X2QN=X,1]>RXI;OA?.!K))&9RS M_D6O>W76&30'W8M^^VQPV6^H,CCGG8O:>>%E<#0MJ1"!(98#$]0X!8'B`;Y, M/O'BT^WY]=>[3U__N+Q@U]\N;P9WGZZ_WKZXUH94Y#/+8U88\HA-X\`>@U0QZR'@0M;8DQ.-@3'AMSL.(FC#4^V_JA7V M^?,Y^Y#L*C9JOWQ3MP;I;_5??L8"="%W7>9$(0N_.Y@&P;PX"($<;&39CHLE MDQR/G<>NZX/E4V&Y%9%UZGS03HZ'9?-6#M*"Q\?W?\*\\946O$.X)E@9S_>& M8D63PGSX:IPPW#@4-ZLB>>=P"<;E1*6\P4361,-J8SHP@1Q&$@4(#7`IB!9P!]BUXK\X)E9TVG@/UIN54_)J]XN MY>=_8EBP^C+QP2I?+D>FP%\C4$TAU@/SO1?E)9&&[)\KP*U:UJZOIV#AR3U, M:@M192,_@*F`GN58[@S805^=R'JGTJ[5M-5DS%>_M-S0S\,A+NF5,XHXQR*) M@WF@R,'`L4H]2CE`JQT'`9#&750H?FI22?$8P1OFM`I0%O@$KOT[MUSX?@XV M'5#7LZ29)V2F(K!Z-(*1(%E5K;U$!01E)RS8ET*U`($O+.\1KQ.D_?3X/+0P MS#:G#@7GSE073Z#*Q2JNP]A6@&1Y7@SZ$I>&357)2#:,.1,&W2(7WS_KDM1* M7ZN@LC^PYJU"6U7K=@YQ*V"V@=L8`BG[&7`7=9@=<7SU'#"<5:916$++\[QM*]+B:`)E?J(;,X M":"O1NW$#Z('D#H@'4KN+*>'J8+#.7V6*`,@3UE4^MVA_&?\ M439S2).!YOG(D"UK(>/NQ6VHV&3G$7"P5# M3TI-@\7OVXZ5D$E,14Q+WQP:E>Z*?G-;R1(NO&"4/!R(0K"H&:=3P&H/W)A9 ME6_`DI`!>@7/<#/&,8!]`G\"@ABP(0?%B7H5J2+\'_$8<'901B/'+E6L=E>[IT0K@3'47("YSY&1@GX M(P7V_M=.1)\)#]"?BVR)$_ZZ/?AWI;#';Q=-:^Z=A9 MWG%VJV$-XP"EV=1J[U3F76^9]W3B0FEEI`>`5B"Z,@&6V)RJ/P2HL6%6Z6?, MAZ'/L;%$!.\C:2$]5N`M)RP<_F&**E)SC">0/35UVO-/$LVN&% MSE"X=]*F0:C'I\!+;2Q0/V\3J:G^-QO%$<:$IH$O2!=F.UG,%""H)1$K>AIS M(`F77G0B2RFT9\S_5>8\:$:,-/I9@ZB<.DY^78A77PN'B.WT M33:\S\]Z@V:KUFNV6XW!9?.\2S:\+Z[ZA[+A?3FX^?KIZ^^W[,/GZ]O; MG]FWRQMV?OWER_57=OOWP5]OU"VF"-$$3)UB2TUVK MDSA[VRF4WH8*9<6YFZ[9!2=V46S];AQPSKY(+^(2O0A\]++DT=S9D@VH;1@O M&I?53]PXX\:O8(;EF)%IY<:2P.6J@WC=O1_$,YU=C:8<<=D67&9&AY3U2P64 MC=#$E,249A&Z)$K:5)_&#-Y\BUWYUB"CSF/O^T=`0CVC.$M;MRSB+-,XZTWZ ME`"-V.[PV&YMM-O,:)L`)[COQ,=;'CPZ-AY1@/NKN6W@L>\"\X0O[^UNR_X[7)XRX(8QQ#I< MP"6.(XXCCB..(XX[#H[;RFS,$ZJV"W:;>V`KGWNOW6)49J+(:E#Y[2B!ZYB'YH-!9[99%R+4*YTA9<85MP MRZI:4)#I@;;E*.A*0=?<-D27-B%('D@>:%N.)((D8ME][0YMR^EP7(YE6^Y3 MKM&:<&Q6MC`5/>)'26^VR/K!:?/NC=&+)FT-T-;`P6C+XY'<9J7?V+_HFB*% M15NL))PDG)NHU5Z--@5(K9+DEDYRFY562YO_>O1JE7;LHE^^+C03W\<.W09\ MV@0^'?HQ#DY;L\!#*%*X-I7*4,6PU=06M7Z5+J9P`H6U"[>8(9@AF"&8&:%/5,K:-?E@($F$P;Z**(>2Z_/ M?,[,RW4\?I*TQV[4WF<&^-8.BVLBPDN#>:D!9)Y^F:?D8`'C6^(IC@>()[]G M7^/YP<1RM_OM7Q28OH^K&^K;WU7;]0IH@3=#$"6X6[=^;D;E: M4_:V4RB]-YF8Z6"[>^B'_)8&QV^R*\37)ZGB[GUW*!]T-PXX9U_@;^.078)" M'*XR/6[Y-.*3>QZP9JU"#H_^+6'BQE^^@AF68T:FE1L)+JE]?*'MX[45_R5< M)+9;G^VTI<\0VQ';$=H1VQG-=FNCW6;F'LS5I-35W2;(3<&0SJ:[G1;"NM0) MGK*H=PN6Q''$<<1QQ''$<XB.]5IEMZ&6U$=:6OAUGY)J_$%F?=G,KW%= M&;*8:]6ZOM,2IB\]WD>E80[$)#">VPAH\D!3:Q+0$-`0T!#0%`PT#7U5>TQ? M>@(:`AH"FKU9-/KJ69B^]&\%FC?N?^TF=C/W0'RG&>6N*;1H+FH?F%8C_B'^ M(?XA_B'^,9`^16V-U6NESR^ZEL:2]Y!/($\;A137(>1@"AY_`(^F^-#)(@L5 MY_11+?)2JX"C$KVZOC8!)'HD>B1Z&XA>\3N3)'HD>B1Z2T1/7PG%XQ:]-P;8 M#\`#_-UR/.9[&$.?^J'E[L#UVV_A(_T"F9[):6@+:;U&(U.X!^^C"LJ&:+A# MDZM:M:NM)@D)%`G4T0L4*2J2*Y(K4E0F"!2=5UM%V8OEV4S[=\RTAE!TE20S M?4-OI\V'UR=J&8(S%!Y?Y4HCO[GWX`W/57Z^\_*:"?1NPIJ;FF:5@6Z,Z:Q9!L4). M71:$B4NH5@HFH@V!P@T7@B^"+VW1F=TU#2X%$Q%\$7P1?)4&OC26"R3X(O@B M^"+XVJGUU2'X*D/RRX$WO!@Z;AS)EM;4=H4:_1A)..(XXCCBN%(0SAAB$<<= M`\<=_6ZIJMQH9@<.4XBDS3\M;LYF!\A,64@*<>U7@1,(E`X$]/6Z,&4A"00( M!`@$-@(!?7TH3%E(`@$"`0*!S2P!;3TB3%G(MX)`N<]+SSWPL'M$4-2+XJP4 M9R6.(XXCCB..(XXS;R_I`.J6[JUSQ9N]R5U[4UKKV2PR1(F<:6W'U0FW#UM> M]'65('DA>3D">=&V<4?R0O)R!/*B[3#^<<@+=?`K4?^&P^FTLH=ZV0??TIQB M93O0B<S8O,O8!E+_<9>^$ M4K,=1;=-/8%"$$D0>2@5@DO-=@21!)%EX56"2)T0N$*5F.X)(@LBR\"I! MI%8KLJ`>[`21;PI@3@"<7+X'>"PT685[_L3QK`C6GOV+X_CXD`U@ZM8#9^SN1TFTV%UVH;%$#9TBL;4L;$/\0_Q#_$/\0_)M*GJ#W@ M=NDMJ[,-V]QOF7NQC8]4FJR,3J7>,"!>9`I+44C(`"U`XID1SUI#6XT@$D\2 M3Q)/S>+9TU9!G,23Q)/$4[-X%G6`[1C%\XWG3LOO<%YLWQ?ZS5)90N%K-G?G M69K"(D6K0-)TQRU3C5:/9(IDBF1*IY[25X:99(IDBF0*=Q6Z9/N]P;_Z&%DP MPV77[VQ@&:*YCL=/QB)UZ;3>J+W/\5\=N2U#UC_C,')&SUHI>S?F##QI;D^(! M$/6'[<9#/I2]ZR(@L^U/IG$D"BHAJ=416@:(Q6\<3]VD9,[R"ZYD\ MC"\:AXQ[.#DMC[SETXA/[GDP4P;-6H4U:O7%9-+],A$,:3'JM__^V__O,_?DVO^BMVHN(P^C"?>B$$N#N7X89VYC6"L,OMSPT6_OKBYPP?[1_/?=Q3OF#.$'RXY. MFKW>X+S3JU_"G\_ZY^>U0;W5[[:ONITFK/-%Z]W?YA`Q2\$[9P(D^,J?V(T_ ML58;'B\!JFXU]):E%U@^Y+8ORZJ=QB!#`8Y8/O[R'W]\NOLW^W)Y]_?K"_;I MZS\O;^^^7'Z]TZ),>KO1)4[*,`A?L0<<(O*O+80Z:S1R7`<^`O>/7.!^+#(G M0#/(PYC^`>%WX-6>0SBTV!?R>6_*[W\:._98//\Y(3K+A%< M:=FV'WOX\\@/6!SBDW`$7"`$FPB(8##4[+#X#[`U0Q8"ESDCL#G%:T9NS&$E M`>CB"(Q,6$7/CP1\!+[+X.$^/")XY0#Y,D"\Z%E1:704!6Q MX%H>]5.WU=)H?H7";`%=,42YTS/"5J>I<82:EOB"V_,K7!]0&7Q88!-^QEJ;T\`?H7"C4&,5%AXF?UW)]/B$@$_]`'\&Z5!2 M"I_P@:F9"<(V>^!JZ0<4B0.8)7P1X@87SV!%2>-L_+-W)1-0)61>>@>""E[^ M5PP(!@!6(I-2I\#V-7HF<_)JB:7`Y=;FW/T$=-0VW+UP@#:!OE*C-\M!.Q$. M&GJ3#BCG4LE4QK;8#$GT"6.CIY&]BQ;%7E^_*!X],VN"ATU=\[6=[IRO_LF# MOZ&INYUWWN_7N^<7C:OZH'W>K]7J]5JSEGCG%V=GS;)XYZ\XUI^^WOYQ,_AZ M?LF^#.[N+F]NM7C4G4(]:OD5+S]U(GB#+9_T#>Q"'H;"C&2?'>L>$#"2ON`U MNE"9WU+>*,%LT_A!XD6.`=&GV;FZZ;R<9%[`X.JL+X(76LM>'`@GU>883D"_ MU(K`Y[1"&6@`[S?R`]P'8;9K.1.P6W\@M$C7%!Q>U_G.P=\&N+[G+(SO,:2K M?'`71H+/DWI)W8[/%W8W/D>$,^2MH++B`(`?C(1+$5QW'CG[GQ@>(WV*9B7O M,H>X*>&$8U1J[&GLPPM/_">/#ROY@(@_&H5C'][G.A,'?YC&P=0/>88F.&IG MZ%@!^!BW?S]G-T[XG9U;`+#@=R""ZR8.RLPKF%\.4.I7+BS`T!(,>\<] M#ZC*@?;PNB<.C\C'$I*!U;N_A+C&$Q#J9^6&X$GOX+OEA99TDOX%1&3_=((' MQW,L-K)L9!:'@ZMRRY%+YH>7>_:2@0YY`A+3?TI7P`H00L7.6B)S.*$@!@Q8\ M69%+\@@*'!EUA`*<%C])^NX073@1/WG)W="*L5_BR MPN`]%R)1%LOV;+:]N]3^`%\LSHDS$H3_`'-5\`#P,=JAMC,5]%D!`7C9`_>$ MK3/[56''D^.ZB7G+?]@<3=45@TELRT4[.V^UHHT8H,\UY(F62%Z+N(%32,/1 M.#:>+O`H%IM<:FC:9++1K#1:#:W!5%UC*SIV5I5;>Y9M![&T.3#Y)$QI+F:2 M9Z_$1Q%;GU^+-L1=P\%$>,[?.,33R@]R^%1Y2R*/(%=L* M<*D<*_)YYF?E1TTM!YR>1S1>G0FOY-A(C@JP$9PY/XQR+Y!I%'(P53#EW63+ M`_4]B,^?Z=ZSA;N(0^QZ)C(F>]&,DTH,5R(`>B,#4C[AP M$#/"@B+QB$XEOGF"CY6O!<1)!YM_B6ER-;!H%N-IS`'RTWEMD#2(0A_RO& MY`'A$@J_/Z$TLD2R'0%0*=@!7%`Q/<#?^6?)_ M@(PQ!`0A(.3<9J34&& MIH'<=BG]4Y!89,PLZE47425077KI"PZEGIO&T!`9_2>WWJVG,,9EGT7TI'ND[JNH>)G2*^@HS>?I MY&PKH2:$XXE(G8.,Y*W#";BJ811@64,1_L.!8@J-'TPD)X*B`_P`JJ3*1"A; MC$%Z(89^`FX-GV>:0C@4`L&57Y0/MN5P*_OVW,@7,""CJ*3QAUHX13-\437) M-YH-70#:H\.?%M.99LNE$$`2,SO'X!ET5@:)J^PL@8)5!%\$6D4M28KLV"1+ MH/SB99D7930T*'?N/&85ZB+J*P61Z&&A67%*F-OK1$DV55;YPL@R/.=[N1>B MO9$D7GDQ2K=ZFJ2VE6:5S)XQ6QF%8]+@EN-2"B6#?#`:2V21.7;L6D&"V1,` MTGLNU@N)'$^?T/*!BX?^DR<_+U66`T_P'C!AF.8P)UIBR.7O0J_%KIQ[)ETM MP=V9UI`Z%LT8P3_YQR6O6?4X9;W,'EEE>MSE'6#8H#QZ(0^MJ%6]!S`J!/MI M>4%;5YAEN29.4+ZJ9[17@!!ZQINJ'Q&GE)85"%IH@[D3NPI)(F%GHA`']TZD MK)4,YWO`IRP"Q`>AE\G[%94[*I8JW;D2>UD9-!%R)>(&N!G&H_S+QMS"-^0S MP7+0"P\82Z4$SXP#%1((,;CCJ.#.*LM(^',"8E4W:IQ+1J[%"0M=@;QFS<3S M*C"P3JM^Z/D==)I$#_YF3Y.4QDH?N!A3><@GZ%M#?%4H?*VL;YF#BA=#G(\]&QP1&*K$:7Q!)LJ; MN/K*KL]:>TF(*&2/'&SEH3,:H4DG'(7$W*OF(^J9L0B\%_LE%G-]#`$]VRZ? M6;I#9?U;WFQ/4UGGXD^6>(0T\64X4(Y_Y'C"\H/E$-7:,[;XVK'P^>"7XPG# M\`$8WDNL15QE)+JM,C5@=-9WF-(S:"HT2_'/TDRLK/MRC%NB&?PH7(_9B08\ MDS$749NME33\9^Z&Y.&QRE/`QRFEQI%\(S?&=^*A!5A]!F-JS42)<[EWI@J5[L.:85^U0RM:IT"57_0H!0J@%Y[:B^(Y,MG=!61!HSAK6"*'OC9;,$U% MPB1N<3O(T?Z*]Z#HJL.70Y5+@%CB^=X)DLD.''3*%12*U*!7WQT^AV"D2#-< M1J8"#F/FE1=GE-`92/)G'(CCH7,KC%I3CB![6.,*L>I_8K#9YDRB6A.6*'+< MY7_LKL;)M3EIMHQI1">7M3L0V/2GXG>`CEF&Q,3ZX4R`;0Q-\LB#"JY< M*"PML%;P2W+:]R]FRZZ#TS*;5M*8=C4YU6Z`9.G&"7V8V5LZ\P-JS;>O5 M^N`T.&`YQFD6,F[\9?$LS5U76UMA:LW,-MG$QE"F1D^.FHJ2230F2ND">M;A MCRG#R[R1B"_38W/94W.I2@L)5YGT`-T:KM?160"@5!H.(UX81;.%*QH]":=- MAG2R^ZW2CU.\(H-OJEB3`$-I).6W(D40"UY9SO2GD>^"P1BFR3G*.D1!>(B= MH3PX)'=X!**PJ\'M&1O<_H$+5#MIM"HLDU#T36;%I9&\-"ZBLG(%?6]4-M[L MCS=I8EPEDXHD(W4@`X$S%8U$+"I"%Y+'@QXVYV'"G- M!E0^@PS.6=&2")W,!)A)LWK//4]CEIG\/SR.!5B3R0E:FOC'!C8FQ@*!Y_/% M87SJ0G#NY_-7" M/>'KT?5L5_?U\\JUBUZCVSIK-'J7K6[GO'G1ZO74>>6SVJ#9/I#SRF=_W'[Z M>GE;AF/*DB.!58+0$6#]=P'%`0S4]K(I*(:MB M7GEB5G\D^]JSF^?\'I'OFMJ(N+-U@K`N=4NHGH@67OYP&+A2`,.>R/TS;==< MQ,I#W&($^S*`RQ-KY19T%*C.,*JP+\[PB>,'A$/Q.WZMKD[74$?BDO->H$+% M3@ZHH:PRSA(,7N5DZ*3,*D?Z%T+;*L,J(6T%S:E0I9<$*J%?[&>ZZ8.KJPLE MY<:[<)0/3[SZ:/_!T!^1I2*1X(V1BX"/P:;#0]CP26I8%8=/6323%.G%49!D MP83Q%,WTS.CRA8^6YZ=DM/=\F)6!+UTGXT;("&%5V'0<+W!`D._3X$+E7 MIH=[-!LOK;$<[H8SK9 MM=R`@S*^V<7E/R\_7W_34H%7E=COS748P.^:9B6_+F2N#.R_8D>F[6Q_6KKX MTSI7_#X0YSO4P:VY^CB(6R(Z)[=\!Q@V8=]4?0,V>`BX#/)^F/,$%B_).05" M+9Y9&!.#=X',/BMG`POFP.O5@7SAO>";D9:8B*U"ZRX(3(4Y$[28D].LXC2: M/&PQ$W&!,:<01ZHD]LP-X!EN86O?@C-V/KJ;_S4U5RB M`0_(R'+,(B-.I,S+7!)-2Z*Y^`F;@./R("IV^$!PP>RHLKX%SB/0_2/-0T`@UTCB>37&IL MBEAY*`0&]&UYZ&Y<&M%)MF)$[%V%O.?2F,51N@`=8;FG?9\]V#>RG(#A0;[9 MZ4,)Q4.Q$R`?J4ZB*`)E*#E')*P5.A?83P;FX/:@I*/4`W1;$;.ACH;OB/._ZKMF5-36;9($9.Z8AU[,->KJ9;$ M+1RQG2V^9U_CX;%.-Y]@@->D#Q9M@$!3N:ZZYK=WM7?B>SBU[.3[YI;LQ,(2 M='*05ASYR0^R]9;XY%3OKN4NK&^Y7W-]DY>N%EW76JSML!8 MS8W:K-6G/Y@H6?FF+FNOT'()_=8'E6U)*_>^JVHUSKLLZQ)V*VXTJ#][ MD7W>4G_M&ZKJ#5A5NR@;WW+\)UW4>96UUFV%N#XQ]+=%7&VPZJ:**>N_E4U6 M?J6HS+M&35_D;`<*I\M;[@-T[W:_%:GS;#?IK?=Y54= M"=L+P_;22]59[+@XM)=W/;84K=))4+O2[?9TRI`IR[P743D6S70UV\RZ4IM9 M,@'I,MG-(KWUHM2UR2#DUX54J<\\ERFD MI[G$#MJN7\Q*/"0=5?V1V)Q(BU/A^7Q5;2\Y1Y14RVXM'E1+BM&`D*LF M6ID]^E!51XLG\L69O.A\7=K%KFQ!6O9-W#]-MNMGAS/4P^`NF6VKMM5SKY_5 MN`R3W>NM8(7GD+6H+%*:X"?*^ M)J=Y`Z.5W87?WD3J-1J=M]M(,-.-E(QQJ9%2_H99X;,BECT^AJ:TJ# MDK519+*GZL^"I<\D^F&1GV3W4YR`'CD_1!4TK8E=K4ICA4^ZS>,JC/_@@>V$ M`D>M4<2S1:2$JDE+",&\9,:\6EQ,PTHJU<_`7J@I^%%\20^6J30P`?ZR`N$P MJ<(0R(0NSY]/\TH*H22LI&JB2/:PTHQAF9R%Y366\N`K28_KF'BD9$C)&*]D MKNW(1U-PJ26XEH[Y'23*>T09JNC*A^XTBE,QJ?K`)/7,T),\==6[XG4MH^]P MHZXC:JK>+6$M82UAK8%8.X@?,*M\7:C5!2_1DZ\'7S*'VO%T>A9IPEPE)2'K MV:1^X9OK`LM=*`?9I4G+BW2.-SVQJ4YH)O@I3Z1R"6%5[N>Z:!8NM'.JGPB4J,D:JL'!2 MXN2%:'`12G`,`JT'KI22$#7KL/\=8H&6)S>;?3TCG$>J3-6"%W6$'JV@*3XH MHD@9K26;GF@J6*%QB`'W^!.VQIK*P[*DQDB-D1HS6(UY_`W1KJ^./?9=*TP" M7IG&V5HPI=O4YRUD0UUSXYY%NT@M[%PM4%B.-`)I!&,TPA<+A.<-*N',>6"W M4\Q("0M0"/6FQOWVK$;X.Q:Z5^I`U:A4*#6_&Q]B.3[5>\@3!>Q=58@DTTPQ MZ5>X`TVB)^RT7).8%7'-Y%(9KN#2*BRS$:],[DA:=V+*&I3B^@F@`%C:S>AFT:'"`<4,_*H:5;1.:KW*"P(J M[8]ZB[%-V6'DPYT_=6P85/MG(<_?TI)^WUS+B^9.4267-SNUGT_9C6@,@_*' M-?1]V2IVR#*%\O'F67U]$1V%KU,_M%SQ!='4]R1LB'Z]EZ*#AA;@F]%7='I- M,H]MN![NL3*]PX_+8#[&1"TY'E%)-I_+! M#[)?Q]P=GL#;3F#6_&=\IUP862,Q!*",^`,0-1P[HTB^0#4WSC3R95RVQ,6E MS--WUO96UFH+92_=>S[K]`,@_^K\1%7R@*MR7_P':#G1L#&S>M8]-A99\:1$ MD\R&$R9>95`.!R-ECG')=AF/+$!]DZ,`S%M-4D%T@H%\&V8UFA7[0> MQGY+:6[U/1#4P\[`@EZ!ROA;[$>!2:HHCTEA2[A]DCY$/5JN<_X%V-D86W9; MTZFKQHFSFF*MMBC"?M+8.DFPB=19,U;!6<[6&*ONBHZMV;5:0L(P;5R')?0E MF."\'BW'3;OAX>]8%J[*_H7MC?&=J%/E2(=@]TCE*58;]XMQ\*H^'YA&,\E` M=E%UYQ*IR?3A$1H_&Z-=2)L'AP)GHK+>D;ZIL>6G>R9B*&E/GZ$C^^4HQD^; M2SM@;4FNSQM?6(@0#^`(NWX9O?04G=^-QL!FOJOUQ5>_.F-8J3SZQ2N/&S1` M8U5T^QRN"6`=5'WVRQPW.F M=82=3':&7P)?06!="SAWXH?1S(5.AJ*&*I@]97*0JS^JMU7V^V#P#4;*L8DI M-J+VT3Y+$;'*/JG-RUD2O>`)@"!A70Y5/U48/AYT29HAIH@Z5#W:0?W(U.:T M`[P?.`^.Z%8A)64X?Q=Z,JF)TD_<:\`&T8[."D0=2,]_FL/O;`@")OP_EH?G M`#(P*U"V)U$1M)EL40=8(%)$DADDHYL?%/Q9/5$%/;IJ8.F@).Y*!RT.Q1VJ ME3?^$O`H\)-&0;B\=CR)74M\4UHUXZQ,.*#U<*%_-U?%,Q4>)OEQ*[E(DHQ3"*U\QU3$4>?.78"<643 M3!2B.9(&BU.&^P)Q/S!EINQH9K9JG5*RJRGZWH,ODI$RAH@RJ[9'X1W:Z>WU M<+=]4FL6C[NWH/%AAV<.9#=]KMO6B,+"::/V,K6_D ML!P5!9G.C6J(HTK,#^#Y,%)PB2WH970M3-(C:;%8D.QUS4LH5[A_`:.TJ:/V.UVP05L;^LH'>VVUXRG/0]TA.R ML%2U\[^YLKW+ACW!Q,FL"8YR)8K#AU'2N+&:(`=R5FJT+R)K8I>*]Z^R.;%7JXM`G\P@L1(Q*U)"J26'=V^%3B:JE"#0S/E0K@3J4$RX M>S&XJ@W.^O765>=RT&BIR-)Y[ZI_67ADB0(T%*"A M``T%:"A`0P$:"M!0@(8"-!2@H0`-!6@H0$,!&@K04(!F3P&:I?&47##FUAX# MJ[K\>@2N!BYQ^(T'MV,KX&=`>'O@#2\<-X:AWB$=-XG)7-3/^JVKQF!P==5N MU5H=^%1+8C)GG79[IS&9CN::_)^\$7:\$LPA^`T8:RI4M2\XUA8,.Y2D$ZW( M@+'``&,?@`O#GU$DD%TGV!,=B2W[KD+QH]T"N,0GA1BZ1^;@VN%-XH[ MMN]>-IM/?SLR]!=C'SH4\-&V)JO7:OJZDM4[;VQ+UNKON"U9O;;K%]($:8(F M3K`D!;E7E_[M;:=0>ALJE!65[KM[Z)MG6)>\.SQPS[[`W\8AN\30.CYZ657@ M6[`F5#W:6F4#:AO&B\85AR=NG''C5S##!R19^P>G?O?<),9U>C M*4=I$\)T(CM#H_MUD:[S8RV"7""R_4V$C6W2^O7>(+)R#`_ M]DGNZ*O2_BIX?S6W#3SV76">5]IH M;,N"&,<0Z7,`ECB..(XXCCB...PZ.V\ILS!.JM@MVFWM@*W_\1KO% MJ,Q$D0FLSK2),V/IH;9]>H.FF-7:NH<7-V?]_;\[G<7>`UM.VY1UQ/O>TKN; M(AZ$`4>%`8TZ80!AP-8&:N,5`[7@-#+]\E"OM'IUD@B2")*(I#M)FS2$#D]S M35]])RYHD<3]S,/PE.%!LX4M":`T>J"![XH&:LE9T4T\T+7E[+7]-JVAD[T* M:-*ZH][0%YS;EGBF,&'1&H^BER2B)*(DHB2B)*(DHB2B)**[B%5J2UP\>LDL MRU[I7C=&MTNIHZ#1`VTM4A"5@JBTS4;R0/)`VVPD$201:VRS];2=!CP4>:!M MMA>(^RT0M;$YD@-+8L)KG2&6LJ48`X4!S9)C"@-2&%`C'3^T>GL7S44N*U&B MZV(!=1)<$ES2K:1;242/7$0_-!JUOC+8]'60$%`0T!#0$-` ML^R^CKY=>((9@AF"&8*9%?9,K:!=EP,&FDP8Z*.(>BR]/O,Y,R_7\?A)TAZ[ M47N?&>!;.RRNB0@O#>:E!I!Y^F6>DH,%C&^)IS@>()[\GGV-YP<3R\T)21VO M21\LPT@V=UUUS6_O:N_$=^`6._F^A#)WSH2'["M_8C?^Q%H`VXD5/#B>'*05 M1W[R@T1V\M?KO7Q6;O(RJ&^O;WE?;]0MI@C1!$R>X6;1_;T;F:DW9VTZA]-YD8J:# M[>ZA'_);&AR_R:X07Y^DBKOWW:%\T-TXX)Q]@;^-0W8)"G&XRO2XY=.(3^YY MP)JU"CD\^K>$B1M_^0IF6(X9F59N)+BD]O&%MH_75OR7<)'8;GVVTY8^0VQ' M;$=H1VQG--NMC7:;F7LP5Y-25W>;(#<%0SJ;[G9:".M2)WC*HMXM6!+'$<<1 MQQ''$<<=!\=M;O+EJ=0KNVGW;&XCH,D#3:U)0$-`0T!#0%,PT#3T5>TQ?>D):`AH"&CV9M'H MJV=A^M*_%6C>N/^UF]C-W`/QG6:4NZ;0HKFH?6!:C?B'^(?XA_B'^,=`^A2U M-5:OE3Z_Z%H:2]Y#/H$\;1127(>0@REX_`$\FN)#)XLL5)S31[7(2ZT"CDKT MZOK:!)#HD>B1Z&T@>L7O3)+HD>B1Z"T1/7TE%(];]-X88#\`#_!WR_&8[V$, M?>J'EKL#UV^_A8_T"V1Z)J>A+:3U&HU,X1Z\CRHH&Z+A#DVN:M6NMIHD)%`D M4$8N):ER4N4D],8+?:W:[NY= MYDLAOKOWX0_,57^]\O*;"O9MP)J:FF>6@FV-ZJQ9!,4*.759$"8NH5HIF(@V M!`HW7`B^"+ZT16=VUS2X%$Q$\$7P1?!5&OC26"Z0X(O@B^"+X&NGUE>'X*L, MR2\'WO!BZ+AQ)%M:4]L5:O1C).&(XXCCB.-*03ACB$4<=PP<=_2[I:IRHYD= M.$PADC;_M+@YFQT@,V4A*<2U7P5.(%`Z$-#7Z\*4A200(!`@$-@(!/3UH3!E M(0D$"`0(!#:S!+3UB#!E(=\*`N4^+SWWP,/N$4%1+XJS4IR5.(XXCCB..(XX MSKR]I`.H6[JWSA5O]B9W[4UIK6>SR!`E='758+DA>3E".1% MV\8=R0O)RQ'(B[;#^,ZF4??$MSBI7M0"<>CXC6JMW] M%_@CV239)-DD]4DB2B):+A$E];G7%*T]9&(=9>>*;>32W`*W.VU0L56`J11% M/"A::Z!J+:$&[>Q,@YHB.44;L2101RQ0.^W9]$TK-=A3=-O4$"D$D M0>2A5`@N-=L11!)$EH57"2)U0N0N>T"4FNT((@DBR\*K!)%:KK`31+XI M@#D!<'+Y'N"QT&05[OD3Q[,B6'OV+X[CXT,V@*E;#YR=RXCE+48L0W8=1V%D M>3B3TVTV%5ZK;5``94NO;$@9$_\0_Q#_$/\0_YA(GZ+V@-NEMZS.-FQSOV7N MQ38^4FFR,CJ5>L.`>)$I+$4A(0.T`(EG1CQK#6TU@D@\23Q)/#6+9T];!7$2 M3Q)/$D_-XEG4`;9C%,\WGCLMO\-YL7U?Z#=+90F%K]G)S;*!-U0^S!T^_PZ(<>;Z]O>__==_ M_L>OB\^XX;;_X,$DAY]`HB)GY/#A(`QY%`[LOV(G@&_>\+-CW3NN$SD\A+_% MD_EGBQ;L\.6&CWY[=W71J-7;_VC^^^[B'7.&\(-E1R?UJ\9%K]?K7EWU+]J7 M[?9YK]7I=]M7W4ZSWFF?M]_];6X5LRMRYTQXR+[R)W;C3ZS5((>H4L9$?L`A^PFI%EB`GLQ0]F0.? M0[@"KGX*7\X!V^.$MN+T-<=K`Z?Q8)UES,%B;:I:_3D>\JKXGGV-YP<3R\TA M9QVO21\L)([9W'75-;^]J[T3WP%.[.3[Y@PXL8('QY.#M.+(3WZ06D[\\N0, MH_%INU%MMIK=]OL$\0#)7&L:\M/DPT(OP]G@@V6*I[54":P1T1$#^NU=I_G^ M56S-`[FZL;[E?**>NOT?LHDU)4YET#;;GR*,C])+*:0ZLB=5ZM[$KO ML^45L\=X.!O[W09A^VZQO?12=18[+@Z-FK7B?>U*M]O3*4.F+/->1.58---5 M''A.%`>\PJZ<'_@AK##05NSRK]B93L#))KWUHM2UR2N?RK%^[2G:`S[MGEX>P M`RPW=0$%F-QJ!&I-K`"N"YGCC7![4NP.!_P!*(R7A4AEYDN2"C/K]OIV<,,> M`LN+0N;/BH7@GK$_8@O)Z_TW[A+7^SO>)=[ZOEUO9V]]7ZLL`SWX"99FH&;+!#ER5#GF"#;< M=IQQDE23(X;2SU!%1/S?OH.[=_H0_Y0*D(RC#_$/X0_Q#^%/>;*.B*F(/N42 MNAU[(:J4-?$3&0&$1T;0Y[CQZ),7!8ZW66E8XBA")$(D0B1#$*DDCLJ.R7AC M>0^<^2.22Y)++0QU^8,'MA.2ZW*PAL*.&>IWD9E%[$3XI(6=,+62GQ!3$481 M1I6`G0BCBG1O]E!3QBSW)[%692T4DN`]2/!1UC4B=C.C,.B1L%NF!R[Q'$$< M\5SY>8YP;K4Y)PY_$L\1SAG*K;7V=X,PAGW$" MKAT`C2^B0H4]L_>!H-6*%S13UA[OHXZ*!B)-<36I]BE<+:TEX4BZ2+I(CY,> M?X%I>HUZHWAQ,X4#"&\,Q1O2YB1=)%VDS4F;DS:GXK8[%*)&M=D5\=-.M:&M M823AL7[Z&,,QNHE0!G1M5]M4IY]`H*P@4,`F0+]-O2M()DHL$Z08=4RZUV\2 M#A`.E!@'2#>23)!,D&XDW6ARU(U"_[1GLL=4Y1T2L0R$,X989>.XEPGW:F,N MG90M1_>S1DNK#MV>Q$?1%(U$FY2)89A('$?*A)0)*9/C$FU2)ML03FM/5QU] M5U]JZ7J/CS[W)U/NA>(I-SR,`L>.N'S)P!O._?*'YV!#VM.%ZGK3;A%N*6%I42%9G9A101=ID#7 M49:@$]%'JB:\CV#],;+;E>4$3-2H+Q3V#-I-*G)3+E,GM\(NN,TG]SQ@S7J% M-6KUEBZA/LQJ'/5FCFVZ-@,.6*FA2PW<*L*,%T;U::VZCR'(A'D)ZZF[87SZ(!,#MGE M7['S:+E<8\?!P_0.&^0;DF]HEIHJ3M#VH+^H9P#Y0^N3\)\\)'=(WO>AH_74 MRN*:%T<,[6SQ,WE+Y"U1M49REK32]MSR\,R'/GWSVD;O87I0'PH\7;D%#8]; MP1DDNN75?(?C@/6J_2;Y7^1_K4O"3)X)N^732.69U$2>B;Z=S==.T&^U4UZ* M6@3UEMYDE%=K$5#)`?+Z#D8>#69>$I4>P?K76)?@JR.[8K'[%W!RSX]51 MN2%#LS_C,')&SUK)=AM/)E8`OPV9I:I;,'_$HC%GLV,X3*2M,U$#@XW\0/Q9 ME,5@W^+`'ELA9]]6-]VQ?N^GV[>6%)G"/C#"_#SE,:1Q_BGS7YYR@/3U)I"D(I M$^A#_$,H1:4I3&$R,T"*2E,<$$L=)6Y1:0KCH.LH:P5D8GR$;;O'MJ/D.:I/ MH9-!J3[%]K1K=>@(4C)/TYCDP%2"=I5I/+=1>8I\AGR3RE,+&MZ>FN/^3!V^?5(Y(7?6R$?GON3*?="*W)\ M;W801M2!&'C#N5]$(OE`E92XPT'<`<7.7/C3W_[K/__CU_1%\7W(_XJY%UT^ MXDYD>A70WT,BW_#1;^^N+M!:^$?SWW<7[Y@SA!\L.SII75U>=J]JK<'Y>:_> MO;CL],[Z%[VKJT[GZNJLVVF^^]OFG06>'K3'T57*+GVV%?0?L)L ME*G,[8HH0(+L:'G/3.2I\R%SO,AGEL<&8^Q3]XC,*T?A!7V^?,YP]OMOV(GP,(?060Y'G/!.V0`1<[4[RFPJ8\"'W/TSN,H%=M?R MP"IC=V,G9"/+=ERLA`.?^8\I%S5P@#L0D0+G/H8IP<3Y#YN'H<[9M+7.!L=H M>5X,;!APP-:8A]67- M?OSX]/14_7$?N%4_>/C8J-6:'_'/'_'"=^KZZ'D*U\.C.4#6\)UX]L>%A\// MOW[$)SFG^"]\_?]02P,$%`````@`Y8!E1U',`'\$'0``?S0!`!4`'`!A=F-A M+3(P,34P.3,P7V-A;"YX;6Q55`D``_[$.U;^Q#M6=7@+``$$)0X```0Y`0`` M[%U;D]LVLGX_5><_S/$^(P,0]U1\MGQ)MESEK%VVL[MO+%P:,ZQHQ%E1&MO[ MZ[>AT7@NUD@415*RDQ=G0J'!QHC`?[TUT\7DY,KF#55/7WZA/U`GYS` M--2QFIX]??+;>_+L_8M7KY[\]?__]W]^^C]"_O7\W>N3EW587,!T?O)B!FX. M\>1C-3\_^6>$YO>3-*LO3OY9SWZOKAPA*ZF3Z[\FU?1W[QHX^=14/S;A'"[< MZSJX^?+-Y_/YY8^GIQ\_?OSADY]-?JAG9Z<%I?STB]2C)?+_D9MB)#\BK""< M_?"IB4].L'W3ID7]JY(_?LH/[I7_R)>EF;7V=/GKEZ)-M:X@5LM.__7KZ_?+ M)I)JVLS=-,`3Q.#DY*=9/8%WD$[R?W][]^I>!2Y>+0&9AA]"?7&:BYP^7S35 M%)H&7YK?_>/Y#-+3)^XJ.&PJD]1RFAOZEX?EYI\OX>F3IKJXG&#;3O=[^4N8 MNVK26H<'Q7M6Y0HF]64F8'MUOA(92J6=@7I,\98U#->B#\Q/HHO=]P5[4>U%/FWI2Q>6<]FP:G[NF:MZDMS-H\(7+ MIV_2+]44IX/*3=[C$\B:;-5^WWH/VKB6S.JI^H,V]2T*A6H[&_NJOY?&OJR: M4$_QV0+BFTN8+5^_M0F;I094K"6=6@GWH^;*',)^_!E?./_\:IKJV<7RA5NU M;"';BY(_N]D43;KF==TT;V'VHKZXJ*?OS]T,MJFX77)@!5MV>.L*QE'W`WR: M+]QD;ZT?U#.P\NT6T[;R_2B+UL3\\Z\P/Z_CJ^D5-/,VIM]FJ0$5:\O6-L*] MJ/EJVBQFV?_XUW2S/@LCS)+WU_#K#= M1FLK/XJR;W$L3N?G,*_"]CFH4V5#->/6V'F37KCF_)=)_;'Y;>H6L<)?.S2E M786C-*>^N)S!.4R;Z@I>35$,\@S:6^-:5C]&4V\MKKY:MZ'&`S5HWS'6I?I> MFOJZGIY]@-G%2_#9\%RJA@O0.U3G_4=WN:TI+<7'4+7E\K%;+;TH_@Y"-NM# MJ!?9"3G[VP([/05O,`M5D\W$ MEIUWE,KVTPWS.OS^51NVXK%1:D#%VO97&^$!U7R'W3BKPG*"Q=^Q&Q\\^6U: MY2#EO+I""WRO1NWUJ@$AN(W(+G]?47[O@3C`NP8$H9TKVT:V'R47OH%_+W`: M^OFJA?_Z2/$A5&G;_1NEUBJ&ADM83):(OL9"JZ)9AYUWO:[KAT]SF,9L^?7W MAK4-&>9%C^Q"#?RR0S1PISVA+[HL-4%=)G6X1\;5^Y?[MLDU?KG+NFC(F7.7 MIYFDIS"9-S=/EK0EE*UV@/^R>ES>J(D#W5?3U00>ZK-I]1^(KR)J7:4J#_S[ M*O^MKN/':C+!>>PU_EQ-JGD%#9997$#\.WSIRXGS,'GZ!'4O!WYCJ2A/5',@ MWG%-C"\*8FB1B!$1'RNN/;C[$$]RI]6SF]X^-HS7MO0UKA_]@_OHJTHJ"Z6# MU@18L"19+TG!\9]@I`"9$@<9MZ%Z9Q0]FX63>A9A]O0)>W+R$:JS\_GRS^L: MW"Q\-;CN)R:L2IRBAM<;`@3=PHL;^9QH<81LJX^NDQ#&;XKVSQ?5)-M-S4C< M__*^,@2JN-*.I$0%"399XD$84A0Q1!!))9VZ#8#BSP%PX)[ZUD9!WA^Y9RH- M/`J^O*]TP7G&-"4T2DL"N(*`T8&`T+Z0TIDDH-LHX'^.@@/WU)U1\-/I`XMW M"#-XG1_9I^7=3U[0,6@TN)/2;\I-GYJUR:09_GV#=T#[5)<^W]HV>V6<=Q[2 M_<4Y_'93\-D5ZI$GIP_U2KTG\I/R5J]?<&%\<4US[(M;GC^;SV>57\RO5;[> M9%OVS4KE->WNJ>92RR1$M()P(]!M21F'Q`6Q^(.1/JDBR6-V,`?M]_K06(]A M(6]O&):8++*1_[:>+3OY7D/_7D_SU(V]AJJ=W>QC;ABJP[RP=(5B*A24H(VE M"*,T$".M)5)I*`+BKMA1ADH.PJ[Z2+OD.`B_%WG+2*7AP7/".#!T?YTGA7.& M>..E-114W+ZT'')*/08R[,S/#JB/P;7[R]-^\^;.=94*&"]LC,1:QHB3Z"-; MJ8"8X&Q0ADH/:N_@&?EC47&,7AB#F2^KJRJBC=^@MYE@-EME!VS@WR,2)0X[ MSD321#'+B676Y9"'(HY'SJER&A>@HV39,:R\_8$Z_M*YWFG'`?(F?7"?6B^B MFZLI@3+*!'@2*7-$"L<(@ZA(`E\DJR0M7,?8YS@[`&-X*",!.VBHLMNIDW%B M)$/'3-N<#!G^?8.'VS8?XQCR32,T;9>3%B.%U^YN5$SCW:GFF@`;INAMHJ5P M>7VBD0258Y@J#_+K7[C+:NXFK\$U\,9/JK/K MQ;`%07:IIV1)@H^.$VU!D:`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`;#M6Z\C.:0MT#,O M!D%L#)Z\RXE;4X@WN7G/0EA<+)8[@2\A5:':Y$]N%RY9E$J&2$G4/I$(!OVE MZ'%)%$90JCU+T#'99YR-E)YY,@AB(V5IW"BZ=(P?N7BV17+RCC65,2JO"ZI( M8#8A%#C)%I.NI$V#UZ\J$W-1!>8^8OYEN< M47,_`9Q[VRDOE&U:<6$M>5+IPR3-C@"06&+\GE;)J,GKE!@-1@HNIYR'B?VWA\%^L)G MI.#J)3J`^8+Q:0,XI2UMM+:V0@OI,C&C)->!..H%00`TTCUO7DOCF$F,L:YG MCL=QO/OCQ3!HC7?,$ZUSN#.O;>#%VO*E=HH%)H%0&Q51.`<2PP(E")R75OE" MNXYYS..XUOTQH2]\1CD7OMHL0&VO`6BU1FR0*J/S+B9GB,;E#N<_M(B\$H9$ M);P!YP/(CJ&X<1SD_GC0+TKC^<$]9ZEVK[1TEC(-,A'MO"$X1E+.K<2_DI"% M%R(P573CDO[&N#0JB..8)C4J.O_\=N*N+^2[N5-S\WWFF\1*'8!IXP0I!#8W M.6T(5XXAU(6BUBDM9<>,@#']E+W"&3WC;34&YS8*EDI8E*BB.+\^) MRN<"G,S'0W2^+%9HZ6+'A6B<>$9_7=F6(UUQ&SGB_Q(N9Q"J)8;X]P16]ZD^ MN\B7`OUG^?S1-K;;"MCK%:4WPC&I*>'412*`.U)PRXC5"JU``4RF_9-:A]RF M'HQZ!X1X//NI5?+KPZ*E9%Q'X)Z(L+S^%R:%\IE9]OEFP%(Q+"R)@&Z,AEBE&/)4"S46I\S2:F]M`MUD&.TB7,@7GI,D+G463VT(B4##[Y=Y) M[G3'9(TQ`^Q[=O>P@-WI_/YO/-SC&_<#7UVWR_?I1[K+;GT*QEO4/,_O(><] MPTNX_N_.F2_KJRE3DM$S`T2CET*DPU4#+!.$RD)[6CA#V=9H\S!HY(T#;`*Z MP_GZV/C\\V\-H/ZK4._T;/5]W\U'Z]I74J(]#0R\)@5+#F?,1(G+Y\=:'_7A[>&Z_>OKH8?#=`Q+I'T#=KPY?[^*RR*$B$Z=(!87`6)X0,T]6&(8 M&FR!<4K=42>C#46,SOSK">7Q\A'^_&+#_MS:O]._ER\SW(TV/P@R;XS)/"I5 M@D,8H9`$VQ.)RSF@.&P=P=7$*,VTC?RHDR(/R*)^81UIC_*J:E"_7^K9RWKA MYVDQN)1CJ==?4N7'B-P$!UM-R/'71&LZYET-8UNV]%8)U,:9Y-/ M5A,$3!#!99YNE2=2YBLTE;,Q=;SZ2X^3/'-`VO2)ZF%6LCNG:W9:P.[(E8); M!B()PH7-T7[K"12J(,X@=%9S'43'><=\]PSJ&]G#L&AU%N?&O%M[)FK6I ML-346DHC)4E[2KR5E(`#20#RE3M<97NQ&^_L'Y!W`T%^&$(^^.A%#GJ$,%O< M^[[!3H1L4V$I%572XG#U%+LA%4[FZZ`LT8K&$)AC*G3]/`W]WBVPT2#OE'!P M&X?-H#V2_(+HU2D#L_R>948DWP;T6!;"'E66&KP'A]:%`J6(5"&24-B;3V(J M&7W73!3&OMNI[P"H=^+:W6#;,N.B>37]^5.`9I4M@./AL12VG>1+'6.^I"PW MQ1L"&A))AL*J/9&KI+I>Y#A2WORA6#0@Q&/=;]("L_4?.-V2_=&YWM(;[V0> M689+G,65X<1R9W(.D?!<1(:^T_>QP;/7%O38(!\P*^)Z2MXSWV9-):4T3OI8 MY'OXT'2(8!)1C!FT:AG7G#-A?,=LAW&H=NA\FWXP/2YF]9-OT[+BDG%K(>A$ M(N><*,$"B71Y.X&P4NE00''49T^&(D9G_O6$\BB;VROKX$.]2JSM?D$)_?\<2YJB9`23<]\.(Q;Z7D/!W,/8.8-PH*'.]]#PGP0LCU?--44 M+56XOB1RN92L\KMWH=N&:DIA9!$Y``F<`V&>:J*M"40P4))QI;G8WY+[HQ"N M7Z!'2MX)`'&9LO:R6D(V7\S@3;IMRN8C'9)?@\![J,VK9CZKPAR6EO".^U=W14L3;+0Q7Q8E+2<.LHN> MSRWY`(QSSYG2'3=!Q7<_8PT`[I@+XR_U[.Z86.YV[.9X[EA325-2!C0.KZ@T M,3%R0EUA*P/%8!;HWTO`;C6]98QAFA,#`@..)*H M5B2@%4&BU2PF:8/OFC]TT`!*;$FM%EO. MS*/E;AX?ORY6%8M54M#&0%L.R!(SF,R-9\'63'TOT`%W-#%Z\V\@E%MP\@J_ MK-6(R[*]2O`[3,O9+GEW2#/UR">QD!THQ1F$M*I8KD)5@HL@:TN6LK.4Q3DZ MX4["A!]2@)\4Z-8^D=_F\V6-2M\]F9VY.?NUV1GKLZV!S)A)&$A%RC?ZXD`X M+W+6UG/V$C6]%EQL"7I+,_BRW*.W2O&TA[V[^4H73=*8:]+;D#SHNM$P)FKR M'Q.9RE+)3B>`O3 MV(5(*LIREC[1E"[+%6;$SS5F]7%MX/UT@%M`)#4;7BFZ91P@F M!RU0&VY>I`NQI:0]'=9M]^W7DPKA-,_WJ^[Z_(M=9#;YJ`,D:PT$2PH*BU*! M#K'8PK/DJ6?22_.78=9@T(Y$I,O9=0`5 M"@,N:_V$+(7VTI?2MZ#\N#<01Z+<"?!N&ZCRQV1Z0V;3MY66L"Z=NE=HRK87 M.UZO)A6L%5"9A5IZ%;0R&E`DU)Q;KG)/=HU[.[$ENP:#MJU`6]']3AG=WZK] M\;5.!MK\;7:D?SH+DHQU2#D4B"&32,]!B)=YU;"MB!H$V+'.9[=`-A>&?>:LSBFE-RC-XQPR8B`4\<[6B8[)>>.6*W2E^F\_UWI/Q MMJ9;H^]M<7N?L)J8[V]JUHAZP_#FFL;T\2ZAF*,DR`#S$!+X8! MTT&`*<9+9H*U?;7N1CEGA^++IO@8'>=F.62>D!Y[?*S[O-ZA)7F9H@.?;8V* M-ZJ6Y[60F/(\1R58WWBBT1EV>B9LRS0S/.!C4NW#=(;A>O(_S&_"9%HG2RTN9Q7F563-$<3LWUFG;;'<10-9&0F!UR*B)6M2"QQG MA81+[P1);6@\/'7VY&93S,<6FE>8KL-\/BF3=+O,^3_+VW0"]43DXO*7WQY- M_D@9V[.WSN@4BS<&N"V<-D;/H52S/4L3,IEB2H:>B2,:W&P27@D_&,1W[IFIN)*9.99RT@'),?\:#(V9< M%\8CG/>E=H=&)'2QAAY2D\((`4[74DAHE+)*H]<[3>J?7=8WBX[NNRXO35+_ M7;UC9VWE7@OXLU3BV#WP5UAN9GB?DQWG=X=]=YO(Q30_;N7PHIH-1]$5AH%' M4K>#+Q:*$@F,F7,,/+V<

ZOYOZ1<"Y!W.ODYJ28+5?^XS"3['P*/;[JP.W-:`,VD20F`! M@2F/M/.):%.V6L:>\:*-?)C'\N!F?$2;!"[4H(J:E>@V>_.SL0@;CW9..*Z, MB>!,#79-/D&R)8&T0EJR$X,6YVUT#TV2`1!JM>:794W472O^\&!G2(G[6:=-SR;%GKH[!IL=)O<$H,OZZ9L//GR70R7\Q6 MGN;=Y3]VO-D97[B7M1P.Z96D2M9`=Z8(O^25%\(GD<\[(>:07!@>K!;D>$D5 M%QLE:1B2%"^OAN+]=GB;H?J*M)DU$L]?*W[V/<(P:64P0O8T35160;!$?J]= M](FAB[GG/?8V5^0&)<704+6@Q1_A^LLLI`7M== M@=+[-=#I)`3+10%WS@$6$I4*8P%M:=I"H(W8/)=SK/M7&B6*!O(('`+,&0;@7W'Y4NV72 MQI.=RS($%3+DFHK-8PR@M'6@LXQ.1M+CTGD[/$Y%AF-A:BAR M(H..`W,R`^WRN29J*X`B"V]\=+[TS`36B`9-SHN&P*W]-K+]DL\>P9>'--,A MH^])546?\0!:!0XP1;4H`,M)`D?561/ M[](8QF%K[K;`^^_@X[,//AXN^+%QN/')"/6O,)O2*&N"YE4"B]>3Z^7BV7HW M3[S1!2^3Q\(`K4<@PXC47Z](T*L44XS>[N'^'BO.C^:RGL9J2D=%ZVVTU0E+ M,-2#=8NE0#:!9`A+$8JG?5!'B:CC.2L=@ZSWP8%VQZ-X;B957XX=U&JGLLM. M64:RQ0O0NM#V&64!%X20H9B45,_0A39JPNG9=FH\QY#:K\)\D@Z0V:OG.ZY< MB=HQ<(@\3`-A*Q MW]DE5S2V=W^&+Z-U_!H787(]/UW_5UC3*U^D=+-K;P^/K%/#7?P99GF=ZOG?!!KF==Q%+2'W_J;^=+EMWI:-/WM$>&UL550)``/^Q#M6_L0[5G5X"P`!!"4.```$.0$``.Q=;7/;.)+^ M?E7W'WS9SX[Q2@)3D]L"0&#&M"@"[GZ>![@9`X.>_?[V>'=W:HDSS[,TK^!J\.K+9))^FV>6; M5[]_.!8?U.GIJ[__[W__U\__OH_J]9FGW^E)3VZ&N9_E1.KNQU\C:?)//E MFZ_F\YN?3DZ^?/GR^NNG8O8Z+RY/$`#X9%UK:XGJOX[K8L?5HV.(CC%\_;6< MOCIR^F5EB_97)7^J?IW.UQ4>%Z8G]S^NBU9UGS3]!2_+0L[YR?+7==$RW530 M-0I/_OGN[8I+/6,GQ3W+,HMW:6WU2VVEZ<[ZKT)=+>0&VKV9>`E5%. M%S-[=B'*TLY+,?GW(BWLM+O@+5OL2Z&/R:>9[2+WTXI>Q%-Y5N:S=+H<_D0V ME4F9EF<7YX4MW0N73\\N3)JYX2!-9A_<$UM)TBC]H>T^JW(M+GV45>7"]?V"AEB[I>A-1)D;GHKWR;E^6Y+51^?9UG'ZZ2PC:)V%RS9P%; M$MZZ@6'$_6B_SA?)[&"IOVFG9^';.=.V]?T(ZZ*)^=T[.[_*IZ?9K2WG;4*_ MW;5Z%*RMM;:I[$7,TZQ<%%7^\2Z9SUU*V"39MO*]"-,2K89JGD1S+:?7#Z[9 M.K<\JU[ZX@SHUUI<:#\'.V85*RBLSR[^4 MOV?)8IJZ7SNHTJ[!0=3)KV\*>V6S,KVUIYFK9JL1U)MR+9L?0M6'B,N7=CM: M?":%#NUC79KWHNK;/+O\:(OKR'ZJ`L^E:,X!O7?B?/B2W#2ITK+Z$**V=!_[ MM>)%\/=V4H7UDTF^J)*0RU\6CO1J$K!!U*9Z7H1;AFHNY[33:LQP`\;2]#8_ M%85SO)=+.Y5W#T7.D[MEWO(E*5QZM;3?O=&C$8V>M'@5KRU>;RCV*^=[16*23 MY0#K?G5R1_<$7MX5X\@M$ME MV]3U(^3B4VG_O7##D+YMD;]N*=Z'*&WIWUEKHV!),:EE6_WY6+SU(ER:S4^F MZ?7)JLQ),OLFG-JRS%>OW%6K@W0IXZ.:/@5R?U=1=9X=3^U%LIC-.XJWM9V> MA,VODS0[7-8GS7@5==GR\;6]_F2+KG)N:L.GD%>NK6*R^&2/UY!T%'5'2QL% M=D:2.@?BBKUU958E*YGV7C.^;]Y^G=ML6N5-WEZP<118OV?Y%O>>63YI&%RJ M)_%#U%NOXF7Q6`9$(2,H8)1(!9S,/%A)2R*DHB9I'[@4 MQ>0H+Z:V>/,*UK56QKS7V%OM^O`-=>X="2>X>[#L:3]-9KESY&]>S8N%?7B8 MNW3OZUS/EFF!ZV3V\GXJ>"O1CS&Z2,I/2Z`6Y?%EDMR<5`9P8F?SLGZR-(EC M`%=[4_ZV>AR_KS(1\37=9+O?E8D!$QI3*32!`3`RR>!V7-3.3R%[QRD_"(_)UW8\/BX7(R*@D9`0`+414AG$ MUGH$@5"=>$2CYO$`_8?@\;=%)5@U$93,;7F:_7F53J[NM[7]A\O]0;3;++9D/+48ORT*EP5>*ENMIYAD MDLXS$<_@R>3X8GD?T_GSR=%'%WT++ED_8>EG4V?U16N/ZSF/6 M2SMY?9G?.EC2*I,DU1^5L9-'":1[%-^G,?6GH[L6?G:4C@V5V(7'@,+(B(!H MIH18\A9IP!5H'+[\:[)M,6A+R3BDG)F0"Q0H!D6$HC"ZM[RHRN=`V*EC>EH' M\H)\[E/_T:[^K#=W_F+SRR*YN:IV<3:L!FVM$RN#(T`#;203!A`#L28U*,AE M^6-:'3J8V+P?5(:8`?MP;UV/)8V>3-)O8GU;G5C",(@@$9H'4<2DY!$$M7XT MTGB\BT@>./O6"CRC].-9P^B6G\9D!!["\5]F27F9?_F'$V`Q^7RW=;5B>^'8 M@(`CPS@A.D18:REI4$LIL.@6=/>V].0![=PS).U[;1VLE?.;HNJQ<+96E70,QWI;9?)'63?]>^'GW=DV M?MZ=Q0A1S1F`+`HXD9J[/%#4\@$)S#BFF7OB9V_]N\U#I).KW'7>VW0VL^V& MOQU58H4CI4BHF4O/F:2&:+#N\53I;CW*^^1Q3X.@/V"&"&#J"8'EB2[E/>:[ M4Y@M-6(68"T8@X83SJ@"W$BT#OZ1&6JQ_ED2&#^8/!??]X?YV,;`M;%N3"&B MD!D:8:(BP;FB*%SIJSFD9KSIS,$,MK`('UC]^#8RNB1G?*;AP>-_^%RYI^F3 M%8_=#G][C9@S*"64F@$2*F0"3J/:3VK,V&!Y:SM_[Q'_O`]\.O$I;O/L?)9, MMN]WW50LQ@'10D.,.)3.B#ERJM:2A0$<6>[3$W.'@=*)KK-LGA1I?G^L3KF; MLTUE8Q2XI-HI5&4"F"/N%(>UC#2DW1;N>TN*>B+.`S)#^%-5K6W:XB8IYG>_ M)==-7XQL*AYKZ08/YV'"*`!82Y6WDC>&3ZW;B`E5!G"`L`R%%,0(0!_TUX"--]0^C,YO/U_H&;"_ MGN&,+OX>J;UXB`)D4A0V6[[_[E>;S.97*BGL?>AXFDUVAP6M*L=2L%"%!"&- M%)$$AH+Q6@NM.TZ>]O%7`3+A!E,CL;7/B>!'ASIKXOYY"K-RCS[1Y*524-"O;ET'$F)L0*$ M,:$1Q5"%B7;N$?=OCSP/FGEKX?Y0&&(!+0Z/'.^.CSSHWMKPP35IN(Q,H@#'0K%&`DY MA"*4M:,PH1:\$[?[?TGT+!-4'@!Y#IH;)Q4V5XA1!`(C."8J,)&.F`*RWC#D M?^B&J@?6#T/F1^!]-5#LFVI^#;A?8G2=WU=#6>/#&]X5C2IAS4AKC M"#'G]A@R7*\!(GBPB<)V4T>'TO(=RP?B,03#E:ZG63DO[B^8V>VUOR\<2\8" MH105$09A6+D\'=4:&1YT.^YH_R]!G\5G'PS'\`2W6@C85B4&Q!@0$4I4M3KR#X9CW9AU"U4[6#T;G1[.!T7GN,5#O8\KC_L.(ZH*"RK&T^K#D:>$X M"$+%A5$HD,!E^#IR_U=+J=T(."YO?#C8&[XK.0B102*N-+-G%ZJPTW2^.DCB MKBF7WE(EQI$6,@A(J`@UP`6J6-):NP#H;KYY_Z_WGR>?]@/*$2;$V<`#QB+=X'$Y@"XOP@-6/;B&C\^?C,PP/WOWC ME3TOTMMD;F62?=[MW#>5C3&C-#0:+L^1PA`K@M8RRK#C06K]9=K>(,_]`C-$ M;SXOXDQJMLN4/8R@H*^T1J=]32ZAPZMQ0$+I-28DH``(B`$G,#Z M#!HJ1>F6VTHL/Q&\)NWB7_RHM:>#5+RK(A8MI<(8:A M9"%G"KKW2`Z9"HFJ-0M9QP&&OXRPR`LDST-VH[/95B4.#0,*<`"@$EA#;2@C MM7;.J$=\]\JA=#6R?Q!"/YH=C"ZR&`O]SS`-EF357;QRDS71Y`Z33%Y?GF`"1:J9TB&Z+'U1]LJO_Z49DO]J[OMT^GJ'ON/19*5%[8H[!3N MZ,C[-!,+15W@0PP3@#+CHE0&6(V"TF&W&+^7+=V^#&,`F(;?I6"2B177U7=V MK7M'=1H1-O$?1N!)T@&\>?.5JVM\LOJ`O"B MJ"Z_JH0NG^:>9;5H?W;A3'E>))-=YM"MP9A2$`6(`H"QD!1"BNBZ*X0&=8L( MO)\UUX>Q#`)8IVCAJ0#W]\7/\_/5I[WK?Q?.#6Z+'O9H(HX8QZS2A&'EM*A& MQ36`6$;=5D&]7V+B/9KH#Z*#0D3/5X:%G)L(:D@48E0Q:4*SFA?1D*J.7^5Y MOZVDMU#1#RQC<@CO;6:_)+-J5/+@#1ZUYO*@B.@(N'`94$5,2`P.:TR0(-T^ M?/=^XL-`ZV%#STP>$?F$;,#W&SS87)EIXN9/;L0SF3GY>H8L.GAM]!X/>]R M35*+Q'93M3A"##J'RZ(@#*!4CN:P_E@$"]%\R58_FCZ@OT'X4MX]^J]ME]IT M;2IF&@@8FHAKZC+62'.EZR52%&HTU-[SC;?>^*7TVRL-^D4J&>O]./Z.E@X) M@`(QC`33U3D$1*Y/6D5FN&G^5NM[_;/>\NSI_4`;#"#>Q\PW`VK']]&1K=>.#[3\)`6>#U[.@H`@$`&%'/` M>(1$4*#<%OCW_+LZ?WP&:*+^S@.EQ+M\E?L+!T#Y/[11JVU MBG@PU#K1.","#X@-80?#'GNJI#;<:8HD,Z'B+CT.X;I?"3'BC<^'T=GY_--N M@/WU#&=T,<-([<5#X##`>;DL8`1#4FW%@DAPR0F7M1::=[RZ:@3GY;9F9__S M#;(@!PN_-O-3I8P+G;Y&(-*62$KIVPT$4T4XFT=/1^X/'&KY@&\0LO%[6 MJB)B,*&2AP1"(H&.V'I$K0YA'&]`X8&SUK>V=D/IQ[.&T44)8S("#Z&!AZM[ MB3*:`<`,0I`$--#$U'X,JR#L=H+E,US=VQKMYJM[]X/D1]V4"B+).0108,!" M;2`#87U]%^9CIU1I]>I%4<]'116F33 MM^[Q:L^-^VUQ;:?5'OS]+.N@5\6"(L[K&^(3%]:19:?Q[29JG5Z_MB3@0%A%"740+.M7,?K%Z6($*K;NLK0]Y*-RY; M[0KL2S-8[7Z[N=^3,(C!KM\70VX"HD(=,,/"D,+@85J,("6[?8C4VTWEHS?8 MKL".V&!_R?/IEW0VVZCO;[8'DVUZ8\PI"04/*58BQ`I@3=&#]Q*&=#):[_O= MQVBTGJ$==NOD_GRZ=F% M<6!GDS29K::$LVO$93)S'-@/5];.'4]B.EWJFF: MF"VJF&NS=NN1:\>P/Z`4,<693VF+\$OD:[M;I_N!I62X<1 M(,;,\4-`($-JA`(1(B2HZ8)!.-1-,WLMO8[.E`?O:AVH&^2(@GUT:'?/0K<6 M8PBD&R)AA$*@$79)0_1OL8H]&MF_1WUXHE!0Q#)51U73N07,$'N8D@@]T:U_("D[[9R?M" MKA/CR\^(IYL^(VBX2[FQ8JPH)Y`1";%AB"(0B@C7TB,FNO'>V_KEH+S[!J^] M0VI[Z?FF.\$WF,+6Z\.AC&2(4(@E(EPCA`EFM?R![KAWLN?O-,8:P'L"V;^1 MU,)L#3TVW*@LJTY"`LU%R&AU@`FAJ_-+%!.8C_!NF\/ASSVC\3*8'$U<^)P$ M'DI<.;\I*N;@\J^*.OB(NNI9_.XV8P8`@14,@*4;&90Z$ MK>75).PVD=S+P9<'$N07B$[$14EV6X5<238]O;W[?_:NK;=M75G_HP/>+X^\ M=A>G70W:KK6QGP355AJCCA7(=MK\^T,ZD9(VMF73DBQG'V!A(4U$BOQF-)P9 MSF6:SXO#27C(V$P;#2RD\4B/V;;`4ZP;3!Q.BRKII8!E%\3L`9)!ZI5M:0J^ MQVVRM8=XK+5&`IMR(*ET2@C,:]M?,*N'JE3Z)M3;#H$^!_NT-_/;WJ`<:\(U ME`"E,M6,0UCNCP*CQ*<+=$*J%ZB>A\Y;H/QKU>4QD/P>Y\\7R*G^(HJV] M=\&KAS,N7-@-8=@A:AS&2!O4J#5<#I9%?F"+QQ/)\HK*)^(QR$W+JU;C^RY1 M7O,8Y[`YN5WMTI8"7S!EA MD:?0!(-'V>:S@$B.5QLXA51[J7XR.F^-!T:G$8R!]!W?>I:KW:?\[HX[\#FAU< M3B(-I;?'#:-3!,;$!`/`!V?N!^:U"SCY/0.*4&1!6 M\J!7(X&HY@ZRIHR)D2C(WG'<,U\"(PY,BB$8]77KIY7[=1>_L(^!Z+?KV_B; M?+[/[#UTB@QSYKFF1@45+QCUFJ+&FR^]%B-IPGA)C-@3]$,PGOL5U[V>+6\B MNI^NHYNIM1GL[D&9P`U#N4Z`#]S4([P(I M/I3+I0_XU^"%?6Q[5!?7954\DN5K_FO_.=SEFS*-`QF\Y(#I8.U2Q"BL@_=C MG9&T,+#.6U=>$N.>ET)GX_:P5'=]74S"I_JX]@.W>RROI[XGPX`Y*HV3!F&% M/,((/=/3)99!Z+SSYL5S^D#T&9D9];FX+Q;K?=4^CI\LBVY'8B5QGC`DE-'/ M[BFI'!M)]]`+X]A^B3`$6[[ZK+9E_17A^]NO21PS3::A\Q!+"2V#5BGK-:VO MR:03+,UXDO_-K-@C_"^8L.N2;[:EHLO-WE5G.&5?5=N:WWSU_"R=3X_PP)Z+NX7"W.N'CX6JYMR M^GYQ7RQ7+\NM#O2ZOLG[?A'$391&'_-5S*$>[$7GK'GW,9_?5?ED-9L4S;(^ M'%"E;N^X#%KO'6=$$LN\)Q@*\WA?ZQ`FWK:6&.WI>KWI:K-M]8=WK-XY.G.& M86$Q"H>-=!)XK+5^VC=2C*:=Q1W7<^N(%3C[6ZFE=-*`$"`NF+3=< M,>T(8_3)[1KSAR4>*M(OL2E4!R0^I.?D<2`-H=\/VSK0FZ"U,N2XB=>5DC%L M8+U_H20>;SC7:>1,[B&8!MA_'^.,+O)KI/S20>S(EW^9S[/E#Y-7U2RH>JUM M)G<]GQ'$+$`&8`P@0C)>&(-ZK>&_D845]4"#LGN4DBCZ]R*_OI[-9_FJ>#2T M9T5+D:O=(S))D,`&>^6`4T(9&YMM/ZV7&Y)6%:^W6*">J=H93H/$ZN[7AF)F MZV+Z-7!GW4Z@J-JR!-)FS(@V++;F5P;Q;?),:/3)2^)489G MD*NJO"Z6R\T=RPM\ZG8VNSN?'C=!%K`$3B.KA2!.>*\Y,428,K5=. MH$F3#+WIKEV2N`=XD@C[M9KE\T^5JK[-5H_WDK7P^QK$Y76UVSEYS/`LME\5 M&`KF#6+*0<5!PZ)*@[1$LL$ZV'>G8/8(6IIOX>G%4U]6KY?UZ;ZH_BI^K;[^ M+.;WQ<=RL;I9[M0$3IHO<]P+)BE!'N,@QYAAJ@820TW9^+3*?DA9G@_,M\U` MHU$R+YAOACEO]JL4!T^0,!"`0%#$ M:B281B,I7]SO!7VOD"5)DVTK4HO%.I]_67^;SVYGJQCCM,GWW25/CI@B`\QH M0R&3@?5)K")`)7O^VG2:%MN;N=(M$_0,UKEDQ^/J:_;]$+=PI-#8,D-FN%8< M61\XWGGNC:;:U7OW3K1,<0L`TL1&(,K=G$=7\O M%I,'-9E4@;O_7DQCN'>\TYP>)DK:Y\E4_!)@.#5%@!X2P+EI]#QG6)HOM+<, MU-X%2N>(G216MO+RA_SGI,U?Q2S*\W_RBFIERNEE?Y;&K75>#*H`;-RFV??_)`>,0 ME5@J)PS&LH$/:9]V@O26X3B0\MDQ:H-4Q5C=1"/I:0/O%]/U!\^182V=<1XC@!A5`&`DGBUXBM(RP'O+,NSGX.@+K8Y-UM_4XJNF M0M7#\9;KKIDR)C27CB+H*=6($LPA;0Y%3=/LDMZ\&#W0[3!CMB/\AI`F_RZK M'T45E*';6)HE?\PE>CH>S;JJ'K/Y_BH7D\=_[!$JQTZ5*0081%8()CV$0[R\8_&D>^-[<(#V+F][Q2^(/=WLW+Q^* MXE]%/E_=_.G6?>J8L?'J3F?WLVD0CH\B'K&)>3I&=^&0S'(8ZI1@X&1O?K54#G,=!%%XM`LZU6\J%#,TMYT.D]TM)X MB9$)D-;&'X$F,;RP-]](_\=0QX`-4_3B"8_?).(+!6T/?[2.S3!C5B+%`(=< M$80!P-EC8\^D^KW MO_@JCUK;3;&*Q:F'7$53ZV3YZ=KDRQL_+W\N_U[DZ^GLA9-Y\)4$3:8J;F*X MRWWQ7/#D[.MZKK`RQJ4,PT2Q?=K7I_9IP>;8++-8KCZ'I7WYF=^=Z[WG+%,1 M96A@VJH(9*@-^@\'E*G8.R[SUF`)J0AVG`YG)V;8/JE:.)S?[5GXP^VUK3C% MSC$9@\03(8A15%DKF:"BWB/D$@\5^[*W)$5'5'JE2G6#R6@+4732@M@)Z"3' M`0UOM/>:(%9#@2P=JDG(4;'='1#VH*;!1T$SB"'65=-83KVBD$&]Z9!.L7$- M3#+L;7SQVMT0ZL#NL4GHO"7ZCR;<>DQD'Y[E4;I#MHAOGB3^L;K:*3R"J+'"1( M`4.X@O6.H$AL1M3;+4_'Q#X9CT$H7,0:@+4ZTT[C+8]G"G%M/46>2::@!,QP M5._*6YGV2?=V5=,UE4]'9`@ZG]H?W'O)*3?`:&JA1S9D7] M9&"&)_5IW9P!1AXCP@%G2&H`&(7-D40XX>-5U4\AU:%MG=/0>6L\,#IU?0RD M[^!Z_5%P-:6N]J27_NSUQ>39U("$^P+A+0* M/R*%4`,H8N'3&)=>WBU?G`/!)#YZ-\^7W\N?\4HDFA+[^6+KPQD308D%T'*" M';78$UBGP&!DI$^SOWK3S+NE(#'%4_\Z&;=6<7SV<(4A$8$&JI&=(*>!( M';"#$7*\M=CY.5*,8F%HL3&]&9%&]"TLVG=Z7K3X4\C MU5'N\N.`&284\?>0E5;*;Q^0(8>$\1IP3"E0E@H!9;TS[O#(U/-.2=X)(I=P M->(=-)9CX#&6C$:H8'U]B*05:7V!>U/-.Z7QR6@DF5,?RL6T7&SXZUN^^/'I M^CHPVC3RV7[+JFU2PX%;EP*GB0V8^PM\Z`32O8!S#!NT6IV MGZ\V,:>UG1DK^;?>A^P>EB%#-!0:".FX`<@85]>&#Z))^;0/^7CRG_UFI#.( MAF6$6`HBAK$?%-"R;UBF+8SMZRFPV`E#H5"PT4Y7,,DD9LS[36&X>I4*C2QVN0.TM]RG MG@3),.4"7I]@;:E).X9DQDK(+$'0("\XH@;B%T")-$?L\27TSIV>U`T\YR+^ MAY@AVMZ%JFUHL'MB1QRL$7$JX&B8ULUN*18C;#/1'0$/X(@.L'KK'#*Z(WY\ MC-'!0?_UIKC:&+&%SA<_6CI";'DVLX12Y;SW-EBUPG`FA&LR?CT86=1D=Y"7 MW0*3>DNSKPC`U^+7*E8KVEWF,F&63%LEE5$2>!E46TL$;"XJ<$#M$@B>G*[> M/U[GDNI/U:YT657ESQA$D-^%OVRMB9DR31:,'^09$8HIB:RA0:6J+\VPYXD5 MQ_KI$=,7?0^0_AW!=[(P\67UY6$Q#5;0*JPQ"K7EQ[):?<^_%_'/ATB2EBDR M`4P0D$1[1A'S2@!?-W3#F\:>XPC;&((A>H9N:(ERH,3(B!6$>,8$H40)RBQJ MLDR($8D]7CJ/Z3B71#@2GL'2I);+=:S3M:D!OO>&[X]G,Z:X%@$49XBV0#D& MFNL0PK1/2XSJ//!C2'*?BE&2E/\];2#NLKS>[+-._=DEVUL'9IIHI(V1)JC- M4FI#`*W#S@CV?J@;G!%0N!?`3C_49_?%?XJ\^IBOUM6>I06=MUYRXS!N&(8&(<) MW'U&ZRF[+^Q+!RX/ULD_X?]Q#R\QW*?]'3M71C'%P#H`@R84@!!![6UT(,Y< M6C.FSGMJ#*HB]HSAV7G*SWX5TRX8ZM5$F8^-:%30JY75DFJC9=VA)GQ=D*1U M:.F\.O%HN.E4``]GI64Q^9_OY7U`ZCZ\*C(2?OHYLA!^P4*/OWT1=_57N=IT MJE*WL1O9%EYI&9%)!24#X9,00"GD#<"-+4V<4HD!9^`2N:);J`:S2!L5^R4> M[OJZF*R>4](#6[=9JX?.DW&L*.7!(K="U5/F\[G+WZ>>BF/ZUKI;1R;IIH[NS?V#"5!D5P!'/*;5<:>844<^? M"H2I4N5RO9O]8SBTXG*@6I(IKRS!$L5PDIAZ:3VI[Q-),`(3A<5ENSG3\4GS M@6R*SBUKSVITN173O^.=[V/*;&#`]6JYRA?3P'T[G2+'3)()2@1EL36,C)%> MQ"C>2#BM8"+5+]+;V3MZ23SQ*'C*ZZ>%E;OO+O8]GI%P*,"LB@-TVF M;5B[3BS.>[D^SVYP&EYU_'NQ7A;35]>N.ZV*A%DRB@AD6!/G$==4+KI4K:CP<]?Q>K3]=?\UQX&.G*F MS&B'+-4,>*V\D0X977N8@YXM$LM37K1+M5\(T[238O7XXO"^IV9R.S63UX^& MTQ9;[J"0V%#K?%@JJ^^=@F8%T]SF\"(]G1UA=(*.^>GZPVP2F*FQ;W4QW>EK MV#,DLXP'=9@8#[UR6!GJ=!T"1H.5G$95=)&>RHZQ&E[?]/FD.%*Y?!Z2`<6$ MET0J%M0@`;P1BM:[\S8Q0QZ](0=D,E;#B`]G7D!EL%=<`^^"S&&P M*GSP[R^+O/^>)[\3$0ZG9].'\<,VEF(#/, M.$\4YUQ8@%1318I"Y=-*H:*+]DP.AN8+?NNZJ6ML.[M8!:4VBK]P'KY;SZ8Q MPO#W!738B?++35X5F_B5EQW7M_]6554$+:*K'YX?N%! ME.3.(1%_KK/X@;$"#E689F]KSB%9Y<]B!6<".A]KO\_''3VT-OK\[;E,.\*P M!"K8IBR<(1`3V6P>F<'*7AR50G\&TO_IP3D!PR$TOW1VF%[-\\5!O6GZ M>%UF'2+>.R4DY/&^%F`@:L&`K`?CS>=/Y(X_!=QX0/U_ENT&W>%9M:7`P`5S M:@?NTB^K3$G&B"+! M-*2&ALUQ[VB]-X[@V`H5G96\Y7!`CT+,M5BI+\S1S^5\[LLJ_K$/:V[O"S.% M,0>4$&DA4IAQ:JVMD95!G[\P%N[13AD#_FGB,77EF_^]7/CCQS)I M@=*(:VDY(408I7%]CEGA35K:Q?AXLR,&*<=#BG.PZ;OPW&KY?G%55+-R^JXJ MESOO2KM_4\8D`9`@1*"4PCH7T#$U/F&C:4Z>WEJ)O"%6/9T8YV#6)_=ST2R\ M)U9]]9X,(JLAAI`P@X!'FJ$Z/U(YN1_;]]@^K?*]S7>M5CSS':BAR]D)GAR<5Q?`"B]>-'=BB\?I1@_^;G(S^C%T7HK`>5L6`# MH]KX:+@CS"/&+9X^LU9U>1-^:*.\92+? M72X!]I$I.<(1.3@/&7*2`A.M;$2J"7-V^TI;[8NAKX="J/'Y(Y- MC,V3\?:7VO%L2:G$T57I+M3@-Z&)3+=I8Q@.9%O;.>+9K$W:8<0INW M_6K1)"4WM\"F3ATH,GC*1RIMM*9.),^!&\*BXASY=E3"9UYUTY>;E"N2Y4#X M="!U;-RHC=_PZ\WJZF-:?TX5^;XO5`C:,2;!$["41JL95>UX9'!YE^CU=B;6 MO;P[!*<#8;^M%V=K^/YO5%P2AM8(CBX-21*1N-R.2>O,Z/'>MO&Z%WBG\`QR MMUU6XK.E2(+CC@+Q`#9AY;9(!:$RKS2Z='O\'`R+"-F;0!:IC]0@,)[63L:9 M"MHPL]5A3PIV#C+9,40Z:1ZH+Y3M!MWB_)T),W4$AN[(LW5O?MMI=QW];N4, M)%O1"^#1V8`\R9>Z%E#\%:;H`=`BB-)>O-9>N[3?J[SU5&9">^V2_ M:N\E=QP])J/62648(?[P45A'GMO$3/I\!`=DP4&SYL%S%:7&!^`D:&]#B#%1 MFMZ-PT@5=;DF=)8TGI?H65A,5[;%V9K#B[08)V8S.Z4)+$URORSJP\;B\5^I M0J1"^6`$1NN4X-239+,[A9HUM2&'.K,_T@+(E-]Q_D8'^)3!D;??EAUP9/N5 M"AD*RV34"0LCI'76Q`9GSP",@;RMW-ZLQ*$XDHM/(1Q)S74QD]S[3F6LM@2X M420$+YF*-.H&!X@F`<'S2LSWMN4_&$^R$2IBVVR7M=Q6<=C\[]K=7'][9"?6]M55(WQ29]6FGK\^//1L9^L&H_/[P M&-\_'N./[(V=UVITWD:EK&*"H%($:;-*8/1;23HFI[;UTC-U1X"\:,IN@PB: M,/=?_DAO?UXN;L,+;DL=],'A@XU6*-#S"(YJ,)*A]9RU42N&JLSHS))S=P8G M==3:]X`C@VDW3?5-MQRU4R'6PEFDF@(&PPDNRW;MW'O.V,TM.R#F5 MD^,"7K21BW_=S*^__Z@LL]X4&GS[<;:XRU9]>*E`'[;OB5VHB-#-A6;`->.2 M0A0AD!9]PC,+179>V+B4*;@\B11M=FS^N'.<;P])?U16ZL/BV-=>1075G(:H M&&@-TFEB1(LK6IX7+=%Y6>92F#XR_.--\R=/RI5)5I-"+KF)SEF,W#+:CHPA MY*7P=EZRN11BG8O?X%FWCT[NW>+#H]^\2ZVM73)IOJ9Y_B5I=C=O%!(5:$AS M`!&*.>LM:R_>D(R&@XKRDC1;5TDAHI(0M#+>1P:1F39%77B?&4!=7M+LT53I M+6GV-*"+39K-"],G()"XP%&8R!T-GF-[V;%T@0Y54F>DF)ZC1;\W3/\T#(OP M:R<0\ZQE>R=ED=J00-C"A)9#1><:V`D_;Z6&FG5[&Q1[>W9+EZ+HIZVP>ZMQ%J*U)_:QXAR54`(D2_:.LC88 MW9XSJL`R-T_*6RE_&M7M5_YYF9>'4CG>[TJ&?G:PUS\&"_.O\P_U8O/@U]FG MYI$4IWXRMJO_*>MO_IO*=TL)(* ME(@J24DI*RTX9]OM=*4)YFGNE+=R)ZZY/0I_\$30>PE&S?\_+4"^J>R]K33[ MD@FZ>\]4!NE0`6!PA#E`J_7MU@5$Y)P?O'W^)1.TKD@D7/-@C<'F["1(>Y>E MEC!T2@U5VK+W\JG'4J6W3-#3@+ZP3%`9T\B)MVGHD7&IA!=;^#4A0^TOCY0) M>K3H]V:"GH9A$>;H%-+J@O'`TMR0#!L90P!%=(NJI0&GD@EZ-#L&R:_+`O6% MLMV@6W@FZ*28VL7N^3TS/W5@5]V?V6J]OQ#FJ=^I'(&H'4@9A;&&JJ!#:,<& M&*=VJ-NK>)_<2M@?T.--G(J M+$VC")9R;XF0W`C6CD1$S*L",["M.Y`L=YFZW<';`U'V59V-'NZ]]2IRRCPZ MI2,$R=%(0J'%4<'CFNZ3C0K.9W.YPNB0U)E*V9;%NQ\LM!GP::3NNO6J*52; MC#ZB?=14(AB_W66/P$R>\U5>H&POI!Y9&"//U*\6UZOY8CV_.IS9T4-[E0$7 M49NTEE%+J0R:2[^=`-C%I/P7,QN?!7\Y\^^]\,P1YM\GK5?!*^UE()1`<#$Z M)4R[.Y-<>LB[R*_HFD3%S+_G"F.,^?=>GP>9?W>V5Z&,AGCC+3&@HR`:I6NQ M2C_S@D^+KGDTPOS;%?R#1\IOCL)W1;ZW/3FCT9OWZ_JOFP06?JT7UT.U,VI` M_\.NO#XF3'_'*Y5!]%8HCD)P*S!QAMNTD#.0E$M48P7?/^SNP3CZ9QZO)!,B M3>`^Z:JCC%+J`[0C"XH/=2_N_I#XL\7R>/?H?"2*C5E_/+;#T>L[WJAHDV;O M*&6"JT@-(RJR%A#E"HUC/TNR!VB2!\P@>^%/>WHXZ&'7.Y4'(X@1+*)O%DP: M"1?M^#Q7JN"`G7,E=I@!9V%T>5PH+XRE&`J,+OJ#E5&>?3Y-EX2#$%$:JS2Q M43!P:5S&21U")'D)Q?T=N)XOG_T2ST)E"&G[FW6RA-9K=_77S7Q]"_C^E7[' M&Y5K[F#E4CK&E67`M&4-4MH'#!Y#7NFDON./NUSINP%F+*$W?UW5AV?Y@^]6 MW"A+J((@/1+C8S`VMN,5FA2\\I\MP2,8T056E\^1XBR"\JC1P;;H/V??UC&Q M:[EXM;GV8KE:OWX=]H<-[GNGA#);] M(#2(O7<]N]YL+_RC7OZYFGWY.+^:?3KD[>]ZIT*(R)B46OJ$7=*,9#IM$/.1 M:$_S`NU.#]<8T=_O")I!1'^[G72_IX>]O%WO5,!Y5,Y+%RUST:-Q6MR-3P6% M!9<([D!FCUG0,4J7QX;B5OB22-#!VGZ[`OTKM7]S]=_O^]?TYYZM4N>:Z)>F M%JO=X=, M['FE0C1<.Z.X\U1$'T1PNHD=X21HCWXP)[J]EB_4>]6M4?Z)[Y^)3/5,%+QD+2!!LCF"@(CVZ#`B5"8V8% MI/X"Q;L^P.L1JY$<]#=U0N:F?E-_6:ZNZP_^^YT[\P$7U_/K[W&Y>CU;7[O% MXF;VZ6`EH4Z^GS2-:4YLM$HJG23%=7*`TNR;_N%II'D>87_AVWUQ;$@0]X>= M_/UOS:/-A<[I'_\'4$L#!!0````(`.6`94?P26'X*:<``)'G"``5`!P`879C M82TR,#$U,#DS,%]L86(N>&UL550)``/^Q#M6_L0[5G5X"P`!!"4.```$.0$` M`.1=:V_C.);]OL#^!V[-`-,#)!6]'XWN&4BD-!T@50F2U-8`C86AV'0BE"UY M)+DJV5^_U--R8CNB1$KL6:!1G8>C>^ZYU'U2XB]_?UZOP'>OSUPY>[<^<.7EY^^/O?_O,_?OFO\_-_NK=7`,7S[1I'&8`)#C*\ M`#_"[`E\7>#T&U@F\1I\C9-OX??@_+SZ*U!^M0JC;S_G_SP$*0;/:?AS.G_" MZ^`JG@=9(?XIRS8_7US\^/'CX_-#LOH8)X\7BB2I%\U?'?U$_MUY_;'S_$?G MLG*NRA^?T\4'0)2,TD)V!R'UQY_??/Z'6GQ:MFW[HOAM\]$T//1!51>/9%_HF+"#_FE-_@)(P7 M=UF09%?!`UX1',75GA*\/'R)59+L72&GR,XIDHVB+.W:+G!*VCXW`?E*5Y?7Y`UX'MR!V.VD-]>DC7H/0;"972>/013^;Q%58!RE\2I<%-\XT>(FP2D)7L6W MUTL_C(A'#H,5<7D9SJ-:ZCRD61+,LYGF6S;4)`59IN;YR'`\VW`U&VFJKCJF MZ"(M\F\C'U$BSSZEXK]K8W_#.QI`()H M`=HZ@'@)&BW`3@WP>ZW(__QRL2-JWY3Q_-#J+/`O@_2A4*(BE2@CZQ=XE:7U M3\[SGYQ+<36;"$)'/U7P7) M_)UE47WB8AZ3]&23G>^MD#RGFU3I>,H;JJ2<$'20[C>N)T_U%ML5OE[>XGG\ M2'#BQ>6"2`Z7(5XX:8H)AOF_MF%"OB,A*@P>PE68A3@EOR-I]>(^>%CA>^+M M7,+XMYGJ6H;K^TC6)463/:394@-3,A5IEC5A^EU/-#8V&I^4'Y"REB$PI00FX71 M%B^N-S@I_&-*`)%?;.(T6/TCB;>;74@T?%\R?$G5+,_4;,U09!NYJHXL!!'R MW*X)+VNQ_'Q0&RG802T\30T6E&BGRV`IZ3SA/7@91A#OP$V]>)SU37]WMZ1= M1O/5-N_:'D:7_W05I]NDY75DPY$EV4"*K,I0MFPD6;#&I7FJ3Y-:<@?#.9=$ MEW?P^O/]Y>G#$6Y^! MG08D%YPL"QQ*^FG'/8X]Q?'D(^G[UK6/2315)E>*NE[">+W!45I@N,6KO!L+ MXS1+[YZ"!.?SJ\5-\++?ZY`,S;9MLZM!U+C:'L@3QR-Y!X- MRD*VF\MNHW.2A-PZ9;/4?=E]IL+G_`B2LGR=222G-54"T/(LQS6A;EMZ#=`Q M#*U?:Y(WJA&;DFUGLN=TVMJ`AY=#7@<4*E6]K1-^9VH;T[8M13)O_X;E&);E MW*H<:(A.3&@=."5-W9PP/X;H'"D%.5Q\X!X/)_Q8 M/[X$\44]P<W@18L;LL8^!VN,XG401C,36BY2',_P?$?W(42& M9-98;1EZ5,GI%`!']%`E(NHDIY;3&^3=B!)\GP>SNRR>?[O>U$.YXEMGLTGP/"S;+^'C M4Y;>!4GZ":\?<#)S).2;#M)U7[-L2S:@"6$-`GE^IRR4CV3>O8H<(*@`%T/O M\B=MS*`$#7ZZSFG-\BHBY]P4<5:R5:F(LKW8.A`^^;(^<5SDK%P\QL)E4AL5/TV=;?84 M)_G>LR\18;P%.8^R)!Q[SSB9ARF^2<(YOLWC=%'&&2[4(31T1_),UT)(=:TF MZ*HR4H:71GSQ<8Z*-2I0P`(%KGY=G$F,-Z1`$L=NE/51'Y.-6"4-XI6Z2!K' MBD+72"-1T*E$&M,<8\25MT"K8D[79-U75%_R%:2:LJ>@77L0J395-W\*?+RK MK2,SPVK320IV>H%MKAAHIZ*@T.T,''9U+#MXG!$4L(MSC,Q!WPE\*_@ZPE7MIONV3.1"6U9=6])TU=*46K;F M>T:O!N`0@9PCT9]EZ:,F@2P&?Y;EC[K=MYTTB%/*9MY8=`[IX1UTT`3FX+[= M(*)[MNO&(IQ%EVX`\?2=N1/$=&G(L>!5M#X<$YV.M=_8$<8B:MS_B"O9-E1T MS_=IS,=ZHYG(.1!1U(L#89@YS M%?_`2?E5N`ZSF6L:KFHBDV"V;=F#FN+;%68?F=":;"!#"Y1SI"ESOWCY*B=, MS\"GX#E<;]=3SE6HC3K!@(6G/469M)R!0LNJ4"CT%"(>L3'96,.7OBM%Z!@V M-A<\QS'###1-W/NRV>QA1I*'-,TR9X1VW4 M">(>3WN*$_<*+?]=XMXKDXT5]_JNE'_'N->;"YYQ;YB!.DZ6^I:AQ3_I]3;+ MSP_)7TCU%>?[S_'"^8Z3X!'OJ3/S55EQ/<W:KW6'UNO_=8:@I:JH)W%LL? M<:W0S/K$@#S"J%"HM=-QWCB*<8Z.*\5:&D),.P6C)!;W3AZ>1?5,^SYO\YGP M];*E4*GA#%J:Y_F>9+J^*>L>LMSFT70?*1;%IE`Q\'+.HOY!5DZVY^^&Q\+Q M;=H[;Q+:G.*T$DI]\Y93.S"6*O\1U\O@W$GH=3,@=Q)J_0S)GU@;B"Y_FFQY MB)L_34?)^_G3Q.8:NPMU&65)&*7A_+^#U1;/+.3XGFD9R)9M6=:AJ>IND^PI MD&)#]%0(.>=(#1I0P#GGD3.-8<=1NTL<33CR7K:S*E"=M2V>'W"QMRK^&$M@ MDJ81QZ7`-M49;4F,W1G:MP#_7E!/BXN;O8Q)`I]^SR"33-CAJ7Z3O]RZ3JY< MPW1U*,D2@H[O.X9FU0^/^1Y"G%J[)*_8>-IVJP\/7G")V>%H: MB]+AZ;%>IN[P\%TW(G=X:-;/A!V>-P8:M;IO2:[EVI*%3%^33$^OCZ3RR?\[G?@T+<*1.SR`1](TAB'YMWC&L>%D M+9Z6>E.V>`8L@?%:/.,LA[ MR\_>'>VAXGUX.AV^1Z*(+O:68(K1?@-GRN.\WY)SXEF1`4P*\H3'$`UB9LN* MTH5<1NF6N+I_I_"E8;7))X1PWTLL#/3UHJ!92%1+#;<^6 M?-5UW4JTXA@ZW=NY&8\PG' M1UD[]=`G0\X%\6=,53IZWC`KNCK[/!AO(^(7-D&2O>0GRA6G)4@DQS!<9$+3 M,5Q/,PP=*K4LU58[;=H?)("S5VMC`CFH?@?3]..NF]?B3AN=FZ)GC(M7.L3* M"3&"^#8. MBL6\URK5!/DW>!NFWV"0)"'Q$)?1O'IYKJ882%*@I*J2K"AY1]B6:F'D/XH] MO-79>AZQBT41:"!QGK]_[RWM31#"O'H+#G ML+$OE1V'A$"3FZ)SQ0=)Z M^>(A[%%XXY%8[.>/^[+9S1T?5_V80V9`E@@NF84:,=LUQ';@0B[F1(M[$B$N M%V31A4OR5=&QT%QH(-5S'AVWS,@F388[#_4&6P;09H2W-6D&_XPHK6S M3SXHL.J1N);KJT@V=<61-;DX4+L1"7W-IO&[0^1P]JW';^1^'=I!E';SFV.Q M2><;!Q#)Q2>>8.F$WV/!K2"^C8DJ,?NE1^FC;I)XB=.4U"#!JN4TK\+@@>2O MV4N5M1+_*'FN@ES+TCS+]UU3@XUT3=5GWW'R$'=U6(R$TMQM;7R=;[HV3K!N M;2E9U4A!6$<72D?&BO=N/FT"PNG-R^M&X@GOQ]@* M@CA"UEK%7)_&GA!2)9)9'ZL,(W\2JGB#*>W0!AV32UHO5Y.X@P9*;+TZ MHH/9I&B+CLEJO][HB27Z<6AG]!WMC[5'69$F0H^4F2XQAU5%X];ODS!872=. M\A!FY>,@==_@/ESC95)OYC(E5[54V3)\J!B.)SNFU(04QY5@YXD6*X&\:_4< M)EE$H`44-)NJ&ZATS5"VC'?P_E.035G*%SQ?B\PS15R8@N]^\8$5[]TB1D=> MCD4.UK2*$$&8ZQ1S7(=4F],J20L_3M[BN"8)]V?\G-W_P*OO^%,<94]IU=3Q M3-\R;%U3?%4EE8L!#:=^$D&579WBE?Z\$(@2<^C:Q9RMTB$,"6$0NKC40`8$ M,SCH+7/<(`<.2N2@A"Z8>6BVWHE@IIY;\WJ;:_"NO9ZD'=W5Q]L((@0__DK& M8ZYKQ@575>X9IFFX4(/0U`Q;]J$$Y?KY&=61U.Z;"-F)Y!P`=W?QDMS%61T. M@]9='.=W<93?Q;("UN_4P'6HR7'D&VV11@'UCF788PV-7;F M9D`I1DFN"/&(@U:4Y5@OTCH/M@_M`+H*(WR9X74ZD_.769J&9FO(\'V-U(,0 MU4(U'W5Z;R0;29SCRY$7(>3X0`&0=@?.0%Z[S:O'HY0N<@QAD\M,^B11)T;1 M;`@69`+-2)F8QQIDX+4^!<_A>KN&<7F>Y0U.+J-YF.\/FJF>C'17=TR'>%!- M4B3=K3<%J8:K.'3;!C*;Z9$TS).T7&8BOE^/0=V%NC6 MCJKE>+ M]SW7')Z^]Y'*/6^O$\6@O/_JK)U!DMZ+Y/[9.6]VF:3EE9=KLO("I@#I^`'R M*//P(?0+G(`/4JM#YCV:3=:0 MYUM(LDW=4A`T'&7GDB6I<_+-1SSG-'QWV%C^T33_8M-^-.;`@T=E\X/R322< M;-,A99_>+'1>M;+(];)X*#W-O]A[6.G0`THWXEB$(J6?WC+]DGL^%NJ6Z/?B M[%C*S]<`(B3_G#6,1UO-_0N"JSA-81QE8?2(H_F+,Y\G)!I_B19A.B]>I[B8 M.7G$E0U7L7S?DS7)-&&S!\>#AMYS.,E`,N?HM[M3\\TP"=[$2?Z>H_RQ=YQF MX;IXZ]%R6QS+4O3UNWI83G:@KAQ&-D'_^B$'"EI(21E18CT#;;33E1'O,]FM MF&!H$?%*"I;*'2\LF%-(5UX<].Q7P8]T&V;I3/9T!UF^8JAE4%M$]F.I!HBMI@/([[U@)'$LRKZ>CMD>B/1_/0Q+XW MW719_$E"WLO:V;`I4I;.2*-#63E+LOH/@._P:EE\DY]0F6;I31`NT#8A@>P& M)V&\F$'D*Q+T%-U6;<>SH*K:S2X?Q?4EBC<\<)'/O54/@_0)X.<-)M$\3[O3 M(C-/">[SL`1^+-+,`0848%)!!CAF4H$&)>GIS M#)PPCVH6EJ/F@>;I/W5^CS&:\3,S]D4(+J0QHYQ+UZDS@R\%S&;? MZ-X`G7AM/Y@7F>_,L%S3]G1%]G7=571--66]:7:YNLE@^VAOV9S[3S>':X%F M5GWV>L\/V.TV758ZL-G]V-\Z/2N&$0W#HEXXN"NHV`'I"V(')IM11[$'ASVI MO>PR=&_J,;+HMZ@.IEW4"H&5>MTVK#*BL7-U\#5.OA&G#^/U!D=IL9R;YAS< M)@E9XTZT^$RX*[^9.8IDR`JR+,/V99D4++[B5S@TV_<,NB*!N7CNM<+^P/I' MB9\$MYT"_>;4[`W1K5B8U`)T8:V"^A?0!KN;#8Q<(]`2=Z)4X&8#02H&?OK% M(RUFFOKA`(A;/,?A]_PD>C].O.HMRAEM8"2:-*X7QQH0S85-J`#5&')H7E M8:@.I<3$-NKE<_==[@YN\2*R$C"H$1=M[JGM0%%*3&R/?J4$>[MT*R7HR3I6 M2G"D7812@J=Z\3BKER;H>>O-*G[!^#<]%^#U.*+@7%B7F=NA;5P_-[JVY: ML,[WV15=M+!1AL;I\C18AR`HB*7H@F$-&E2VVO5PZN<;*^#5>S!JZ*#&+HJ! M***C((;J%R4Y&JQ;N.S/WK&P.8(]1`B?8Z@9C[O,*3MS3>%*@KA?/`!1'I/A MX@@O\RUS2#=MY/J*:T/?5A6H.GJ]94Z3H=;Q+")FXD;NO#6/BI3=MKTG1LHM M:V%9Y2_`PS8#V^C5'U"VYX9;HUL[;E0ST$6_??Y+FSL](DYK4A*_]?XX+URIC4YF:F&@6S%,213-AU-425-;9IW"$%(YP"' MR^/N`3_'T?G;7EC:GD3\9;^11G5<&T/FNSF[<2FG\W:[5/%VO^O8@C>RMWN7 MKA/NCAW5@O@[A@K%O%8EI4I)EW3T&"FUU.NJ[HKF%!54$NU`S; MUMSR63KD057NO"^P]_4Y5M05I*+^*D!-M^GO&#TG[JK!C`IR,PW7(V:\U*AZ MCY6P_*G4_$5?\7H=1X78>_R6?6W#B.Y/&OPHB-W>B)\'2`!TAP]@G$ M4>78*LLKJ7IF8Q\4*HNN4K0MUDBRNWL__8*7#A\43I*].P\3U;:ES/R#^"&1 M.-BX_!?U3+>,9UW+453M[$=5.'T`%3,TO-FO5^N'I_WZ.9_E8BJVWJ_S'?O] M[N%IE:^X$*-LFM@V8937'51_+'Z7MSV][.35!Q6GNSTUJER. M/K[65!OXSIKQ&(#'SIJ2G#?EZUG`E5='TO,4P(KZ'?.%?EMW)).+GH,NANQ0 MBN/)[.GK+O_GD\ANV+/XO^.YIA3'Q`\C,54*2X`<73)JWT:;L+_GCH='=A8T)'T2?,X"LM/FF'/*1/`3$3XZP(C&E.`_-C' M&?%IS.,D*PW&,Y6!NQ?&N6?:?7Z[G_^5]9O./$^I=W_S"9O//[&:N MF/H8J*@'(#<"&A.H=,NK_!J:00>!%""D+NI(*:01R`4,Z4JC7;,_&@QY%@=1 MA$@8K"5/&@E+X=]^5%/+VYOODP\W[Z-)G-_N+=LJE')I\_ M3VZ\V4<\98I,,E!4;QG$C93FZR##0>E=A1260M15'0F4+`1R83%$5QKY,M5= M=0NGL$F^BZ%`W<" M2G?DF_RWHQNWVV(C_GF7/U83K,VJ\>MZ<_HWZ\W=^L=#?I+YI#3@"6,@)9!2 M"+$?)G[C6T;25/)\1:\N.<]9IHR(V9*'"9E\N9F+[,7[\.6:XANBFJWTTT)R M"!Y=TZBA6;COG>#Y/("*TBVQUYOS/VRC&#)GLB%^!\Y[;=N18+[?F(L!.Y/R MUMB[XC&?[9?[RJ'C;5C$CY(8QCABJ3#A\TC,=$,201!"@F/9JK'NU[OT>;SIV79FJ.I#,:A_%JEZ4-6:2[3'VNAXC9UV3[;;E9_T]S4O8Y MWSSE-_E^7;YW6Y][/ZC>CXS^OR$4XB$=H`%41@C'$>M M8XR24"V-:G1L#C>6 MSGNGWE]YC9>>"*!<9V]"\)H8#K\^1M$S38U5[^!N?RTZ$D+W&'`Q5.=1I'YU MT7(Y;R^OL]^=WAL:)-RG691A!)*4IQS@K+$7@PPI;L'2-N.^-O^/6W8S8[._ M*7)97S@YW/:BF!I%ZRO:JV)@X]1P6>9[\G3@SEC1D5#,/(["\J.FP9S)?4.Z MW2+)*`<";)B+_Z4@"C#`K94X0(IIH^*7.^?+Y$>^79:S7PV^J(@D3Q5'ZJBS MI$RX6E<&P,=1APO0T!!L1*C0\?X-0&B+(/\:AK:G?,J7@D+3O@W!HD067E_< M7"57I56+`$#&2)9B%`0"E&$"`3M8#S+%.V@L&75?^7KSG0?67DRLIK`;=3EE+$^0-.!=8)(A'R:8\"PD"$99$(2')!$FBOF:J37GP&L[;GF=D*Q#NPZ*V5!\ M)`2S$DIA_X$T7+1;I)"D41I#1`CDV.KH MAW37FI2JBNEMSIG52335;F!E^(4EN"D91L)/_3]O[#DIBB$>DV] MWDQ6SA,7$?-]"B),&8SC%*88'DW%&8E48*'S_8YY,;EE4UQM6+^^(9//JMO5 MM113K)4[$DNW0M[L':WO/ANJ*G[41*86KJ'@2!!B%,)[=6]M.>3/V12;XMQ: M@Z[#9@'&802C.,L`"S@(4\!AVAK.$JIXFM?[&ZWCSGNWUUA&5!@S`(PB3+?(Q21@!%$6B,)P0PI5M2[%A4 M2IPT;DRIW"J/CFWR??ENB*H[/E07HA;WWI/XP697/*Q7R_)2N>7]_?I!S'I5 MZ]N6Q)>#7_^ZJP'P+/.J+WYK6J'VTCMQDZP"A7>E'`D/+0;UYX,>N M9`I0%,@01MJB._6YSQ"/("-$)&SW)1H,53?=?`<1$!O.Y MX(*F4.!)S$!9E#+J0P1HF[`E*$6A2FE)WTHO!>EB_SW?:N[,-!#0<-)G53N+ MD[VQS/!T9G;2FHZ$-A8"D9W)*4JC.8.K=SX]">--04S,4[+\OMCF]=_-E[_G MN\_K3;$5"57+2+Q9R>5;"*=1FD$?"H8&*4$9#?Q#OD5"I,*T,?GMF))U\=WC MT\EGCTS*&V2^E#7YICH_N9EY&>.3*6NJ]-X<_X/-C.:2`S\&.C/2/\\38#RO M/8;J'6/UOE;!OC_IO6I'BDJ)*Y&([K=+0YX^[:DN%0-]>^/E0 MCRVU3H-.F)VVK/2T>QS/UTC&O5%*TUD"&(F/.F.S<*W)`9JW8"Y8$D01R$`( M4,P(A#&,#JE`Q`%0+2CH67%>6+B=3GZYGHD!SA.CF_G@IJ&CRD#D2$"304.X MU-8;O)\:K_J>'[PCSD7NZLLY*D8:A/$FSTQEL3@O6%`09RE)(I0PAB/`>0;B MUC+@";2;SE\TYSH+K_M4\W:@0P96'!RTGG%?%MA6HFQ56T?Y+=[OM^NO3_OJ MW;C[PKM=E@=Z1Y>9&B64TNTP*L;9B4@Y?5,42Y-\=+UK>GN^.MJN[AD2+#Y] M*.?%-/]1[EC>?&/B`_L_CB^(2X*,!1!RPA&$&6.`90='4:!X+4?__CG?_]/D M=LV=_E6A@U[/FEH'HR>E#M7-00,TI@Z4Q]:*Q@P_#>B$XE?M[7`BJJMWD#[T M?9L6VT1Z,.BS_4\LU">_IT[:\,_C[$;Q&S0^K!<;TI/)QOQZQ_%;ODPN7_S#P_>^5E< M>L)PG$0^3$`"R<$[@BA6V4/;V`PJ48H"2D.XO&]R MO:\.0&3PYT@4-;B5 MP#H#W)^'6T?].JBD(?)(F*/C>6'\A"F_-G1_Q-9Y>?S\(6F?D87O1SQ+N(]P M%/DT!1!$[2W"*`J30&W[FGW[SC>V?%/\X_5 M/V=L^LLU*5\6*#[WLPE"+ZNJ@4>K@MI&WR#;Z\[DD:68M(QC))2\\UWT491` M8>WF>;W*-ZO=K6CD?+O-5[-]^:IAC%G".(,P#!(2TH@RU-;_4$)\J);!Z5KI MX0"",#^=,NK-YA/R'R5FKBF[H:KG#[1EE%TO<:B?Y@)(XU'U,H7:)Z]RJO=5 MC#>EZ5R6,!-S))`Q#N/5PH$-630GE<_+]4.=6)'B\;'85*:_%P]"PUVVW*WO M1&:5PIA#1'`2LH`2'D#_D%DE4#_IL6"[O[2H/"8EE0IYXL\_3VZ\V4?QNX^3 M3U1\Q&B&::&%=.:7_3:.<8K5NEOF5[7#WJG'5U[E\Z"SRXN*2L\M[;7-2)#J M++S.>:5M&:41S);;C9B\[F[S[>R[F`Q4Q@X[7`7H018R!D@8`I1"'"3M.Y01 M8SY0V8YC9LGQ+AOAE'=7]]5=Z9SW;_^"`M__=^]K=U]UH:D<(ON34PV(K5_E M]DFO\JP!WG`;_CNEZB"='8E'PC5+P10NGD+KAU:%.Y4GE4^+%"8TPS1#@`($ MLS@EN#T[BY#P1/]B4G/;CKEVJ:H],X0>VTS$H0Z"T_Y4*R)C$[VZ9T[ ME/D13-(L"4.?`PK3F'#>.A0FG+H[":OFATK?UWM5V-M;]EP`V&K[Z*!XJ(8Q MAO([>_RJ-P1=WKS]8B_@F%"NT"*6MOOIM?(H\>XD4(.-@";2FE4#%A$)"`QY M"$`,Q'-':03:-)X"7VT/MIX%U\755]?W_W!>#[BLJD$=P*J@EN;_8YCTJT[V MI74<"<(,@Y"9W"M*HHT>NGYXVN>KXV%['!&2Q!'EE,5^%((@.IB-LE#I9*"I MK:&*D:O:3T/\*"NK!R*7HIHCJ?%N/$7)%W(ID$I7Z)$R2SN<"_0RD\EN<;+Q MI(%2K24LEBB=-8++(F5+S>'G MMA*JFA8JM5IH)%!U&*!.L=)`2E?ERC.7*.`IY!DF+`8Q$Q/J+&HW5C*&D.*K M.%UZ\O^J9*G61DZ*ELX:9WQER_'`7:E5[)4NM=IZE,!W%*I9^=)`7M,JPL+G M@&&?1S!$,0P2S!+>7B++H(\#DQ*FK(WQ%#&MUA$N:VM4/[`JJ[6ZP3B*!>I% M`FDU1X(UXS#DB@**LDCCZ&0SYW%K?6LZOQ/)E+"=<8HQ2)*0MNY-N'?ZQXK,LM,`<@#K77DU MFIUN12\Y=CR[\2:C7`?KK`H_$O#9C:EP^*0J(O'O^?K;][(.*[BQ M_);?/#U^S;>3^\KV;O*TW^W%!$8@^E"G#3*<09]FF<@*"0]2P-+V0@N61+ZO MAD?KYIVC\N_L^L/'N6`B_H5-\0=V=JIGYDV^S&=S?$.O;SZHWIIOORGD0#EH M&ZA!LW75:WSU:F?+>7/MKG?B[PA6E52E[:"JLU8:"6'=Q5?T]+@[(F^]S)]E MP"<)\C,00,0X(#RDK1-Q$$0JJU)V+3M>D:IW[_U4S9AWJ@5.RQK;Y:E]>9W" M=(A=0TI26H"G6I/\R$UP#%&&1=*,Z*&. MP-,(6TE6M:WWL'A4YS]VZ:FOMA$_>Y&YCW1T'`Q]3TYUBAHWS+@Y:AZ>'$DM MR2A_S5#^=5\N$CT4NZ=M?LAVXSB+HLQG0^,QPG*0D@1"_TH3&6K;YK? M[JZOE@YY1X^&FQ.^K4Q'MS.4Q'/$(H(AAB2M,8092T!I-4;1^TOA7'<[#2L7)0JUWS6M^\ M_ZZ\Z^A`ML648T\_.JKA1UM")PQZ5Z$.#)FK.A(260BDL/W`J?*HV'P3_?BQ MI.!(HR6*-'.F^7/Q\+S>?#O/HS[G97ED`1`F$17)5`H% M\T#J\P2W1DF&%%^8;&;+>=WVX)YW5T\7[AL'%0ED**DXI)P,J8LEFP@YU4DU"3J1:"C0O%:D,_/1EF\D M2#&)X%7&8RB&/#SR_;Y<]:F!U=H*DHQR&/`XC;&?@I@D06N+TS15PH>.`=<` MJ7PZED%5&:*EF21%7,NER)$72@V&DC=DZ8*)B8ICP8E1#"^!8BZ(TH+N]6:W MWSX]YIM]51[B/$U@0@!/LB"F-`.$@M92%C.EJW8UOMXQ3JHEW:-+>K5@'=7D ME\`="J:Q_*V@E;.E[W-%+BQ[:\HW$I*81/#&1&)H4N5D^MF4?$`8\#*($ M)'&09@#$T#_,HJ(D4KH71]M(OT2Y\DK7=.N_^DKJ\,61B$:4D=:O!]H<]9%F MCH:DHR2/3AR=_-$6YB*%EL]WRT6=+.%OVSPOK359D\]0P#*(,Q[$&8`)AR!L M+`4XCF,9_AA\O6/R-&G^P2M)UICHU4V9GJ12X\M+E22F1=;D6A5WU<-?7:0Q MM&QGSKB4[P69R_`JWH(T!!5MWP_X#?N>9+SG MXK&Y+=:;/5\_Y[>Y>(1$IOFU>,X_K;\6V\:S-`4$I'X09%C\,\!!<.!]$(L, M5)K"_;CCF-KOKS&U<7C+O1?]#/_5:R+PJA"\3]?99*H"K9Y:3V),&%_#V5H7 M/+09%C\4'_>J*+PRC+>:3VOPZ:D=%0:K\;6GWN#69[O*C8I6E'UO%.VWV<8P MZO8<<3%8'U$9U3\\+'??BM_F^?:Q7+QJ+,6()1GP:1*%#-*01SYN*\P!2;G4 M.K3!USL>=1NGO-(KKW1+!<":@DD,C.ZU4AOH7LFD-6!IZJ4P`+G736]`T=%/ M;F!X,^+W0&\FSQC`;1A!8>U94;TN[@SV5=$]\",DV`UQRN,`8\`BW.Y]#`*6 M*%W#H?'U_12ACAOE=!;4=%23*W@[%DRK%"6ME9N;VEXITE'<-I!O)&5MDPA> MWKEF*H8F19JRN0\)CE(6`8"BR$\@)>B0"L(L43HVJF6@;Y+H+:'I::=#$P>R M&?)DF$6SMU219HJBB*.DBFH,G5S1$D3A%0OU]'.ZW.>SWY8_FFPH8`$B/`-) M""'`%"+DIZVUA(5`]>T)6D94.HK6&8E#46\@V]>XUQ-(IV:E+FB"N6I7I75JU0U"J\/"A>-PN78^+-IM>J2`.\5KJP) M-X8:EKU@"A?/EO(FS^WZ63QCS_EQ4]=TO?NUG@>3*/-1!E#*$@("0I@/#D,( MYDAMHZ>!(>>;/5O?3C=&E][I[B0W$54NK>Q-3S7$ORWE0'O,WU>H<^>G!6%' MDFG:B>75#E!K`FE@JGR187G!V\DU!!GU84`""&C($($^POZA7)?&7.FPG)&A M_C#5.F=T+8F9J*J8CG'B MCU[F9""@'(_ZT4X-1DJR.6'0NZIT`,AV'3)4[^;>7YAK0I5$2 M!2&BA"*8<#^(R>%:N/^E[EI[V\B5[%\AL,`B`_CN]H/L!_83V23O!I/$0>*9 MQ2)8"++4CH6QNSUJ*8GOKU^R'Y+L6#*?K*1;(HE"[6:@5I M/LJHNF.6#%E0J*@\H[!GHSSGR7^.\G)*>ZRYG(KVV!OR7'L<4:.UZ?1W,>)V M\=?09HF&G,6\2/(DCY.$\R!-B]U(.%*:D%E\O&^UZ4!=@`&6P29*7<(4ZO[^ MN=+4EN5+?].I1]ZL-IUJ\:>UZ?2IQ<=J]W;T3*%@;VG!"YM.KL9&;V*"B:!5%J$]2KV_)CNPY0DGGUUY"P080PXYS3*$^R(DVRC`T# M$1ZH-Y`Q^G3/VB4P@0-0.I,M,[(4YJ;>>=(3H6<4&4U,S;C2F)=ZY\QL6JK/ MG=JD]"5SC\U)K:B9PI34SH#:U5/B(D44WWN[*>^;&:=%G(Z3S)(?C2_J"%Z"0Q5&?6(BOT0JJ3E%"1S_'2P8$JW5Q0F^(I M)X+ZQJAD@884*1]:^'K57UZ#J^7SXQ)7Y8_-=GZWNSB44)SC`N49':&KA+^D!O3,4Y_*$\8F*_C*SY>"1U4\'#EV[(G<*63,ODRK M_3^;#K+L]_,?J_OM/:G7Z_J[;#XU?Q`_V3S.**$13V"&$YQ'M$"4YL-YXIBG MA=XU0RX']IR#'[T7K7U!-V*.>M\A!W?J7:'\>,`\.1^%?$?EVQXKV($%`]H) MI.['B-3,Y*W],>'$WMXVA3S?$8'Z:3^OUY\?J^5*$"]`R4I)\[Y>;[[.OY;R MQ[,L*"!"D/`$10G'6<`)&<9G!"LV2G`^[#@)_SZYN:G7H!D`R]=<'D5LP'V/ MN?TETSS3V@6::?Z8W%OE^)+TSX>DMUC!`+;]I;.1;IC9CTF^D[1>Y2>[?$&67V,T@S"'F29!!!G*&$1KM+>V"1D4*O-X_6 M1X\=5M:.+C'6XT\_[W9*G$%,:!E[FF&?,7E63(Z529M@\JN._41RJTF`WO5; M3;.="[.*NMDTLP2G)"MPS@I(:(!9$NP.+<*$JFFRK.U_\O5TU M*QG)P4*B,KEH2X\S-9GP2Y>>5G17:_5@@$1SCNNT#LDX(17FQ$U$+RP,>.GF M+`LJU*:]3^_GDAE/?=,6-(>+968$DH@415[`K,AS4L``#8W!8,RYTE%D1T/Y MW@HE`ZJ(I5WEWN1"+0=L*LQ;QR721&T.+O(;2&U_8'1+F0-2->:EXY)K-ANU M)EEM_ODJ%<=FG>XXG,)Z6HWB/7-\6LJ135T>!3YPWP,TKIYITZE;H_3)I/X$ M%.R+DNV-2!(:>#\ZB:8U1Y]DNBDR_O1DNJTH/B-`J81H2MH4=-R-(4>+A';4 MJ*GW4':4L]__66UN/ZY7U6+U,+\[V'_P0"059`M"O-IPE#FHMLSLR5N]SZW[R^H*ZWKASWZ07&Q M[JP.,%W1DV@OP!XOZ`&#`?$N'C[Y+8E_[.4_77Y/K1%Z\]5$%@8\&OA\M=$S ME6X$F*]^E$_V3,]X%$<$0YIA2G)$"I+G=!<&0A@Y5%_]P4??6R<1[G57;E'^ M^1R!2R$V\(<#%?;K".<2W,+]-?3W)V9-Q=?<1;^"\EI8IR.[MB2^JKFKZIOX MY(,NUA]J.;<3N?=]O:TVLQR'>1((6<\"C"->!/%NCQID&!.5TK[M&)X+^P,: M,&_AR/6PIY*YW`%7W2ABS>IIB1R34-UEW`'2!=CQVJ$R$KFF7/S'U_K;?W86 M2XF+^W]+<8L/Q.T53EY0,5@K)2K6IZ M8ETMLSL?X99[4IZ-/!-72H#-#&4!@SQ%B*:8)`Q#O%?S M,%3+[[P-[COQ:Z')?*^6X$#5H0.+#AX0R<=VK;=0Y,4%"JMWYV;?2EC!'B_H M?7)Y`UK(H,<,>M!G]X7QCL#Q?>)DCZ`3WYAL&U3B2VTCH5OJI[`\Y]6^XYL- M?1!I5!6>88XIC/,H"2''"%+*X=##$\*(Z/4FU_E@SR%I=V:]`?5VTVSFU5)\ M85&O?9TI_6JL4Y)L:JUGK)LJ5D65J9I(JFR&_41%4Y,`QI-L&A5M<%IP/[7QOJX,H, MMS\2NVH1@VW;!'O`;"`U/MR@D.:>CW]-F=H3W[>PZ:""/YX2?SD)XG5V0I_- M`89;HT^_`9O;5=.?&W_Z&MCOF-8AZN@6:B]L3R&!]619[?U1U0E379)[YZZ>CO:*((ADE,(.-12E">WD>J)+^C1$=-@# MPN>K]9_SNVUY>;/_YKO5_+H5AED296%(*.$,"_#/==TT^Q^.KI!J%)Z41\=>F(PVNK;K)V'T0IRR*N*%F)ILY4+8\E+D M2^NBOG]8E[=EU8C1WU:+^KY\)Y[-#^7F\N9J_F-6$!911)*`$\R+G$7B&P,, MFF9:_=1"/A_G8!!&(Y21:81Y90349/**DOWTQ$4+V95X_SB&N53,M--Y(8@)15>=-6 M"&*:LC#+XP)1QL6`R=`0`\$L1.KE4H,/]UTJ[=Z^[IA6^UYNYC_`=0?NPOSH MECF9*L53SSQJ%D[+S:!I`@_H`7GG2:=>ZIDOPUIIN7GAF;->^'K!V*,U4@M> M)E$?M<%?.WI`]!>D+F_>K19"U7<;MTBY;&8T2?,\A@4/.68Q+A`CP]T8*$5( M0V4M!AEO8:H'M]OS>RW@Z:^S&%*IO$#EGT7C1:J!P&$3*!F30.W%*O]$VBY8 MO?A$VJOQ<>M/KUS9$38)=79AQ\\K6"Z(,5S%XO-%V1=\`YQD/(LF=-GLMSDB3G+M26):@JK2'MVE)>, M#`B=R)3=WHZ3BT'&Q!@*C]S,.^-9B(N8XY0$G(DXDX3!<`\E*E`2FTN.TL=[ M%INK06)V35/[0[56DJ-&G(G8..?,4F8DGK/JBP2@K"Q:[$U24_0L.*DF!F0X M.-7_>2,+C?L3L?)[G\0C5KY?5?+VQED1)D52,`YQFJ89#2(<#@<'4(@Y='/$ MWQJ&9UWJ8;0=G;HJX(/"6?/1?6$B86=S@Z74/>L"T$%_WM()M.@O0(]_,FT! M7B-:64*]>&^24NO'4N7N`8[)59?N5;.XJYOM6EY!5M\_B#EO6]OX5+9+1.W5 M0I]OY^NR;<;Z7'W1%W+=7%)5\0N[0E/,=\G9O M^`%VT(-O[SIKA+!+_/_H6BD.%H`OT@;0&O%_8XNZ'>>GE'TD;TY%WL.WA:#)6` MUO?S5343"27+(\A2#AG+LAS&$1I&D=\PT0+%CQY/#3I`IGJ@RI2>(G@@R5@3 M7N7'JRITHROH@B9E$U,&7?1'M,&(!+6M(U??ZZO;>MO,JR6NEO+2JJ'+Q]M* M3DQE=SN!XGTIUTAG:9:F(88Q97$61#R)8Q;O$$"BOIG$[;">547\9P3V-]SM M$`()46=OA&.R3XO/F7G6$R:!$PQ`@4#:W2!XC'/PI0.LJNX^R-?8JG(^)YAM M7G'N#+4]+5HT'=OEXH?K*>Q[\619[?U!-0]';/7U=O-Y(^;('\6C>BMFSP?# M,YKB*$*4!#0/0YZG49@,PZ,"AX:QR&I,_X$H`RTV,("SC$%V#&L'H-'(M8P^ M+>PH-PX[HU'O*.;8N,`DWISB1RW8.&%X>I'&C5G'PXQ#VDQBS%59 MG0IR,0HBEFK;K50QL'F,_[TN1\89U3$.`)IS'%>L)C'R3!P5G"U8IN[T3R'G"[1NZSN M'ON<[Q`LZ-""-Y\O)>+?-(OZ#JA6J_./R[)>R#G%*O[4_*:O;6Y6!%[E[,0B M@3N^)[)NX-"@VM>CJ:ESG\IFLUXM-N6RA=`/!A$IDB)D)&(Q#HHHS'DQ#)8B MO7-.9B-XUK,]J$[/-"7+D#4UF?)/F)XT/>?J7%+T(B\GY,>.QXE(CJ41MSC/10S#8W M:?&C)AV^J-$3#%56O*C$`04GM,&$J(DH@A'TVOXY,7O[^[T189B1@L9!D9*\ M*#@7.A/V@V0HX5K-V/0^>2P%,-O0I,F2E@IX(,A0!\ZSF>D)#:]K@29=TU(# M7?`OZX$1!>HEE=T>Z\-=V/C[?+V\6L^KQ6UY695]2E+P$":DR"#C.4Y@')(` M"0@)2R-YWSK3*JXX'-=WF>7@[,.3,Q(MV@O0XP4"L&Z1Q27YBN66,_&N67A1 MI_QL-1AU(D]58SRX8R(BZ,6TYQ4:;_0Y%-"K[_6P,ALQF$>(IP)*!E&.\XQ+ M#2<1I5E&E19&?8P[$0$5@)T+J`;YK@34#^]^!%0NY4U60'=$6@FHOCM^&0$U M,$U;0$WI.)51CY*F(J(3L M7D9U7.!,2#VQ[TE*)=H)B^F>3#LY-7#*KR.H)L;I2ZHQA;:BNE[+9AERQP]Y M_.ET=0MQ:.S8_K3!V\UMO5[]JUS.4"KO,B@"%(RK$<@EG,'PNL1 MG6=QWK%_1^+LTY56`CX1+[H2^;TY MX/KQI3X80QS8/P.=76!OV#2"@;EC]`/&"`_!M(/*&`2H!9[17*$7G*Y?!WK] M'"C[\;!:M[_\L>U'.4OR)((!2Y*`A7(.PCC)!X`X0EI;8L9#Y3D8[?&8M>T< MT3T:@69RGAD]P!SX]>,K?O475ERXX;5P,JJKIQ1&QC7\I?!Q!NK]AXW=&:GU M:M&UF[JOJ^[T5-=)<,8@(S&G.$QIAB*6DS@:CN5F8:+7Z>F,,#T'EH.VGB++ M_7M;R]V']_/U7^4&/$C0XMLWXA&HOK;=6<<*.P[O9T0/3_JAI_Q"` MSL)N9^K%T`[V5PE7KWK+1_QR]XC\Z@'-(1.N(IQKYZB=N6T',)G/#1N*]Q&9 MQ6F1YU$:01I1F$."@MTY!4R8>M^'$3&-=-A`>YHTNF].!Z+W1'\0F)P+A=.X5#R M.KC:/^R;Y37M+\=7MO+I\D!_1_%-\Q*9Y.^`/8)H444#C M-(I12#DLBF#`'\19JM>`?C*P=03+J%-]BT?.:-;[\W:+;G+3M%+VIEOPTSY> M/14&?:_UG=/CXU=H6V,/+DAI^EOG-\)>T!M\`3J3P>J<==P1?.ECU=#7XS2E M2?.D>'&UQNC7@^E$MBS2-J%4"&QY7QQ"Q[+^1J\V5_I9113Q_>MY]KQ:$X=/5IV\[GA M/&)GV\7!W6&_2KWXE(=\E(J=/!%3"GCG(\%5@=BA2RSGCK,L8GG"8A1G'..< M\3B/PF&TB%'L8J;WZB#>@TD[M>]E97&`S,DT['4.;29-3LES(]J3F(!H3Q>4 MB9R2UEE8H92*:Y*BKC;;ZZ;\>RLDC7T3?UW-K^_*&8H@1"(O+Q#&812&(2DH MS<.(HC`NDEAO3[C)`+[/W.PP@184^-+"TNTG8<:=HL;XIDU38;09\Z,P+[!R M2E]L2)R*NEC9\%Q;[`DQ5A;QO]L6."%%48+#,()QPL,L"A(>#<,E.(AMQ$5U MC+'U10(SZUMES**9S/@@T%)IE+@;16UZ5-2/-\4"8[>SJ3-T&7N)%768T>9RFQ.@:<5I>C"A1EA:R;595 MV31X\?=VU:S:HK;,JS`B,8T1PE&=%;XYPOO59I43N: M;CUA3%/!S-B>L)89&J2@:C94J1W/^N_Y]X9O[S9U];;Z5C:"V^;=NV*X&(8R M6@1YDC.8!S3,A:YF8D`<)JS("%+*K.Q'\:QG$AOHP($=N@L@\.DX]IK!4W4]!6 M.P-J5X^)W<+%.Y&+O]V4]\TL8XSD,(D9A'$.649YG`\+)8@E>I>QF@XR^A8Q M"0VTV"S74#6(-%K.\,.A[8J&$GUCK&KLZ%%?V-!G=")SK]_-FPVN MJNW\;FB&P:(T#G*>)RA)A:#'J9BDYV$JOB`A#VV7C3T@\BRL[,=#V1YHG;>@ MP+JSH)''7:OMNI'G&^5IL')MO[;CPU_&ZS]G=I6+-:+>!##8(`^M#E:`SHRV MB;\T!'26G*=M@Q/Z]1:GJ;BN0X>MFLYXO-K,D0SP600KB..,9RZ,T[;O])@G$H>:!4U>CZLB(T0E4 M`7#7":AM5O;O_Y9%8?A?X%HB%I%@"98=9DW-=\:[FJJ?@W`]W1X02MGM^@E< M`+(CN<<)O@Q(QRX;*!)X0GE=NV`BVNK5IL&;S;K MU?5V(P_*7=6=>@MLG6C35;.XJYNMO%QC`,7P_[-W94UNXTCZK^"Q-T*[P1M@ MO^%BCS=\A\)-7%`D@`1-7V/$RXRP>^_!+X M,I%,``EF64:C.&.,1@$7N7T/*F:4JJFF62S&M?3]\7N]"2KWOX/6$K!J30&K M"UO`H12K70P@W%P+[M_RU?;PK?GE5;[_4:SS:E'__?^ZH\O?RJV8Y]7OBBIL MV+MRVNR.6]44NW-B!QS@>T[\*-RR.RS`!>CYY'L2QP.B;L=WCDB])6/+.9;' MJ+#PMJRJ3-!$2S'^[BB`?+CMZCS5,H)1#"EG'F=A0%&4^8CV(X=1F(W1_DD# M&A?X3A#JB2/$N4<(RA/$61;]$&?/KFPMA#NU?/58].@:U4B6]$)\GQ_.@]]5 MA_>"%H%$4"3^_LV;NC"75X=EFF2`& M#2QM37CM<5C\B>UQ(W[TL4X5RIT46A)F813$F/H>QS'V>!J?L@82X'!Y*`^K MK:[(;02BTL>0DS7Z8OVX3=VH_9M]]ZML[)SV_*@=WV^U2?_1^OYL%3B;U?BR M-0QTECW8'MXU#O36.96;,[;W^>'#]>?5SV5$(Q^G-/4"/TXRAA+&.1$_9)#PB(1*QY>T#FRX MF[67]>U9UC<7@%WY:C-,HO1&6Y,O',F[S=@VN"G62N#$[L3^VZX'LQC!,$)) MEH20,(A@ULD'Q#"(=?0DRHXUB$]UP8WO@5#EV9!5J,D:JWVT<11H_HP@X M#9(&TQ(E/D_JBO:_1_N M`WY>-?B6*>&)AQ%$*2(\CC%,,M)#\\-8_CX52W@,)]4GA*"03J\78) M:C.4)6,^URH7OISPZJCBU]M3P>32ALOBU]GSEW_E?>O9QI3V-(.+CAQ=!7/" MH>,J8?+;7_#$HKZ[;A=M'JZY+#:68+G2F''WN5<>,V_RTR4R2W0K?$=^!,\? MJV)78_BP$[]]6U:K[8?K1_]@#_)NJH(18U$`TR3U*!+;$YKA^)2J,.JK5-/F MP&3NX&-CH/5>!NTN&NR#F&]".++IG)6"!_T7<[O#R#>>NX!B%GA!AF(> M!#"A<7T3?G]0%*:$&?O@HX;"<"!B1O:BLW\/&E?(,N$W1]3%@J$3/AM-H59O M;;L[3=X"@?4900\'""..*>,0^OU1)1C%*310W58:WU9]^U44MB^9G5K:'N4E M)Y5`JX%CRML3J+14X.X0+L6^&Z9QEE(O">MWD3$\'5R$OMB.VRMQRR)RIG-D M(5<[UM&U5O$XZ>K^[-E"Y(LNQ.F[5O$VYUI?K=W8(U?_V[(]E8!5S5 MB:^B!JYLM-8J^#C*[=?![^0T09;&(:0D8(1"&HN=3-0?_D(>"KQ9*N%*"/^J MA8]UK>5JN#&O.E,/[Z__>]$5<1)X<<0R/Z5)TD/*DB`P6!M7PO%7=5P#R_KJXZ-\YXC26#%U6HU\`KW2JO'/ MO+CY5M^G^D,`N,G?'^NWI#Y<-V-6'XZ'ZK#:U?-"AK]\'J4]IM.C!!?R!VTF-:(,J MK0."8,Q#CJB`.?M*2U-=]635OX_%X=>[_/"MW+0/1J?`X=S3+D&4<6N#'S[A_?,DKCQ.7]X<^="';?BEN15-0OU0@! M6L:9EZ4I"WF8>"GW24!0U`-(`ABJQ'%]HQH.X&W85;EMMBLFA>`KJ^+;2%^J?KJ@SZW3-%;TQ[1H[0+<,()SD"=$-A' M"%26UBE.<%I4)QDF):?3J9N:)RV1Y_DH\?R,P90DW$.7_L&,:_ M\U]*X-&D`DKP.2F_U$JEICS2"2$;N@%]*I=.BY2"&7(9GB(M\N]N'\0B:T3O M.BMVJ]VZ6&T_ENTS8J'72=@((>H3S[<)D>!M8:%II=V35Z;7I_KO3^@F37H]XNRW_%$/F6;EGY?'K MX?JXQ>MU\SK)IWR=%S_JZZ[H<5_?=K5DT*=!%L3,C\(L3'!$D[`'(;(5Q4=` M](YMO(WX!+=Y6G/3`0:K#C'8GR`K)A&:?2`GCO.1KZ:2=UGOD8(>*CAC78`. MK66Y5&)R0#?->,01`35D7&EC4BM*ZMW;?C^N]A_VC<)O_K':'O./W45(RS"$ M.,;,3YB?4H(\BF+>C\X3I'CID*9!C8OHO4NN%_5EG.!'C1'\-KD_2A?S<@HZ M`^5JTGGF^JKE6F`4*QVT*$$#\_P^J675E&-O0"XUT^^(3NJVJC0Z9R9GX6X#0@*(U]OQ^5>5@QNYPXF'TEK-HO[*L31O!; M^Z-I,JA.\QCY,\KO1-GK6A?.X&:5NOM,24O<:(J=E+;QU@Q*VD22)DG9FZHZ MBA%A0F&(:!0C&""2091AW(\804RFRYCD0+-)6-'@TRE?LM2.ERX#G.J1K1:8 M`Y+5`E&4*T5:'98J54LD9&H4.9,DZJ(E:YED,*)9"AE#4?V8L-#%T[!QR+WI M.J4RVFQB59Y!ZE0L):;'RY8IBO5HUP4Z!P3L`HVBBHUAV6$I&V6.A)Z-ITE: MU-INY.'=:^9A[GD91S")(YAE":.T'QJSB*L)FXX1C8M;UZ1MH*:FA7`Y?;/- MM)K&]7WP[I72)'@;T#N=K#NB>5I-*LU-TO':]V";&WL0IP1&L<]"XF&1/'QD"DC6=8Z;56S2>PJ"YQ16J<(V]S%L@&.Y$1L-+/NB==X4YX6K8GT MC!>K;K.+6((S&M*`AT$`8T;H61MI&BM6Q\:.,H](3:N+C69TI#@9H'*Z,"WF MJ8<]08Z*(BG2Z:H:J9KQG!*-HF6\"EUN47E,4X\'29J(/6J`O"R(3V/&"8TF M2I'*4//HD8;2US2"1RJ3*69UR--\):\AFE2$:@R[KJK5*%N>DZSQ!$GKUN=] MOJJ.^U\7HRX)3Q@6_SHFT(OB-.-BW%-3AA\JMD>,&<&X2O6@[NG42&T:1:*< M))EF3TV)3K3=T2++\O,()0.J,X5`1\1FD@FEOOFD?*&2&*CND:TO:MF6XC_R MS_G/`Q&F_6M)$NB1Q$=>@GSF^QGQL=><^JDECF+EN\(G#&5<;-Z\O_K[)_R> M/#%E5^48D8;?YKFHND\)[@>FF.3%5D5_G/_-Q]:O^ M&?YSM=^<8<90;"9Y'`4L]1'V("6\JV\A$H=)HGISJ4UL*BMXQ)'HJ^/W[ZNV M:+Y:'XH?]\AKD[1G?]859X%;\Q8&,P@U/RFFJRTY4D^$+\15N:W#^Y]<: M*+BT!ER:`[[^NO,'.Y-`8Y.0\/I\#)A/R#7[9D#[YYH%CH2+VML3*MRH#%',6[-ZVRY(/9B M_*P6T2Y=_%0\6]SQQ/ECFTF7#00Z)V:*(U'/#2[N7__@ M!*A)\?!!0&YP?;AMKOZM>Z/:2%X)U6Y_=@]E0OV(9AZB8N<8!A3&)"4]2@^& M2M=/688V3\PK=M?E_GN;WN_S&V%6_0VOJ9J#LK6C$<6K#U?X$[@1&=3ASN>^ M:1'1N+M'Q4"7/*TGZMW9G"VZL-89M``GD\"%3D0]LMMSO9BBS9OUP M\++KA&EO(GU>_>37U_GZ\,1#%\L0P83C-$Z(B*$A833",?%1B%!,15R%RYU0 M7A&$Y6N'^C%(B5+:BM(E7/EOBZN?(&\@UJ_=E/>>3]/Q@-%T/\C7_69R@-8' MB&J/\,XC3[TYY,*C0L]1^TQQSIRK'%%PPT;*//JCF5)M>OS@19&A!XF6E$90 M@(NS5,",&8QX4(,D"*6Z M:,XN_5DK>WB0B!'DL")(` M^UG@DQ1'07LC<@93$OEJO5&F4!AOFVK@-<6E[I'DYAFY.Z\I-Z>-UUW'^?"! M6+L>4JTKS>>:\06D'O/Y./("G'W6/SWJ4)E(B62I>I`9MSFB],;-?++"8Y+6 M$>I-CE6QRZL*K_]]+-K;LBORZ^*_&D!+Q#WLPXRE/,[\A/&4\NY)(A9`'F3C MOBUH&MSBUX,>,;B$O*C[@2Y^T.G"@!A8>46+=]3TJP$2*?U=[5C_5J>?6O8KO--^^/>P'AAN8[H4?O\OJ]QR5+/,_W M2!*'J8=2%N`DA/UP`0FXC,1.'<.TDK;(0`<-M-@D97(R?\-J:),Z1=%[E#7P MI04F&V4FT[J=1"K*3%;U>P:T?N7@U]_RU?;PC8KLO!WVS6[=C8P2%(5^A*@?^`%. M21JEI!^9IQQ*B[2>X0SK=0L2M"A!"Q/4./M%(Y"JR(\FCB6$W#Z]:IHNP^PH MA==$L8+8VZ=ZG.YKHEPN"DB1\E1`T,NH"[%!LT6EL>FG6$=Y9"?Q5OS@S2'_ M7BU9@'P4^X@E,/$))01"WHT98LR53B1,&LATE'AD(PZ^U/!`@T^U#C*-5+F: MAS4^%"J-U#&&:!JH66AAUY'ZA!Y;2@/3;Z16T?+[UV+7-<6ORYM=W0O] M9B,$L[@NZL('KJK\T$+;YQN\V[P5/RZV`F5>-4V'=??;;K/$<9`BH:-^$J,4 M8B_"W=%EQJ(L"<@8?;,&SK`FUAA&RIX]_ZA)I9.N&2FO%[;4!Z%Z:\"E.:"U M!_0&-5_^+DP"G4T+,.QLH\*LRRD28F[=_XX%`/OV/Q$T9G+$+(&&'(MM?=2F M6J81CKTHBCT!,DUY1#,4]&`QITHW4,R#T'@:W@&9,>XHN,M^\#'C*2B&/@_/N#V?1\E`>5ENC46LR1J6X=3)'6OD^UW\%W(K?_;:J<]HK++J.(O1:@%ZRQ9/!RYAW\L(6<]Y27_0TC8O7G;8TD>#GL"E MV2WRQPR>NXOPJ:L(N[LN+MX(^%1NMUFYKW]SB<,0>G$4I

?BN#=-T5:^RY@+0#+UTT3 M(`C]!1"Z$BF=F+#NO^%PY;[31D0I0(:C%.FB5/?G[EZWWMIT)T2U5KGM9I7C M-"Z[>^0AG#G<+GF`1S/;3Q[[FXO7S!M.#E02"_\SWZZ+*3TB7?L"('_I^E-#`RP*2!'%ZRG*2(%2X*G0>@%)J M-?FJT!Z7S61BA+/,IQ*&'&0ND9#9>)Z,`F_Z..*VG^TE$&;];3!]T.YW*XG# M`[H-I0WCW?H*DH8)QFM,&::ZP$K"D)7[Z[QI]ZWP;L-_WA;M5;1GT,S#*$(H M]#'T:$"83\FI3,)(G%E.(*8#MI50W#8MM>4>K.OWA.OK<2S&'`U^-9]K6/+E MO-\Z+HP$N&ZC/YLY2S:B86;8RT[LSI"9/X],G"E6\I=G'6(HG]$W$5Y!?J.1 M#(WYCFX7S=2S04.,J9=D!&5>&GL<)]@_)6D>[WLV^.Z95[#F0:?>L=$;,JY? MXTI,]:YAPVL:-N+_MY]T95WS"@1H@O%&/^FJN6".UNA_YL7--[&CP#_R_>HF M[_>('^O3*G5[VW77WI:D60I]F&;<)QD7N@E9+Y6<(JSV0KI[\%]F2_4"]/:# MCH!3A0DT%(`O^&MUV*_6AQG[K;5-,>N]V'/,+B?ZM/5,+->;N"7=:Z?!6_=< M>WW-W]H9,M<8;L:9MC<@0U8L/0@I]Z.$,R^!B'$<^+R'3J(8SM9*/@FUTPWF MMO/KVMOHH<3,CD>CNS3I7*7203,('Z4LI8$/$G2NIC0M?IN\-P.XZ7.')W?HMR< M0>:^2MF>29H2*FUN&IU4V9\H+R*QFH$6I>1J+K?92;`>]!L-6A#'418SSR=! M)`Q!"8RRI+<@HEYL+2LXRE7V9F3&O(0$SQ(S.',RD\]QHJ!XTB-1/GX7,]Y.( MTYAQ%L;1R2#$4UN'OMH,<*`MVYKS76[9MIK>S3KC'&KWMC;S M7D(K^.S9H$%GSM5&KF6"O8AXV?I=)8;2LSD3AK=)9=1X?6Z/.X.Q>[F8[DMUD5> M?:YQ+$D2T2##L8?BB%"/I#3M^B*BB`54ZM&U20,8SEG.L$"/"WQID,F>NY]& MGT1.88,YM21@;M(4@JL-\L9%PU$DR@6M)XQ^*LI,YV7,PYA@'OF)EZ4^9V'8#Y!F4:)R5XO\OVI88AL@X$L-1?4N$P5F MAH74+"EJZBG'AY$K.$[F/R(%XRERY,**$<#+J;-CS$I_UWP>7I(,Q22)48(X M8AYF)$VCTQ!!IO2UL_+[JMB-6N^R_"BL>`/4C%KSS[)B;M6W%#RW M[A6)HBF#S%%ZK=&!!M[$4J("EZ-JL/]'W=4U-VXCV[^"QTF5 M[UY^$]PW``1V7.L9N6PG^W`?5+)$CYG5B%Y2=F;VUU^`7Y)M60)`@.)4*HDC M3]2G#XC3C0;0M$.C@3KL.1@<5)"UPZ1>47:?/?!0E*FW/A'RE5IV\:59K M-?PX7K'5)48ZB6N.-\T>;ODC)BX9_^LQ7SY2CF'[<_:4E>+#>4P#$B.'>5Z: MI@[U&?-);QIB9_Z2E?>%;')GPJ+*%-H')SV#&I"@>`!5#5.\;_4O`11D-5)0 MM%`5TT(C=,LEBV/SK";Z.X)OWQ#<0`2SDP1;R2TE6#N2<9KD?")YJ%&7"GN/ MJ$K.VMG]^EQ67&P)G]-9R1;+?)UON>C./1KR=7*"B8>]!./88P[M;.*80>F\ M=:@AR[GK;A)N&H!@62-4NDL)$CY*84UQ-X4TUI@OA86'RZ"LS_[:9*NYGP8H@@Z#GH\C&CIA MX'>[(J$3A/)]_HQ8.Y/`@X<>)R@$4(,:)4GS<-4WS[!QZ0>S\Y!K+@J8)]E: M*#A%MI&`4-O0C`IJ7/X"H4'1(87XH$.5D2!QE8E3S7/FPC""KDL2%.+`(REE M_:HC9)[\I6LSYB80)M8U4H-2)LOT\$!A@63SD>+J7/R:BQ46>+87+$[Q;21: M-$8TPX4BG;]`O%#U2"%@:)&E$C&*AZN.:0>7$2>=A/ M$>1+&Y+X;MK9AR&5OVMKTNAHT6/=@NW#R#V'"SC>-IZHJYLAUJ5CR/B$ZY;- M.YR]Q.&.Z]>:=S;.E>/*^-P/BBY&QD`ERDCQ5#A]H`-;2-C:M`T*(97J-10XUFO7"Q7LN9*/$`!:G M&!R&N',L)@RFZ60H6&7YO-D8OQ*,\H>NNSSW./$((IB0(,`Q)` MF$0)[+XV#.040?:[+"O`[#$O)*>[M/?'I[<-Q]6F\^SSY6S0W!4NB,GKUC^) MV>ONS=[6P0.S5=7U,\].9;B%W@BKS+XOL[GGA32!C@O3*`DP37!"4/>U#G:8 M].R3^"[+L^]+7HG?Y2HS4(8!B1EHV'FU&?CE\O9V]OO-I>U9^&7VT2Q4<'\* MLU`%;J$WRDH%DWSY6*P7U4N^7F?_Y&NTY^6_?[87H(B?$A+$%'I!`''(`NI$ M_:PG5"HX#C9BNT2R#^T"=."4UNY#*)2IA8S$GF(1Y#!Q$K<<#3.H4O88B4G- M>H>AS`M2?/]>;*KNHGX4 M)9X;,I$,^XF7A*[G=H;".)0_?JCU[;;+.@TFT()2F?EZ9$EHHW6>%*M`KRG2 M4DD]KA2DTCIG>GJISIV<:!YR]R/E'$3-%.1SF`.%J:=$>7<,]T7VN@%B`AU$ MDC#V'<88<@(_<9/.CN]"K+8]IOCEX^R/W>_O_:AT)]4G37:+S")?6GMD*E09 MVR5[3<+1;3)-OB:S3Z:+_]U&V2`BI-2B^_ZFE277HP11Z(3,C9D;(>8P0GH+ M"90JVVM\K66%V#WL:GU,=0@ZK0D6N5%3`P5:#*C`:[<_F/^:W$Q@YNLB+P8_ M&"J+K,_/V^5COJF*S3\7FVK1I2$I%B_]=`(($?5"WR4Q[M,0[/A2TW[(]UN> M_SM4%Z#!I;)^T.5,8K4U`EUJDO">*:TEERYE"HNN$:C36W9I42BW\CKL\T=K MKX$,36'U-=2%PMP#HZ*R_RBS;'-H_X"OZ:*81D',PL3A:SXW17YKC/FA*]4; M=I@%RTJ[PZ6WX:K/G(3:CD*:FMX>XDM+ MP3Q-07N'.U&8?'34LMS-MMF_1?RSQ?=%:PLZ$0F9'Z<>#4@0>S&BW2D;QC^2 MOY2J:\!ZGMO!N@`M,+6L39,VJ4S7/F.JJ>X[LC1S74W6E))=^^SI9KLZ+,JF MNP>]_CC?'4;2%$1WL`^%P:=&L8/N=2EZP6Y_WC[?_YDMMW?%K$0OBWPM#OFS MHFP:6>:;;W6'@KJ>&<8A<4F00NJG,4%!@%G8`6&,4)57)9BW;EFL.\"@10RV M!1`=JCO0=;_J'G;3ID/OM6L6!N:XXD]C3-3"@97AL-*95YG5`X)I?X0FTK77 MHH/%6`^[31UN:\T1C#"F?AA$@1,@UW62H*V"4` M"WIL863&4.3SO)-/@UE3JJPX3K^B+JNZ.$29M>@N0],X M0=L8I2J7J%&8MGD%_W\SLP2JK1;2NKMKF>+B2OA/.\[S"3(HZ):D< M0OUDQ7&04R?E<#AE"N]*_+,H.P1DO:BJ.A5V8PSC!!*7/R8X<2&)`])9BZ%: M_JEIPK+$U:A`/Q-K7'K+>5T*Y;1L!/;4Q$N+.$NO6SQ$S1%Q&LCE1-1HJ!?O MWL1H@)0!>M,F>#&##G$2QW$)\JE+60B#SAY7.J7WM6L;.8OFZ"U;]8G4U1T+ M')I0GO,L,#^B1TE]%!F=K/ZH^G%2@;2(D=:@J\5FA38K_)RO5SS+ZJY^I(1% MB"1)@B$FQ".NXW3&&'-\%0'2LV!9?6[_+;:>5F]:Z2O*CB9W,*,Q9Q:OJBQYGQ/HE71]Z+;(*X"=P& M&>S"AST3=>F0SU:RJLHR40KBLH7*DC]`F3@75+TN$U5W6?E]]D"*S;9<++?S M,'32R`LY3S["H>N&7@C[]1OSU-(9.Q`L*U)31UU\*[,:+.!?\5TUV['$O60Z M='[:%?.E&C!H$8-]R!=O"]S\$X%;])SND(^=5&G1>RSKLCM>4TG++'OY-F\; M@U3)CBBO+,Z>A/QOBVL^&1[Y?_?_+O-E-D]AXD-A%_J$VV00.7TP\'$J_Z9F MDT8M"VX#3FQF/;6PP&(+'O(??-'Y)``J=0DQ2?9QO3TKSVH*^T9$A:IVG'<0 M+_J?P/5925?IV'(F\C4;N9@+_($'0A0UCB>PA%M*WX5EA].2VN`FVR3 M_;58BU@X]](TH*GC1(D3DH#%`?/C%HKKH4"JQ8Q-^Z-D_V4#2+SZ*B]D7V)I ME76SJ;\MPJWF_2WH.O^?:,Z_QZN!A%]GE'ZQ;%_+1_=BS]IH:_.ZUI%JSIG$.'$"&#DTPBQF">KJQFX4,_D&'09L6=^TKA&"3?^. MJ.7B*=_R^;L^(+%*G3Q,$"V1VH_,L>JF=D/O[M7`3>3J1/+Z/+0J).\CTZN7 MLP^F62Y//\W%1^FY01:GD)6;=*>P\[`IYN"W_(FKP]'LX7*S++YG:+,BQ?>G M,GO,-E7^DK6?WE=-!2KQ`\92L0D0.W&(*$8LP2[T(0P)A7$@F0F:-FM/R7JD M34UW#R)H,(+_ZU".O7^N2.*1E,_6<$PDW;/F7C'.4ZU^_>,AWUX5536G,8L] MOEQW\/.0NSRA=M+5MX7"K<\9+]894+N8Y">EU_I';C\2F9?Z/AW M"5H2CDPH#:8F,E=TD+\_^J_GO/03/ML^9N6!F25L?LWX]+M;_&@")_^\K"]< M94?M)UA?U",L\7CZY;J>PP+:(0TID]K+/B,\R_4Q\BCJE"#?@(=% M7H*7Q?HY:ZIDU2-X6!=_@<=L]2V[`)M&@;:+'X:"A,TA'18T)C*:QH/(SB\@ M'&L_!\4&['D'6O=`XU];6MJ/0!,)._JCI!&&1G@D)AZ6QF!`,DR--AA&UBDW MV5)<"LH?\O;="ZL_GZNMJ!XP3CZ:D+/%=\V MM?QQ\1/Q+*\I,+CHL3;6PU=!9QUD6Q'MK5,`[0T]=PL(O]X$N`F&L@'CH[FD MLOTT3#R8C4*!PJ)KG.$P6G:;>\P)L(_#V/=PA&('80=VMGT_)O-ML5VLS975 M3AI46BGUV*3EZ$[\+Z"H16GY2I2,AQ%YCLU5QXS2:['^-2')'JC!RLS_`J*J M[I-&:4J1,&G9.V"V,\G_:_TL;MY>%V4MT-MMF=\_;T73M[OB*R=.7-THUOS; MOUV*B^E9M9VGCN]ZH4/YFD-T(0DAYJK<+38@=%44=@3[Y;R@Z`_.H*I;RB&G+1SAG@`T-W=S27^_0[A*PKN M9B#EO[NYO23HAH+/%%W=?:Y_O*4W?UP2>GLA_K^_F8LBI[D?'!&,TFY)W=]J M^?6BY.O2Z4BWG@Q+,S]]295W15X>%>G1.89*%M4C6Q=_5?V>LA^@A/@)#"@B M,8V\,"5^ZI/`(S%D+$C4SYRJVQCK@*G87JV13>)8Z3N>Y,Z0ZM,[D5EEQI>/ M3X<.)4AZ7O%Y*VQ=E\5+OLI6^.?O5;:ZW/17C]!RF[_DVSS;(4E#&B$QRXD' M4>!$;ASA#DE,D:]V,,X"`.L'X0BZ_0S8U>Q?MX#=S+Z`V36]07>77_\!$+F[ M_./R[I+>JAZ)LS$0N!B_V(].\$M61?/.KNCA)4=\5-)NC)UV*=OP-W5Z@&48BI!YTDQ1A[F/*U3$B< M7F822-6F^%D@6I>"/:]$V:SL_&JC:',^J7T@1*:[4POQQ\7QM/H,]M-^@OS< M)M=5ERKG>3+D%C.3?R34ECMOGH7>H;K0^JKV*G[]RRR,;(S2D7AT MUH=B(G'KO!P4$YJEZ@NTE[SB\LJ*,BV>[[ESJT=6'HUBC69\>;^X-D60M%:EV4-6ED(HA8SRQ0']\91M MJ@QGFXRO].?,]R`W[?D412Z*'(X!=V9I"%,UN1IJS?ZBN@789<[;Q0]PWX!3 M5*O!Q,H)UIB,JFE63V6;=(H+Y2TX\*F%]]O(RG6"K2/B98KGB>B7,7<*.X^C M>M'PU=WQR\UMMGZXW%3/Y8+S<9-56?F2S7'@1'$2LP@YB"2442ZEG74OH)YR MN="$T9&SL(IC_)]<@*R;C1IB@Q3E^#5>"O./56Y/L3T0C37OUOF)K MGC2YOJV[-;/PFO[GF4_Z+]GV433A>,G:939?6Q?-:R+$D3Q1++Q>Y*LY1"D- M:<@XHYBB."413#L\;NA'W5WA.\F^KC:Q2$WGU[>"[S1>Z%5C[B[Z?FHRQ]_` MFKN454)&G\4)WZI8YRMA`2P>'KC,\A][G.R.XV1TQ7BO1)H M71EO![#!#O;`]Z=37SD`A`>3&2B%_K-3&3"]QK36!TZN<>T`$@]$T-'&90JM M;D?QLQCY@5>)N_L%GJ9#^^6&_ECR#+PYOWG=IMKST/$BYGHI$7K[.*:= M<<%:J%6+<62C7"VC&J)<+7++,?!2EC#,[A9!DWJG"YL.HTUQ#7##D MMII8V);CYDE(8>@Q[/G\'Y@RYKMA9Y#_134Z/FG9T8@G:J&DAJ;3+T./-KEJ ME66^!G3&:$'U!T5:7&/7Z3\DZ$@1:CBI$ZD[&7#D4*<+`]0,J,?WQS!(\TZ< M7<-Z)W9#'.$P#D+7\X,D@4&'((U].+0FKVW8>EV^Z8=:)[:+JLJV%5AL5GT5 M7IRV6CP\9,OMWHF]08?P3`Z*;E5^E-$P4IG?'7]KH9[O[)L\C4HU^L%C,1&] MM.'9R5J](?(&*.I-MLSR%W%5OII'Q`]"/R(H(%@T*$IBF/3Y8QA%:NG<,%O6 M4[H],'4%?;`,*C&IJWS&*30I=GO@SJYM>UB4Y$R'X,DJF)8S)T5+GZ(!.G5= M9D^+?-6=#&DS3[19U5DIJC.?.4K")(4TY$M@#L$G+DJ\#@V*0\4.Q)9`6%>V M%B7(&GA-0MBT@6PRQ,%29V8P=#5PO%$P*8[=J'2'U\2@-*ME=&)01E),&5J5 MI-3H.$U68\UZ>5)\+9`Z0)6[<\77BY\B'G`8_)/RF2O6;OTY)]@3]P2CD*6> MQXC#"(XZ-#%Q(Y7KY98@J*B!QE7TNW*QROH+"V+'J>Y-)21@T8#MQ7JP-IL9 M$EUM'GTTC&ASAQI<[XU,"QSL(3^[1LO0JZ311L=KLAIMULN3&FV!5`M]E4A_ MDW=WMWL>DR1&)/$8S^,IQ=1+<%]WH$Z"5+HW6H:BI-GJ#1Z_'KK/?/#VL[6& M2WHC)"?=$QH<-0G7:,1T`78^@)G$N)VY*=,AQH^H^DA#.1%U'\M;[<9-!DB6 M;\0K!^EP(X\Y#0B)0AAA%!#D$!_Z;A^"6`H]E<3<+A++^;ER$YQS#(:A$T8)<2`F81)Z M-/"BOLCC!="QDZJ?-'N.M/S0N09K6?EIXDUGX$8YMYYM3S:M-I)"2X_%1+35 MAF?:J;$B>4-5L[F><;AICT,CYD>!QPC$+'"<%.'^8D8,?<4&.A8`V#\X]J:9 M].77/^BMG6;2@P9BD)J.-0)&5;4'/8F>:>K,J@NMB6&:MN`:\5!.>,V1*=^K MK+V"<%>@Y7^>\S+CF+C\;W]>\^=^BS8K<6ON2?R1>1HD<1IYU*4>2?TD0BCL M3XR@R$=J9S0,&K9_+H-__KAH;W,_M3CKK::L`ZG:R\P@[7(R.S;?>K?16I"B M-64+$W0X+T"-]*+FG9[FW4[K,VD6CTBIA:&8B(3:\.QMDS1;Y.E+)GZN\DTF MNCW4'9:%LK>_6+((,D9@%D;E]M0$3Q9*Y1T]9ELT92Y?5K&C\4 M3K!]+(OG;X_@OG5%O/'X/M_4U9JAJCIH9#1UU?J0&%/6'=)=OP21VW9PSZVM M1YA445<3`S)5?37BVRF%-4>@2@O=99:MVF;V=5:\?2ZSV<,.R]S'#D:.EZ;$ M":$;DLAQ>M/B;\67GPRV9WFKJX/8M#ZI%NM,3-B5D0TP(W1+ZN7(3"O*Y"N2 M]_`)KG<(QV^X>XJS8X)HD/&IZ*!)E]YWX35,UZ!+7GSYGR]YZB54=PX]XD8H M"A+'0<3!?I3B9%<$<,GP>UY*YJQGD,T567'0L^R1U9M(!NY\J1$K)V[C,&KV MYE?/*SG*ZVBWO_;Y4CH1JTGU1"3-G#\2U\`&$*6\3&9%N2^I]6V'`X7.N8=B M&B6NGQ(8D]1S8A>17E-1XNBME$U9MRYU:?94\+7R_IVO5==!^WZQ%BU!E;,Z MTR.@MB(>E?IABV+19NS3J]SOM_:*UZ$=G3.MBR7YE%@:FQZ9B4BH-?<^6"#; MH='"WOG!@ZV0!-2+DM#U/3_U<>#Y@=^A\B.2&CB%9`K*.4XF[5Z`9O'J@+&Q M,KW5;GV8K&^[3_KJ@"3C1K;C!PWE1)1]+&^UM^G_G[VK:VX;Q[)_A0_S,%OE MF25(@B#VC03`&>\FML=VLM75#RI%HA/5RJ)+'^EX?OT"I$A)CDT#($#"3C]T MQ[%CX=YS@8,#X%[``,B]2@>>,>F%]->48H@A"?V(T@@E.(UI:Q3P(]"W=,"< M)6^V=,!@,.1XW9TXJ-&Z,J6[6SH@#;=BZ8#Y,#I"Z0,Y*U$Z8`MB"T)^0EE( M69P1`K,@!3D$.&CO:T0XP79$^ZO-CBO0%RU7F"XBT`J!:2UN%'WKNMM9@6U$ M3$O'PA&6M>&9MDA6!*\O?^:+U70U>SZ;EJ:AG^8))W'Q^"^)(F-`%?%\U3+)=W'\K5U]MB?4^++R(;=W\][DTQVZWK28`%.,A#%&]6BT:>N'?*VU5>H6-],KORP77[5V'LR"+D>SPZ.M1;`',P7. MPM"_;;FEGC#U[.COSU=L&SQ&3((X(PUG(HC#("`0Q2]K'9;@6]]6TKCT[K$O> MT^3.Q=[XAHI[I,P:CH=DFH43@5!,N#B)P/E1!$Y)^@7ZK/I"G/U M]N.%I+&>P/34BS??IKSG?5K-1:;:C-NS^"YNN:V^G?%%T)R4]^(ZZVH9)"IJ M-_R?+7=S;NW-MIS]W^7#_B0L!B#P4R+RA2,8@)"`-J6-`J*X?SJNK=9U9ZMS MA*I9%_/B_J&IB>5?+LO'HJCJ845I[!_3];Q/]=8(H>XC5UV,L2E)6_OF[81S M7NM=U0FJ'_WMBW#0._:PNN*`R]S62:_RTMN[Z83T-10R97D\=%=Q92)R`PPI MF3U.B'0J4JZ+A_V=+I=WUYR1BWMQW_O5>E]Q45DS26`4(T`0!I0$/B$HS8/# M3DZ8*+S";LL$#?6N\1[[]9F'"VR.6::X;I^M%K;13E'A7&8]+A\YA)[9;T`MLQLNOKS8L[)P9`ZD-E MIQS*A6W]C8*#4YM"TCQ%(4R#&*`@`C&BK+VC,['&O.Q=>)US"<&GMH49409"W5L6M1JSSK%T(>[O^+*K M-DO$A7XKWG?*U99_XE+L&2Y6VT+Z(>QFJ4:A/KX'=*SS MM^>QDB#"GB`[QGE]O7GQGD,#(&GHRHHPF\W3^BPP!9P\HXS&:9HQFB&0'0K, M,IAH7K&MU=1@2E%L!GE*147`]P':.N?KZ\J,MZ`V2AQNK9JQ`("`F,:$*"(/0!#G.$VA,=D.>) M@;I54Z:H#$_SM:QW;<*/Z5I68Z&2HTB'HJ1&HAK564[?-2.)>`-V=.*C1NC*ENWO7C#3<'9P^3!@=H?2!G)6X:\86Q!9T_"0+&"0, MAR1G<1X0G-,H;2Q(D!_;T>RO-OL+Z?/70V!:BQM%W[KN=E9@&Q'3TK%PA&5M M>*8MDA7!4Q+$5079YIMX:.S[="EV8JZ*]:*@AA!ULI"^8J*-1X11^C4 MCF_/:%1+`/:DU)0S_7K]R$G]\W2Y*R8!@0QA`)%/LS"/$YKG;7FN'Y%@\E`9 M?;.=KK=]&%6U795Q_-1$^2']$FN>>5^*KXO5JKJ<_,ZK&S!"IUE5YEIA.<^00Z9;+4A=YIEM1V2HH>^T%FF!%]E*,FG`3*OJK-@8:((3"_&$SNML^(9'J2S^;VJ42CNE-4K5(),> MI3>[AX=E(<[CITMA0;XL_SA?W97K^VHCK[UZCX",)E'"`(YC@D$"8=`V'\28 MJ57,FVI599QJU;[??+JZ^L`^\G&9?N#KO_SR^F-Z>WYYH7JUJ#&8Y63*&/BJ M"95C"VNQ(FSTCHP<[\Y02?0Z6-`T_H[PH'&W2KO=5OG]TCI/]FJZF(LKE7(8 M0PAI2#&-*,4H`DE;98ARD*N<_ZI^MN43W6K$'=\RV21=GWFK^BGUZ7VY$S^; MU9=-+?[=]:"Z&3CEN,TFDFH&-)FPZFJMC\7V MF]C3%J]25*-,Y%TLR\UN7=P6/[;94E2OQ0'T&8J3+,A($%"^1`0D"R%-*$O# M,(Y52,9@LY;)1^R=W/[F?62W_[RD?)'VF=WUPZVLQ`<1UC0AF>E M]9XMR9K3[[/IA):SG6@P76X1B<7M,4'$4!BG+$HCE$40(YAG*(QR MD+SV**VYANR-W<:\:JC6!BKOL-A"=[[_E.K7'$/YQ#8]M(L:[<7!TK]+LZ!P MNN(V'X=^Q6S2,#Q#:.8A')G'+#A4VNIMDJPU+Q:3NK'KXJLHCY^NMA?3^V)" MTA2&.0$IABG_Y!A@%C7M(,Z4,HI.^\-MZ[9ZB!R,\H15DDRDCU@WK0\"EJ(" M4\2I0U-MBMG?OY;?_Y-[*>14)+X03!,=J:B7$'B&6GJ#-3*3]+>_--1KE'F" M<(9:3Y?GJWGQXW^*QTF"L\AGD'\R\?,DBQE*_*:A($1(C2A4/WT8IMA;Y55F M>=PN9:Y01DV6+&P"IL46"E@9XXLG('02ABY@SC"&M@,_448_**0XH]$TM_Q7 M)B1)?`H!RQFA.8VSQ(?MYZ<49[)4H?2AEAFBU=["&`5:4`/F=3:PAHGFPJ\; M#@,C_]CA%P:\%B8.C',]N\N>G4%C5%\U&6ATNBTF`0Y)M8O"M4;@XR1%8B>Z M;H@1[*L.;[5/'VJ<[TL!N%F>L$MCR"NB)C_V[0&F20+26!GD@Q,07B$&/<`< M8@A-!YZABCY02'%&REN9BY;RY?3K!+&0)CF+4!:F/N8T!)*V`4IB)LL5:I]J MF2-:8SQAC0(S*&+S.B/8@T6-"601,3#^3UQ^8=SKP>+`>-<(PK[), M0QDH8R>O#6S"IJD.%!`SJ`^>`/&*0M"%S0'.Z.W",RJA'QP:/%++DKHQWDH8 MAB@&61CDD&5\+8.:QA)12:?%)"HM#,PE>_G<[RBY<2+S*(/B12WD-UZ?<)BS7J'92AA211FE`$:![S9G#5M84EI'H;(@&3L'/?&_\Q14#RD'>**7^3^=@/:!025GXO#L M5OW4Z^5NN]E.5^(!UTD()N(>\J95DC+I4U$#30V437'TX-Q9 M\]KSD9GJR16]X)4EE\&0U>(:?5#-96%T`-2=DF$"66>XR8PW/R=KF`-)N@(H MVVT6JV*SH<5FMEY4#QFGJWDVW2PVEW=7W(8F5?F059]4]ZTF$0V2E`9AP!(& MJZQZ%OD)31*UZQHL&*`R$K5N;B"7%S>7'\YI=5U#==%*EMZD?65NGRE;VB M%Z MB62,_XD`Q?6`]"&COE2VNIF6+*^U#L;M7S2KS//^R@W<=%Q::P-2.3DQ')IJ MRJ$32._WVKZA14(G6!V<9`9D1^C)D#.EC7ZH>M7"_<.R?"SJMX#W3>5I`!GF M2[@X0FF&69@RT#051$PJ1:[/Y]O>#-J;]-KSV>;PDN,AVU`I[NZ$MF; M&!P-F.S]I&Y9;6_B>%L]S,YMJH/&NF-"=+33.3+7NHK.TRMB'373.850D\"$ M1BF`F4]B$,4()CY,,]0XX`=!KO[NB#NVJ]"V]MLE1^=[9QXM9I5R]$)PYHD3 M6/=F:]FX.S-16PCVFYFCW]]47/LU[BRLV*-^G0E8%9CAYUZMT#DP[?Y#W/BS M.5_5F?,32./8)R&F21SY/D@3&)'&?N`G4M=V.6>TY<5X94W7)?-OC!)/T1V% M$34#_.X)41>7P?BP5^`UP/;T0YL_K0C??8BY`!0NWJ6L29MW2'CNXH,W'/CO;N9^2^^`PV M,QL)I`,S].=JN=4JC##(0`;S-((@H#%?>X4T:!4&1-ED57R=\E^X=6&"5K1= MBJUQS=8_N2G-W+51SLS(JO$=>R:V$5/'9^#:96^QVL_%[V;>/8WE*/.M9G=Z M]_.L+BZ#S:^]`N?`O)J7Z[MB<>P"QHPF:892YOLPC[(8H$8:Q"$@P*FI5=W\ M8697,N4#9[ET:(+5"/38O\.9]J>(CC+9ZO>K=S_?]H!FL"FW M;_@6FFU;U6UJ'2/<;6- ME8[\ZR@@._`-KY,L=H,WI:8F`<(I"9.(L2#"D`6$XJSQC6(<.EF2T=^M/ZLU M[/26MR-8C':1=Z-2?D%IXK@>D>ZG?XH0#F_9J[(J5M]XIQI868_8'5_5%CA:9Y0!("$J3E((\#C$D&+1I9`FACN17F?;*LE)VNC;3 M0)\8>Y]NS.[@JBY^6MWYR^W3*78*!\I$S77<=[]/9PVXD0I-38?>`>6Q+^O9 M<3:4T%4QC:,\YI[$,8:8IBENZFQCY,N]O/[&7+*L.9RM6#74(<;6'*/U!5<% MQQ$@OYS64.D,8Y;(FNVM[UYEV$%MZ,):&T%W0%\HI%<1DL9IE"0^B((HB6@. M09O-35/&'"S'[>_4GY6Z?R:6ZO:9=\_L-C!S,;%4+>#2K)YN-L5V0W;KM3!Z M7^0VR=.$`$;]/(XB0'P*LCC(0!+&A$\A&"L^/JS7A@KKZ;WK_NGZFEW<>NG- M#;N]^2_%U94F<'*+'?N(J:T]:GO.O+U%XY5#/@M,!U?W`](1\NSI1&FR;RG2 M"YENOJ6KN?CCZ'0NW9+I>OW(Q4;-;3C@+<=Q!%$0H8QK5!RBIG$69;X:W9AI MTS[]#KC*0!2B+(!I&`($21*BE@8PS`+%B;]/4]8'X,$J/K/Q_VV\ MZ7)9_B%V6[V[@(V_1THC39M13YY6I=/$P7<_9#;`85 M7,E5H^YD835!4>0'#"9!GD:,)6D4!%&[H(H31;8QT:)U[MD;Z16UE9M*)945 M(;F<3<$6XS MZE)IKXLJ\M[Y:E;>%[?3'\61G)M$L0]RFJ4I"/,XS=(@0'N2!3Z"8:;&='IM M6.>VVBQO._W!Q=7=;C479BGRF"9\A:>#E/K! MZ0@-]72B--G#M,ZE+N_H8O-0;J;+?ZS+W0.W8+D39]3\NQR"[6*U*^:7#\6Z M.I!KR"])$A)!@@(80<`B1$-NW]XB_D6FDH%HT0S;68,GBDML7/KL MN=X`X$IS."WN"M[`G$\9M7%'*_,P\!'&/LE#F+*`1>*_=MK(?*(F&ONT9%TZ M-L9YBU9#*F_+]8)2CE:'PE"1-QOPN%DM)7++Q(0FCLGV*=#-P:(!RS#/D88I21""%`?=`T@F,<3K;E=KI449*RGZPD M#ELCI$?5K?B5?IMRBDBI2#L;("D>3CJ@O63EE"I:CA"&IO%=R4R*$"AL]XO5 MTO;QBO>1;5K?,_`@\CFYQ-IL)G'&H)_E/@5!F*`0T!"AIM78AU!UI[]78_8W M^:\OK]CU[6]>>D$]]J]/YUK-RTS%4K$`KNZL_&*:J&_JU86=> M95JUH=\:)VYHY.8-OI??A57G-KX1D!VA)U/>_+1Y;Q`DE92OW?UN*5Y,I<7# MNI@M*MG,OUX652K[:I[>E^OMXM_5]U\T/,C?ZI1/3UR1#U);*#H28HTI\*FFWS6 MANK8!_'2P]Z+*FK'?G"./F7KLU.Z'CY?S4@4NG/;A@VT(]P_O-\_Y\R-`7Q_ M01ID"?%I&/DM-^)0M<:Q7UOVTX)O_\FN-2L=>\(HQT_#X:=&4*?I=0?3 MQBN![$2J@Z+,(.P(1QERIK31"0VE:H`JG]<^O_E75UOXSB6_2L"=K'3#:1Z)5(2)>P3*4H]P::20A)T M8U$/AA,K54([5M9R:BK[ZU>4)=E)')F7(F4.YJ&KDG3*]]Q#Z9#W@Z0A)@U7 M3'>H+2B:[L``ZZ8*W%NB9;J\D:B>*I,$5K.DK':;S%>+/<->P@*,/9ZZ"-5! M:>9S-^X,9RP$M@N/MS>=ICT4J_J-$SU?>QLC!&Z5H%$#T3"AFX9A1:UKP)U( MOCXD1D+!QI-JF8AI<.@#'=-%U;CP<88Q#\,PH%&MEX&/2!BYJ#-6AZX9I+M8 MS8+AQN%MQ+/:13I*[2&*Y(T(%K7RIB=(M"$RA$:$TC1:(CPCG9")`(&4C!08 M@I%/*4TS+W8I03Z/DSX9%I%,1U[JJ`WS^2BHR%C\PLB2:?4+(^V$U`L#HT3N M*D)Z_[_/1;T.N,CG5?Z]7"[.5_7LEE>;UW%-X+F<8!ZY#,4L)'&&HWXQD-;_ M25\1J,F>X=FZ0^DL.YA.T>*$1!5:&1Z>Q$]%+K1#H.6U1^B<][R*;(K,+&^. M8L"=<">@6NVNMF./\F]CKTF38^*`_IO@T89KQ72[5)I[[)3Z^/?M,!HR/^"( M^&GLI4G,<-;/2!ZC\%9^P(<;[D38=O-O\TDC>ODA;,G%:4:)`NKYJ8,SP#)3 MF39+5ICJ^`]V]RL3`52+&1.'GU+B)3Y+/8(Q#L->BW`6*FSW.?J1DRC#"$TX MS@E$";32H?+^G^2=/_JF2]-BU?LMC_K@6PUT6OI=OBCF=\6RV!3YNS.."0O$ MH@*[01)S[H//+_;-(<^/Q5B'A=A MT=7=LOBV/86EV\+HNB$->(QIQOPXXJX?>'V3413X":2\I->RX416]ZX]B;[V M:I\TB,LAP30R)K9HJ!GGWLJJ00K!)]M_F;^(H\ENU_-%WIF, MH\Q%D$)BX'DS8RP97_PU:':'UC]M,2J>3*_$I61,.!&) MT,1_RUL+Z\QI@)WZ6/H#)`W%E1JHM42_M+CRP9GTX^E1"4N5CN@*:(()1UE" M$>/UGQ'WH@X62TD$6A<:QC+12G&Y:1G$GDZ(9?@16I#HEW9RJ.,#:]8-;%MB1)J=.C] MZE4K5=)JECX^+.66;EE>8LG78/JVWX&Q8'1[E:T#7 M]'%MB:YI=*@T]5@"=>TF7SZYU7^?K'+AV0DB!$`74)05X2^2[* M^FV2A"3`JVG'6#*N90+C:1G15->N$)C@#-@MI&',LXQCBE- M4A+O%DPN56[/5;!E/-BZO+K4VZ2K0BA8:0PS.4)T;#B9;Y`H.34:0;!]PC3& MF8\U:C1%FCMW9]CCR*6$93C-8AX@%*2TKQTF2&K'N6:3A@.Q"V!C[EG]HZH: MF4?2-1J2HC?]0`#5#]"@:V5?[NB&7&GR;5%&S5XIM>`"21N50]_?N!FE<1:$ ME!**..<^C78G/)/4]\:GT0'&3I=)WSOP1E\R'4*S>C[=$+]Z4NHGV]4]S!0P ML:Y`L272ILL;B?2Z,DG*&?8]BV%,O#B(>1IB3I/0]8/$[2QZ6<#')-D!9B;) ML^]IE;Y4.X1+M6R[(1I')]Q/>RK@08(`:7<%5BV1)AV>'$F^*Y,S+G$V(P1[ MF%":4IX&-/!0'/;'$L9A'"JFX`$6)LG":Q$B109'9,BTDJF$3-H+2(FTR"3EXV.Q$>>V52)^;'KEO^6K^]KX+/12ZO'01]SW4^;% M/DOZO?$N1P06OXVQ9#QX2ZX^?SZ_%9?:WC1WW"97E[?GE[^GE\EY>@-4G5&4 MRFG/5%S"%&@/U38UM8]K8AT:8&A`C73P:HDF:7&EU/_805-,F_+^+W&28!W1 MB.O#-B]]`8`1A`F)/9*FB+DTHBCM(\$PH\!+>2_FENX;_\'6CL<0Z=D&FD:'H$II#U0?W.VL!RZV:R+N^>-V`WL;$KG MR_RTE<2/F1M**8VGVQ+!TN')VU22+G(`EZ2V%U^UV)!-G:<.G5,)>&?._'GSO5PW%<+:QIGKND[U MO7[1ZACEWW_S7.=IOG9^"">:/'GN%%4E]K@U=^4\;ZI-_44]QX#O5E48!3EY M,TT_3-=Z-,[-ENX_ME2>-RQ.?HOJ.VH&A&L,D98HUB@7WEV5.I8.4,A7KO;L MN$'@UA^:<,;B)(U9DN!=)T5,@)=/@#_>?'#7(#JH2$*0WHB2Z^V+4GCFQU[S M&T*2PC,<17N_W\K56?L_41#O_:H7A/N_NB=G9Z(Z^)3?;XH?^?)%(;R$#9]\ M3&ELW."!9#U@%FC:6U*.Q(Y*_%FB9NKX#T2)(XB0UK';=3ZOGMY82CR#& M.8VC^H,I28(@8KOC9;DW6^7?FFV&4F^$@@&I=R+>OA/[6.2SXRVFK9HY\TUS MF>"9@S!Z)38/]<]WJ@>4&!5FY43&%*5*,M-SN2\T$PO,>T(&)&8$>Y:(S!@/ M2FV/$O1`E\6B$&T[\^67>;$X7[5=5GLZ-R.>Y_/,JY=G/B)>1A(4^KW$>1AZ MHLMX@\8750+9IV+5]8!"#W310*FK/)%.E^OZI"DHO?WSX_/S2$,/'\H M[HO-S'.1E_A^3&+&@A#YV.?]^5AN'`/WYF@P:%S4]C`YBRTHH+#IH%5.V";F M$R9L'3BG0^?\LL]M"_#7B77M.&4#NJ:1;TMT3:='I;&'$W[Z7F>I:=FJI?1I MG7_/5U7Q(S]?U5%1?E%6U66^N7JXG?^7V/NO3][SB"-(UH!9FG"4,!Q MDF(:):'KIG'65_%XQ!&D&5+AXR?IA&PR.BVNKOB?-_A&U_Z/\Z=:\]=*G;%: M_\D+_*#"OC2GELC3&`^.%O*!9*@T7=/5XH!=E[LNJ:6-)FD21:X;IEG?YT32 MT%/LOU8S-HD`[1^Y+BI;>X+TMTI-BL:S+"=,DQ(,DZF+-ZRF1W@TW:U]D)\! M?=)&K25JI<^?C]NY=1!U5,F:BYC?[`OF^;KX,=\TR[5JLV[NZ:YN\Y\;MA0I M)DR2C-,T2[W,RS*4(I3@FB9O)Q4`&#!L/?RZN+G__=)M>?W9XRFZ; MUN_SR_K[].;6N::WJ7/S)_T"N>M=,_'#,G=BQH&"5^-T;ONS"VJHS@ZKLP?6 M^2K@.@W>@1Y,X]R_NM#>UC%X!?)D8_%F@Q2?>)) MR*1GI?'G%+C$WF8,;NI'-A<&V7PI=GK??,]S@6E7$1%W=RS+ZKE^CMG+J^L] MJN'[/:I;$>;-@I03QD*4\2!P4YZP$,<-?)X0/PI!AZ/:@AFTX(=O`M^ZZ?1^ MGCFMIT[C:K-0W:M9[GGKW+TXKV\!JHY?`R3D1;@MJ_*VC89D%&(+7'-SNXF1 M-Q+P3#04`W&3;0^#)>&7=;24=K_#ULVY]&=1S7!4P_7=D)$@HXG+D>^''7HO M)*!3\2R!;'C&?:V?DX+U8S<1@B#CV.B)LB3-(P#-(.#@^\ M%#)]F<(PZ7PDLY(_:\5MBQ\Z;1D;*KEYR(91TC"Q'.7>R-2B2-[`7&%Z."P1 M?^-NEM,^Y9#*U'59Y;?Y>CV_SR^?UU4-(ZDGF'S].7^\R]B<%I[3XG.V`"$5C[%D2I27)N01)H0#%#I?M^A` MU:.Q7`+*11-RJE8?&L>M7#5HF(2/RC^:J+.AWJ/+E5+_DP5J-1"'C2]N_BJ6 MRWSQRFC56DV"V/+LM%OA)/'_7F4I](=<*,M6'X_>V0.2HO\FC^))9:$U$'>_$/LZ:TMAI# M'V!1-1&-:JLI93KE5E$?^_[1\DD#6S:LFW2X4>I]B"#*S.>K'V)M-E\MSG^\ M+.;+_(!AEC"7>X'H^`@Q86X68-89IBE&TAJMQ9KI*E.+L6DH;%&>J4NW'H(E M1'QR;H&UH>.T*FF['GX!*C\YSVIZKX=O.?&7H>2C:4`KG39,"'H=*DT]>:IU ML7*3MY9XDK`@(]@/0Y81GL4L)9VED&2A4CE,_N,GK8+5L%3K-0#"@"4O,UR- MJ735B$;7MP!\*9:US/"FHYHEQQ^\AM5[+%.Z@M-C@^R.]."C0I4J&7)Y2GH] M2UWL,Y_AS$5IE,8^\6L[[<WM"!NYCT9"?I]4?928#[-F0G(7!+M5&V;@_"1;'*S^M/KV8!C@/* M$QQ&F)&($]UD4MD>6#LQ^NCME-H748Y"8X M*T8`F#-_-=\Q[R$^YY0)`\,#D87S,+)D)S/LYM.O"'+'2&MU:6WUK M^L6JZWJJ27\^Y:LJ_URLBL?G1_&3^;*:81)FA`4)#6)&LI`%*$&=_8Q%($W6 M9M1T*CI?/-\+]L4=#//5ZKE6A.8ZT*?Y2W,L#E")]9$MI[PGX1FFM#U$9XOQ MS!&8G!;FF=,"=5JD$RNK+($#2JI]#"Q13OU^E88?7J`RIC^%\>>B^BY>]:N' MYGBLQ_)YM9DEV.4L1:F71AF-4)Q1U^\LQC&/(%HXPHSIK'*#0BP^'\OUYMO\ MFSCX?;ZJQ:\8N'%/.Y=R4C<1C3!Q>PU*,"E@G3E;8!-KV<<,#:B7!EHMT2L= MGI3:GSEX1/U^G?C[O%B)H_:SVN=N>5F#.?2K+'\HU^WI_.)0?H;K`#^+B1LR MS&OA#`.OVP(0!SZ1ZB\[%3;#ZO=EG6_F/YUOM0-.O0!<-."+X>C.CC&3CLJM M'2YPL'XP)!?..+\(=WYUA![LLLA"B#_X1W>-6TZ;KJX=FSZ6USDLPR'^21X` M2^:#D[G_/B%PPF$8-_/4]M*'A_R^GOMV-[Y(8)YA-TP#<>UO@C!%&<(([1+. M*>P4UFF1&9YU:MQ.OHURG'E5E?=%; MU<_\I6X`CABS.>QGV9^B"*:L%WO2DS3,#-43Y(U;SR+ MV<`P5S62IEE[O<@$PZ8K14>'X]0UHA:@GNH0=(3LT6-C'JI7A-3(E-PI7*ZJ MLF(U7]5KDF7?E]#<#/`\7]*[:K.>WV]F M*0M9%A(B^,^+[ MWIU=JU3E_-)Z]*OSM7,*M@UWJK$=%GAK!Q4F^?\RHPG9@6WAJ"INUWXWNG?= MZ#Z]&=V'?G2KWJ'?1N_GUL/D1_M-IAXH&W:H3.YS><(W`QA-O8+WI?[J_F5W MUP]/`IHE210&$:'UWX03TMI,781`1Q^/,F0X0GJ%#1@GC2-0+B*:C+L1$^&9 MLP7F?&W_5KDC3$^L,T370%2CA65+XA<]OI0&'D.@/K5R2>_O15VU#HRV=M]: M)YQ[A)!0'%R&HRQ!*$XZZSA-?(A2:3)I6+/Z-><.)U"Y=%$KIV$G8!6F9@<( MM4C3Y.@;4#?-_%NB<[J]*HT^M$#MN\S_L6=Y7:[J+^^WJ\/#.!*/(QJZU`U\ MBF+JTC1Q.QP,P?+]Y8M$3;G,BDAY3L>'[]@K*H^"*)%$71LCK= M59TT!8#G\N%<@`/PU[]_OQX=W,9YD63IAW?P/7AW$*>#;)BDEQ_>_?'E4'[1 MQ\?O_OZ___U?O_[/X>$_U>>3`Y,-)M=Q.C[0>1R-X^'!73*^.OAS&!??#B[R M[/K@SRS_EMQ&AX>S7@/GC2_@Y/6T,AQ-'TUWG3(EG4T`\+C_[Y\>3+E,7#)"W&43J(WWD9 M'!S\FF>C^'-\<5#^^!?=#B+/*J1`8%`R^K?G[<;W-_&'=T5R?3/RO!UM]G(3CZ-DU)B&9\T[ M)N4V'F4W)0";D_.BR[9(6EM0RWINB\`2E,/)*#Z]D$41CPLY^/-A>\(; MCK@MAKY&YZ.X#=U/.W9"GL[2(ALEPZE-D^E01452G%ZGKADM2; M@R0:??%/XI*26NHW'?=5F6N(K(Z&?U56SWRG05*/QJ[&[X19DQ2#+/7/)O'P M]";.IZ^O96%UKRT2UA!.C3IW0^8L'/)ZM/Z%X_OC]"++KZAL7XR:AW^I>6R2L*5J;=.Z$S..TF.1E M_O$Q&H]]GE='V;+V6R&FH;1JNG5$FA\YN?[AFF/OED?E2[]V,FN M;_+X*DZ+Y#8^3GVWN+2@G3'7=8F^$[8?4D2R^_ MQOFUB<_+P'-*FG=`GSTY7^ZBFSI6&G;O@]2&[F.]43HA_',\*,/ZP2";E$G( MY6\3K_1R$;"&U+I^G1`W#=5\SAD/2YOA#<84>HN?RMP[WLLI3M7]CR9GT?TT M;[F+39'[?UZD\;#,9+[?Q`/_UZ]9^>AT,B[7/\L%Y>EO<3Y(BC),;*B\ MG22V&S6,L\&W%SS4RF-EKRT2UE1?33IODZ$KCRS(N.HG.XV?QU*)^HSQ_TJW<^!/E MQA\,IO0N&JU#*C_%XVX)?3Y@A[2>^=`S&]JT8]$N'K9SNGV+N%NJ7P[9);W9.!IU3.^+(;NAMP48QB]);*#YFT?[,2>^U:QM.>;:V_8/ M+XB_C^-TZ%/7Z0O\*T;98!$?4QXNHN)\RLBD.+R,HINCTAX?Q:-Q43V96NA# M`&?%#G^;/0Y/\\LH3?XS)?SY7E/M)I,\]S%,-)C[G%$IIP_O/*5AI^.'E%M` M,9>*!P!H2J3#2F%JN"4,PD`^%=VH%'&65\K9FNP^1>-)'C].R5<(XF7C$&(H M)<(<&B8=)Q)B("JN+"2VCJO'H)/YX"#+AW'^X1U\=^!_N8CS?.;35I2T3`$X M?F$MHGSP`KI/.\Y:'-U,UQX.!U?):+[*4E;VO"H*LHY%[YF=S_2CYU.].P.P M,%#Z:0<>( M)@1<6DR5M`0&P`EH#<85_<*16JCO/GBZ45_6C0![`\#'^/H\SNL@\-`J5(Y3 M%5`><,L-D$8)0>8\(+='%J2%WA9IOI7<^M#]QR1-KB?7M=I_TBZ43EMF&';< M2&4T][/"S?B@7CYDS_2_KO:R[F37"P:B[\TP\+A=B'QTZA0D!$#KI-(.\3D? M02!U2PR@/<7`!K);C8'&L:(/_^-C']LL\O-U74+J__$)B.+>XUG)#>0\\P5Z,MKW,;Y>=8OBEHH_OEB0><";F56*C(^3?+"\Z?C MLA+!18-DE(R3A0AITBU$EGI?*)1&"@FE&'+`5I0KYOC>FI?VP-B"7#="Q$DR MB-,B'LY(4?&P%@T+NH0<$2L49PP9B@,-$!-SU^@4P2V1@/\J2-A.(ZP"2P$EN`J\*""4ML0%^:O@HD/A;@,@)W%9P=`2 M(0^=0PWNW1*\!'\-O&Q#QIV@1A9%4I9&GB2WC>*0 M53U#BX3#V.+`>>D0B@B4<]=I:`!;8H3]U3"RL6A[V^M<YMU#YI2X(2'HH2:8B+0(ZZDZ6]5>YOK$Z^$@_K* MA_6$W[\U^%D$40<&IJ"65G&M7,"R*>/#^,KL]&L9) M*392_J64%GDD+?\H?%@0J^[D658=L:1ER*C@C@F)`LVA-,@PXRH.#`"U9NWM M;&OUK/&L2[GWL1@^9_:W.+O,HYNK\@A;38W$TCZA=M@`&EBGN'2`.(@MJ?A# M!NQ!0=W&FLVV(\M>L!)?/J?49-=1DJ["RK(^H8(L\.Y.6A$8PY42!H**/VIL MV_7/'<)*ASI^CIJ.I-HJ#?UM%!67V=T_/`&3P;?[I;OIRQN'#@0".2X(L0QA M:Y6B046EQ+)MLKF+NM]<4UG'XFQN*JI@I!C?Y*69@-._E9"`C\Q#^2P\_7T! M`F:_A$AKK:P.?&I--.%:-QFXQ&<3.3O:)+J+'1 MFC#+$2%<44#UDD4VVMS@F6]`AY M@*WD'#I!!*>ZK"Q'\[@8N3THGNLZ(^A&DJ^%DH<+1>/:O*"V;T@AHI`[:C#1 M1@JA*6(S?JV`M*UCV<$8<6.--T#0)K)MY7B^?"LMW?#))MEJO[.\1R@X5`HJ MRP%A&KE`4%.97(LYWZ-58KREA0O_FR^[YCRUK?3*"M5'WJY9TGV<,]D\5J?2]J&Z+`Y[*>H3(0 MQ@()SSBL:*2,MJUMV<%\8DM*[T"J?00/NMR&CW,OJO']I^BZ[ES>HN:A5=YH ME6<530"P53Y49KKB2GJ3]O:QTG5PV8$8>SFH%]],\L%55,3RTD^',A%[3GEM MA-EXC)!0[8``""LFE21.`OJ#?PO:UF3O8'2QF?J?G_?;DH!;^1T5>3>_?? M_QY'H_&5]A)Y"'2.T\%J1]2H\2QS4LJ8^K@92"\HP<,[+A6`!Y_1CR-7;7RKKRCEU),+N M(5`1L]37O&SD(RTA?2Y%'60.!M(!I^\;2 M(DO_$:5%5).C+&X=&J4PUH!P+BVB&&JFYO&T`GA/M-Q6.5G7`FRW3^U=5[K& MOL>R]J'/D`)F`\(<%E=BQG+*;F=V%!/M()\M+Q<>S2\6_ M^K?6K#4L:AXBAP2P3&K."1,02J8JY^:8E:(E+G;HS%77:PT=B/$UP%&[L+"X M0X@,")P4F.C`&6NX!JHJU/`IDNWMT/_VT\/-%%N#DE;2[`K3)NJ]`5"-I1E'^@H>3U.BW'^\(VX MU0[F9>-0<1Y(K:DT&#!6VEEK*HZ<"-I>-+9#1S2[=B\;"[%_6#1:MU[6)03$ M.6`();HL&X:62SJWL)#M4T'$)JI=B9+6TMRD4+K\G$UIPQH52C]M'`8!TT(Z MC0(%?,YDC?]/1:7UTV9?==Y&40OJI#>29B]!19+&IQ?:JR$9SRXBN*_+3I9T M";'Q>5;@T]E@A951#30RWV#`M"5%N/L.\#F MLN\#U- M.Q'DZT"DUB\NZQ(RQX$&`@"H);;0.LJKNX:`GPI[]/F*3=5;BY96$NUE92!* MRX\CJXF7C[=_]5M3B]J'R&@72"V$4%QIC30$H.++.;!'.>#FJGV^!M"!0+=5 MOEK9SI,5GT18T3HLXT&E&*#0.!D0RW65#UL@-&@=O8#=P47W5:R;BK'=0?]N M;R?WV,4!)0)1S#V)#A@TAV\@$'K[]J`3?36]F'P]%MGU^=).K\?+1G. M+BK\FD=I\:`HN,*;K#-,*#7ULX@X+@'ESD?D'/!*"MJRMM9DQPHINP)5#R+N M?PO<18-87I='/QIO@?_H$BJ*%2M79SDQS#I27JQ;<0PEF M/<[CN,SAO>64>5Y^D&IZ%>/3_+XH-W9/+_PTJ+OQL]V`(:7`!(AZO6&I*(04 MT?DT8@ZU#8=W^O#.YD#K1=CMCJ4_(>#TIN1WG)W-3KG-_\R]ZUX6+:TQ1&BX MP+SDA&/MN2BM\5R`6)FV.ZH[72R\8?2T/?%N%$YW_/DG)H0ST$*B$:>:*\?< M+*FPD.K6YX9VNLROH["Z&Y'NDA/['*?Q730JK6$''NS1:"$RAEB?I`8"4$T< M(PZS2B9(DK9G3W>Z%*@_]]5>TJU,T>R+FO/TLJ1A1L)9G"?9\@2_OF?H):Z4 M`(0'P`;EW!&R2DQA>=7U/F[+;VB0.I?J(U3T=,?_E\%5/)R,XM,+Z2$_+F;W MS@Q_WOU?=Q.\)YX!HAV'TKLT;0\SN_MZN8/M<<-[]6E!$` M)>(826[+$^-$S:]&1&ZO-C:WI_:&]XZN)^K7@E%W]XXR(JU3`;>8*L00(6A^ MT@0!CH+]@=;&&E_[WM'U9-LJ6N[TWE$3``"!"B@6@`N#9%!%]P8AA?;@>R9; MT%W#>T?7DVT?=J6+*PDIL3XEQ'Z68(#\O];I.5=&!'NPQ=6[8^I`SGV@I]\[ M"[6R3GA.D>*.:>%S30;GLU'NTQ=4-E-_ZSL+UQ-P*U?5PYV%/.`$0U(6P$$D MA1)$J(H+*UI_KV$'8;(%S:Y_9^%ZXN[#*G7[?3?J^7&!M]5(&DNISU;IW(0' MQK3]-OT.[;_W[MVZ$G8O8.KT`W#:$(<)58(1"(D"UO"Y#2]O"-L?V]2!CAM_ M`&X]J6YRK\$F'X`CVED.`'<(01+0P!)7&4JL`];V-JU=U/WFFJK_`-QZXGRE M-9J3%37(3;J%!G'(:?FU+!9`I95BK+KU!TMIV^96.U24LPN+?FWEO:]%J\`H M(2"`$@/.K(,0B M*:?@TXU4F0Y/_.-9C8K_;7)=JCD=KH?*C5X52HH$]P$&#"@73`(BJUUH[WD" MU+8*9`?7HOI";I_Z>&OHKLX_-7'OG;XO%$120`CUR3L0PI9[J]5^!9%6M]VQ MV<&L=.=QWE8I;PWLUO\VK:3I">SS]X50N(!H9@/N.&,4!C]6/@G2JNW!K!T, M@G<>[&V5LL-@_RW+AG?):+20WT_Q%N!>]\904,*D8!1KR;`&V%+TPVM*5UMQ MU5DM?3:.1G\9P'>LEOY+'*=Y\<]*QN5U:,1QH0E`AC-BG0G*[UDK(@S!%$O& M:K.#;5T\H3^*U1H6,G;PJQXH%RSD`*$('6$`'F\@0, M[='][SWC;VD=Y&OH;E%K51_VKFE.,/$T2#PR8="FI?;+,8\ MQ&:6`"AX[1;X=N,S$Q>#/+E9KNXFIFS]P4+NE".&$Q]62(,PLGRV8.REP@WO M[<[7VS@_S]Z$O6J,HR4!V-:4LZ,FZ>=9DCI$!09#03@-,/*^4`E.9B&TQ5J# M^EK!AMNU;158XG$2C5:(H\OA0ZN\&PX8#@*'8/G5*`-<)0V?:/1V`]7;L4B- M\9.]NKKZ6/(HEV/&]Q_C\54V/$YOXV)<$GYZE_J`^"JY.8OS0>8[#9*?ZQ8KK)Z%/BO3 M5$-C!/=Y(Z2V0I)E$M;N]FSK[,`C?J9:O&\2N:_J%AI-I=.:!Y0SZ?]DAK&* M4X#VZ?1)S\AX<<"@,R7TLK3_8$OD8%!6(R?IY0/)S4'7;("0_3][5]K<-JYL M_Q+VY2/6>_->,G$EN3-U/Z$T$FVS1A;SM&22?_\`693M6`L%D12M3%529><\>B%8.$-0M+4(\?.Y`;>!Y@^<%GZ=2*./HCX6_'WLT[/ MJUG\;7`/?\+TO.C@73L1EF MR\6X2EU?%9--$9>(X$6,J]U=B3*,?_A:+4;3?\VKU=8"(< M)Y(P!.7FX*9)IWLOM-'SLK/O9N/I*B6.[!Y<^G1:+5;S1CL[YS8=(%,00&81 MQ-!`(2T0ID:,N.PJ70,TO#KCTL\E*/L5R474RB4#GI?3+B))A7#'@1#1!D6'50[%=!_5H&E?&XO-]42SC4-1DLLZN&$V?J+;0/TXB MZ;$Z.CWU(%!GN=8,>4LI<-9HAC?78QI.!+NB@\"=,;-Z"Y+KPZ#O?N1'3I[V MTX&`182:`*8Y]%Z+`0)M M,(M>&P<.8>X8HZ[&QE)X15'&H9'M'!LY6X!9)WX_58MHB\_CLEJ<4%CI\%M! M4R"B,:^,5L0#+0U\ZC=1Y(JT<.>2K;I"/8LMZXJHDUVEGQ:'"7/TQ6"H)%`0 M#;$7B"+`E<5U[Y%0N9P98$RZ5\ZT#7SS%?2TZZSTMH;O'D-RWZ,!:JLY0AQK M1*1#"!,LZOXSEUVY9(#$&:K)UY)HVJ=6W9F]%M;KAX).4XLP)Q47-%6=)W13 M=-X(A65OZ9-]E,W.%5?5$GJG2WRQ_#I/(H?KGY+,X3.9I\_"'[_O$/3F+T%@ M(H@7`MJHY2B*763U$`6,7;P.Z>8*I3H'K"R#PJRFTVI2S/XH%LO?R_E=.2M' MARV)_6\$`1E!AG*@*48^FN1$;/OK",\-F`UH)6A!N.V"F"5T.YI]2_;(:#9Y M]^W'9#0MFHN_R;M!&PTLI&GE2J5'@:=8;S%Q./5_- M[B*X#^G^LR_Q6X\$'W<]'M(=,B12G`-)I5-"8%X[\X)9?04WS@W=;FQ1/)<@ MW=&XW>X7`M:$:R@!C`/RF&K'(*Q'1H&Y`AND'<$>84D6FOWP9#1;W(Q^I#EQ M_,[N5P\'+EP<#6'8(6H"4L!+YHRP MR%-HHC>@['8R071%I3W/$>U!EF2C>?;F3K7]!S0 M[;AO97%J2T:]<+#5XN-1F%ZAZ%L(J+A"0$3]O)UC2.8:2`/46"W(N''Q\=-0 M[22PKS[M"^RK3\$!3#31V(-44T$23DR=12P0=M=4L:J2F\HH,T@^1#U9FHSB+9^W)'C(37(/QK5,[>5XN%C_C7X,5Q['I4%[?5O'@4RY?1]\.V0YO?%#2.8O"2 M`Z:QC9.:45BGZJ>B[;EY;;]DD*`5D^*"TKW83(E==;>WQ3A.\\>^-QSNJ?,D M]WL"!LQ1:9PT""OD$4;H29XN^]P\_V>6M#9+>I+MP%S.3\6W(G[0CK.Y:2RD M#1UB)7&>,"24T4_!>ZE<=KDL\0_;.W8S\P38W^[+LRFYZUQB$>?N8>OGE&:" MALY#+"6T#%JEK->TCM9+)UBNHRG_H7$.C3L47=<%G*KQ8\[6;/)XQNW=+%I9 M#R\LD(;UF_:=7CGP#<H43$<TZ%V#&K?H\$H1;$W4$7^Q5XS*!VIQ\`IO((DC`[D^>HX[5F@ M=G52.^TOS4?3=W'N?/_?XL=!5OST;!!2$^!H[+(!7FCFN`#U"!#FN;O<`]K8 MZ8,6YZ':/B_JX:84_CUT>/Y(M'@$2`4+O#/66Z8%H-O^*BMSM_<&M#/2+0O. M`+,[X=\4\[**`YW8:-@<8<&+9P.2V"@8]5?49PA(H;B1]0BJ-BE2>J6GX[N]O#AQ3.!.VR%=W',6`$9N0O%ML?6L-QR50,*Z7?+ M@W/0[$XO^.@\C*;_+49S'S_95]EES]/!4>BMUA$-Z9D0AFD/M]H-F]SB+@.* M>/>C&\[#M6MV/&JNYOQX]GR(0\`8IYMS,?+4Z;@$\GHD@IC=E-?[K\WU$:/%QM5PL1[,4,3T=P+VFB%"HFV+%(LL MM4ALQRBP[.WD8=.#Q M#GO&.`5''>!^1I@N.ANO[VN8KI;%)&/`>UH(3$3J>BM(NAE-.(DXE_7XB8*] M%4NZZ"QN3((CL[@=D/M+07A,(5VHY7)>_KE:IF-]7ZI/Q==JGM)-'^V)9]OD M#6AW5KO!*::L]X90;ZTAR$&):YRH-;WM:EZ"C&=S9V>*03^2Z#]IQCSF2\0Q MO+Z<[FBJS*Z7`^&$3]PXF/32@A#ZH-UO MQ?*IWR^A^JV:I;2=B'O\UKMWZ51HL3BD'$]N*TCFG:/4`6.)P%9Z;<46:B%R M3V$TW\^7CZ2<%7>CJ)2^])2\U3F[OYPJ"QQP11 M92!PBBK@)-W*4"/5W['.:CF:7B'7!R&V?A+'OY63Z(XN;FJYKX-B![/#=[X1 MB->$&P$#U^@'&N5W1ZWL:5:<3+R.=:#Q@00Z"2 M1@($*8O^*K/.Z?BAY=JE`ZEO/Y-D2.MVJ\+HWX_Z-BJGCX@]VZ[:S*=U(*2Q M%W6TI0BXDIYZ'O]#JV"Z8X-L`.((X M0I%2>9A/MWI8+KBOQZDXZNW>M&L(9K:)]#"<\3B2]2!>['=G>=DO6@J"02>L MI,032IR#R#I88V$,Z^UZM':'"CVKJDM MMAZD=@PHP844VE&J./-ZJ])D-SN?/6_A/:#-0B@+R@ M#B'.#&42V=K.B@97]IV]`SKRU:<-T!WR%_-N3O5J@@-`$0,(Y\P)#P`RN`[" M\1FH7\8O MWG2X,\]XTWZ('AF7U$L# `&\6W>4T<1D?M>GWC<_EW23F\*?^XH?;LY/L" M\I)B;C2RVG"3+D8B]=Z!``+EEIAX`VM[6_IU"'(9H)^<91.<'\#OG(WMD&7Z%_0`SK=\PG&>Z4P)LH!YJ./9R2I=SJ% MPS(W(OX&?.:VF-4.LGVPYH^BO+M/0XY&_NBNJ*]U>74$MX$C?6I3`3H$903! M.((HY#)"7!]?$D)F1ZC?@`9KV[/N&/HA$?%8&/"D=@+!U'/.G:(&>:\C%ML) M+@#UN0;@@.I1=D^13"[F".""1'R^^A\I')'94E"""4.P8E)32K$`1M0)F4(1 MGJL/!YEY/LE"*J(_`X>7R$24GTIB"U,Q@> M=V8:!M[VX[D!\EBAYL8-!.HA(M8ZQB6"6!`$63TB:Y'-/7SQ)H*WIXNUZ@'C M/A8/%1W(25(MY;?BS==7;;KOZ612,7D,03]\73V*]>/M*^".W7S52ON! M*FFQT,):P1ABQ'-D:]PH1E>1;-<5E:K+"^1BB\[Z`N6W7SL%,6`,]\8K3*FD M2%HN-J5J.+?H:$'9;D;X>7Q?3%;3XC5)?O(6UU)H4@,IL\40E;0`%B&&%/0( M:JD(JO&)[FBN'3HH]=`>2:I+@-ZU"OB_5;G\\:%8WE>3=[-OQ6*9*K]=9N+O M[,HBXO@_53E;_AY_:5CCY<26@L)`1JGSZ(5B!:#&41EOE+)B]OCF4*]X/)V, M:50=K7$C@2$*'&="(VT0LNO2X34*&+/>RJ7U$*3KBA\_!X>[`O\B2N&B!=4N MIAL8A=!YZ93!QLE@Y*@@-08,\=R*%U>@&1JSHY%F.!_[7K8?=V-T^IP+`@`H M&(#>1L.'.2"<-SEQN2'F'1T45Z=BG3_:1:G*@'C<7+O=&D2&F_?3$L"YP[]B<>3>+ME:Z8O'#:+E\5@FE5PMFVXE&-2I_ M>C9`YI"Q!%NK>?17G2/H\89%AY@S_FB,N>,QG>:3''HM:,93"H8`3$`+H==0 M@7JDTJBK2H4^0\ZO9F5KD/8\&2_I59PW)Y%``&D'D31:`\L1-FP#*S1*':UZ MU'5P\<-H^C5UM!P7V\ZO0U&-`HE[WP[.,"RB4A?1EG`2>*PW6ST.(<7H%7D# M9\A\;ZRP+5S[L-%,VK(HYA&LY8]T_ZCZ7AXRR78]'@#"@J4#L%PQ[0ACU*!Z M5%CB*XHJM2KCJG5H^R#,I^+K:CZ^'RT*=3D/O_;?"H7?YG1?%Y&&*-W\:%( M>3O[TC+V/1\(8A8@`S`&$"$)A)6UD8/BO]ZJ8W=/A@[D5[6/1+9/:[282IO(T_'3%K,EL,1!MFL=,*>$N5LCHJ[!H;ZF3N6\@I4I!`:DS$L1ZC\:2WS,.+,^Q\%E1= MH=X'LV[FU6VQ6$0ICJ;/\'E?COZ,:CO%9_T%R0P%,P;Q)2#BH,MP94&N?7B![@KUX5EU"'4>2[\YHLGOIJ_ M[M;'.!=_*[XOO_Q=3+\5'ZK9\GZQU^@YJ[W@N!=,4H(\QE%W,L-4#22&FEY! MJ+$;T5?]@]^5=CJ\?#5N(##.F3;$&$Z8A-X``^O8&E8`Y\8.AD:E[J5]HL[* M@K\/$WN7^GY?SHIWR^+A4/#@X'L!6N\=9T02R[PG<;(:6X^3>)M[`_T`S\5W M&2)H$^-+<>G#Z'OYL'HPU>/AU9MH5,[&Z;*A0WO2IS44L(.6:JJXBG.+``2B M^5@CD:[`NB;WK25.-&!::X!GK8F[>J1FL]5H^GGUY[1\*)?I8%>18L'[5L43 MF@B`&6TH9#(J82*4XU2R)[VONW9P9_YE-4EVXM&UZJ)3:2>T$E681C&N]B-!#`C@W6S\I MFKNY$?/3"ZR],>KU@?99ZFSG/'@_^GNQ*G<>6VC^)X=T,X!WL\EJ ML9SONEWQP)+7N(V`M73&>8P`8E1%.2+Q%+>CV95JQ?5SKFNL6PXNO'`C(OG] M:+S6L*?'&/:U%)C07#J*H*=4(THPAW2[F&O:VT&@[I?!#F3>+.S0$O:]U&JL MYG]%0:022\5LL3EYM%G6S6J>8%:SR6_5;/SXRP%U=FI302'`(+)",.DAC`K> M([]!@TCOX(_2]'MZ-.G8ER4W]*^A*_F[OLX&I,W\^*A7#VL ME_U]BN[TEH+`S%DJO(5::A/]9:!Y/3[KZ16=4>Y8T76.?1:WW,/7:?6C*/Y= MC*;+^Y^W#6Y&/U+OUKL&D_);.4FEZM;*>;IW,Q"SW0UKQY/ M6S2:#@V6\J@%>:2E\1(C$R$]*-L$FNPHY=8VL(_-N9[@+E/J8X_'+Z?Q"['T M#+LNC@V8,2N18H!#K@C"@.!:/+#6Y+HDY1CIU8_.V37&O5<0B)+*-'5X6T7F M/Z2L)#V9;>TS3U6U'J:4P&]Q+=O$J[M'/YW'AYE.9I\7J^F659=-+$V&!TY% MPIS"U#B"4:E3C#B,(HP!S'@W4!$0M5I%T`^2^^6EGOQ\\$H8Z"SPC,13"D1Y MC*'#VKB4N9%0HXQ-Z7:S7Y(K4%)JNGJ.>EWU(1H1^3V;9:M4=I`.J611W" M6J9^Q>$Q5XU8<_+S@1G**37$>N69M%1)SP[K(A+FV@M'&;_4+5VZP+-,PF7U M/)D^N#^3H2EE@6WUOE^P.,.:!J,#3_&BC@KD%7%.1*$;D1I!)G(Y-$I#3;<< MZA[=,CIR*JNX;05\?`G.ZL4G/A_(ML2G5BI*C4QIA1#?ORD0<(KU+9E:NF5- M%W@6$6^VJ]XVV=VVV_W'5B<[FS80?K(G#4((0ZCAB!(*'>$V MJBL'A.(?+E9PB/,GBI6V)UAVJYXZSI"55?WY*YJ&Q**KDVA'-H`3RL0[+LPF^MPXSZ M;UO#.C\P,.THT#X"A;#@ M&%K,^6&E#-#<*.Q1ZN^]&A<[Q;F0-6CS?3-+/@);Q*&FGJ56I1+0N_]-AWF;&R/<;'` M\+V$6,?:-0T&?V]UNLURS58C5(7Z)=076%<@E/=]2Q31&KA+)7"Q;S)LTWL8XW6[IP]W>`ZF(345C(*&%O&&%4BGJN4(,X$0(=U14&P6,3U M1^5+%ZA^'+9PC(A2RGDH@>*(6&EJ/4%P?U/R3+>%;35;5 MTV+VL(U3C>?;)4FXQ>A`(;`<6P$TDIIQZ?'QE'3QYW;<;=VRHS^,RWE)&ATK M;YA/M6*:4(LX<1(Z(S7V-?.ASBWZUIXQ']NZ1XM`0[2#' MJ;MXS6_L6:[WK+5O]288T1+-DKE: M)P#`%+42*Z^)%!80"NM[75"2&_6\4FSY+2+8X-R0DJAI.(>T:B_ M,J1QK;XBG9MN/\K,@7[.O$X!+N+=V)>B^%)M@U[>/OLY/\>EL0$X@;&F!F// MN<+)@5/'&Z?8P5MRP7:X^Z_]'AWC7()7=;W#77&`5;7\T4`@.S,J2,("@==(AY6-O< M&(/P=N2H_KC3#;;#V+%:V:^V,7?60@NXC`_01B-P"DNUK;_=NY^Q7 MZL[#LS!#6L4PGAT7N&``"HB\M1A+I8SC\GB"@ER/R2@+"I6R=UX-\WA,GE?; M.@.&%@'%M2IYNY-4]/S!0X:2G M3"FND(VGO!+'Z'+N2*Y<-$JINA]*=0KP$$)U\YBCDX,"DQQ**JUCV"K#`*$& MU.%WGMK;$:W[(5!GT`XF-[65EP+G&&*NE%/6444ADJR.P9-,%BM14E2^[O(: MZP#5$FPQB^_?I[LHW73;UBUX3O?I:C`J,.@4M(P@2XC34!)M:J4$6)1=VA^, M\<+J5<3N#N4B\L]Z_-]JDO%8H\\>F@D>8<,BR%<91AAJRH50.&7:Y# M=J2\N7YKWY;8NA+24O?68MZ((Z\_&@"E(#ZZL5I+XZ0V!A_O=,ESX_!'J5'U M0)`K\2S!CJ_+:A+UO9^-^/'VP\%`CK2U2HJX`,4-I4(?XSYM_[Z(HM4:.F?( MU8@6"=1X>-A>K_&BG4P?/LWWEJ87[#X7J7%Q<.`0$NMA/"<)XM!S@]BQ'A/$ M-Q6JT0.'.D>X!*>^5.O)=%X]N,ER'F7UU2_%2AZG]V<[:%\>'"!`T!`BHPZJ M*4,$$UN'.P$I<[T7H\P@ZX%3G2-'P; ME'%&"`"8\[6)BSN6*X3#UGK:!\]EZQCH%[0:H@'0YRV@3]5Z>C^9_?ID-]0- M2!)O*';4>:LXC_LM(-=$6H(=YTQ?=+_T)(K,9HO_IJWPBZ5=;/Y8/VYF;YM` M-,CJ:3-/L!P:Y./!!PGVF"EB&#Y@(:7-+;(Q4GM>E^1X+9#T"'MYTW`\".Z6 M6[P>MB:&S]7RMZ<(J7VP1\+U M@G=YIFV?>J0DTD)2"`\KM4#E'F6C;!Y3 MD%E7XCP4HSZM5IO6;-H-"IP9CE.K`,&1T)X+K]1AA82KW+R=D5H7"S,I"^.A M6'2W6:_6DWE*E6Q)I1J=$4%8IKS!)@J)"'%J MM3F^)$;27/'IXY8]ZHQ`60`/0IYF@M.Y8<%1(X%#3+)XFR,!/*+U*BDSN9%$ M'S>;K#,:Y:-'VL\5_5[_/)YN'Z?IXGPWEU:B?J)TWX\VP@(F2!DM! MG#+<,42MP18;@DS4I3VY&`+5STI3S[SXJ)^7BQ_3B*O^^?NJ>O@TW]<6FG]3 M]^OICYV[[/+ZVT\6+'5,B+(=5J`YS14U1IA7W.?VOFWKE(=O"88< M0X1\Q.AD&;0F45]MI@F&4D`0B;I>JOEGHJ2NX`&%B&QNR-=;C'I1G MXBX1;1,1.CY\8_Z=&ARL5\Q:XR`PF@+@B,/NL&+&4&XES_;YR;T'^@S&N0YP M+Q.4_[^;?=.8KXLO57Q-[J>S*J)V7,W717?26Q]?%X1V44F55FN-=,0T*B*@ MODFDR+5VC](U5Y#/(]BK$F_`RZ:FKWJ9GB'RF5%!*$XUHLQ`J`%TE#BK=FL4 M"'J:'43IBZ,#!XC M$=>+L%,,*@;BPO5AK8Z*8J5O_G8,['9C"FDYR91+KEG*>)>NE3!M5XY(ME=;T$^+HY#!R5V%OBB;`8VL/*C).YEN=1!GF-BGF=[,=YIKW3N/"XV@31._U9 M(RJ+QV0A6$[_V&Q-`RGG^@2_KITRBKW644=]W%#M%+>&B7K%D.+%MRR+J2XEU6^US]6GN_KRO5GL7Z>?)S_>Z.K<:'RA(Y:^1 M-41C[2S&FKO#6@`VN9[WYK%C?U\*]K1'):[@;09WJN07'W.'VUZ>/7,+OSLF M2.H$15XC''_1SGL,Z6%]\;]<$V'S\+."]65&0;^NMV08?:1&9%\,I8&%N_DD M00(.J6::II!/A(F4@AP0L!SGIKV-,IAM5*3L;8^&8>DQE?2"6_#]<8$93*)< M810Q6H.('A>RO@`HRY43F]NL"QZ0?6S_18;E@ST,J3XOJ^C)!+AP`8JB0[(*)[M.FENO[YU&O:P"\/P\U4WS>3N M>=/EIQ4_FTP8C$8I5(11;Q'R!GBCV0$9;F#N,3G"PNZ#L+.'/2C!SN9.^9:A M/-=-'+B17!F)?+Q?G(O"DM3UQCA0KGK=387Y%-V3(GDZS59S.HCN7"+/-?,& M1XQA5#`=A20%#!88UF^YMR+7:=,ZA?6FPF]+;LFX#MY.#ME`:!3/I8DBNZ&2 M(D<00T=/EY+69&&X)\+#6B)1)E<='Z6Y:$@>=K<' MA0)K[ZOJ89_ZLX5GO5E6=X_'99R/K[TT.F`-M`+(6@.H@#25!J[7G'YNQPQ4 MDG6=`S^4.R8",;V/YT%"KJ5'YN70()"!3#$B`5`&:,RLED3EZA?+EZ_)UFA_`J(&]VO#F0)249J6$%LCN+$(<*A,_<8IV7^=NMOD M8+_;,"[-MQNC=\.)@S`DE:ZA$*.H`&J",,$'I#`SN0D([0V'0]EH^J!KT3T9 MRNA]8C6=&+T;SQN4E512@P&QEG`A%;,U3A!DMQYO;U^\);FRY):,Z^#MY)`- MUF'KF#:&:J12JJ1$=:`>ER+7Q-BZ=-_?]$!MB?^`#-R7&NO&Z'UFLF`5!LJ+ M^#JFT#_#J/,U(MYE5R,=98YA2:-W=YB78.&7ZGDO1-\]_G,Q__:U6GZWU1_) M3KJ/4/FMNM\L+YV$;:8)#DGD,6<:2X.LX])#?D"!6=-_:O_PVE`G)'G3)["W M/2AM<$SE6%-RX^6%1'P;FB%;S1D0(ZDI,'8$(VTH9$[4N1SQ%LG5V$?I$BS( MT5(;4M*<5)<'G7\SB]7YLA/O#`E>`RZ$0QI*XPPAU"-]7%UVR.XH6S>7I%LW M>`]W_.TJP_X^?T@&K?NXE.F/%-!Y.C,W.3A7\6.S32I`O*TL>_=\2=?N]7N# M8A`BH$PR`!.*(#:PMKA9:'*%S%%6#1C\&!UFTPI;[J.4LUG>/\7EW#U^J1ZJ MZGL*;<#G,[][$59 M$?]LWX"#I-M>RWPX+"L:7B&C+E-+.:IZJ9-6:'Q6Y4;?-ZP7< M-KJU[0^UQUHWV#G<'\A'V0L^BF M#!5X<6(UG01>-)XW"$T5!!!Z`[EAEGKMZZQ,$,7J7/)^G&X??9"WY)Z,Z^CM MY)@-&CF:RA(:[YA'1GI+ZIK5@H/LHBRM73E_TR.UY0:4.CZW?J;54TH&^C&9 M)='E<[62U"\BB_];RA+>/PM[";;H M$>OA&*?B.[1<_HROR[89MD0]0[&&,T2%2UM!A(.2,2.AH!35 M:T=,YA8:'7NC].XHU@_093(!H_)6K=:I@//YV*Y7GPR>,DJC[&JE)=9*3J"H MO8/Q.-3/CO?W3>I?=<@6RA?=->>HUHU(:$Z0--`8*?FQ MCU'\EU+1?;?`E2O!?4&7(=I8+[['V9^J^6KZHSI6T1U-4^O=(R5IX>V#MNMS MW62F(#'QW@JC%`><*J>5EQH*+$34X`6_V*ZWM]"X5DV''?<<"06`YA0J:.*S MT\,J."2ZU$U06'SH=H??[SG<#MX2U\$VX?>=5_G0H/:TJ:#!.W3]Y$%@IK!W MCE.#Z+;(@D<'Q+SEN>$\HPPF+T7(XMLR))%_G\KRW9?C MDZM*TJ\A\XOMV]!'^I?J?C99K::/T_L=4^JV""D>6MV93[\L_(I7X8IO"T1Y M+$CRKDCE%<&>:'W`5+OL-/11EM4:X=M0;NN&?AVNY'>]:N1!:EQ$.4::Q=M8 MI:X*^U5CS&^HG_V89)26L!?Q)+Q]XL/3U@DCGU-7Z+C/ZUW/M12M_W616A2E M+FR+67RF;P.$ M+?>2E1U9P"(P4+X=I`'S[ MQ4T[U!*ZXFS;HW#B-3AO/0T^915'V$0A-=(8&TQ(A:9VN4SK84JO'JR-1Z)] M6B/XB[O@:>W>:PBK-SNL3N"F%@$;2#BC3!$7IS*&GIA5AE,*,#6*[;U`;D>^ M_XW'\\6]B1R^FMT-)J/_KD#_7#P5D^6:.=?QFRC'EV+V-$JEO5=_J>J/[C)_ MU^X[*!D702KB?`,.$A9^ MM]_&SG;!"F"9(>TI#3.F2:A[8)"GP;CQR1P9'@Z MTZVCM.Z*R?#']:QX&"T?]H6$'M9!0(`Z9[14`J$X<3"GP%62(YWKI-_+G(B- MDZH5C+M@UX=B$J?#.!7*O'D8348)AW0A\(S,#EKM:1F4T0)2KHS7V`A*-$*X M6HSI?G^:KOC:#\DPNCX+["#1CE:!*>X,!T02 M[ZFQ##AI2AD5=KRKB(ZS)%!SP)[BO'7$.2M(:B21C`ICJ%?0&ZRJJ4`X["PJ MHWW;7BOJ^@HVR(&-T1?-(MUEE-?^$]:[)X.%'CKA&;7:QBGH!;>B ME,52U[XEN!6]5J;$*Z=&/!(TNP^V^A8I>1^1FD(:)S"21FB+ M8+7&FP[R%)^MAM_?4>HTDO9Y,NMB4MR.#@JG?=LB.(X(`1I@()@SE#)*JE6` M>)";*;:7.8O;X6!=3/NQLM9:$(,%3$O#B>#.*0*\UX"5$@.?'2IW?/&^"US' MC@2W>SIMSF%7^M2]]>3\7#PF<^[DSL4&BQ\'.XLU^%N!16].IH_3N>#<J5`H*B^+F2@%&;N]WW M,`%]TTS)1O'RHQPA)%YS#X4B!%H)*""E1ZD@F.+X'FI8#?T7DH1(3C.O:UPZ@F4#T%6^QHO(QGK0Q%[%W+0!4Q MAC-BO74,$@P0J60E&N=>[<#C8Z?.7A6K!VUOE+%G,1I1QU[W%;3R'@*')$16 M02&!QQ4>F.C<8,XS4,BRF9&CDM7`O(=*618;C^HU6.`E]5H9QP!S43W0I+0. M.B=$;GS762AF[3"S3?Q/N-T>O\V&J&XZ%7<4B@6CB"O'?>ERZ"A4N3<_9Z"@ M-<6L9I#M)H*]LNJ]V)7+MTZIN&<[*71(\Z"]50IPCKUWQ!FJHM9;2BVKUYY?+1?SQ6"2\A`? M:+H_H)6@-H MN(`:("JDLZ<7[M8`4]-QX8&X14A^Y%/^GJ%_GVQ&`T'X[?O>G;) MI5/NNI2]SB.!E3,`>X++U-[QWR=*+KWQR)DB"F]OB^%BBY?TL9[S^_H+6'#F M5*I9;;7"VAJBJD3Z$MGV35P]\,4YF!^'.+PWC/C)@CI>R?&3J627'W\-AA[U M.\$8PB-^U,N()+6<.)1PU")=XF*16S0T-['(UY/=!K1%WS:'H^7][N-TO$3H] MWNP%>GPG`7/CK7+>00^]CWQ66CQ+)KD!G16$[T)OK3NXTXY0/NU$M<5B,!K/ MSWJ^,J93)1F'F"/Q<*H]XR7>D&"YUP#:CG1QH(JK6Q.GQ&CA!\/1>+3X\37Y M>NX0<&N;P"#Q1`AB%%762B:HX*6,7.;?R??/_%%WD*?M0-J%FICFZN)YKGZ- MOZK^'NV*#-GT>'!.0"=YU$V(-]I[31`KI4*67E`.P09&]CU7Z@-Z"IK8Z<-@ MM.M8L+E!W*>H5Q0RJ'VJ4D^Q<15,R3G@@JA2:V#WL"0+S2YX\KEXFHZ?1I.[ MMW/D4Y$,:SOHLK-=`$(98N,$DS0B""3T7)5R&BTN*OM%W:&>M@=L-PO-8#*_ M'OQ(B^I>UOS\<%#&2VR510ZFHCOI_%KJVA`*F'O$` MG4!.4Z5]5-X!Y9X"_/R62#&6ZZC;^S'/&:AIPVAFC?D6';C*&[SPT^7L>CJ: M+/SHJ;@N9L/539((YT'*8&)ZC="6L6/2"%4`8I8G%:7L^DT MRZE3H)_%P0_CP?QN^CV9Q9.FO9M3&Q\.3$0]#4#+"7;48D^@*E4M9*3//=KT M4'%MEB--H-F)X_8;"N]17']^."!(1*0O5=(SI!1P1)5*&T(NN\QA#_G1O.): M&\[N";)7:=WT>(#4*"(=`4`0`CFU1E1+'=7\@BYUZ@SI3G9D(?F6'^=DD*PG M_)F;(]_?7>\U.6UN$)!#PG@-.*84*$N%@++$BSOKP/O:!4\33_:Z]E=WNS@`Q);HQ`2,<-0,8X"*KE M0_G<^,7C<\F=H:K<(+#=TB*9GO M[#ZZBY-X$X.]E4&UL3U?M;H9$-K7EMJ9E97#^X=B>C<;/-ZGB*0]*_K6-L$! M!CAE1EAML7286%82$4MFIC'L?GEO"E4.V%-L.,OP!;DM-C#&[UG3$*IU;.G_%U]@.?QKNW/9]H=3J5V'O6&2 M24@=C7W^D-AC3:\'9B:?0AH5RGV_SEB;!6`F9)0@:Y`5' MU$#\"BC1?DW-,]Y>&@+U5)3YF()29ON]G?E-_P`]@4`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`@CK>(Y1%DMJ39:2EO-34ARRYG(?[C8`OR'$W%>#/_G;OKTK]'D*?Y4 MHB%^_IP(B%\1PX3@E]MD5#NTG<*PHY919*R0W\1@L M:74FC@!GEY[^1:WE;8+?@$'"3,?C^"ZSP;BL,'#U?5+<_+ZLF;WCZ_V'3[ MK=RNQP.)^ZV7FBG.J(`,>E.%H\1WU]E)8']%FWHS&'>O:/][LIP7-S^Y,FP] MOV7T$B@BD&%-G$=<4\F]$B_G5`>RJP8>;9H_]]6H??"[C03U@]'LC\%X65S= MOGSY<33XMG*SV$V_`Y*,'5+O5:0 M[X)W:CA'F:G%?S,ST(8[A?3&9K\)JRWH\95WJ'?0[LJ=@M$.6:@:\ M5MY(A^(7)1:6B^SLE$<;[<][H^T&_CR-K%BL?SC^GBXFQ>T.;>SG1Z.6@"UW M4$ALJ'4^OBHK[U2C-@ES+W7@T9;T\R9(0_C6T,FO;C^.AI&(E25"%S=;+4H[ MF@3+>#P^$..A5PXK0YTN74DIIS27$>@7LX,WC'/W^KD?#(LCE?&7)@$H)KPD M4K&H^`G@C5"TE,[;[`09Z!_S=AVP5U\"[N-8Q6*4# MIH8RG,N<7\QRW1C"I[V"6R4NN'FYNDG??1Y,[HI/HTD*APU7=[P/*&Q[338C*JQ>,N#@J4E+M M.$#D>33BN.POSML.$K\7WU^DN)Y-)_'C<%T$/0KS+-9OD]?/K#P`Q\7.4J=- M=A^D19X[!V2*S:)40%Y8 M];+Y6S6;)0&3N/K'RR/7@Q^KVAS?![.;J\<5T'_$E;:X22/P]V/$OKCY.DU? MO;HW6OTMKL"C>7(X/&EMUJH"Y]7M:VD_%RN3RRJ89"7LMU?"'K+(U>LX4(::`L0)F.Z3T1Z/JFFSO$W*=:*@Z,:"O7FY_<=HWSP7M",,2 M*&PYBYHCQ$16G=NA_[]Y;Q&LAWP:!\7%XDF]Q3@\J%M?%SP3I$ MO'=*2,B3YQ#`H%P9++(^V[>F?WS.9-/[%?'T@Y!ET/^RB+KIL_H67V#U3_48 MQV@X6F\DH[O[N(4,9O/=>:B.[2\\&`"Q==9#!CE26C@F78F8C9]RK7D]I/7)]8#.AZO7 M!'^>UZ\.VY^GX[&?SM(?VR#]SA\,"F,.XI%"6H@49IQ::TMD983\%UK?&Z1A M4S.@R;'+TSMRWWSUO]$LU_^IT`D=40 M0TB80<`CS5"9!B@N`@SEJNR'W[^_=9[^^@_7NQO-4S`]XG5;C!;+V?JR\N_' MT6S50=O,W_N[(>Z&@@B!H>+`(&VAT=5V:#5MO\K=/S.A-Z/[:VGU!BME`/-: M>"`I<(J5M2GCJ@%9_V_OVIJ;V)'P3UI=6U+5ODAJ:9=::L\6!\ZK*H`+7`=L MCIW`LK]^-4[&Y&8[ENDT(LJ==:#I`T:SZC2+FIN"7,A MQ*T\G2IVJ)_0FTKUB7^5AVHCV'\G]2DYT()SI+0)6)!Y2\"EV,I!(+C*`B2@+5>.@S9^<;T> M@3]H)Q'MF1!>$&\:ZQDT>M[*ALKB_)M3LO'*3^EJ@&QD.H^P)CRQ]:3`B1@X M6D<9:(G>0NOF')2DI0?44S*UJJ%^AT#V'6/;N-<_&/-+L.NM^$/EM7>$:FZ` MZTB\B/[&+8DZPN+!:]>1I76;K4\*[S_QRXEG6E/NFI*9G`F6*4U8*R\J:>G1 M9I61_4-1ZW[^D$$A&F4*>@F[?T@7E%)&3020_),SGJTJZH1!P?/^Q1VN8?`2 M=C]+0@:M*()DS`$2S9RP6QD*75J\LL*0CZ'(UEO8_7%0#>$DT\8W'HBZO_U8 M(F!L"'F.5V"9S+.M$*H=A=9AL.7PG(+MGHS\LC/!#TF?@]'R]^)HA57!,!%4 M%"%H;01GLAU)\XOI4*@,P!TL*))>T0'$VQ_+MY^75^N+19-8J*G3VB:2>[5H M,J0UQ99RI_9'IQ_UD:2T4M2*O,OE.IN*P'G@VU$)5YRGN%Y.'`OGIU0H;-)]USI M4+`=$.7M;''RS++_&XE+PH+1@@>;AR2)R'K0CDFIXMC1"H_8NR=+IZ*M-X^4 MH8%XRRU%XA!-EI7=2LH+*,YE71]%QC=I3Y%\%7$#9Y!'RD6J`S*>5WK&&7BE MF=YJOB,3LJ\+V31$'JGC0!B$VCM2#]DWO^]<;Y_\;K(:LXW@!/)HC0\\ERG[L=`S,$$=_,UI>K>9.K=M/[@^1[]/F\`CD/G@;'`K?$,VJB M;\>E9'D%BA?"[25<%V`,0;(F"7*3_'B_(7CKJ:11.NZR]:*%.87PSL%SN`W+GH/5VY[E$J78>.?'*&>]CS(I`;\:A)<3!0LKZ MYT\1>H\SH$AV(VX$-M3/VI$UZ+?%[+#=]/2O)!^I`.>U"-%8$)PZDLU7"T$Q M+AB=T%5>(?9/,]L[D&T=_'K[8]D!O[9?28$%89B,*LM""VFLT;&1LV.(6F/I M25B%!M-0_"J5;27\RLUU,8/=^D[21AF"7`/QWDD&D4;5R`&CSH+@!RLIG(\- M-1C'BJ5;Q7'9R*F!)DD3LZNM))74)+B\S7P#:8&[P^/\?W],?X*N=R99Z_S-A(88(($`!)H8WZ%Z+9(6B:?T]%@ MS[0?`:ZJZ;YUJFA"8S9^JE^7BVMWB^L:F'WP_V"C*8C@>$1+%6K)@G&+F]C]NUF3^K#UC^Q" M(D*!9P2Y8EQ2C,)[TDJ?Y!U=H:HXD*JCCU$1@JA=(JHD4KUV!XJ=,4O.A)=>"-M\00E2&"1*]`.Q<91J;;)"#"N6(7 M^@H/FH2-#\IY`/`NY#\5Q:W0`Y()^:J.2Y/]SO,G@3($^<+7;U^6/V>S MI\5I//)TBI8U-]9.@5#6FX]!(."I M]Q&(`&:-,XQL)4;]E(HHC6YB#@Y7U00_>"OP[^7B>UY,9A_?]%MPOJ@C25#/ M"$@BHW;`%2`G;>T":1B=T''`D+0=[,JI`TPGHET[\X$/WH>$PC;YI3U0`8U_ MH+1.M?(GC`WFRUE]Q;*>Z3V\%A81X+P5L#X_"HD`Q'.#&@0AU&HIVFKNDA+M M)V0+/G?%.PGY\]:[ZR&_6GQ8S?*[.+O^[PKB3O'L^F?-S(&OB@%\F8@#J;_S:03!3A@*IV M"@1.??\%U5Z4<&`E/)4#YZV'-9['1"_14Q]I4(P&G^4NVMLZ\(277J$>[3!< M>5'#J2C@:?!/1/WN%0+;;)0QKP#Q8K[ZX^++U:R:VXAC>IH<4F,T,*K($+<4KW?).^KN@1].>BP)5K;6+*6,^U"($)(P/S:-IJLH#&\$)5?T3C\; MM>^7.V4I%`[%-K[?E1'ET<%>_AHLSK_//\X6FP>_7WQI'BG1Z`I[F:375F=# MDG&K8E3@I1`M+A#%2PGT:G3Z_-ESWBOZW7/X.E?T(_N89V6JO;+:(HW`C?2& M;D]1M"\.;YY2(I=*M/_NG]S_'^5Z5ZGXA_3P20!043(*`$8:=!:TUXA M@B*A5.N/SDGSHO7C:WV/Q#EOE9_.F9WW%JS0FE#!A!88)=V2#FUQ#-CSO2D[ MW=':#,L80F3IXJ/^2@6662"1<\2Q#'1JO$"_-3=Q=EJ$% M*$WQ6F'(U5!DZRT#RW%0U9N!1<8\".),'D5D7()PPK7C4!G7Z5!N!.SW9F`Y M3O)5V,'GD('%:X?,!LA6D8S>(Q#52M50/Z$"7(5L&B0#RU$@E*>ZOK'3<@=V ME5"]6*WWUZ$_]CO)$HS*HI11:*,I>.5].S8,<4H3YJC4>)#(NC^0QIM;-[^] M537D7=Y`K&Z-MA%>EO+-UN,ZN?R;1OP'UO@>6DO@O/0>I"5!.8W(G=XBQ^F4 M2L^-;RF,CU_E.O%PC(7FQDFM)2FHS,MM))$A5S0P_+7J(A_.DVVLQ6`@1G:G M'1TA>;+)\K`?^RK1'O-ZM@0-S:/PAG)GB)!<"]:.1,106KYQ6IP\G0>[[)/N MH.F!9/O*T1[S>C*>R1!#WF\PXBT3EMXXD.>12)2EP6LU&@/G0;)2:*HX5QB[ MP*B7>4."&+PES&(P2FWAX)S+";FO56K9]@C7V1FRKY<_9JOKO\V_S@\6F^NI MV>04.*Y092D;0X,7+)H;*4?,N_BIFQ']4+)/2_8T!,].3]Y]^S:&GMQK-B$) M*(16E%CA48('W$J9.5+J^WPVEM#YZ+.Z/;&RW0 M>^LIO[A<`19 M#^TEC38&I?,:2@VETBLNW7;R8`.D-7JFI!\F2/,^P]:3]Z!/J/&_FO*=H0I_-)L/06?3Z/=M-X?&/+DFSGI]]?7Z=Z5:<6)#"3P5/A+M&1C.O)+. MN"V\BD\HQTT=>C`L7GT;M5?OU[._KO+KX7O^,8H=>Z\/3[%0=[V2C,WBY4(Z MX-Y$UKC7*]0Q"LO`!GHPRF:8$3YIEMCU3K(:`8FF0*WS%"&"NX,,L*# M0=6//)XD$R*/RWEI+6644N4>^&#E\T94R2>#NU\E2^0YB'5XKYN' MPYEWO)%HDR724LH$AT@U(Q!9.S:PDPIL/@G:`SPI$^=(5#D<`[3KG917(4&T M8#&XYB241L)%.SXWJ=.?DQ$^S)@BF8[`F9VQ$'N?S[I%.`H1I3:@B(F"H=V< M0+V;KM?WPU]5\/=]`M7\AVO%&LDUU M+2ZE91P,0Z8,:R2EG`_>!5]:8Z;"`[1.%Z)NQ#D659J_KF:'%Z2#[R:NP1`* MZ*4+1+OHM8GM>(4B$UJ83D;\"0PZ1;9%]_O_O/BQCE=?+I>+5YN$:ZRGN7[G]JP]__MR_X#SV;,J=:WR;A;+.D2"]Y)3D/B(@6J(93@CY MTW%:=BO-$?;"KY\2:[WCE:1#<$8`#T)P(X+&R$T[K\H`I:$_-48Z]'C85BK/ MHOFA]7I]/?\P6ZR;DIBK;&Y]KK__\I)Q9`\AYI(.5-[,LF:O9F]FWY>IR]M'] MO-D1?@R+R_GES[A0V4;( M_W`TTM(->?U;JN[X.20`AWP*_OZWYN'&M2G_X_]02P,$%`````@`Y8!E1V6P M96W&#P``D:4``!$`'`!A=F-A+3(P,34P.3,P+GAS9%54"0`#_L0[5O[$.U9U M>`L``00E#@``!#D!``#M76UO&S<2_G[`_0>>/J5`%=EQDM9&W(-LQZEQLB78 M2M/[5%"[7(GPBE1(KF3=K[\A]UW:5TFV-Y6`(EWMS@SGF2&'PU=_^O?3U$5S M(B3E[+QU_/:HA0BSN$W9^+SU]:'=?;B\N6G]^[=__N/3O]KM/R_N>^B*6]Z4 M,(4N!<&*V&A!U01]LXE\1([@4_2-BT6GS:>7=T_.'H]`20`58FS_#4_1/(^&^Y6(, ME$MHQ7R-2:6<1@MCCSI^WO0?C\!;X'R%3 M`^ATQH5";,US#I8CP^K)]ACCF?%#^^BX?7+<0GZ]Z1DWZ8J:Q)S)V"&NDN&; M=BSJ+>C00IV:^@CN$KDCA8RLK372%6)7&AE9&VE45)-R]%EGT;_:(5];OVH? MO]M2C;A1UE,CY-N)&J<=+"SM;O"9BAA47RVOX74TU5XB4E,^Q$*WC MJ=;Q^.,V.AK1C(QU**^N4Y)KMXK4,$S(L;T"V8&YBAY)SCN?<9?J;*;*%GID M=R,56U'(H$O^4+-,2:RW8S[O6-QC2BQUB#JI$MNR^,(?[5C(IMIX0D!"9,2^ MKZ5.DC'ZU8[%;*B036AM74(>_;"]!N3)FE3N>=:8S--&G4U*'F5S(E7M2I)@ M"YZWKR(,4\MTQ<=U-(FY_,=V+&!#/22U:FL1\NB''6B@9J*^"B&3>2I2`C/& ME9%DWH5O9S/*'!Z\@I>Z#S\+._)[XB"3KYX%O6AQ5MN9"3XC0E%(KA*)O1$P M$<0Y;^G10SL<(OQE8?$ MX%\F2!U\0"+A#'U9G5/2Q@"!:(PX+OP M)&5$RA;2K[_>WQ0-J$W9$4C=K$`S%S2U18-8DU'2 M-D[?'[VKXI5#.TD80\_ZV9Y+^DY72J)DU_KN44'L7?BM3':Y/T^J^3,L"'$' M^46AL*R?#MY.F&J(1R[9SJF!B$+?G>BT)[^?2OG.E[=WSKGD3'*7VD:3+K,O ML*2R[PP2P/K.-668612[#_#&+++4\-W&)91T?N\R.K]460@S&YG2='M,EJ=_ M1R6BN,B#\ZNYIG90WK:@D@C]+J/'W;(J[&^XWM17`V"R:)VHOG5)A=7BW1'\ MMQ;\MZX68>%[5R^T&3D##WH@84:$T:B&MW/XBZ,\C.[7HWQ2$HI%'1RBK5`[ M-A>+*8Z\QT<9\P`Y[MG?B!IN?X$0]QGLHI8WS.%B:A2KX:/!1:MW;$*Q=5DF_^DI%OEOEK?\-?J;F'Y$EYV-VA M`T.)Y7YLKLU(0KXH%,LZ>&2CE8IB,24A\->,!#[//_O;A=TP M,(W>;'J+E2*BAG/6.$O:RX>,]A+)0(&0?3=_[2:2)Z"D<7S(:!QKSMCG5@'X MZ32>4B/V!7:U;1XFA-19(RB55.2HXVA\&\W3&3\9D2@I$P5"D2_UX*^TE0>0 M'C$U(8I:=;+Q>F++//G!-+F:GD1O4H4<6B*QXSGKOG.)Y>3:Y0OYE6'/IF;; M_A;>+1%=XN&/%=MJ8M*=.TB7@TQ!Z$U4U,'/*\[@4\`X(4S2.;EAX$.B!T'/ MX/6R@DKJP,EF=2!9*O*+#8=YATJ1YZMX!G[W]2!+=HGKWVWD^N0RPL'3U;VQ MNRZ]5D%E=:!B)U^E#NQ[U]_C;#PD^LCS2"\-&3O">/T>+/>PP+/J/B\35#)P M?9\Q<-4BVUHFTD+-4E,H%FFY2`L^."QEY]ICVXKR2H:Z[S.&NI758RYPF+KQ?>G&;'@<8*C=CINE=DFX^)BQU^I0C9J9S5\2 MI#YF!"DC*:.*'#RB1='4 M;8>)Q"Y++:\^'ZI7G^3Y*+^J!&H<.NX:]:?N+IM"*24[;#YF[+#)]^^>[JQY M\$:2?/<`Q.=YK2TUJXS%&=5QUD'W6`0R,O;<]O6#939_<=@[SCK^ONJ)O0A; MGSJK%ZH$;](7KYAK5X+[&1$>0;Z`+77>4L(C+>-&?5'%7_'<17C(!M0A-XI, MP:'Z(IGS5C$)=5T=@4+!$CRBJ/*T&E\$]V;G+7.MX1D%^A;R+Z_PW^@,AHVU M'`VNA?RW,R(HMX>&SO9$,&SJ;`7)Q,A\..'G:E!L=38![83EC8P1=@HJ`<(_ MP]PC$/,GW(WF&.^(NN/,OZE*Q9@J4F_NK2EGT+3$<#5QLD5LR'1$1`5U[O0DB__+/,YM/,66[KX`76)O[4M>RY>\$NVIR MB06Y)-HG-\Q*(ZI*W$"D2&B=5W;$@AC!=!?(^ M-M'EGNMRF[!O$%O^H&(,71A>`5-$T4!$5YC-02T"(Z";^=+&+LG'5I'V]5#& MJ,A(W4#<%>;`V24'C2">8/?.TSKVG?Z"$?O.$Q)JNQ]KHNY^,];-FQP%$6.( M=068BWJ0',AZ"8T[9GTN;%?9`+,)-X<3^N<9:FK!8<356%J1MGF!LN!X2G:O M48?AU>#&\*8SER\)\7OZQ!;I)SKUI@.\U/H-=,]OTSFUM?H0%[#K+B.\VTCX M8=*_:\]5G/T':#SK<9F.PCG?&MBW?'&Q'/-%-HR\C\W%H4-ECV.6B6/M8Q-Q M0(#W>_`SU+M.(2FB:B`H&0M+XH`NZX>E*"I;_ MN9%8E#6!^`?1"C.)Y2J4G*\-R!_C_<77@NL]B?IJ">@!X_V`W>"/@VA-A]S? M#VBZ73W]D$@G=R+I&?LMRPR^=F6I[(L]@B=(("+B.Z+ZSA`_$:F'N5:VM;:0 MME$=@@H$LHWM=UV%-H!R15W/;)S>D6EB>4TRCOY;/-FG2;7JW-$MQC0/C6^` M:88]-A'1O!:5&T7-I*;]\*B#_LK`,QU0JQ`V(+;VB#G#V'?\>9\;*:$.?V40 MZN[)G+MS&&3'*[,QMGI,6U1QO:=QT]%XOA,YLW42`B!&F#WV'8<`$+VC=<6' MY71-<&%Z_^\5")@#FSZ7$\XKF&G)"Y=;CPEHM9BVP*E",;O/:4JV/N>,TFMS MO?Y0/:GR-7CIOP2+6ZP\`7$V"U8&S2O.(F7#X.)A"1'"`K/WG0MH7_*6"S7& M8Z(_9Z(J96E>3Q)AO\7N3-GB.5R8FN/!TV!D9^D0TJ\#:Z M19AIPG`NWV1,]X21!79]]66,O0+EL\[Z5T041",]]_2-JLD`7&'1F9[VC+J9 M8%;T%O+@B;LTNZ@BF!NS-R&X0WKO#P-@@',!SG%H%,2S/[U*U=PH8;RC%HS_ ML2R8KBLF:4":>""!,1F.2"Q(WLV*2UU]5"_5+#:>"/L]"C^ MZ+$BH(BX\;#,(U'_V&+L]BDKAA?2H6JM\9<3-@:59 M9(["4:817^Z=AEF7N2FPN1-,8O!@$B,-+.MS@U0/XG,7+*X/P_7H/#.2EU`V M#U"BPP%9J<"0AZR8Y=4@YJ82?0:)"^7^UH"5.<.<;PU('J*Y;-/7^(E_((_ZL]8Z;AC!X2Q*..3JJFON MB0&'D*#GU0;^K'1WQ.>D1T=UG;X%WPO8EH@N."-D2;H:#8[8NN&%'ER^K/ MH;\G3VJX(.[VC.1NL>BD2Y);)^>[P_2-T/%$WT+BKU8$7]+IXHN5]IS[ M+5[0KCKS2B\0/(/'1?Z`_0W)8C3W<)+V+A6B4TUL'DKNYZ:<$'_ M%VR/3=R\-(`X+E-@[K5YPG6UQ'C&-TJQ<9^AM(;&W2V1)N^[>GZ[9I76#+N. M"IKG:!F3)%NGOZT_L4&XKR9$J`EFP2U>5_J0)V&&<(Y=3;+2>DW3OL**7&,J MUK.P)FGU:H$E?SHTXS#!RO1N$443IC0S;R*KD-R$5PSJ)I<>M^]28A,/VB0_'-;A@M?! MFB1O(-;A1.LZAY"K=_&G@>5\:R**M36E<,5I2*?$$0"G^T2C%*,Z>>7+OVQ@ M9#((/"]S*48%%"O^K,'01"@E!+8[&(]:[ M%,)#.#=,;U;0VQ9*0)`L``00E#@``!#D!``!0 M2P$"'@,4````"`#E@&5'4&UL550%``/^Q#M6=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`Y8!E1_HFH\6N.```^\@"`!4`&````````0```*2!P-@` M`&%V8V$M,C`Q-3`Y,S!?9&5F+GAM;%54!0`#_L0[5G5X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`.6`94?P26'X*:<``)'G"``5`!@```````$```"D@;T1 M`0!A=F-A+3(P,34P.3,P7VQA8BYX;6Q55`4``_[$.U9U>`L``00E#@``!#D! M``!02P$"'@,4````"`#E@&5''EFJR-1C``#8]P0`%0`8```````!````I($U MN0$`879C82TR,#$U,#DS,%]P&UL550%``/^Q#M6=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`Y8!E1V6P96W&#P``D:4``!$`&````````0```*2! M6!T"`&%V8V$M,C`Q-3`Y,S`N>'-D550%``/^Q#M6=7@+``$$)0X```0Y`0`` 64$L%!@`````&``8`&@(``&DM`@`````` ` end XML 50 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-Based Compensation (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation $ 924 $ 441
Restricted Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Grant of restricted common stock (shares) 74,000 68,000
Restricted Stock | Share-based Compensation Award, Tranche One    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vest of restricted stock on each year (percentage) 33.00%  
Restricted Stock | Share-based Compensation Award, Tranche Two    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vest of restricted stock on each year (percentage) 33.00%  
Restricted Stock | Share-based Compensation Award, Tranche Three    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vest of restricted stock on each year (percentage) 33.00%  
2005 Long Term Incentive Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares reserved for future issuance 700,000  
Expiration period 10 years  
2008 Stock Purchase Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares reserved for future issuance 150,000  
Percentage of quoted market price offering rate 85.00%  
Restriction period 2 years  
2010 Long Term Incentive Plan | Stock Only Stock Appreciation Rights (SOSARS)    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares reserved for future issuance 380,000  

XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 86 245 1 false 54 0 false 12 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.advocatinc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Interim Consolidated Balance Sheets Sheet http://www.advocatinc.com/role/InterimConsolidatedBalanceSheets Interim Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Interim Consolidated Balance Sheets (Parenthetical) Sheet http://www.advocatinc.com/role/InterimConsolidatedBalanceSheetsParenthetical Interim Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Interim Consolidated Statements of Operations (Unaudited) Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfOperationsUnaudited Interim Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 1002501 - Statement - Interim Consolidated Statements of Operations (Unaudited) (Parenthetical) Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfOperationsUnauditedParenthetical Interim Consolidated Statements of Operations (Unaudited) (Parenthetical) Statements 5 false false R6.htm 1003000 - Statement - Interim Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfComprehensiveIncomeLossUnaudited Interim Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Statements 6 false false R7.htm 1006000 - Statement - Interim Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfCashFlowsUnaudited Interim Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 2101100 - Disclosure - Business Sheet http://www.advocatinc.com/role/Business Business Notes 8 false false R9.htm 2102100 - Disclosure - Consolidation and Basis of Presentation of Financial Statements Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatements Consolidation and Basis of Presentation of Financial Statements Notes 9 false false R10.htm 2103100 - Disclosure - Recent Accounting Guidance Sheet http://www.advocatinc.com/role/RecentAccountingGuidance Recent Accounting Guidance Notes 10 false false R11.htm 2104100 - Disclosure - Long-Term Debt and Interest Rate Swap Sheet http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwap Long-Term Debt and Interest Rate Swap Notes 11 false false R12.htm 2105100 - Disclosure - Insurance Matters Sheet http://www.advocatinc.com/role/InsuranceMatters Insurance Matters Notes 12 false false R13.htm 2106100 - Disclosure - Stock-Based Compensation Sheet http://www.advocatinc.com/role/StockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 2107100 - Disclosure - Earnings (Loss) Per Common Share Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShare Earnings (Loss) Per Common Share Notes 14 false false R15.htm 2108100 - Disclosure - Equity Method Investment Sheet http://www.advocatinc.com/role/EquityMethodInvestment Equity Method Investment Notes 15 false false R16.htm 2109100 - Disclosure - Business Development Sheet http://www.advocatinc.com/role/BusinessDevelopment Business Development Notes 16 false false R17.htm 2110100 - Disclosure - Discontinued Operations Sheet http://www.advocatinc.com/role/DiscontinuedOperations Discontinued Operations Notes 17 false false R18.htm 2111100 - Disclosure - Subsequent Event Sheet http://www.advocatinc.com/role/SubsequentEvent Subsequent Event Notes 18 false false R19.htm 2202201 - Disclosure - Consolidation and Basis of Presentation of Financial Statements (Policies) Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsPolicies Consolidation and Basis of Presentation of Financial Statements (Policies) Policies http://www.advocatinc.com/role/RecentAccountingGuidance 19 false false R20.htm 2306301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.advocatinc.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.advocatinc.com/role/StockBasedCompensation 20 false false R21.htm 2307301 - Disclosure - Earnings (Loss) Per Common Share (Tables) Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShareTables Earnings (Loss) Per Common Share (Tables) Tables http://www.advocatinc.com/role/EarningsLossPerCommonShare 21 false false R22.htm 2309301 - Disclosure - Business Development (Tables) Sheet http://www.advocatinc.com/role/BusinessDevelopmentTables Business Development (Tables) Tables http://www.advocatinc.com/role/BusinessDevelopment 22 false false R23.htm 2401401 - Disclosure - Business (Details) Sheet http://www.advocatinc.com/role/BusinessDetails Business (Details) Details http://www.advocatinc.com/role/BusinessDevelopmentTables 23 false false R24.htm 2402402 - Disclosure - Consolidation and Basis of Presentation of Financial Statements (Details) Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsDetails Consolidation and Basis of Presentation of Financial Statements (Details) Details http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsPolicies 24 false false R25.htm 2404401 - Disclosure - Long-Term Debt and Interest Rate Swap (Details) Sheet http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwapDetails Long-Term Debt and Interest Rate Swap (Details) Details http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwap 25 false false R26.htm 2405401 - Disclosure - Insurance Matters (Details) Sheet http://www.advocatinc.com/role/InsuranceMattersDetails Insurance Matters (Details) Details http://www.advocatinc.com/role/InsuranceMatters 26 false false R27.htm 2406402 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.advocatinc.com/role/StockBasedCompensationTables 27 false false R28.htm 2406403 - Disclosure - Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable) (Details) Sheet http://www.advocatinc.com/role/ShareBasedCompensationShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableDetails Share-Based Compensation (Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable) (Details) Details 28 false false R29.htm 2406404 - Disclosure - Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityDetails Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details) Details http://www.advocatinc.com/role/StockBasedCompensationTables 29 false false R30.htm 2406405 - Disclosure - Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationScheduleOfStockOptionsOutstandingAndExercisableDetails Stock-Based Compensation (Schedule of Stock Options Outstanding and Exercisable) (Details) Details http://www.advocatinc.com/role/StockBasedCompensationTables 30 false false R31.htm 2407402 - Disclosure - Earnings (Loss) Per Common Share (Details) Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShareDetails Earnings (Loss) Per Common Share (Details) Details http://www.advocatinc.com/role/EarningsLossPerCommonShareTables 31 false false R32.htm 2407403 - Disclosure - Earnings (Loss) Per Common Share (Details Textual) Sheet http://www.advocatinc.com/role/EarningsLossPerCommonShareDetailsTextual Earnings (Loss) Per Common Share (Details Textual) Details http://www.advocatinc.com/role/EarningsLossPerCommonShareTables 32 false false R33.htm 2408401 - Disclosure - Equity Method Investment (Details) Sheet http://www.advocatinc.com/role/EquityMethodInvestmentDetails Equity Method Investment (Details) Details http://www.advocatinc.com/role/EquityMethodInvestment 33 false false R34.htm 2409402 - Disclosure - Business Development (Details) Sheet http://www.advocatinc.com/role/BusinessDevelopmentDetails Business Development (Details) Details http://www.advocatinc.com/role/BusinessDevelopmentTables 34 false false R35.htm 2409403 - Disclosure - Business Development (Schedule of Assets Acquired) (Details) Sheet http://www.advocatinc.com/role/BusinessDevelopmentScheduleOfAssetsAcquiredDetails Business Development (Schedule of Assets Acquired) (Details) Details http://www.advocatinc.com/role/BusinessDevelopmentTables 35 false false R36.htm 2410401 - Disclosure - Discontinued Operations (Details) Sheet http://www.advocatinc.com/role/DiscontinuedOperationsDetails Discontinued Operations (Details) Details http://www.advocatinc.com/role/DiscontinuedOperations 36 false false R37.htm 2411401 - Disclosure - Subsequent Event (Details) Sheet http://www.advocatinc.com/role/SubsequentEventDetails Subsequent Event (Details) Details http://www.advocatinc.com/role/SubsequentEvent 37 false false All Reports Book All Reports In ''Interim Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Interim Consolidated Statements of Cash Flows (Unaudited)'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. avca-20150930.xml avca-20150930_cal.xml avca-20150930_def.xml avca-20150930_lab.xml avca-20150930_pre.xml avca-20150930.xsd true true XML 52 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summarized activity of equity compensation plans
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2014
271,000

 
$
6.67

Granted
—

 
—

Exercised
(28,000
)
 
7.21

Expired or cancelled
—

 
—

Outstanding, September 30, 2015
243,000

 
$
6.61

 
 
 
 
Exercisable, September 30, 2015
243,000

 
$
6.61
Schedule of summarized activity of Restricted Share Units
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2014
130,000

 
$
5.45

Granted
74,000

 
12.31

Dividend Equivalents
2,000

 
12.09

Vested
(63,000
)
 
5.50

Cancelled
(3,000
)
 
8.93

Outstanding September 30, 2015
140,000

 
$
9.07

Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2014
46,000

 
$
5.35

Granted
36,000

 
12.31

Dividend Equivalents
1,000

 
12.05

Vested
(22,000
)
 
5.09

Cancelled
—

 
—

Outstanding September 30, 2015
61,000

 
$
9.58
Schedule of summarized information regarding stock options and SOSAR grants outstanding
The following table summarizes information regarding stock options and SOSAR grants outstanding as of September 30, 2015:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$10.40 to $11.59
 
$
11.09

 
48,000

 
$
—

 
48,000

 
$
—

$2.37 to $6.21
 
$
5.50

 
195,000

 
$
893,000

 
195,000

 
$
893,000

 
 
 
 
243,000

 
 
 
243,000